Informe de búsqueda sistemática de evidencia de los efectos deseables e indeseables Guía de Práctica Clínica de Cáncer de Pulmón

2018

ÍNDICE

TABLA RESUMEN

Problema de salud	Cáncer de Pulmón
ICD10	C34
Fecha de entrega	01/12/2018
Investigador responsable	Gabriel Rada Giacaman
Número de revisiones sistemáticas	2387
Número de preguntas	1972
L·OVE	*Lung cancer*
L·OVE URL	https://love.epistemonikos.org/loves/59e7cade65dee011b13d6643

ESTRATEGIA DE BÚSQUEDA

Se realizaron búsquedas en Epistemonikos, una base de datos exhaustiva de revisiones sistemáticas relevantes para la toma de decisiones en salud. La búsqueda de evidencia fue realizada en las siguientes bases de datos[1] con las estrategias descritas en el Apéndice 1.

1. Cochrane database of systematic reviews (CDSR)
2. Database of Abstracts of Reviews of Effectiveness (DARE)
3. HTA Database
4. PubMed
5. LILACS
6. CINAHL.
7. PsychlNFO.
8. EMBASE.
9. EPPI-Centre Evidence Library
10. 3ie Systematic Reviews and Policy Briefs Campbell Library
11. Clinical Evidence.
12. SUPPORT Summaries
13. WHO Institutional Repository for Information Sharing
14. NICE public health guidelines and systematic reviews
15. ACP Journal Club.
16. Evidencias en Pediatría
17. The JBI Database of Systematic Reviews and lmplementation Reports

CRITERIOS DE INCLUSIÓN

Consideramos todas las revisiones sistemáticas que están sintetizando estudios primarios (tanto experimentales como observacionales) de acuerdo a la definición empleada por la Colaboración Cochrane y la declaración PRISMA.[2]

Una revisión elegible debe cumplir con los siguientes criterios operacionales:

1. Reporta una búsqueda en al menos una base de datos electrónica.
2. Reporta al menos uno de los siguientes criterios inclusión de los estudios:
   - **Tipo de participantes:** Se incluyen todas las revisiones sistemáticas que resuman estudios que respondan la pregunta acerca de intervenciones para cáncer de pulmón.
   - **Tipo de desenlaces:** Se incluyen revisiones que presentan una síntesis (cuantitativa o cualitativa) de al menos un desenlace importante para el paciente u otra información

[1] La actualización se realiza de manera semanal. Se encuentra disponible en la plataforma digital un sistema de alerta que permite informar a través de correo electrónico la publicación de nuevos estudios que dan respuesta a las preguntas definidas, de manera de mantener continuamente actualizada la evidencia.

[2] "Una revisión sistemática intenta recopilar toda la evidencia empírica para responder a una pregunta de investigación específica, que cumple con criterios previamente definidos. Utiliza métodos explícitos y sistemáticos, que se eligen con miras a minimizar el sesgo, de manera de entregar hallazgos confiables que permitan sacar conclusiones y tomar decisiones".

relevante para tomar decisiones poblacionales o individuales acerca de intervenciones para cáncer de pulmón.

RECOLECCIÓN, ANÁLISIS Y SÍNTESIS DE DATOS

SELECCIÓN DE LAS REVISIONES

Al menos dos revisores, de manera independiente, realizaron el cribado de los títulos y resúmenes para identificar los artículos relevantes. El texto completo de las revisiones potencialmente elegibles fue recuperado y evaluado, de manera independiente, para su inclusión final. Un tercer investigador resolvió cualquier discrepancia que pudiera haberse provocado entre los distintos revisores.

MAPEO DE LA EVIDENCIA

Con el objetivo de generar un listado exhaustivo de todas las posibles preguntas relacionadas con el tópico del L·OVE: Cancer de pulmón [3], se realiza la agrupación de las revisiones resultantes en formato PICO, es decir: población, intervención, comparación y desenlace [*outcome*]) utilizamos las siguientes fuentes:

1. Guías y documentos
2. Criterios de inclusión de las revisiones sistemáticas identificadas
3. Consulta con expertos
4. Retroalimentación de los usuarios

Como resultado final la plataforma incluye toda la evidencia disponible en revisiones sistemáticas y sus estudios primarios incluidos, segregada por nodos de evidencia que representan cada una de las preguntas priorizadas para actualización de la guía (Ver “Diagrama de flujo PRISMA” en Apéndice 2 y “Referencia Seleccionada” en Apéndice 3).

ACTUALIZACIÓN – “*LIVING*”

Todas las búsquedas a través de esta plataforma se mantienen continuamente actualizada gracias a la tecnología implementada en el buscador de Epistemonikos y sus distintos colaboradores. Por lo cual, tanto la cantidad de revisiones, preguntas, entre otros datos cambian continuamente. Los datos presentados en este informe son los correspondientes a la fecha de entrega.

[3]Ver resultados de la búsqueda en: https://love.epistemonikos.org/loves/59e7cade65dee011b13d6643

APÉNDICE 1. ESTRATEGIAS DE BÚSQUEDA:[4]

Cochrane Library - Cochrane database of systematic reviews (CDSR)
http://www.thecochranelibrary.com
NSCLC OR SCLC OR ((lung OR pulmonary OR bronch* OR alveol*) AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*)), in Title, Abstract, Keywords: Cochrane Reviews (Reviews NOT protocols)

Medline/PubMed - US National Library of Medicine
http://www.ncbi.nlm.nih.gov/pubmed/
NSCLC OR SCLC OR ((lung OR pulmonary OR bronch* OR alveol*) AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*))AND (MEDLINE[Title/Abstract] OR (systematic[Title/Abstract] AND review[Title/Abstract]) OR meta analysis[Publication Type])

EMBASE (Excerpta Medica dataBASE)
http:// www.embase.com
Frequency of search: weekly
NSCLC OR SCLC OR ((lung OR pulmonary OR bronch* OR alveol*) AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*)) AND (meta-analysis.tw. OR systematic review.tw)

CINAHL (Cumulative Index to Nursing and Allied Health Literature)
https://www.ebscohost.com/nursing/products/cinahl-databases/the-cinahl-database
NSCLC OR SCLC OR ((lung OR pulmonary OR bronch* OR alveol*) AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*)) AND ((TI meta analys* or AB meta analys*) or (TI systematic review or AB systematic review))

PsycINFO
http://www.apa.org/pubs/databases/psycinfo
NSCLC OR SCLC OR ((lung OR pulmonary OR bronch* OR alveol*) AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*)) AND (meta-analysis OR search*)

LILACS (Literatura Latinoamericana y del Caribe en Ciencias de la Salud)
http://lilacs.bvsalud.org/en/
NSCLC OR SCLC OR ((lung OR pulmonary OR bronch* OR alveol*) AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR

[4] No se aplican restricciones en base al idioma o estado de publicación.

masses OR nodul* OR oncolog*)) AND (tw:"revision sistematica" or tw:"revisao sistematica" or tw:"systematic review") or ((MH:"Literatura de Revisión como asunto" OR MH:"Metanalisis como asunto" OR PT:Revision OR PT:Metanalisis) and (TW:Metaanal$ OR TW:"Meta-analysis" OR TW:"Meta-analise" OR TW:"Meta-analisis" OR TI:overview$ or TW:"estudio sistematico" OR TW:"systematic study" OR TW:"estudo sistematico" OR TI:review OR TI:revisao OR TI:revision))

DARE (Database of Abstracts of Reviews of Effectiveness) - Centre for Reviews and Dissemination, University of York
http://www.crd.york.ac.uk/CRDWeb/
NSCLC OR SCLC OR ((lung OR pulmonary OR bronch* OR alveol*) AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*)), in Any field: CRD assessed review (bibliographic)/ CRD assessed review (full abstract)

HTA Database
http://www.crd.york.ac.uk/CRDWeb/
NSCLC OR SCLC OR ((lung OR pulmonary OR bronch* OR alveol*) AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*)), in Any field

The Campbell Collaboration Online Library
https://www.campbellcollaboration.org/library.html
NSCLC OR SCLC OR ((lung OR pulmonary OR bronch* OR alveol*) AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*)), in Title: Review

JBI Database of Systematic Reviews and Implementation Reports
http://journals.lww.com/jbisrir/pages
NSCLC OR SCLC OR ((lung OR pulmonary OR bronch* OR alveol*) AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*)) AND (review OR meta*), in All fields

EPPI-Centre Evidence Library
http://eppi.ioe.ac.uk/cms/Default.aspx?tabid=56
NSCLC OR SCLC OR ((lung OR pulmonary OR bronch* OR alveol*) AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*)) All records in chronological list (http://eppi.ioe.ac.uk/cms/Default.aspx?tabid=62)

APÉNDICE 2. DIAGRAMA DE FLUJO PRISMA



APÉNDICE 3. REFERENCIAS SELECCIONADAS

1. Duan B, Xie J, Rui Q, Zhang W, Xi Z. Effects of Shengmai injection add-on therapy to chemotherapy in patients with non-small cell lung cancer: a meta-analysis. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2018;26(7):2103-2111.www.epistemonikos.org/documents/00222e08dc3e9e141b060c612fb1632df60bbdb3
2. Begum M., Horowitz J., Hossain M.I.. Low-dose risk assessment for arsenic: a meta-analysis approach. Asia-Pacific journal of public health / Asia-Pacific Academic Consortium for Public Health. 2015;27(2):NP20-NP35. www.epistemonikos.org/documents/002f9aea74b4647223fd1469761669c75e75539c
3. Sarah Burdett, Lesley Stewart, Larysa Rydzewska. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane database of systematic reviews (Online). 2007;(3):CD006157. www.epistemonikos.org/documents/00404419fc6c43f8db6b482e1a05869934ef58d4
4. Fang W., Qiu F., Zhang L., Deng J., Zhang H., Yang L., Zhou Y., Lu J.. The functional polymorphism of NBS1 p.Glu185Gln is associated with an increased risk of lung cancer in Chinese populations: Case-control and a meta-analysis. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis. 2014;770((Fang W.; Qiu F.; Zhang L.; Yang L.; Lu J., jcLu@gzhmu.edu.cn) The State Key Lab of Respiratory Disease, The Institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, Guangzhou, China):61-68. www.epistemonikos.org/documents/007d0b2db61fd1ad56ef63c4d030c1a636f47295
5. Fritz H, Kennedy D, Fergusson D, Fernandes R, Cooley K, Seely A, Sagar S, Wong R, Seely D. Selenium and lung cancer: a systematic review and meta analysis. PloS one. 2011;6(11):e26259. www.epistemonikos.org/documents/008712b27ca3fa4e5e9e010cc12413ec4c7f386a
6. Ren Z, Zhou S, Liu Z, Xu S. Randomized controlled trials of induction treatment and surgery versus combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: a systematic review and meta-analysis. Journal of thoracic disease. 2015;7(8):1414-22. www.epistemonikos.org/documents/00a7f5194746b96c6322487ceb393caf232a9581
7. Wang J, Qian J, Hoeksema MD, Zou Y, Espinosa AV, Rahman SM, Zhang B, Massion PP. Integrative genomics analysis identifies candidate drivers at 3q26-29 amplicon in squamous cell carcinoma of the lung. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013;19(20):5580-90.www.epistemonikos.org/documents/00ee9c8dd063c78417b4dfd995dd29b9b4a8ae31
8. da Silva GT, Bergmann A, Thuler LC. Prognostic factors in patients with metastatic spinal cord compression secondary to lung cancer: a systematic review of the literature. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 2015;24(10):2107-13. www.epistemonikos.org/documents/011f7fc2ead363fedbe41d6d3163fb5e4a2e951b
9. Ai B., Liu H., Huang Y., Peng P.. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer. Oncotarget. 2016;7(28):44583-44595.www.epistemonikos.org/documents/01389a0dcfb1005f1a6e916fe8a7a743ef34f224
10. Renée Manser, Gavin Wright, David Hart, Graham Byrnes, Don Campbell, Zoe Wainer, Sera Tort. Surgery for local and locally advanced non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2005;(1):CD004699. www.epistemonikos.org/documents/015cfaa122b74306c0dd02c3382fe5d399767d52
11. Zhao S, Jiang T, Zhang L, Yang H, Liu X, Jia Y, Zhou C. Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis. Oncotarget. 2016;7(24):36065-36073. www.epistemonikos.org/documents/0170bb2d33bdd8ce40a7b6b4463c6c9b59de7777
12. Barni S., Gregorc V., Cabiddu M., Ghilardi M., Borgonovo K., Coinu A., Cremonesi M., Vigano M.G., Petrelli F.. Activity of gefitinib and erlotinib in pretreated EGFR wild-type NSCLC patients: A pooled

analysis of 11 randomised trials. European Journal of Cancer. 2013;:S824-S825.www.epistemonikos.org/documents/018dad8194a63526def9bbc48b2ff6d3b5dc3474
13. Wang X, Yue K, Hao LR. CYP1A1 MspI polymorphism and susceptibility to lung cancer in the Chinese population: an updated meta-analysis and review. International journal of clinical and experimental medicine. 2015;8(8):11905-12. www.epistemonikos.org/documents/019c15fa8dea4a7f865e0a9325204499fc4b5f66
14. Sakamoto J, Teramukai S, Watanabe Y, Hayata Y, Okayasu T, Nakazato H, Ohashi Y, Japanese Meta-Analysis Group in Cancer; in: Japanese Society of Strategies for Cancer Research and Therapy. Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with resected non-small-cell lung cancer. Journal of immunotherapy (Hagerstown, Md. : 1997). 2001;24(3):250-6. www.epistemonikos.org/documents/0245b8a8cc6d4668a844fdec8722551557f4617e
15. Jiaying Y., He J., Yu M., Li T., Luo L., Liu P.. The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC). Medicine (United States). 2016;95(50):e5599.www.epistemonikos.org/documents/024b09b5adce337b6679065753ed2c84f0078464
16. Xiang T., Kang X., Gong Z., Bai W., Chen C., Zhang W.. XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies. Cancer Chemotherapy and Pharmacology. 2017;79(4):791-800.www.epistemonikos.org/documents/026035bdb279ca3926f0f36aaabc9ab8d881e8cc
17. Sun JY, Shi L, Gao XD, Xu SF. Physical activity and risk of lung cancer: a meta-analysis of prospective cohort studies. Asian Pacific journal of cancer prevention : APJCP. 2012;13(7):3143-7. www.epistemonikos.org/documents/0290ef42e11909a4db0f74c1900275ff94a2e10f
18. Huncharek M, Kupelnick B, Geschwind JF, Caubet JF. Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer letters. 2000;153(1-2):219-26. www.epistemonikos.org/documents/02a01ede4aa7f104a28b4fb976fdd4c7d1a3e7cc
19. Ji YN, Zhan P, Wang J, Qiu LX, Yu LK. APE1 Asp148Glu gene polymorphism and lung cancer risk: a meta-analysis. Molecular biology reports. 2011;38(7):4537-43.www.epistemonikos.org/documents/02be12d9ee7280a0f4788a45af7645ec30bfb7f1
20. Hallqvist A, Alverbratt C, Strandell A, Samuelsson O, Björkander E, Liljegren A, Albertsson P. Positron emission tomography and computed tomographic imaging (PET/CT) for dose planning purposes of thoracic radiation with curative intent in lung cancer patients: A systematic review and meta-analysis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2017;123(1):71-77. www.epistemonikos.org/documents/02c29a00ea8d2b1bbd07f41c0f366fa07d19e296
21. De Velasco G., Je Y., Bosse D., Awad M.M., Ott P.A., Moreira R.B., Schutz F., Bellmunt J., Sonpavde G.P., Hodi F.S., Choueiri T.K.. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunology Research. 2017;5(4):312-318.www.epistemonikos.org/documents/02ffe641061fd0207eae40c82c085804f5595da2
22. Gao XL, Zhang KW, Tang MB, Zhang KJ, Fang LN, Liu W. Pooled analysis for surgical treatment for isolated adrenal metastasis and non-small cell lung cancer. Interactive cardiovascular and thoracic surgery. 2017;24(1):1-7. www.epistemonikos.org/documents/030f399a0656c0d8bab819f11af137c97eb4ab50
23. Peng B, Wang YH, Huang Z, Feng SJ, Wang YS. Prognostic significance of osteopontin in patients with lung cancer: a meta-analysis. International journal of clinical and experimental medicine. 2014;7(12):4616-26. www.epistemonikos.org/documents/03441339a40c46d429da5ef5bd3169439e7fd669
24. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu da T, Zaatar A, Osorio Sanchez JA, Vu VV, Au JS, Inoue A, Lee SM, Gebski V, Yang JC. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. Journal of the

National Cancer Institute. 2013;105(9):595-605. www.epistemonikos.org/documents/034ae6f4adeaafb9350e8b1cde2edabcd67cd1aa
25. Shen ZT, Wu XH, Li B, Shen JS, Wang Z, Li J, Zhu XX. CYP2E1 Rsa I/Pst I polymorphism and lung cancer susceptibility: a meta-analysis involving 10,947 subjects. Journal of cellular and molecular medicine. 2015;19(9):2136-42. www.epistemonikos.org/documents/036d26a64d4876736fc06ac605ccffd99dc847a4
26. Yuan Y, Xu XY, Zheng HG, Hua BJ. Elevated miR-21 is associated with poor prognosis in non-small cell lung cancer: a systematic review and meta-analysis. European review for medical and pharmacological sciences. 2018;22(13):4166-4180. www.epistemonikos.org/documents/0371478217b16852c90a56557bde78770db3eed2
27. Hu B., Zhang H., Wei H., Wang Z., Zhang F., Wang X., Li L.. Does adenomatous polyposis coli gene promoter 1A methylation increase non-small cell lung cancer risk? A meta-analysis. Thoracic Cancer. 2017;8(5):410-416. www.epistemonikos.org/documents/03b4ae6b2eceeb14a434a0f245d7c6b9d30c46c7
28. Gu M, Dong X, Zhang X, Wang X, Qi Y, Yu J, Niu W. Strong association between two polymorphisms on 15q25.1 and lung cancer risk: a meta-analysis. PloS one. 2012;7(6):e37970. www.epistemonikos.org/documents/03daf4a51a444687f28ca5ba8ef776ca919213f8
29. Dugoua JJ, Wu P, Seely D, Eyawo O, Mills E. Astragalus-containing Chinese herbal combinations for advanced non-small-cell lung cancer: a meta-analysis of 65 clinical trials enrolling 4751 patients. Lung Cancer (Auckland, N.Z.). 2010;1:85-100. www.epistemonikos.org/documents/03f82718f3ede5fa34d67bdc6f4b1043f26a4d98
30. Zhang J., Wu J., He Q., Liang W., He J.. The prognostic value of metformin for advanced non-small cell lung cancer: A systematic review and meta-analysis. Translational Lung Cancer Research. 2018;7(3):389-396. www.epistemonikos.org/documents/041598fb0e4e0e480c913cd7da5cd607a2c3b5a1
31. Petrelli F, Borgonovo K, Cabiddu M, Barni S. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clinical lung cancer. 2012;13(2):107-14. www.epistemonikos.org/documents/043ff0ed88a19a85ac897e28026d30ba8d4dc0e2
32. Zaim R., Thunnissen E., Dingemans A.-M., Postmus P.E., Uyl-De Groot C.A.. Molecular screening in advanced non-small cell lung cancer: A systematic review of cost-effectiveness analyses for firstline therapy. Journal of Thoracic Oncology. 2013;:S604-S605.www.epistemonikos.org/documents/0451664915e22401b3a9cecec43ea4870b537614
33. Holdenrieder S, Wehnl B, Hettwer K, Simon K, Uhlig S, Dayyani F. Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis. British journal of cancer. 2017;116(8):1037-1045.www.epistemonikos.org/documents/04553eb0d263eaad8677f7c06d56d2f8d5716095
34. Burdett S, Stewart L, PORT Meta-analysis Group. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. Lung cancer (Amsterdam, Netherlands). 2005;47(1):81-3. www.epistemonikos.org/documents/04860656eb492afe75e20bc67496c54bd6411f05
35. Tun N.M., Soe A.M., Bo Z.M., Yoe L.M.L.. Does EGFR amplification have better predictability than EGFR mutation on response to erlotinib in patients with advanced non-small-cell lung cancer? A meta-analysis. Journal of Thoracic Oncology. 2012;:S214. www.epistemonikos.org/documents/049ec6a9fce209c5d1307be8a2e839d867506786
36. Soon YY, Vellayappan B, Tey JCS, Leong CN, Koh WY, Tham IWK. Impact of epidermal growth factor receptor sensitizing mutations on outcomes of patients with non-small cell lung cancer treated with definitive thoracic radiation therapy: a systematic review and meta-analysis. Oncotarget. 2017;8(65):109712-109722.www.epistemonikos.org/documents/04a2765b2d7621d7cc16ccc8ab7a94497e141dd4
37. Mao C, Yuan JQ, Yang ZY, Fu XH, Wu XY, Tang JL. Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A

Systematic Review and Meta-Analysis. Medicine. 2015;94(21):e775. www.epistemonikos.org/documents/04c7d2b276d42032eabd41e4b56ae7730d69afc6

38. Guo S, Gao M, Li X, Li Y, Chu S, Zhu D, Niu W. Lack of association between NADPH quinone oxidoreductase 1 (NQO1) gene C609T polymorphism and lung cancer: a case-control study and a meta-analysis. PloS one. 2012;7(10):e47939. www.epistemonikos.org/documents/04d1c8e2855e1c2546e7ea867e6bf0f6432f9ca4
39. Wei Y., Li Z., Mi D.-H.. Argon helium knife combined with radiotherapy or chemotherapy in treatment of advanced NSCLC: A meta analysis. Journal of Practical Oncology. 2015;30(2):133-139. www.epistemonikos.org/documents/051f9471d6a859052889fddc279ebb597482ec1b
40. Wang S, Wang X, Zhou Q, Xu Y, Xia W, Xu W, Ma Z, Qiu M, You R, Xu L, Yin R. Stereotactic ablative radiotherapy versus lobectomy for stage I non-small cell lung cancer: A systematic review. Thoracic cancer. 2018;9(3):337-347. www.epistemonikos.org/documents/052791445bc91068a276e0e7d898a531b845fbaa
41. Zheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, Chang A, Lv F, Orringer M, Spring Kong FM. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. International journal of radiation oncology, biology, physics. 2014;90(3):603-11.www.epistemonikos.org/documents/0544390aaf181b9db37032e4ebf4258198443989
42. Zhu W, Li G, Guo H, Chen H, Xu X, Long J, Zeng C, Wang X. Clinicopathological Significance of MTA 1 Expression in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis. Asian Pacific journal of cancer prevention : APJCP. 2017;18(11):2903-2909. www.epistemonikos.org/documents/0552728b768171454d71ba1d55e3fede71cb73c0
43. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2008;3(12):1468-81.www.epistemonikos.org/documents/0554118f2f6837e6c52ae13f0edc7f7c57a123af
44. Riemsma R, Simons JP, Bashir Z, Gooch CL, Kleijnen J. Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer. BMC cancer. 2010;10(no pagination):436. www.epistemonikos.org/documents/0573178b99f439b404972e32a6ebbd0384c2d4a4
45. Zhu M.-Z., Wu W.-Y.. Specialized TCM prescription integrated with chemotherapy in the treatment of stages III-IV non-small cell lung cancer: A meta analysis. Tumor. 2013;33(6):534-540+545. www.epistemonikos.org/documents/057f6e95164fc31dd904343fb89394625bb48d3b
46. Gamble J. Lung cancer and diesel exhaust: a critical review of the occupational epidemiology literature. Critical reviews in toxicology. 2010;40(3):189-244.www.epistemonikos.org/documents/0593c51fb95a7cfe9e164baf65367c93af58fe84
47. Chien CR, Liang JA, Chen JH, Wang HN, Lin CC, Chen CY, Wang PH, Kao CH, Yeh JJ. [(18)F]Fluorodeoxyglucose-positron emission tomography screening for lung cancer: a systematic review and meta-analysis. Cancer imaging : the official publication of the International Cancer Imaging Society. 2013;13(4):458-65.www.epistemonikos.org/documents/059ce3ae7d5b47309b28452fa614731e2b64b724
48. Cai YX, Fu XN, Xu QZ, Sun W, Zhang N. Thoracoscopic lobectomy versus open lobectomy in stage I non-small cell lung cancer: a meta-analysis. PloS one. 2013;8(12):e82366. www.epistemonikos.org/documents/05a84205c42a1b2390769b180f435b7ffc980d55
49. Pérez-Moreno MA, Galván-Banqueri M, Flores-Moreno S, Villalba-Moreno A, Cotrina-Luque J, Bautista-Paloma FJ. Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer. International journal of clinical pharmacy. 2014;36(3):476-87.www.epistemonikos.org/documents/05ba2a4fa93617376a2884201c89e30ba9bda8a6
50. Liao S.G., Liu L., Zhang Y.Y., Wang Y., Wang Y.J.. SULT1A1 Arg213His polymorphism and lung cancer risk: a meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2012;13(2):579-583. www.epistemonikos.org/documents/05c75a573005d2edba97b2ec5499c2a5a099dd9f

51. Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA, Velcheti V. Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A Systematic Review and Meta-analysis of trials. Chest. 2017;152(2):271-281.www.epistemonikos.org/documents/05d41e38e963634c33826920595f38e57bf5b94a
52. Maturu VN, Singh N, Bansal P, Rai Mittal B, Gupta N, Behera D, Gupta A. Combination of intravitreal bevacizumab and systemic therapy for choroidal metastases from lung cancer: report of two cases and a systematic review of literature. Medical oncology (Northwood, London, England). 2014;31(4):901.www.epistemonikos.org/documents/05e2a7649246182865ed86b0392959e9bd6e9236
53. Zhang J, Yu XL, Zheng GF, Zhao F. DAPK promoter methylation status correlates with tumor metastasis and poor prognosis in patients with non-small cell lung cancer. Cancer biomarkers : section A of Disease markers. 2015;15(5):609-17. www.epistemonikos.org/documents/05f46d9234b5227c91bd46fb3334affc45fd3009
54. Huo W, Du M, Pan X, Zhu X, Li Z. Prognostic value of ALDH1 expression in lung cancer: a meta-analysis. International journal of clinical and experimental medicine. 2015;8(2):2045-51. www.epistemonikos.org/documents/068a6061ef1111c89ada3b89f27e04652d090f21
55. Zhao F., Xu M., Lei H., Zhou Z., Wang L., Li P., Zhao J., Hu P.. Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: A meta-analysis. PLoS ONE. 2015;10(2):e0117333. www.epistemonikos.org/documents/06c0745cf24646cab282d0ded83b7c84d54f33af
56. Micames CG, McCrory DC, Pavey DA, Jowell PS, Gress FG. Endoscopic Ultrasound-Guided Fine-Needle Aspiration for Non-small Cell Lung Cancer Staging: A Systematic Review and Metaanalysis. Chest. 2007;131(2):539-48. www.epistemonikos.org/documents/06f4a0c33e8f94a458eb39ac134f3da601de16e9
57. Turner E.J., Mccloud P., Germanos P., Dehle F., Norris S., Tan J., Mitchell P.L.. Meta-analysis of progression-free survival and objective response rate as predictors of overall survival in locally advanced or metastatic non-small-cell lung cancer. Journal of Thoracic Oncology. 2013;:S243-S244.www.epistemonikos.org/documents/07033ab6419de1a235042ab38b26c0b6f28f6f76
58. Na F, Wang J, Li C, Deng L, Xue J, Lu Y. Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014;9(6):834-42. www.epistemonikos.org/documents/0714f99c6ffd58a0e3c5a38aae33e56029a5953f
59. Ni J, Qiu LJ, Hu LF, Cen H, Zhang M, Wen PF, Wang XS, Pan HF, Ye DQ. Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis. Lupus. 2014;23(3):284-92. www.epistemonikos.org/documents/071a3841489bc904664c0e4146a937f5f71ea3b6
60. Zhang Y., Sun Y., Wang R., Ye T., Zhang Y., Chen H.. Meta-analysis of lobectomy, segmentectomy, and wedge resection for stage i non-small cell lung cancer. Journal of Surgical Oncology. 2015;111(3):334-340. www.epistemonikos.org/documents/072eab27af672365824b5c905a5fc3147096e532
61. Taghizadeh Kermani A, Bagheri R, Tehranian S, Shojaee P, Sadeghi R, N Krag D. Accuracy of sentinel node biopsy in the staging of non-small cell lung carcinomas: systematic review and meta-analysis of the literature. Lung cancer (Amsterdam, Netherlands). 2013;80(1):5-14.www.epistemonikos.org/documents/074262389d4c66c042ad7552c94fc72e793418ca
62. Zhao F., Sun Y.-G., Li J., Ge P.-F., Wang W.. Metastatic rate of lymph nodes in clinical stage i non-small-cell lung cancer patients with mixed ground-glass opacity versus pure ground-glass opacity: A systematic review and meta-analysis. International Journal of Clinical and Experimental Medicine. 2016;9(11):20968-20975.www.epistemonikos.org/documents/074d55a05aadccf769a475417ec8210314f5e04d

63. Zhou H, Zeng C, Wei Y, Zhou J, Yao W. Duration of chemotherapy for small cell lung cancer: a meta-analysis. PloS one. 2013;8(8):e73805.www.epistemonikos.org/documents/076c35a623fa6babe33d80084b6ac87d25cb4404
64. Fang X, Wei J, He X, Lian J, Han D, An P, Zhou T, Liu S, Wang F, Min J. Quantitative association between body mass index and the risk of cancer: A global meta-analysis of prospective cohort studies. International journal of cancer. 2018; www.epistemonikos.org/documents/076e7c19f5f9af743b309193a35fb68b3885f3db
65. Zhang XL, Zhang XJ, Zhang YM, Zhang Q, Cao CX, Gu DY, Gong YL, Chen JF, Tang CJ. Decreased risk of developing lung cancer in subjects carrying the CLPTM1L rs401681 (G>A) polymorphism: evidence from a meta-analysis. Genetics and molecular research : GMR. 2014;13(1):1373-82.www.epistemonikos.org/documents/07726db0a9f481f841c265e4687f76f020e0bdf4
66. Harrison J.P., Goncalves T., Kim H.. Systemic treatments in advanced non-small cell lung cancer (NSCLC): A systematic review. Asia-Pacific Journal of Clinical Oncology. 2014;:158. www.epistemonikos.org/documents/0786fa9ad03c5f64082ee73810a72bbe15b130a4
67. Piccirillo MC, Daniele G, Di Maio M, Bryce J, De Feo G, Del Giudice A, Perrone F, Morabito A. Vinorelbine for non-small cell lung cancer. Expert opinion on drug safety. 2010;9(3):493-510. www.epistemonikos.org/documents/07a3f0e81972d9dadf66ff5905f74d46ad38a7c2
68. Yang, Fengming, Qin, Zhiqiang, Shao, Chuchu, Liu, Weitao, Ma, Ling, Shu, Yongqian, Shen, Hua. Association between VEGF Gene Polymorphisms and the Susceptibility to Lung Cancer: An Updated Meta-Analysis. BioMed Research International. 2018;2018:1-16.www.epistemonikos.org/documents/07a96edde5bad00eea2a5fb202db281842030b65
69. Li S.-J., Huang J., Zhang W.-B., Fan J., Che G.-W.. Prognostic value of Ezrin expression in non-small cell lung cancer: A systematic review and meta-analysis. International Journal of Clinical and Experimental Medicine. 2016;9(7):13664-13676. www.epistemonikos.org/documents/07f08cb00c4102ae4554c2430c6e2cc01423a561
70. Fan J, Wang L, Jiang GN, He WX, Ding JA. The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. Lung cancer (Amsterdam, Netherlands). 2008;61(1):91-6. www.epistemonikos.org/documents/07f30bdbba22de90e58ac06827f6158ac8a33c0e
71. Aydiner, A, Can, G. Third-generation drugs in the chemoradiation of stage III non-small cell lung cancer (NSCLC): A meta-analysis of efficacy and toxicity parameters. Journal of Clinical Oncology. 2009;27:7536-7536. www.epistemonikos.org/documents/07fd46366f266102ae4634e3082a83b1e75b30d5
72. Zhang J, Zhang W, Huang S, Li H, Li Y, Chen H, Wu W, Zhou W, Wang C, Liao H, Gu L. Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. Experimental and therapeutic medicine. 2012;4(5):849-858.www.epistemonikos.org/documents/082238e7ef27036ff81c740e7c9d612441ec3765
73. Pujol JL, Molinier O, Ebert W, Daurès JP, Barlesi F, Buccheri G, Paesmans M, Quoix E, Moro-Sibilot D, Szturmowicz M, Bréchot JM, Muley T, Grenier J. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. British journal of cancer. 2004;90(11):2097-105.www.epistemonikos.org/documents/0838a928251820150ac95799698fdcea84dc7efa
74. Zhang J., Wang S., Wang L., Wang R., Chen S., Pan B., Sun Y., Chen H.. Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review. OncoTargets and Therapy. 2015;8:3361-3369. www.epistemonikos.org/documents/083b54b312bcaeb3e4d432bb8c6ae860f744eb89
75. Zhang J, Zeng XT, Lei JR, Tang YJ, Yang J. No association between XRCC1 gene Arg194Trp polymorphism and risk of lung cancer: evidence based on an updated cumulative meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(6):5629-35.www.epistemonikos.org/documents/0864a5bd4e234206dae250ee8cc897bab130acda

76. Ding P.N., Lord S., Links M., Bray V., Gebski V., Yang J.C., Lee C.K.. Toxicity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of advanced non-small cell lung cancer (NSCLC): A meta-analysis. Journal of Thoracic Oncology. 2013;:S593.www.epistemonikos.org/documents/08793d3b26412a9d2f3b53484f6c71d6273be242
77. Shah AA, Berry MF, Tzao C, Gandhi M, Worni M, Pietrobon R, D'Amico TA. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. The Annals of thoracic surgery. 2012;93(6):1807-12. www.epistemonikos.org/documents/08855f39717814acb68e8e0b7608c46c3906f952
78. Sun H, Qiao Y, Zhang X, Xu L, Jia X, Sun D, Shen C, Liu A, Zhao Y, Jin Y, Yu Y, Bai J, Fu S. XRCC3 Thr241Met polymorphism with lung cancer and bladder cancer: a meta-analysis. Cancer science. 2010;101(8):1777-82. www.epistemonikos.org/documents/08f7015bffd9724a17e31543e3f06e6d1ae54d4b
79. Edwards S.J., Welton N., Borrill J.. Tolerability of first-line treatments of locally advanced or metastatic non-small-cell lung cancer (NSCLC): A systematic review and adjusted indirect comparison. Value in Health. 2010;:A250. www.epistemonikos.org/documents/091a2bc901dcaae6b1bbec7e2e57f355a2255496
80. Bepler G, Goodridge Carney D, Djulbegovic B, Clark RA, Tockman M. A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest. Cancer control : journal of the Moffitt Cancer Center. 2003;10(4):306-14.www.epistemonikos.org/documents/091e44c60da0f9b93970d7437f76e4432113b45a
81. Xu F, Ren X, Chen Y, Li Q, Li R, Chen Y, Xia S. Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis. BMC cancer. 2018;18(1):808. www.epistemonikos.org/documents/0923273810b2f5fb02eafd9595eac913870b74fe
82. Wang, Yang, Gao, Wen, Xu, Jiali, Chen, Xiaojun, Yang, Yang, Zhu, Yizhi, Yin, Yongmei, Guo, Renhua, Liu, Ping, Shu, Yongqian, Liu, Lingxiang. The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data. BioMed Research International. 2015;2015(no pagination):1-10.www.epistemonikos.org/documents/09317e2e6270fd15b0ffc169f65f1f52eac49a89
83. Hou L.-C., Huang F., Xu H.-B.. Does celecoxib improve the efficacy of chemotherapy for advanced non-small cell lung cancer?. British Journal of Clinical Pharmacology. 2016;81(1):23-32. www.epistemonikos.org/documents/093db89ef62e7f9a9282e4d1f10589a1f53bea9c
84. Yang H, Ma Y, Liu Z, Wang Z, Han B, Ma L. Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis. Molecular and clinical oncology. 2015;3(2):420-424.www.epistemonikos.org/documents/09464852d9f9dab4d92324b8c758d1773b462020
85. Madsen PH, Holdgaard PC, Christensen JB, Høilund-Carlsen PF. Clinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer. European journal of nuclear medicine and molecular imaging. 2016;43(11):2084-97. www.epistemonikos.org/documents/095a0f9ffdd92e56d431db998343d30cfaff2fb9
86. Qiu H., Wang F., Guo G., Zhou F., He W., Xia L.. Non-platinum doublets versus single agents in non-small cell lung cancer (NSCLC) patients with elderly age and/or poor performance status: A meta-analysis. Chinese-German Journal of Clinical Oncology. 2011;10(3):134-139.www.epistemonikos.org/documents/097df6f4fed05d786d1afebbd4779c908101ebec
87. Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, Chung JK, Kim EE, Lee DS. Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis. European journal of nuclear medicine and molecular imaging. 2015;42(2):241-51.www.epistemonikos.org/documents/09abab5f57ab79903127cedd1ab757772af84402
88. Rosa, Bruno Rodrigues, Peccin, Maria Stella, Lisboa, Sandra, Silva, Brenda Nazaré Gomes da, Vital, Flávia Maria Ribeiro. Preoperative physiotherapeutic intervention for patients undergo resection for lung cancer: systematic review. Fisioter. mov. 2013;26(3):677-688.www.epistemonikos.org/documents/09ea32ea776ec0af5055dc4c15e8f665a7d264c0

89. Nair VS, Krupitskaya Y, Gould MK. Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009;4(12):1473-9.www.epistemonikos.org/documents/0a5823dbcc5e262542b70b01c246a1c81466ca83
90. Santoni M, Conti A, Andrikou K, Bittoni A, Lanese A, Pistelli M, Pantano F, Vincenzi B, Armento G, Massari F, Tonini G, Cascinu S, Santini D. Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. Critical reviews in oncology/hematology. 2015;96(2):206-19.www.epistemonikos.org/documents/0a6b14f3ede16082697303042db6c7b34968cb8c
91. Wang J, Wang B, Chen X, Bi J. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcinogenesis. 2011;32(3):411-6. www.epistemonikos.org/documents/0a78f84c1904984a12bdc71bef5a1ede10160e6d
92. Kowalewski M., Lewandowska M.A., Kowalewski J.. Different measures to prevent atrial fibrillation in patients undergoing pulmonary resection for lung cancer: Evidence from a comprehensive network meta-analysis of randomized and observational studies. Interactive Cardiovascular and Thoracic Surgery. 2014;:S32.www.epistemonikos.org/documents/0a82d5fb1d866aa78e62861f77239175cd067579
93. Feng X, Qin JJ, Zheng BS, Huang LL, Xie XY, Zhou HF. Association of epidermal growth factor receptor (EGFR) gene polymorphism with lung cancer risk: a systematic review. Journal of receptor and signal transduction research. 2014;34(5):333-4. www.epistemonikos.org/documents/0a8dc184ac10fc8616dd8b6d7a214dd98a32dad2
94. Zhou C, Luo Q, Qing Y, Lin X, Zhan Y, Ouyang M. Association between MPO 463G>A polymorphism and risk of lung cancer: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(6):3449-55.www.epistemonikos.org/documents/0ab7b9f4d59b50539938606d840a2d80368d5f79
95. Lu JJ, Guo H, Gao B, Zhang Y, Lin QL, Shi J, Liu JJ, Liu J. Prognostic value of urokinase plasminogen activator system in non-small cell lung cancer: A systematic review and meta-analysis. Molecular and clinical oncology. 2018;8(1):127-132. www.epistemonikos.org/documents/0ab7faa9e846555d8644b60fa4233937b75bdffe
96. Ikeda M, Ochibe T, Tohkin M. Possible Causes of Failing to Meet Primary Endpoints: A Systematic Review of Randomized Controlled Phase 3 Clinical Trials in Patients With Non-Small Cell Lung Cancer. Therapeutic innovation & regulatory science. 2019;53(3):2168479018791135.www.epistemonikos.org/documents/0ae1c5fe2185764584ed7ea2b942b095c299800d
97. Li A, Wei ZJ, Ding H, Tang HS, Zhou HX, Yao X, Feng SQ. Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials. Oncotarget. 2017;8(34):57365-57378. www.epistemonikos.org/documents/0ae3468b36ad6338d2225cafc990c300ef0ca1cc
98. Ma H., Zhou J.-G., Bai Y.-J., Zhang Y., Wang F., Wang Y., Lu S.-P.. Anemia of erlotinib for advanced non-small cell lung cancer: A Meta analysis of randomized controlled trials. Chinese Journal of Cancer Prevention and Treatment. 2016;23(1):49-55. www.epistemonikos.org/documents/0ae5ddb9dd6f8f22eb7abbb21113dc4f89730e6f
99. Chen W, Gao X, Tian Q, Chen L. A comparison of autofluorescence bronchoscopy and white light bronchoscopy in detection of lung cancer and preneoplastic lesions: a meta-analysis. Lung cancer (Amsterdam, Netherlands). 2011;73(2):183-8. www.epistemonikos.org/documents/0afb7b4a1c3d0feaf6e422a3f0983a2dd89f5b4a
100. Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991;9(3):499-508. www.epistemonikos.org/documents/0b0dfd14d2a7fd982d15f53df2ec591b478c36c6

101. Fritz H., Kennedy D., Fernandes R., Seely D.. Vitamin D and lung cancer: A systematic review. Journal of the Society for Integrative Oncology. 2010;:205.www.epistemonikos.org/documents/0b14406d36d696fabc03dd629ff2aa1732aa3327
102. Dammeijer F, Lievense LA, Veerman GD, Hoogsteden HC, Hegmans JP, Arends LR, Aerts JG. The Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(26):3204-3212.www.epistemonikos.org/documents/0b48fe1409c6486be0f5444411ef5da55f5048b0
103. Yamanaka, T, Yamamoto, N, Seto, T, Takahashi, T, Murakami, H, Tsuya, A, Naito, T, Kaira, K, Nakamura, Y, Ichinose, Y. Can meta-analysis suggest carboplatin/paclitaxel as a reference arm in randomized trials of first-line chemotherapy for advanced non-small cell lung cancer?. Journal of Clinical Oncology. 2009;27:19039-19039.www.epistemonikos.org/documents/0b4cc51a8efe56b9b818e6d121c036d16b4d720e
104. Raymakers A.J.N., McCormick N., Marra C.A., Fitzgerald J., Sin D., Lam S., Lynd L.D.. The use of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) patients and risk of lung cancer: A systematic review. American Journal of Respiratory and Critical Care Medicine. 2012;www.epistemonikos.org/documents/0bc2d635d4971614ac9b373cbe20e2facbad8d6e
105. Talebi S.S., Badfar G., Shohani M., Soleymani A., Azami M.. The relationship between selenium and lung cancer: An updated systematic review and meta-analysis. International Journal of Cancer Management. 2018;11(6). www.epistemonikos.org/documents/0c095852ccfe3f7d5ddaff179ce222f3d0721df7
106. Yang Y.-L., Yang M., Bai G., Zhang L.. Efficacy of erlotinib versus chemotherapy in the second-line therapy of advanced non-small cell lung cancer: A Meta-analysis. 中华肿瘤防治杂志 (Chinese Journal of Cancer Prevention and Treatment). 2015;22(8):637-643.www.epistemonikos.org/documents/0c0da87c6087c4b1a8b2a7165634c60ec56bda2b
107. Zhang W, Wei Y, Yu D, Xu J, Peng J. Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis. BMC cancer. 2018;18(1):780. www.epistemonikos.org/documents/0c455d07cfd967fb7bb33323ddbff32b10cb3248
108. Wang Y, Wang M, Wang Q, Geng Z, Sun M. Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2017;8(17):29406-29415. www.epistemonikos.org/documents/0c7fc104605c4339f17b6c36b942e4224a1a4370
109. Takeda M, Okamoto I, Nakagawa K. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2015;88(1):74-9. www.epistemonikos.org/documents/0c9db3945b5a3220200162be7aabbabd330ffcef
110. Chida M, Kobayashi S, Karube Y, Hayama M, Tamura M, Ishihama H, Oyaizu T. Incidence of acute exacerbation of interstitial pneumonia in operated lung cancer: institutional report and review. Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia. 2012;18(4):314-7.www.epistemonikos.org/documents/0cafee92536e0e54dba62562d48b00df09d26c6c
111. Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, Imaizumi M, Wada H. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(22):4999-5006.www.epistemonikos.org/documents/0cbe9375597ce91d9abaa22c625b7cccb04356eb
112. Lu Z, Chen Y, Jing X, Hu C. Diagnostic accuracy of MALDI-TOF Mass Spectrometry for non-small cell lung cancer: a meta-analysis. Biomarkers : biochemical indicators of exposure,

response, and susceptibility to chemicals. 2018;:1-21. www.epistemonikos.org/documents/0cc84d139d38424f11ea22125e7062ab9a0b261a

113. Rai M.K., Goyal R., Bhutani M.K., Kaneria J., Mahendru K., Sharma N.. Efficacy and safety profile of combined targeted therapy against EGFR and VEGF in patients with previously treated advanced non-small-cell lung cancer: A systematic review and meta-analysis. Value in Health. 2015;:A430.www.epistemonikos.org/documents/0cca229034431f8f5c9ad28be5b1da8350dbacf2
114. Zhong D, Li G, Long J, Wu J, Hu Y. The hOGG1Ser326Cys polymorphism and increased lung cancer susceptibility in Caucasians: an updated meta-analysis. Scientific reports. 2012;2:548. www.epistemonikos.org/documents/0ce4028dd0ac91d08122f501c89f493ae1592daf
115. Feng X, Zhou HF, Zheng BS, Shi JJ, Luo C, Qin JJ. Association of glutathione S-transferase P1 gene polymorphism with the histological types of lung cancer: a meta-analysis. Molecular biology reports. 2013;40(3):2439-47. www.epistemonikos.org/documents/0d0728536e7e530e8cfacb28f3b144b4eccf0a0f
116. Xue R, Yang C, Zhao F, Li D. Prognostic significance of CDH13 hypermethylation and mRNA in NSCLC. OncoTargets and therapy. 2014;7:1987-96.www.epistemonikos.org/documents/0d096a433362fbe74487e0c9bd1afdaa21bc79bc
117. Amelung JT, Bührens R, Beshay M, Reymond MA. Key genes in lung cancer translational research: a meta-analysis. Pathobiology : journal of immunopathology, molecular and cellular biology. 2010;77(2):53-63. www.epistemonikos.org/documents/0d16d4571573c154faad55cfe69df1d65740ebc2
118. Zhao XD, He YY, Gao J, Zhao C, Zhang LL, Tian JY, Chen HL. High expression of Bcl-2 protein predicts favorable outcome in non-small cell lung cancer: evidence from a systematic review and meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2014;15(20):8861-9.www.epistemonikos.org/documents/0d31b4cc5098841079bff319e8ce799ab20e0253
119. Hao TT, Xie YM, Liao X, Wang J. [Systematic review and Meta-analysis of Shenqi Fuzheng injection combined with first-line chemotherapy for non-small cell lung cancer]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. 2015;40(20):4094-107.www.epistemonikos.org/documents/0d72802f8fcb2aaf7ad297a5792e1da5c5423d0b
120. Yan X, Zhu H, Wang H, Wang Q, Li P, Ma Z. [The role of adjuvant chemotherapy in operable non-small cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2011;14(3):281-5. www.epistemonikos.org/documents/0d8e323c0d3437fed4f8375f30c9e513dc128a94
121. Zou Q, Zhan P, Lv T, Song Y. The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis. Translational lung cancer research. 2015;4(6):792-6.www.epistemonikos.org/documents/0d9adc0a96e0730622e95cb4f02ab006a4306941
122. Udall M, Rizzo M, Kenny J, Doherty J, Dahm S, Robbins P, Faulkner E. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagnostic pathology. 2018;13(1):12. www.epistemonikos.org/documents/0d9dc7dde9e31755ba6f58ce60b03733d34a0a7c
123. Cho E, Hunter DJ, Spiegelman D, Albanes D, Beeson WL, van den Brandt PA, Colditz GA, Feskanich D, Folsom AR, Fraser GE, Freudenheim JL, Giovannucci E, Goldbohm RA, Graham S, Miller AB, Rohan TE, Sellers TA, Virtamo J, Willett WC, Smith-Warner SA. Intakes of vitamins A, C and E and folate and multivitamins and lung cancer: a pooled analysis of 8 prospective studies. International journal of cancer. 2006;118(4):970-8. www.epistemonikos.org/documents/0daf5668785e3cbb6c52b24d5edcad2dbc59138a
124. Yang Y, Luo J, Zhai X, Fu Z, Tang Z, Liu L, Chen M, Zhu Y. Prognostic value of phospho-Akt in patients with non-small cell lung carcinoma: a meta-analysis. International journal of cancer. Journal international du cancer. 2014;135(6):1417-24. www.epistemonikos.org/documents/0dbdd81b9c45d3481b12d3a9064d69539bc76300

125. Geerse OP, Stegmann ME, Kerstjens HAM, Hiltermann TJN, Bakitas M, Zimmermann C, Deal AM, Brandenbarg D, Berger MY, Berendsen AJ. Effects of shared decision making on distress and healthcare utilization among patients with lung cancer: a systematic review. Journal of pain and symptom management. 2018;56(6):975-975.www.epistemonikos.org/documents/0dc32c350eda14b39d72176f338fd22d76688c80
126. Wu N., Xu B., Li Y.. Association between helicobacter pylori infection and lung cancer: A meta-analysis. Cancer Research. 2013;www.epistemonikos.org/documents/0dd76cb574ac8ab92fcc7aae85f9085832f84509
127. Deng Z, Zhang S, Yi L, Chen S. Can statins reduce risk of lung cancer, especially among elderly people? A meta-analysis. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. 2013;25(6):679-88. www.epistemonikos.org/documents/0dd7923612b1b5192e8dcf044886784d155b7598
128. Xiao Z., Wang C., Sun Y., Li N., Li J., Chen L., Yao X., Ding J., Ma H.. Can Aidi injection restore cellular immunity and improve clinical efficacy in non-small-cell lung cancer patients treated with platinum-based chemotherapy? A meta-analysis of 17 randomized controlled trials following the PRISMA guidelines. Medicine. 2016;95(44):e5210.www.epistemonikos.org/documents/0de5e0d2c67eb4da9ba0eeecd77dcbd9ed6f0328
129. Stevens R, Macbeth F, Toy E, Coles B, Lester JF. Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2015;1(1):CD002143. www.epistemonikos.org/documents/0de9b842369af6a20f018c5afceb73195a19ee58
130. Bruce N, Dherani M, Liu R, Hosgood HD, Sapkota A, Smith KR, Straif K, Lan Q, Pope D. Does household use of biomass fuel cause lung cancer? A systematic review and evaluation of the evidence for the GBD 2010 study. Thorax. 2015;70(5):433-41. www.epistemonikos.org/documents/0e39205ef96310f8d826bbd92e83c72ba35a8d9b
131. Petrelli F, Lazzari C, Ardito R, Borgonovo K, Bulotta A, Conti B, Cabiddu M, Capitanio JF, Brighenti M, Ghilardi M, Gianni L, Barni S, Gregorc V. Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies. PloS one. 2018;13(7):e0201425.www.epistemonikos.org/documents/0e46302cc8636268ffead734a18809b0105403a8
132. Horita N, Miyazawa N, Morita S, Kojima R, Kimura N, Kaneko T, Ishigatsubo Y. Preoperative chemotherapy is effective for stage III resectable non--small-cell lung cancer: metaanalysis of 16 trials. Clinical lung cancer. 2013;14(5):488-94. www.epistemonikos.org/documents/0e495ed6b62fac314916fcc63d035f2293c37e40
133. Huang G, Sun X, Liu D, Zhang Y, Zhang B, Xiao G, Li X, Gao X, Hu C, Wang M, Ren H, Qin S. The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis. Oncotarget. 2018;9(3):4239-4248. www.epistemonikos.org/documents/0e4c2f0b4d03ca35a81bddd489c8e5009fa22150
134. Tong S., Fan K., Jiang K., Zhai W., Fang B., Wang S.-H., Wang J.-J.. Increased risk of severe infections in non-small-cell lung cancer patients treated with pemetrexed: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion. 2017;33(1):1-7.www.epistemonikos.org/documents/0e5ee28121476f70dc6331135bf5fac855f80af6
135. Bottomley A, Efficace F, Thomas R, Vanvoorden V, Ahmedzai SH, Coordinator, Quality of Life Unit, European Organization for Research and Treatment of Cancer Data Center, Aveune E. Mounier 83/11, 1200 Brussels, Belgium, abo@eortc.be. Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials. Journal of Clinical Oncology. 2003;21(15):2982-2992. www.epistemonikos.org/documents/0e7dd976f528c89b5d4b3d825d5722189b9bb2af
136. Lacasse Y, Martin S, Gagné D, Lakhal L. Dose-response meta-analysis of silica and lung cancer. Cancer causes & control : CCC. 2009;20(6):925-33.www.epistemonikos.org/documents/0e939e6a8a03c6a730570b339036e0868a6a37e1

137. Guo L., Liu S., Zhang S., Chen Q., Zhang M., Quan P., Lu J., Sun X.. [A meta-analysis of body mass index and the risk of lung cancer in the Chinese population]. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. 2015;49(7):649-653. www.epistemonikos.org/documents/0ead664bcacaf17b7aba24b819d21550afcad7c2
138. Wu H, Qi XW, Yan GN, Zhang QB, Xu C, Bian XW. Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis. PloS one. 2014;9(6):e100168. www.epistemonikos.org/documents/0ec33aabae56220a6a2448601e0336ce03655661
139. Liu B., Zhao Y., Yuan J., Zeng L., Sun R., Meng X., Yang S.. Elevated N-telopeptide as a potential diagnostic marker for bone metastasis in lung cancer: A meta-analysis. PLoS ONE. 2017;12(11):e0187860. www.epistemonikos.org/documents/0ecaa20f111d343cca735f1b795a33b97fa135f6
140. Ma L., Zhao M.-J., XIU-LIN Wang Q.L., Wang X.-G.. P53, FHIT, K-RAS gene mutations are associated with smoking in non-small cell lung cancer by meta-analysis. Respirology. 2011;:133-136. www.epistemonikos.org/documents/0ed47d27195bb79e4f3a2afc0cb2752e22606c1e
141. Korevaar DA, Colella S, Spijker R, Bossuyt PM, Konge L, Clementsen PF, Annema JT. Esophageal Endosonography for the Diagnosis of Intrapulmonary Tumors: A Systematic Review and Meta-Analysis. Respiration; international review of thoracic diseases. 2017;93(2):126-137.www.epistemonikos.org/documents/0f12aa1d7f9d06404ad975d60d2a4154f1f742c6
142. Gong W, Zhang X, Wu J, Chen L, Li L, Sun J, Lv Y, Wei X, Du Y, Jin H, Dong J. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung cancer (Amsterdam, Netherlands). 2012;75(3):374-80.www.epistemonikos.org/documents/0f22c6bffb343a3018cb4b07899b94bf02507471
143. He YQ, Gong HL, Deng YF, Li WM. Diagnostic efficacy of PET and PET/CT for recurrent lung cancer: a meta-analysis. Acta radiologica (Stockholm, Sweden : 1987). 2014;55(3):309-17. www.epistemonikos.org/documents/0f235d53216ef3c46e5033a930a834cf985f06ae
144. Zhang X, Zhang Y, Tang H, He J. EGFR gene copy number as a predictive/biomarker for patients with non-small-cell lung cancer receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2017;65(1):72-81.www.epistemonikos.org/documents/0f470573c0c1953096cb2544bc6275052483db67
145. Huang K., Rodrigues G., Yaremko B.P., Yu E., Dar R., Palma D.A.. Stereotactic ablative radiation therapy (SABR) and pulmonary re-irradiation: A systematic review of the literature assessing safety and oncologic outcomes. International Journal of Radiation Oncology Biology Physics. 2014;90(1):S633.www.epistemonikos.org/documents/0f49d10498e087067dc69949f769eddcd80d80ec
146. Schulkes KJ, Hamaker ME, van den Bos F, van Elden LJ. Relevance of a Geriatric Assessment for Elderly Patients With Lung Cancer-A Systematic Review. Clinical lung cancer. 2016;17(5):341-341. www.epistemonikos.org/documents/0f59134510f18fb4908934d23c8e20d254cacafd
147. Guo J, Ma B, Zhou H, Wang Y, Zhang Y. [Gefitinib for non-small cell lung cancer: a meta analysis]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2011;14(4):351-7.www.epistemonikos.org/documents/0faad7dbaffcfe468f80bde48adfae4e57078e11
148. Yang SL, Ren QG, Wen L, Hu JL. Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban. 2016;36(3):321-327. www.epistemonikos.org/documents/0fb22ba86b981b9bc64a1005660791008e44f60f
149. Wang L, Wang R, Pan Y, Sun Y, Zhang J, Chen H. The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high

thymidylate synthase expression: a meta-analysis. BMC cancer. 2014;14(1):205.www.epistemonikos.org/documents/0fd708d4efa418803f3cc68d43cd59ab1c2c2d71

150. Hamada C, Tsuboi M, Ohta M, Fujimura S, Kodama K, Imaizumi M, Wada H. Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009;4(12):1511-6. www.epistemonikos.org/documents/0ff265de9e3c47caa2be527474bf9eb694d5d51f
151. De Mello RA, Escriu C, Castelo-Branco P, Cabral PL, Mountzios G, Lopes GL, Madureira P. Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. Oncotarget. 2018;9(14):11805-11815.www.epistemonikos.org/documents/0ff437dd6db60d455e0706c788044a9d4dff4558
152. Zhou YX, Yang ZM, Feng J, Shan YJ, Wang WL, Mei YQ. High plasma D-dimer level is associated with decreased survival in patients with lung cancer: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(6):3701-4.www.epistemonikos.org/documents/1009b02abedda4fa4447b39d9422e674f498d275
153. Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. Journal of cancer research and clinical oncology. 2009;135(11):1483-93.www.epistemonikos.org/documents/102ebd2585a7564abcb841792d108d1ee5aea0de
154. Tan PS, Bilger M, de Lima Lopes G, Acharyya S, Haaland B. Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populations. Cancer medicine. 2017;6(8):1847-1860.www.epistemonikos.org/documents/104fa0cb6073bae458dbcdc7203626ad9b6e1be0
155. Cao C, Wang J, Bunjhoo H, Xu Y, Fang H. Risk profile of bevacizumab in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials. Acta oncologica (Stockholm, Sweden). 2012;51(2):151-6. www.epistemonikos.org/documents/106a7aaba0d5d603425bcbbaa4ed63dd37816066
156. Bayly J, Wakefield D, Hepgul N, Wilcock A, Higginson IJ, Maddocks M. Changing health behaviour with rehabilitation in thoracic cancer: a systematic review and synthesis. Psycho-oncology. 2018;27(7):1675-1694. www.epistemonikos.org/documents/1078575244b5f74424aea3bb425e5330ae7005cb
157. Kim KI, Jun JH, Baek H, Kim JH, Lee BJ, Jung HJ. Oral administration of herbal medicines for radiation pneumonitis in lung cancer patients: A systematic review and meta-analysis. PloS one. 2018;13(5):e0198015. www.epistemonikos.org/documents/10965fdedd5fb008db7555c2d9dd90eafe7692b3
158. Jin Y, Sun Y, Shi X, Zhao J, Shi L, Yu X. Prognostic value of circulating C-reactive protein levels in patients with non-small cell lung cancer: a systematic review with meta-analysis. Journal of cancer research and therapeutics. 2014;10 Suppl(7):C160-6. www.epistemonikos.org/documents/109eb78cefd4dcb9574094cd7ca386e68f9e8100
159. Liu Q., Wang H., Zhou D., Deng X., Min J., Dai J.. Comparison of clinical outcomes after thoracoscopic sublobectomy versus lobectomy for Stage i nonsmall cell lung cancer: A meta-analysis. Journal of Cancer Research and Therapeutics. 2016;12(2):926-931. www.epistemonikos.org/documents/10a5e78ae343476bec97dcdbf247b252fc3460ae
160. Tan Q, Huang J, Ding Z, Lin H, Lu S, Luo Q. Meta-analysis for curative effect of lobectomy and segmentectomy on non-small cell lung cancer. International journal of clinical and experimental medicine. 2014;7(9):2599-604. www.epistemonikos.org/documents/10c7df03a6045e37dd9e9fcf17b3e9ef171f0ea7

161. Westwood M, Joore M, Whiting P, van Asselt T, Ramaekers B, Armstrong N, Misso K, Severens J, Kleijnen J. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. Health technology assessment (Winchester, England). 2014;18(32):1-166. www.epistemonikos.org/documents/10ccae4b22b4c16c57c69f2ceb739b150a239c15
162. Fan F., Zhu Z., Gao C., Liu Y., Wang B., Wang Z., Feng J.. Prognostic value of lncRNAs in lung carcinoma: A meta-analysis. Oncotarget. 2017;8(47):83292-83305.www.epistemonikos.org/documents/10e7a43cb2c3d7d9e488d2ac59babc8f961e278c
163. Zhou XM, He L, Hou G, Jiang B, Wang YH, Zhao L. Clinicopathological significance of CXCR4 in non-small cell lung cancer. Drug design, development and therapy. 2015;9:1349-58. www.epistemonikos.org/documents/10e7be054946061ac1f37d81c8831323e3bfbb63
164. Meng D, Yuan M, Li X, Chen L, Yang J, Zhao X, Ma W, Xin J. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung cancer (Amsterdam, Netherlands). 2013;81(1):1-10. www.epistemonikos.org/documents/10fbe70a3bb76f2bb123d135fe575545d7f04249
165. Fischer BM, Mortensen J, Højgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. The lancet oncology. 2001;2(11):659-66. www.epistemonikos.org/documents/11115ead006160e400bd8abd7b300a621ba77ef7
166. Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, Souhami RL, Stephens RJ, Stewart LA, Tierney JF, Tribodet H, van Meerbeeck J. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267-77. www.epistemonikos.org/documents/1126a14a24d229cd93a9069432c55afab172a0b7
167. Leschinger M.I., Helsberg K., Langer F., Schuette W.H.-W.. Gemcitabine in first-line therapy of locally advanced and/or metastatic non-small cell lung cancer (NSCLC): Review of the results of randomized phase III studies. Onkologie. 2005;28(SUPPL. 1):1-28. www.epistemonikos.org/documents/11281e4890f63b70a80ec27b865deb1a3b8f352e
168. Fan J, Wang L, Jiang GN, Gao W. Sublobectomy versus lobectomy for stage I non-small-cell lung cancer, a meta-analysis of published studies. Annals of surgical oncology. 2012;19(2):661-8. www.epistemonikos.org/documents/11286194293787d5667dbfa9ddc737d5253424c1
169. Enstone A, Greaney M, Povsic M, Wyn R, Penrod JR, Yuan Y. The Economic Burden of Small Cell Lung Cancer: A Systematic Review of the Literature. PharmacoEconomics - open. 2018;2(2):125-139. www.epistemonikos.org/documents/114763589c7ae949c7ba52443e0db7158120bdc2
170. Biaoxue R, Hua L, Wenlong G, Shuanying Y. Increased serum amyloid A as potential diagnostic marker for lung cancer: a meta-analysis based on nine studies. BMC cancer. 2016;16(1):836. www.epistemonikos.org/documents/115a549950cd18afaf3cbbc927ca9dcdb7ad9082
171. Jeremic B, Bamberg M. External beam radiation therapy for bronchial stump recurrence of non-small-cell lung cancer after complete resection. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2002;64(3):251-7.www.epistemonikos.org/documents/117bbcaad8d5692380f32d5f7f85c30953cf5c66
172. Wang J, Li K, Wang B, Bi J. Lymphatic microvessel density as a prognostic factor in non-small cell lung carcinoma: a meta-analysis of the literature. Molecular biology reports. 2012;39(5):5331-8. www.epistemonikos.org/documents/119dbdcf1b1280faeab12823000ff9e5f062dfb6
173. Kiyohara C, Takayama K, Nakanishi Y. Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung cancer (Amsterdam, Netherlands). 2006;54(3):267-83. www.epistemonikos.org/documents/11d3f12ebfd54897ce1b4f1224c92d9cf61174f1

174. Luo H., Liu R., Chen C., Chen X., Zhu Y., Xiang R.. The efficacy and safety of Afatinib in the treatment of advanced non-small cell lung cancer harbouring EGFR mutations: A systematic review. Anti-Tumor Pharmacy. 2015;5(6):466-471. www.epistemonikos.org/documents/11db83a011be800aefeb14127375dd7d45df9ecf
175. Liu J, Liao Q, Zhang Y, Sun S, Zhong C, Liu X. Cyclin D1 G870A polymorphism and lung cancer risk: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33(5):1467-76. www.epistemonikos.org/documents/11e35384e912a74f2ecd1abfdb7fbe3c3889a718
176. Huang X., Sun Q., Chen C., Zhang Y., Kang X., Zhang J.-Y., Ma D.-W., Xia L., Xu L., Xu X.-Y., Ren B.-H.. MUC1 overexpression predicts worse survival in patients with non-small cell lung cancer: Evidence from an updated meta-analysis. Oncotarget. 2017;8(52):90315-90326.www.epistemonikos.org/documents/11e4669e398a0b3fdbbe5291bdff1ba0b0816633
177. Wang F, Wang LD, Li B, Sheng ZX. Gefitinib compared with systemic chemotherapy as first-line treatment for chemotherapy-naive patients with advanced non-small cell lung cancer: a meta-analysis of randomised controlled trials. Clinical oncology (Royal College of Radiologists (Great Britain)). 2012;24(6):396-401.www.epistemonikos.org/documents/120a6c4e9202e1534c8522ddef16ae7d3493fc6e
178. Wang S, Zhu J, Zhang R, Wang S, Gu Z. Association between microsomal epoxide hydrolase 1 T113C polymorphism and susceptibility to lung cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(2):1045-52.www.epistemonikos.org/documents/12132c497c46558f366f26b088adfcf50efb3bea
179. Shi X, Zhou S, Wang Z, Zhou Z, Wang Z. CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. Lung cancer (Amsterdam, Netherlands). 2008;59(2):155-63. www.epistemonikos.org/documents/1215e853d3d78a2ae63cac692c38f9b41c4fc432
180. Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, Bradley JD, Kim TH, Ramella S, Marks LB, De Petris L, Stitt L, Rodrigues G. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. International journal of radiation oncology, biology, physics. 2013;85(2):444-50. www.epistemonikos.org/documents/12243d24aa1c57dfdbb273096a4b511c2463e487
181. Li X., Tan J., Jiang S., Wahg K.. Role of let-7 and HMGA2 in occurrence and development of lung cancer: Meta-analysis. Journal of Jilin University Medicine Edition. 2016;42(6):1116-1125. www.epistemonikos.org/documents/126d6d9d2dab9b3206b2a67c65ad32d5c8f52d0d
182. Palma DA, Warner A, Louie AV, Senan S, Slotman B, Rodrigues GB. Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis. Clinical lung cancer. 2016;17(4):239-44. www.epistemonikos.org/documents/12930b1ea62969e5af3f47a04e46b3c711f5f0b2
183. Neuberger J.S., Harley N.H., Kross B.C.. Residential radon exposure and lung cancer: Potential for pooled or meta-analysis. Journal of Clean Technology, Environmental Toxicology and Occupational Medicine. 1996;5(3):207-221. www.epistemonikos.org/documents/12c0261a68abb362f19beb68a92ed8966654fbc4
184. Forrest LF, Sowden S, Rubin G, White M, Adams J. Socio-economic inequalities in stage at diagnosis, and in time intervals on the lung cancer pathway from first symptom to treatment: systematic review and meta-analysis. Thorax. 2017;72(5):430-436. www.epistemonikos.org/documents/12d0da08f47fc145556037efe5049af6e1db3364
185. D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(13):2926-36.www.epistemonikos.org/documents/12d20ffda961623934b800724a6621a1d122b921
186. Li B., Huang X., Fu L.. Impact of smoking on efficacy of PD-1/PD-l1 inhibitors in non-small cell lung cancer patients: A meta-analysis. OncoTargets and Therapy. 2018;11:3691-3696. www.epistemonikos.org/documents/12dfd1b9566496e2d88ed6bd16394d3e3b572c84

187. Wei HB, Lu XS, Shang LH, Xu G, Hu J, Che DH, Liu F, Wu Y, Zhang GM, Yu Y. Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Archives of medical research. 2011;42(5):412-20.www.epistemonikos.org/documents/12edf56d1d1ff51ae5140b5f32835be09cc565cd
188. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2004;15(12):1782-9.www.epistemonikos.org/documents/12fe3685016be68593fbc8caac09324697012712
189. Cui Z, Yin Z, Li X, Wu W, Guan P, Zhou B. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis. BMC cancer. 2012;12(no pagination):71. www.epistemonikos.org/documents/1318c47f20949454629efa508c8e112cead65b48
190. Wang J, Welch K, Wang L, Kong FM. Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis. Clinical lung cancer. 2012;13(2):81-9. www.epistemonikos.org/documents/1324961eb009943a9398ac23a452e2eb82b2107a
191. Deng H.-Y., Qin C.-L., Li G., Alai G., Lin Y., Qiu X.-M., Zhou Q.. Can lobe-specific lymph node dissection be an alternative to systematic lymph node dissection in treating early-stage non-small cell lung cancer: A comprehensive systematic review and meta-analysis?. Journal of Thoracic Disease. 2018;10(5):2857-2865.www.epistemonikos.org/documents/132c074eb054e682e4e936a45d636cb47ac0bd3c
192. Dovell F, Boffetta P. Serum uric acid and cancer mortality and incidence: a systematic review and meta-analysis. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP). 2018;27(4):399-405. www.epistemonikos.org/documents/13310608af10ea1e0399f785583e5a1ceda1b7ad
193. He X, Wang J, Li Y. Efficacy and safety of docetaxel for advanced non-small-cell lung cancer: a meta-analysis of Phase III randomized controlled trials. OncoTargets and therapy. 2015;8:2023-31. www.epistemonikos.org/documents/133eaf857ace982b4d2acbf293f20a0c4836fb11
194. Liu Y., Xing Z., Zhan P., Liu H., Ye W., Lv T., Song Y.. Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer? A meta-analysis. Medicine (United States). 2016;95(47):e5115. www.epistemonikos.org/documents/135fd7f065bac23f0bc60127c2f86c392006b910
195. Zheng X., Reddy R., Schipper M., Ren Y., Chang A., Lin J., Orringer M., Kong F.. Comparisons of local control and survival of stereotactic body radiation therapy versus surgery for stage I non-small cell lung cancer: A meta-analysis. Journal of Thoracic Oncology. 2012;:S213-S214.www.epistemonikos.org/documents/137f2127e26fb6d48f55407d7414bd70f606143b
196. Guha N, Merletti F, Steenland NK, Altieri A, Cogliano V, Straif K. Lung cancer risk in painters: a meta-analysis. Environmental health perspectives. 2010;118(3):303-12.www.epistemonikos.org/documents/138ea054e8880ca1ec92930eaf128b0b1285e0b9
197. Hartwell D, Jones J, Loveman E, Harris P, Clegg A, Bird A. Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation. Cancer treatment reviews. 2011;37(3):242-9. www.epistemonikos.org/documents/13be8088a3397defb8e894d29bd0fff050161664
198. Li C, Lu HJ, Na FF, Deng L, Xue JX, Wang JW, Wang YQ, Li QL, Lu Y. Prognostic role of hypoxic inducible factor expression in non-small cell lung cancer: a meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2013;14(6):3607-12. www.epistemonikos.org/documents/13d56a3d922a1272401e632ad597fb34e0742bbf
199. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, Chan JK, Owens DK. Test performance of positron emission tomography and computed tomography for

mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Annals of internal medicine. 2003;139(11):879-92.www.epistemonikos.org/documents/13dcdeb453c0381dc8822793f52fafa21be47ccf

200. Chao C. Associations between beer, wine, and liquor consumption and lung cancer risk: a meta-analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007;16(11):2436-47.www.epistemonikos.org/documents/13e5a946e08c74f0820cf90362b12f01aba6b4fa

201. Zhang, L.-P., Wang, C.-P., Li, L.-H., Tang, Y.-F., Li, W.-C.. The interaction between smoking and CYP1A1 MspI polymorphism on lung cancer: a meta-analysis in the Chinese population. European Journal of Cancer Care. 2017;26(5). www.epistemonikos.org/documents/13f92621e63aabde0dc586411dfad7d52bb62759

202. Wang M., Ma X., Zhu C., Guo L., Li Q., Liu M., Zhang J.. The prognostic value of long non coding RNAs in non small cell lung cancer: A meta-analysis. Oncotarget. 2016;7(49):81292-81304. www.epistemonikos.org/documents/13f94f44ac92f9d951c0b8c3221eeae9d2d53fc1

203. Tabatabaei SV, Nitche C, Michel M, Rasche K, Hekmat K. Prognostic Impact of Extracapsular Lymph Node Invasion on Survival in Non-small-Cell Lung Cancer: A Systematic Review and Meta-analysis. Advances in experimental medicine and biology. 2018;1116:27-36.www.epistemonikos.org/documents/13fbcaa0e3abe1993ee7cd4445fdf581b01fad98

204. Zhang Z, Zhang Y, Feng H, Yao Z, Teng J, Wei D, Liu D. Is video-assisted thoracic surgery lobectomy better than thoracotomy for early-stage non-small-cell lung cancer? A systematic review and meta-analysis. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2013;44(3):407-14. www.epistemonikos.org/documents/13fe390196023f6488ec1a33f0f57531c0a15108

205. Bai L., Guo C., Wu H., Kaye A.D., Jin C., Deng L., Wang J., Guo Y., Duan X.. The prognostic value of C-X-C chemokine receptor 4 in non-small cell lung cancer: A meta-analysis. International Journal of Clinical and Experimental Medicine. 2017;10(2):2285-2295.www.epistemonikos.org/documents/140d32c7955893224e7f5a75558423805be4675b

206. Lin H, Jiang J, Liang X, Zhou X, Huang R. Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung cancer (Amsterdam, Netherlands). 2010;70(1):57-62. www.epistemonikos.org/documents/1433a33f3b7feaa0c81e3b1487d62d54d19d8445

207. Hawkins N, Scott DA, Woods BS, Thatcher N. No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2009;12(6):996-1003.www.epistemonikos.org/documents/143f1a8ad2f06057463b24c84b8bd0fef1b5bd3b

208. Li Y, Zhu M, Zhang X, Cheng D, Ma X. Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis. Drug design, development and therapy. 2015;9:1785-96. www.epistemonikos.org/documents/144ab4505c1b1e93aea886495cc7a25cfc845bbd

209. Liu J, Dong Y, Lu C, Wang Y, Peng L, Jiang M, Tang Y, Zhao Q. Meta-analysis of the correlation between vitamin D and lung cancer risk and outcomes. Oncotarget. 2017;8(46):81040-81051. www.epistemonikos.org/documents/14658e5be8073bd9e1bc6f639632e19a4ac28a3f

210. Qiao L., Wang J., Long G., Jiang Y.. Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: A meta-analysis of randomized controlled clinical trials. OncoTargets and Therapy. 2017;10:1279-1284.www.epistemonikos.org/documents/148097b03beb21c38861d8b7087ffc67c58b8637

211. Cao F.F., Zhang L.L., Wang S., Zhong D., Wang Y.. Effectiveness of EGFR-TKIs versus chemotherapy as first-line treatment for advanced non-small cell lung cancer: A meta-analysis. Chinese Journal of Lung Cancer. 2015;18(3):146-154. www.epistemonikos.org/documents/14869efc7dbd5ce527469504f5e0e92990581cb1

212. Pöttgen C, Eberhardt W, Stamatis G, Stuschke M. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence. Oncotarget. 2017;8(25):41670-41678.www.epistemonikos.org/documents/1493776f2dd683a860154ba51b556097b5d25b90
213. Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM, Gebbia V, Smit EF, Morabito A, Gallo C, Perrone F, Gridelli C. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(11):1836-43. www.epistemonikos.org/documents/149932dae4d954e48b7b8229cc0bc77daebfb81c
214. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D, Rosell R, CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. Journal of the National Cancer Institute. 2007;99(11):847-57. www.epistemonikos.org/documents/14a2275d80676b81bbf548633e392f2ce3248051
215. Liu T, Wu H, Zhuang X, Lu D, Cai R, Wang W. [A meta-analysis of platinum plus docetaxel or vinorelbine in the first-line treatment of advanced non-small cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2014;17(4):327-35. www.epistemonikos.org/documents/14af92cf463457bcb061cd303fa08b14c40f48ca
216. Lacasse Y, Martin S, Simard S, Desmeules M. Meta-analysis of silicosis and lung cancer. Scandinavian journal of work, environment & health. 2005;31(6):450-8.www.epistemonikos.org/documents/14b66b116d366fd4e0dcfbad2d0e8c58a3fba252
217. Chapman A.M., Sun K.Y., Ruestow P., Cowan D.M., Madl A.K.. Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. Lung Cancer. 2016;102:122-134. www.epistemonikos.org/documents/14c8967adfcf5befd8665e1a22a10f463a48e1cf
218. Benbrahim Z, Antonia T, Mellas N. EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis. BMC cancer. 2018;18(1):891. www.epistemonikos.org/documents/14ceff1b404f2bd7173a0ccc058991a7644a39c8
219. Wakai K, Inoue M, Mizoue T, Tanaka K, Tsuji I, Nagata C, Tsugane S, Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan. Tobacco smoking and lung cancer risk: an evaluation based on a systematic review of epidemiological evidence among the Japanese population. Japanese journal of clinical oncology. 2006;36(5):309-24. www.epistemonikos.org/documents/14d71b598e9826998fe3220338cdc18ca3df7487
220. Qie S, Li Y, Shi HY, Yuan L, Su L, Zhang X. Stereotactic radiosurgery (SRS) alone versus whole brain radiotherapy plus SRS in patients with 1 to 4 brain metastases from non-small cell lung cancer stratified by the graded prognostic assessment: A meta-analysis (PRISMA) of randomized control trials. Medicine. 2018;97(33):e11777.www.epistemonikos.org/documents/14ee9edc994802a9188bf0c5ea03a9ca5134e092
221. Zhou ZJ, Zhan P, Song Y. PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Translational lung cancer research. 2015;4(2):203-8. www.epistemonikos.org/documents/14f6a0aa12ae3fa5067ebe5749b3c3ab09c312fe
222. Zhao H, Gu J, Xu H, Yang B, Han Y, Li L, Liu S, Yao H. [Meta-analysis of the relationship between passive smoking population in China and lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2010;13(6):617-23. www.epistemonikos.org/documents/153486e313c59e727822b2001463a504c3bb4638
223. Burdett S., Stewart L., Auperin A., Pignon J.P.. Chemotherapy in non-small-cell lung cancer: an update of an individual patient data meta-analysis. Journal of clinical oncology : official

journal of the American Society of Clinical Oncology. 2005;23(4):924-925; author reply 925-926.www.epistemonikos.org/documents/158186a866e4f2d6d742e7d8b4e7f250d8fc2039

224. Goss G, Paszat L, Newman TE, Evans WK, Browman G. Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Cancer prevention & control : CPC = Prévention & contrôle en cancérologie : PCC. 1998;2(1):32-9.www.epistemonikos.org/documents/159935e400c15676a99fcca5154545cb3e476c73

225. Singh N, Aggarwal AN, Gupta D, Behera D, Jindal SK. Quantified smoking status and non-small cell lung cancer stage at presentation: analysis of a North Indian cohort and a systematic review of literature. Journal of thoracic disease. 2012;4(5):474-84. www.epistemonikos.org/documents/15b61e0b9dcc95382cad3fe352f857313531b3e9

226. Burdett S., Rydzewska L.H., Tierney J.F., Pignon J.-P.. Pre-operative chemotherapy improves survival and reduces recurrence in operable non-small cell lung cancer: Preliminary results of a systematic review and metaanalysis of individual patient data from 13 randomised trials. Journal of Thoracic Oncology. 2011;:S374-S375.www.epistemonikos.org/documents/15d58dd0fc82b44ce0155062835257d63707c893

227. Wang Y, Yang H, Li H, Li L, Wang H, Liu C, Zheng Y. Association between X-ray repair cross complementing group 1 codon 399 and 194 polymorphisms and lung cancer risk: a meta-analysis. Cancer letters. 2009;285(2):134-40. www.epistemonikos.org/documents/15d9505bf46b7362f022da2ac7dc5b9d2f4a01c0

228. Gu XB, Tian T, Tian XJ, Zhang XJ. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Scientific reports. 2015;5:12493.www.epistemonikos.org/documents/15e662bc30e5c3d253a726cfae267f9bb959d5f0

229. Sekine I, Minna JD, Nishio K, Tamura T, Saijo N. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006;1(1):31-7.www.epistemonikos.org/documents/15fef3d88507b6266a232bdaca4aab25c9c986c8

230. Wang X., Wang H., Li L.. A meta-Analysis of elemene versus DDP intrapleural injection in the treatment of malignant pleural effusion caused by lung cancer. Journal of Cancer Research and Therapeutics. 2016;12(8):C244-C247. www.epistemonikos.org/documents/161b8171c6cd17ec5ec74c0b4c990bc8e6b79ba9

231. McCaughan GJ, Blinman PL, Boyer MJ, Stockler MR. Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancer. Internal medicine journal. 2013;43(4):424-9. www.epistemonikos.org/documents/162f37afa7c0031be84d2b56e0683ce13fe17d36

232. Yang W., Yao Y.-W., Zeng J.-L., Liang W.-J., Wang L., Bai C.-Q., Liu C.-H., Song Y.. Prognostic value of FGFR1 gene copy number in patients with non-small cell lung cancer: a meta-analysis. Journal of Thoracic Disease. 2014;6(6):803-809. www.epistemonikos.org/documents/16371f831e09c0823656b432d100ea40036c43e7

233. Zeng J., Li J., Bao M., Long Y., Li G., Luo Y.. Association between CYP2D6 polymorphisms and lung cancer risk: An up-date meta-analysis. International Journal of Clinical and Experimental Medicine. 2017;10(3):4508-4517. www.epistemonikos.org/documents/1694321389959a01a27d05bc23eaf43df0ab3f9b

234. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561-71. www.epistemonikos.org/documents/16b01639185ce12a71d0b53e210453f46c2080a6

235. Wang M, Qin S, Zhang T, Song X, Zhang S. The effect of fruit and vegetable intake on the development of lung cancer: a meta-analysis of 32 publications and 20,414 cases. European

journal of clinical nutrition. 2015;69(11):1184-92. www.epistemonikos.org/documents/16b9370d88b44f756f7c4ad8a9b510bcf6da4b53

236. Lu J.-J., Guo H., Gao B., Zhang Y., Lin Q.-L., Shi J., Liu J.-J., Liu J.. Prognostic value of urokinase plasminogen activator system in non-small cell lung cancer: A systematic review and meta-analysis. Molecular and Clinical Oncology. 2018;8(1):127-132. www.epistemonikos.org/documents/16de15ecfef5a75e910244ea5da641ca4cebd139
237. Marchevsky A.M., Gupta R.. The prognostic significance of isolated tumor cells and micrometastases in patients with non-small cell carcinoma of the lung: Systematic review of current best evidence with meta-analysis. Laboratory Investigation. 2009;:357A. www.epistemonikos.org/documents/16e43dbd00eacf62337f120aa355ff5a12eecda8
238. Chen J, Chen YJ, Wu MD. Herbal extract elemene intrathoracic injection in the treatment of lung cancer patients with malignant pleural effusion: a meta-anaylsis. Journal of cancer research and therapeutics. 2014;10 Suppl 1(5):56-9. www.epistemonikos.org/documents/17019c280fc4bf3bccbda13018cb2199563136f5
239. Berghmans T, Paesmans M, Mascaux C, Martin B, Meert AP, Haller A, Lafitte JJ, Sculier JP. Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2006;17(11):1673-6.www.epistemonikos.org/documents/17031a9c431cd455dd960824d7cd5f6dcd54d67d
240. Wen SW, Han L, Lv HL, Xu YZ, Li ZH, Wang MB, Zhu YG, Su P, Tian ZQ, Zhang YF. A Propensity-Matched Analysis of Outcomes of Patients with Clinical Stage I Non-Small Cell Lung Cancer Treated surgically or with stereotactic radiotherapy: A Meta-Analysis. Journal of investigative surgery : the official journal of the Academy of Surgical Research. 2019;32(1):1-8. www.epistemonikos.org/documents/17164e8ed17f2c1de568c274ff5f3a1cb9a2a98a
241. Treadwell JR, Mitchell MD, Tsou A, Torigian D, Aggarwal C, Schoelles KM. Imaging for the Pretreatment Staging of Small Cell Lung Cancer. AHRQ Comparative Effectiveness Reviews. 2016; www.epistemonikos.org/documents/173a3b49bf32661fb66ff93aaa6facb1eafd76ca
242. Liu ZL, Wang Q, Huang LN. E-cadherin gene methylation in lung cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(9):9027-33. www.epistemonikos.org/documents/1753d7fe052e0990c7b8eb9b08d89b1945c67774
243. Yu S., Xu Q., Yuan Y., Li X., Cai H.. Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials. Current Medical Research and Opinion. 2016;32(12):1-8. www.epistemonikos.org/documents/17b563b7b585695305ea98de418860366461fce7
244. Xing ZS, Zhu G, Yang YL, Feng GQ, Ding GC. Meta analysis of XRCC3 Thr241Met polymorphism and lung cancer susceptibility of populations in East Asia. Asian Pacific journal of tropical medicine. 2014;7(6):483-7. www.epistemonikos.org/documents/17bda96841fcf6ffae3d81ba75190dce08e1169c
245. Blumenthal GM, Zhang L, Zhang H, Kazandjian D, Khozin S, Tang S, Goldberg K, Sridhara R, Keegan P, Pazdur R. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis. JAMA oncology. 2017;3(8):e171029.www.epistemonikos.org/documents/17c5e91cd6e7212ae92b80d6b8de70a4a553e4bd
246. Yuan DM, Wei SZ, Lü YL, Zhang Y, Miao XH, Zhan P, Yu LK, Shi Y, Song Y. Single-agent maintenance therapy in non-small cell lung cancer: a systematic review and meta-analysis. Chinese medical journal. 2012;125(17):3143-9. www.epistemonikos.org/documents/17ddbbf1e73c51151430da80b166f873178f1754
247. Ma WH, Duan KN, Feng M, She B, Chen Y, Zhang RM. [Aidi Injection as an adjunct therapy for non-small cell lung cancer: a systematic review]. Zhong xi yi jie he xue bao = Journal of Chinese

integrative medicine. 2009;7(4):315-24. www.epistemonikos.org/documents/17e1c004014e7dca4307de36726c7ffaca46db21

248. Savina M, Gourgou S, Italiano A, Dinart D, Rondeau V, Penel N, Mathoulin-Pelissier S, Bellera C. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review. Critical reviews in oncology/hematology. 2018;123:21-41.www.epistemonikos.org/documents/17e868542a6e5cc22c3107c64c74338273249a34

249. Popat S, Mok T, Yang JC, Wu YL, Lungershausen J, Stammberger U, Griebsch I, Fonseca T, Paz-Ares L. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis. Lung cancer (Amsterdam, Netherlands). 2014;85(2):230-8. www.epistemonikos.org/documents/17e9379e8059fd1fbe225912a022646c149ec5b7

250. Wang F., Li H., Long J., Ye S.. Clinicopathological significance of p14ARF expression in lung cancer: A meta-analysis. OncoTargets and Therapy. 2017;10:2491-2499.www.epistemonikos.org/documents/1804a089283341250ac06f676c96598015aa5a73

251. Yan L, Zhang D, Chen C, Mao Y, Xie Y, Li Y, Huang Y, Han B. TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis. International journal of cancer. 2009;125(12):2903-11. www.epistemonikos.org/documents/1826567f233ed4e4285b09413392b9c503d9fb58

252. Wang Y., Li F., Wang Z., Qiu T., Shen Y., Wang M.. Fruit and vegetable consumption and risk of lung cancer: A dose-response meta-analysis of prospective cohort studies. Lung Cancer. 2015;88((Wang Y.; Li F.; Wang Z.; Qiu T.; Shen Y.; Wang M., qdwangmz1966@163.com) Department of Thoracic Surgery, The Affiliated Hospital of Medical College of Qingdao University, Jiangsu Road, No. 19, Qingdao 266001, Shandong, PR China):124-30.www.epistemonikos.org/documents/1832dadd3ad1ac95fa570525ebc5602373affb05

253. Wang X, Xu Y, Tang W, Liu L. Efficacy and Safety of Radiotherapy Plus EGFR-TKIs in NSCLC Patients with Brain Metastases: A Meta-Analysis of Published Data. Translational oncology. 2018;11(5):1119-1127. www.epistemonikos.org/documents/1851ae62ac3c3b32f7bbd14f8c5a3e6647244989

254. Wei HB, Hu J, Shang LH, Zhang YY, Lu FF, Wei M, Yu Y. A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer. Chinese medical journal. 2012;125(16):2902-7. www.epistemonikos.org/documents/1858342079e1a8fc083455e8fa495096258c52c2

255. Zhang L, Gao S. Robot-assisted thoracic surgery versus open thoracic surgery for lung cancer: a system review and meta-analysis. International journal of clinical and experimental medicine. 2015;8(10):17804-10. www.epistemonikos.org/documents/18a2a9dadf87e51d35f1e96597d1452a2192bb20

256. Jäkel A, Plested M, Dharamshi K, Modha R, Bridge S, Johns A. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer. Applied health economics and health policy. 2013;11(1):27-43. www.epistemonikos.org/documents/18a49eee398934a06bde323e1cb190b7ba54fd46

257. Paramanandam V.S., Dunn V.. Role of exercise for the management of cancer-related fatigue in lung cancer: Systematic review. Lung Cancer. 2013;:S52-S53.www.epistemonikos.org/documents/18c7508d0d5a7a79596badb5ea1e824911a892d2

258. Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, Yang ZY, Mao C, Tang JL. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993. www.epistemonikos.org/documents/18e8c21b1b4616fee33c7b3785c9fcc026f1435a

259. Zhao S, Qiu Z, He J, Li L, Li W. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis. International journal of clinical and experimental pathology. 2014;7(10):6694-704. www.epistemonikos.org/documents/18ef3697ab7924e790f2b458678a071719424d32

260. Zhu Q, Zhan P, Zhang X, Lv T, Song Y. Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis. Translational lung cancer

research. 2015;4(3):300-9. www.epistemonikos.org/documents/18f9099de2b1a037f6d2fdb59553a5254c5cf51f

261. Gu AQ, Wang WM, Chen WY, Shi CL, Lu JH, Han JQ. XRCC1 genetic polymorphisms and sensitivity to platinum-based drugs in non-small cell lung cancer: an update meta-analysis based on 4708 subjects. International journal of clinical and experimental medicine. 2015;8(1):145-54.www.epistemonikos.org/documents/1904a249c14040fbb3cb27efd837fea5f8c9cb12

262. Kurmi OP, Arya PH, Lam KB, Sorahan T, Ayres JG. Lung cancer risk and solid fuel smoke exposure: a systematic review and meta-analysis. The European respiratory journal. 2012;40(5):1228-37. www.epistemonikos.org/documents/19123a09cc3cce6c4de0a908416fd1aae856ff5e

263. Chen S, Flower A, Ritchie A, Liu J, Molassiotis A, Yu H, Lewith G. Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: A systematic review. Lung cancer (Amsterdam, Netherlands). 2010;68(2):137-45.www.epistemonikos.org/documents/19194059a92664c2147f3a603860697e2212d921

264. Wang S, Wang Z. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer. International immunopharmacology. 2015;28(1):22-8. www.epistemonikos.org/documents/193ee72c9fdf0e26336b3035ae0dededfb5bd110

265. El-Osta H, Jani P, Mansour A, Rascoe P, Jafri S. Endobronchial Ultrasound for Nodal Staging of Non-Small Cell Lung Cancer Patients with Radiologically Normal Mediastinum: A Meta-Analysis. Annals of the American Thoracic Society. 2018;15(7):864-874. www.epistemonikos.org/documents/19609e3a986c31086e0e540638daba0357722095

266. Zhang W, Wei Y, Jiang H, Xu J, Yu D. Video-Assisted Thoracoscopic Surgery Versus Thoracotomy Lymph Node Dissection in Clinical Stage I Lung Cancer: A Meta-Analysis and System Review. The Annals of thoracic surgery. 2016;101(6):2417-24. www.epistemonikos.org/documents/196f9e4637c49971f456db879fea63d78f5a181b

267. Fairchild A, Harris K, Barnes E, Wong R, Lutz S, Bezjak A, Cheung P, Chow E. Palliative thoracic radiotherapy for lung cancer: a systematic review. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(24):4001-11. www.epistemonikos.org/documents/197372b46201961d28375d1b86036e61aed9efda

268. Guetz G.D., Landre T., Uzzan B., Chouahnia K., Nicolas P., Morere J.-F.. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis. Targeted Oncology. 2016;11(1):41-47.www.epistemonikos.org/documents/19963154e6da73ea7fa6ae3c30c0aa60e95ef6e4

269. LeVasseur N., Clemons M., Hutton B., Shorr R., Jacobs C.. Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials. Cancer Treatment Reviews. 2016;50:183-193. www.epistemonikos.org/documents/19a33c089037953ac349767577db57e048a7b709

270. Petrelli F, Borgonovo K, Cabiddu M, Barni S. Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials. Anti-cancer drugs. 2011;22(10):1010-9. www.epistemonikos.org/documents/19e7c4dcb757b3a6504419395a9474a459c26bd6

271. Xiao YY, Zhan P, Yuan DM, Liu HB, Lv TF, Song Y, Shi Y. Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials. European journal of clinical pharmacology. 2013;69(2):151-9.www.epistemonikos.org/documents/1a013fe6f547945bff2e8e25a90456d78ddcbf8f

272. Zhao B, Zhang W, Yu D, Xu J, Wei Y. Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(68):113105-113119. www.epistemonikos.org/documents/1a646dda6ee7de1862b79cbeab77969823065174

273. Yu Y, Liu H, Zheng S, Ding Z, Chen Z, Jin W, Wang L, Wang Z, Fei Y, Zhang S, Ying K, Zhang R. Gender susceptibility for cigarette smoking-attributable lung cancer: a systematic review and meta-analysis. Lung cancer (Amsterdam, Netherlands). 2014;85(3):351-60.www.epistemonikos.org/documents/1a7387656ffc969985e01cc4d64ca05d80de79ac
274. Wang T, Chuan Pan C, Rui Yu J, Long Y, Hong Cai X, De Yin X, Qiong Hao L, Li Luo L. Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis. PloS one. 2013;8(9):e74284. www.epistemonikos.org/documents/1a9214078d35213c1b815a2639e67a8738b54167
275. Cremonesi M, Gilardi L, Ferrari ME, Piperno G, Travaini LL, Timmerman R, Botta F, Baroni G, Grana CM, Ronchi S, Ciardo D, Jereczek-Fossa BA, Garibaldi C, Orecchia R. Role of interim (18)F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review. European journal of nuclear medicine and molecular imaging. 2017;44(11):1915-1927.www.epistemonikos.org/documents/1aa83d49b3d43a30bf5df2b6594303c4f2ce82c3
276. Syrjänen K. Detection of human papillomavirus in lung cancer: systematic review and meta-analysis. Anticancer research. 2012;32(8):3235-50.www.epistemonikos.org/documents/1ad6f2e7590a3e31e1faaf77af7cf1d7d8c6eabf
277. Cheng D, Sun Y, He H. The Diagnostic Accuracy of HE4 in Lung Cancer: A Meta-Analysis. Disease markers. 2015;2015(no pagination):352670.www.epistemonikos.org/documents/1b10e74297865fbfd9347832a6a6e456a1350b8f
278. Behera M, Pillai RN, Owonikoko TK, Kim S, Steuer C, Chen Z, Saba NF, Belani CP, Khuri FR, Ramalingam SS. Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015;10(8):1142-7. www.epistemonikos.org/documents/1b2a105917543c554d8369d5cae04a9e1c86cf5a
279. Tang NP, Zhou B, Wang B, Yu RB, Ma J. Flavonoids intake and risk of lung cancer: a meta-analysis. Japanese journal of clinical oncology. 2009;39(6):352-9.www.epistemonikos.org/documents/1b3286c462418eb0e5229defba3fdbe061ee9005
280. Ampil FL, Sanghani SV. Timing of radiotherapy in asymptomatic patients with inoperable non-small cell lung cancer: a survival analysis and literature review. Radiation medicine. 1996;14(4):211-4. www.epistemonikos.org/documents/1b3700bbe53c92723c5f2c774c947768abe9d1e1
281. Deng SQ, Zeng XT, Wang Y, Ke Q, Xu QL. Meta-analysis of the CYP1A2 -163C>A polymorphism and lung cancer risk. Asian Pacific journal of cancer prevention : APJCP. 2013;14(5):3155-8. www.epistemonikos.org/documents/1b4740441c9e7bf8c49e0a12f809bd2856dafa22
282. Ren Y.-G., Zhou X.-M., Cui Z.-G., Hou G.. Effects of common polymorphisms in miR-146a and miR-196a2 on lung cancer susceptibility: A meta-analysis. Journal of Thoracic Disease. 2016;8(6):1297-1305. www.epistemonikos.org/documents/1b52535dbd6b5abaa976926ddece39829da2ba6a
283. Wu H, Zhu R. Quantitative assessment of common genetic variants on chromosome 5p15 and lung cancer risk. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(6):6055-63. www.epistemonikos.org/documents/1b6da8f2ee30ed23a8889121861a18fd8a339b8f
284. Lin X.-J., Yan K.-K., Zhao L.-Y., Bao H.-H., Li S., Liu X.-D., Liu X.. Meta-analysis on association between smoking and p53 gene mutation in patients with lung cancer. Journal of Jilin University Medicine Edition. 2014;40(5):1046-1050. www.epistemonikos.org/documents/1b841ca0f34f7d047c6018c9e73f4ae9b2925973

285. Guo H, Zhou S, Tan L, Wu X, Wu Z, Ran R. Clinicopathological significance of WIF1 hypermethylation in NSCLC, a meta-analysis and literature review. Oncotarget. 2017;8(2):2550-2557. www.epistemonikos.org/documents/1ba0ba81dc0e4cfb3a886464065729f31821a987
286. Zhang W., Liu Q., Dong X., Lei P.. A meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer. Journal of Thoracic Disease. 2015;7(3):478-485. www.epistemonikos.org/documents/1baf32aaf72a1f1724a97c172d48e242ff2e6d59
287. Niezink AGH, de Jong RA, Muijs CT, Langendijk JA, Widder J. Pulmonary Function Changes After Radiotherapy for Lung or Esophageal Cancer: A Systematic Review Focusing on Dose-Volume Parameters. The oncologist. 2017;22(10):1257-1264. www.epistemonikos.org/documents/1bb660cae10df61942965b763caa1061fff77f63
288. Liang Y., He L., Yuan H., Jin Y., Yao Y.. Association between RUNX3 promoter methylation and non-small cell lung cancer: a meta-analysis. Journal of Thoracic Disease. 2014;6(6):694-705. www.epistemonikos.org/documents/1bba13a386811e475cd8ebfb97357165e4dc7129
289. Paesmans M., Oliver Wong C., Patz E., Komaki R., Eschmann S., Govindan R., Vansteenkiste J., Meert A.-P., De Jong W.K., Altorki N.K., Higashi K., Van Baardwijk A., Borst G., Ameye L., Lafitte J.-J., Berghmans T., Hossein-Foucher C., Scherpereel A., Garcia C., Flamen P., Rami-Porta R., Sculier J.-P.. Is primary tumor standardized uptake value (SUV) an independent prognostic factor for non-small cell lung cancer (NSCLC)? a meta-analysis based on individual patients data. Journal of Thoracic Oncology. 2013;:S244. www.epistemonikos.org/documents/1bca2a145e6d353f8a6dcb2c394024501741caa2
290. Li Z, Zhang Y, Bao W, Jiang C. Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis. Targeted oncology. 2014;9(4):381-8. www.epistemonikos.org/documents/1be65979e8f7a50f5b358c5ae230fab26f987a91
291. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis. Cancer. 2005;103(9):1865-73. www.epistemonikos.org/documents/1bf710432a631121fbd6c905a917434b13c7469d
292. Zeng Y, Ruan W, He J, Zhang J, Liang W, Chen Y, He Q, He J. Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. PloS one. 2016;11(9):e0162630. www.epistemonikos.org/documents/1c810aa4b323aceb318a1bac7369b2fd748245a8
293. Collins J., Noble S., Byrne A.. Assessment and impact of sarcopenia in lung cancer: A systematic review highlighting implications for research and clinical practice. Lung Cancer. 2013;:S47. www.epistemonikos.org/documents/1cc3e8bd002bb55ca0d508d47cc2bcb668815ca3
294. Goodman M, Teta MJ, Hessel PA, Garabrant DH, Craven VA, Scrafford CG, Kelsh MA. Mesothelioma and lung cancer among motor vehicle mechanics: a meta-analysis. The Annals of occupational hygiene. 2004;48(4):309-26. www.epistemonikos.org/documents/1cca90c2b42f4984d296b055ab9088f723351058
295. Maher AR, Miake-Lye IM, Beroes JM, Shekelle PG. Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness. VA Evidence-based Synthesis Program Reports. 2012; www.epistemonikos.org/documents/1d701db1e3258ff6052c3edfc99a0275d556dea2
296. Cai H, Lin Y, Li W, Li X. Maintenance treatment with different strategies in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clinical lung cancer. 2013;14(4):333-41. www.epistemonikos.org/documents/1d79cce06a2cfb92462d7dd3b26aba6219ad135b
297. Wu X., Wu G., Yao X., Hou G., Jiang F.. The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: A meta-analysis and literature review. Drug Design, Development and Therapy. 2016;10:699-709. www.epistemonikos.org/documents/1d9ee704e145271095ad21e69d64b4027c90c0cc

298. Zhu N., Zhang Y., Gong Y., He J., Chen X.. Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta-analysis. Biomedical Reports. 2015;3(2):235-241.www.epistemonikos.org/documents/1daab3a42d1ecbc53110bc04fca7cc50211b2936
299. Chen Z, Li Z, Niu X, Ye X, Yu Y, Lu S, Chen Z. The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies. Mutagenesis. 2011;26(3):437-46. www.epistemonikos.org/documents/1dd0f4c465389b4699889d556e42c1b9fbad6b7e
300. Damm K, Roeske N, Jacob C. Health-related quality of life questionnaires in lung cancer trials: a systematic literature review. Health economics review. 2013;3(1):15.www.epistemonikos.org/documents/1de2ec75b92b4251a29c476562591185f683bcbb
301. Zhu YJ, Bo YC, Liu XX, Qiu CG. Association of dietary vitamin E intake with risk of lung cancer: a dose-response meta-analysis. Asia Pacific journal of clinical nutrition. 2017;26(2):271-277. www.epistemonikos.org/documents/1e3c50590429a3d48339f5b06f8471c3920e660a
302. Popat S, Mellemgaard A, Reck M, Hastedt C, Griebsch I. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. Future oncology (London, England). 2017;13(13):1159-1171.www.epistemonikos.org/documents/1e4d707af92a77bb632a26aab6ba7dfa43876fa0
303. Yao Y, Gu X, Zhu J, Yuan D, Song Y. Hormone replacement therapy in females can decrease the risk of lung cancer: a meta-analysis. PloS one. 2013;8(8):e71236.www.epistemonikos.org/documents/1e52a7b5604e5d42267a81dfe3464f776bb704b1
304. Nie K, Zhang YX, Nie W, Zhu L, Chen YN, Xiao YX, Liu SY, Yu H. Prognostic value of metabolic tumour volume and total lesion glycolysis measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography in small cell lung cancer: A systematic review and meta-analysis. Journal of medical imaging and radiation oncology. 2019;63(1):84-93. www.epistemonikos.org/documents/1e9648f5329aea639f5979bf5025cb4edea8d1a2
305. Zhang H.-X., Tang Y., Wang L., Wei S.-X., Liu Q.-X., Li F., Yuan X.-L.. EGFR-216G/T polymorphism as a predictor of clinical outcomes in advanced non-small cell lung cancer patients treated with EGFR-TKIs: A meta-analysis. International Journal of Clinical and Experimental Medicine. 2016;9(6):10273-10280.www.epistemonikos.org/documents/1e9b2489a057c8591a96f295c4bb57b013d5250e
306. Ardizzoni A., Tiseo M., Boni L., Di Maio M., Buffoni L., Belvedere O., Grossi F., D'Alessandro V., de Marinis F., Barbera S., Caroti C., Favaretto A., Cortinovis D., Morrica B., Tixi L., Ceschia T., Parisi S., Ricardi U., Grimaldi A., Loreggian L., Navarria P., Huber R.M., Belani C., Bruswig P.F., Scagliotti G.V., Scolaro T.. Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. Lung Cancer. 2016;100:30-37. www.epistemonikos.org/documents/1eddc9f6f05af09cd46e1cc6d2ce796aa8f19799
307. Taioli E, Lee DS, Lesser M, Flores R. Long-term survival in video-assisted thoracoscopic lobectomy vs open lobectomy in lung-cancer patients: a meta-analysis. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2013;44(4):591-7.www.epistemonikos.org/documents/1ee6540434b390e1d75d568533114c9157d43720
308. Wu QJ, Xie L, Zheng W, Vogtmann E, Li HL, Yang G, Ji BT, Gao YT, Shu XO, Xiang YB. Cruciferous vegetables consumption and the risk of female lung cancer: a prospective study and a meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013;24(7):1918-24.www.epistemonikos.org/documents/1eee9664017f5ffc0ee8f0f91564f36a2aca9e02
309. Popat S., Riley R.D., Billingham L.J., Hubner R.A.. Excision repair crosscomplementation group 1 (ERCC1) status and non-small cell lung cancer (NSCLC) outcomes: A metaanalysis of

published studies and recommendations. Journal of Thoracic Oncology. 2011;:S438-S439.www.epistemonikos.org/documents/1ef9c2150985aa12d9f97483c96535a82bee8426

310. Zhou L, Wang XL, Deng QL, Du YQ, Zhao NQ. The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis. Scientific reports. 2016;6:32020. www.epistemonikos.org/documents/1f04703e858deaa2690c9c6e8a01540afc478063

311. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2006;17(4):543-52. www.epistemonikos.org/documents/1f462fc870ea3604978098843a44ff2e4057be6b

312. Wang X, Bao Z, Zhang X, Li F, Lai T, Cao C, Chen Z, Li W, Shen H, Ying S. Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(35):59901-59914. www.epistemonikos.org/documents/1f6bc04c4ba55c0d6c1d5893916db510dbefcf4b

313. Chang MC, Chen JH, Liang JA, Lin CC, Yang KT, Cheng KY, Yeh JJ, Kao CH. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer. Academic radiology. 2012;19(3):349-57.www.epistemonikos.org/documents/1f9020ed400f5d3c5ae585de430b3890bb37efbe

314. Xiong Z., Zhou M.-L., Zhou H., Liu J.-K.. Role of low-dose spiral CT scan in early lung cancer screening of high risk population: A systematic review of the literature with a Meta-analysis. Chinese Journal of Radiology. 2006;40(4):437-442. www.epistemonikos.org/documents/1fb91f888a4b1a0893436d123ae531d394a8afd2

315. Zhang Y., Miao S., Wang F., Fang W., Chen G., Chen X., Yan F., Huang X., Wu M., Huang Y., Zhang L.. The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: A systematic review and meta-analysis. Journal of Thoracic Disease. 2017;9(7):1980-1987. www.epistemonikos.org/documents/1fc138d5234cce26b1c526977ad8670f5114afe7

316. De Ruysscher D, Lueza B, Le Péchoux C, Johnson DH, O'Brien M, Murray N, Spiro S, Wang X, Takada M, Lebeau B, Blackstock W, Skarlos D, Baas P, Choy H, Price A, Seymour L, Arriagada R, Pignon JP, RTT-SCLC Collaborative Group. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology. 2016;27(10):1818-28.www.epistemonikos.org/documents/20221702e8d11f83f7d58a4dfea96ed9abdcb58e

317. Hasegawa Y., Ando M., Maemondo M., Yamamoto S., Isa S.-I., Saka H., Kubo A., Kawaguchi T., Takada M., Kurata T., Ou S.-H.I.. A meta-analysis of smoking status on clinical outcomes of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor. Journal of Clinical Oncology. 2014; www.epistemonikos.org/documents/20481944f65b867a8344d08c25bb26bb74c633f5

318. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA : the journal of the American Medical Association. 2004;292(4):470-84.www.epistemonikos.org/documents/207dd59f75fec455469b4faa3841c7d7952cd04e

319. Dong X, Qiu X, Liu Q, Jia J. Endobronchial ultrasound-guided transbronchial needle aspiration in the mediastinal staging of non-small cell lung cancer: a meta-analysis. The Annals of thoracic surgery. 2013;96(4):1502-1507. www.epistemonikos.org/documents/209f8c36e83db1b7cbc40d10f71b479531092ee3

320. Liu X, Ma L, Yang K, Tian J. [Vinorelbine plus oxaliplatin versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: a systematic review]. Zhongguo fei ai za zhi = Chinese

journal of lung cancer. 2010;13(2):112-7. www.epistemonikos.org/documents/20d8a8c4eb03b661e74355a84031128ea78a38bc

321. Wan J.-T., Li B.-Z., Chen Z.-L., He J.. Meta-analysis of association between SNP309 in MDM2 promoter and lung cancer susceptibility. Chinese Journal of Cancer Prevention and Treatment. 2008;15(9):655-658. www.epistemonikos.org/documents/20eabbb931d9bb55a436e1286b42faee6b3b8285
322. Salander P, Lilliehorn S. To carry on as before: A meta-synthesis of qualitative studies in lung cancer. Lung cancer (Amsterdam, Netherlands). 2016;99:88-93.www.epistemonikos.org/documents/21251a4bf5315c0bcc2933af9204c21cc63d5332
323. Zhang X, Yu Q, Lv D. The single-incision versus multiple-incision video-assisted thoracoscopic surgery in the treatment of lung cancer: A systematic review and meta-analysis. Indian journal of cancer. 2017;54(1):291-300. www.epistemonikos.org/documents/2142f61ebb0c77edb31f95d0e885dc4457879efc
324. Smith G.D.. Smoking and lung cancer: causality, Cornfield and an early observational meta-analysis. International Journal of Epidemiology. 2009;38(5):1169-1171.www.epistemonikos.org/documents/216a1ae6b9254252c21252effe59272962c70025
325. Fritz H., Kennedy D., Fernandes R., Seely D.. Selenium and lung cancer: A systematic review. Journal of the Society for Integrative Oncology. 2010;:203-204.www.epistemonikos.org/documents/21777f3419e3c0cfdb5c71c981d7e1905c187d8f
326. Lin L, Cao K, Chen W, Pan X, Zhao H. Four common vascular endothelial growth factor polymorphisms (-2578C>A, -460C>T, +936C>T, and +405G>C) in susceptibility to lung cancer: a meta-analysis. PloS one. 2013;8(10):e75123. www.epistemonikos.org/documents/2189d5abe5a28cd7b6f4dc6e0842e5403cc49d0c
327. Deng XF, Liu QX, Zhou D, Min JX, Dai JG. Bone marrow micrometastasis is associated with both disease recurrence and poor survival in surgical patients with node-negative non-small-cell lung cancer: a meta-analysis. Interactive cardiovascular and thoracic surgery. 2015;21(1):21-7.www.epistemonikos.org/documents/218a343904965fa82bc589503ba8b9b495231108
328. Gao Y.-H., Guan W.-J., Liu Q., Wang H.-Q., Zhu Y.-N., Chen R.-C., Zhang G.-J.. Impact of COPD and emphysema on survival of patients with lung cancer: A meta-analysis of observational studies. Respirology. 2016;21(2):269-279. www.epistemonikos.org/documents/218ccc2aa659e55242a64700d04512a9aaa2bbd7
329. Wu P, Wu D, Zhao L, Huang L, Chen G, Shen G, Huang J, Chai Y. Inverse role of distinct subsets and distribution of macrophage in lung cancer prognosis: a meta-analysis. Oncotarget. 2016;7(26):40451-40460. www.epistemonikos.org/documents/219d27900b8188465f7e2c32f9a56a9e1dc3e21b
330. Al Feghali K.A., Ballout R.A., Khamis A.M., Akl E.A., Geara F.B.. Prophylactic cranial irradiation in patients with non-small-cell lung cancer: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Oncology. 2018;8(APR). www.epistemonikos.org/documents/226401ee9905059f4f14bad1bb7d4528acf52ae5
331. Chouaïd C, Crequit P, Borget I, Vergnenegre A. Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review. ClinicoEconomics and outcomes research : CEOR. 2015;7((Chouaid C., christos.chouaid@chicreteil.fr) Service de Pneumologie et de Pathologie Professionnelle, Centre Hospitalier Intercommunal Creteil et Universite de Paris Est Creteil, Paris, France):9-15.www.epistemonikos.org/documents/2265b5ba32a8e34354c5592d63c2a26d152be4b7
332. Sohn HS, Kwon JW, Shin S, Kim HS, Kim H. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. Journal of clinical pharmacy and therapeutics. 2015;40(6):661-71.www.epistemonikos.org/documents/227c46367ad723ee252c6f59c691d847e113f873
333. Oh SW, Myung SK, Park JY, Lym YL, Ju W. Hormone therapy and risk of lung cancer: a meta-analysis. Journal of women's health (2002). 2010;19(2):279-88.www.epistemonikos.org/documents/227f758fe5a9d7c532dc641da5e57dc229db5cd7

334. Gu L, Wang Z, Zuo J, Li H, Zha L. Prognostic significance of NF-κB expression in non-small cell lung cancer: A meta-analysis. PloS one. 2018;13(5):e0198223.www.epistemonikos.org/documents/22895f1fd534bece328f51cf5487f56bd314f13a
335. Luo J, Shen L, Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Scientific reports. 2014;4:6269. www.epistemonikos.org/documents/2294fa04a4a402f9f4963eee3653e7c4e3ced4e5
336. Liu B., Yuan M., Sun Y., Cheng Z., Zhang Z., Hou S., Wang X., Liu J.. Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: A systematic review and meta-analysis. Oncotarget. 2018;9(10):9480-9488.www.epistemonikos.org/documents/22a9ea82c3581de7a22e880ca73ea5e741832fe7
337. Wang Y, Qu X, Shen HC, Wang K, Liu Q, Du JJ. Predictive and Prognostic Biomarkers for Patients Treated with Anti-EGFR Agents in Lung Cancer: A Systemic Review and Meta-Analysis. Asian Pacific journal of cancer prevention : APJCP. 2015;16(11):4759-68.www.epistemonikos.org/documents/22c3d2c4cf19da7498317a1ee9ea524f44ba3389
338. Zhu N, Gong Y, He J, Xia J, Chen X. Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: an updated meta-analysis. Yonsei medical journal. 2013;54(6):1384-93.www.epistemonikos.org/documents/22d0084336871012d449ed15692d4e90dfd47f75
339. Oshita F, Honda T, Murakami S, Kondo T, Saito H, Noda K, Yamada K. Comparison of nedaplatin and irinotecan for patients with squamous and nonsquamous cell carcinoma of the lung: meta-analysis of four trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011;6(1):128-31.www.epistemonikos.org/documents/22f553320aecb5fece3dd07975a3177ad3bb3e72
340. Hu M, Hu Y, He J, Li B. Prognostic Value of Basic Fibroblast Growth Factor (bFGF) in Lung Cancer: A Systematic Review with Meta-Analysis. PloS one. 2016;11(1):e0147374.www.epistemonikos.org/documents/23189f35fa730436b75c2b5b1ac4842b5cf68c6f
341. Chen Z, Xu L, Ye X, Shen S, Li Z, Niu X, Lu S. Polymorphisms of microRNA sequences or binding sites and lung cancer: a meta-analysis and systematic review. PloS one. 2013;8(4):e61008. www.epistemonikos.org/documents/232d69a200aa463b2e49c401b96086a54161dae3
342. Handel AE, Joseph A, Ramagopalan SV. Multiple sclerosis and lung cancer: an unexpected inverse association. QJM : monthly journal of the Association of Physicians. 2010;103(8):625-6. www.epistemonikos.org/documents/238cf823f054ca34c514de9b03a302dd449b939c
343. Han C, Zou H, Ma J, Zhou Y, Zhao J. [Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2010;13(9):882-91.www.epistemonikos.org/documents/23b612e491532faf6f15691874302c3d3c5b2d6b
344. Wang C., Yu X., Wang W.. A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer. Medicine (United States). 2016;95(52):e5539. www.epistemonikos.org/documents/23c0201aabe265b4b743e4db9f8c9f5bd499c75d
345. Li J, Guo NN, Jin HR, Yu H, Wang P, Xu GG. Effects of exercise training on patients with lung cancer who underwent lung resection: a meta-analysis. World journal of surgical oncology. 2017;15(1):158. www.epistemonikos.org/documents/23d699fd6f2770874dd8aba67f7fbb74924369e5
346. Wang HM, Zhang XY, Jin B. TERT genetic polymorphism rs2736100 was associated with lung cancer: a meta-analysis based on 14,492 subjects. Genetic testing and molecular biomarkers. 2013;17(12):937-41. www.epistemonikos.org/documents/23faeb41fce55343a800019fa047af61602e4bbb

347. Zhang Y., Sheng J., Yang Y., Fang W., Kang S., He Y., Hong S., Zhan J., Zhao Y., Xue C., Ma Y., Zhou T., Ma S., Gao F., Qin T., Hu Z., Tian Y., Hou X., Huang Y., Zhou N., Zhao H., Zhang L.. Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: A network meta-analysis. Oncotarget. 2016;7(15):20093-20108. www.epistemonikos.org/documents/2423d24b4f56d32f8a93a84f843d3c82f25be58a
348. Liu L, Shao X, Gao W, Bai J, Wang R, Huang P, Yin Y, Liu P, Shu Y. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010;5(12):1922-32.www.epistemonikos.org/documents/242b6c54c50fa07ca1d66f00db52bf96b9d6fa3c
349. Selva A, Puig T, López Alcalde J, Bonfill X. [Efficacy of screening for lung cancer. Systematic review]. Medicina clínica. 2011;137(12):565-71.www.epistemonikos.org/documents/2452228dbfe711419ed344dfc674d09b54cf5810
350. Yokouchi H, Kanazawa K, Ishida T, Oizumi S, Shinagawa N, Sukoh N, Harada M, Ogura S, Munakata M, Dosaka-Akita H, Isobe H, Nishimura M. Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review. Molecular and clinical oncology. 2014;2(5):744-750.www.epistemonikos.org/documents/24655d0762217396cb3a58d6ccc6d636caf06bdd
351. Song WA, Zhou NK, Wang W, Chu XY, Liang CY, Tian XD, Guo JT, Liu X, Liu Y, Dai WM. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010;5(4):510-6. www.epistemonikos.org/documents/2472a996eda05994ae90ccdcba342c13b0137de2
352. Wu SH, Liu Z. Soy food consumption and lung cancer risk: a meta-analysis using a common measure across studies. Nutrition and cancer. 2013;65(5):625-32.www.epistemonikos.org/documents/248b4d0af8e000917a78a6926671bda021f09c42
353. Zhang W, Jiang W, Luan L, Wang L, Zheng X, Wang G. Prophylactic cranial irradiation for patients with small-cell lung cancer: a systematic review of the literature with meta-analysis. BMC cancer. 2014;14(1):793. www.epistemonikos.org/documents/24a8eca964347b6fb2d881ba4922b6790bf93d9b
354. Marino P, Preatoni A, Cantoni A, Buccheri G. Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study. Lung cancer (Amsterdam, Netherlands). 1995;13(1):1-12. www.epistemonikos.org/documents/24bdf2d3a91498156ba1b91ed57a680efaf204de
355. Poghosyan H, Kennedy Sheldon L, Cooley ME. The impact of computed tomography screening for lung cancer on smoking behaviors: a teachable moment?. Cancer nursing. 2012;35(6):446-75. www.epistemonikos.org/documents/24d2d250b4ba62dc3a04582cee7f93e1044291b6
356. Liu Y, Yin TJ, Zhou R, Zhou S, Fan L, Zhang RG. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis. Cancer chemotherapy and pharmacology. 2013;72(5):1125-32.www.epistemonikos.org/documents/250debcee7a634e1e67f85dedbc7a1e89ec0f0b3
357. Lash TL, Crouch EA, Green LC. A meta-analysis of the relation between cumulative exposure to asbestos and relative risk of lung cancer. Occupational and environmental medicine. 1997;54(4):254-63. www.epistemonikos.org/documents/2512cf99175c45f6a4817d7b2c6d17469d8a16b5
358. Tomioka K, Saeki K, Obayashi K, Tanaka Y, Kurumatani N. Risk for lung cancer in workers exposed to benzidine and/or beta-naphthylamine: a protocol for systematic review and meta-analysis. Systematic reviews. 2014;3(1):112. www.epistemonikos.org/documents/253383e3234ad7812a1d01831a8595b7789ce1d8
359. Soldà F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison

with a surgical cohort. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2013;109(1):1-7.www.epistemonikos.org/documents/2546aa0114caab1c95ae48773cd39090b265c640

360. Barlési F, Jacot W, Astoul P, Pujol JL. Second-line treatment for advanced non-small cell lung cancer: a systematic review. Lung cancer (Amsterdam, Netherlands). 2006;51(2):159-72. www.epistemonikos.org/documents/2563470e045f974f180d58ba765c07154d0ded31

361. Zhou F, Jiang T, Ma W, Gao G, Chen X, Zhou C. The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysis. Lung cancer (Amsterdam, Netherlands). 2015;89(2):203-11.www.epistemonikos.org/documents/25725de777715980a29db6a732be4e1237d415cd

362. Quast E, Williams M. Distress with breathing in people with lung cancer: a systematic review. Internet Journal of Allied Health Sciences & Practice. 2009;7(4):1-11.www.epistemonikos.org/documents/25767d911b59142893ae08bca4ef77b280b11a51

363. Zhao L, He ZY, Zhong XN, Cui ML. (18)FDG-PET/CT for detection of mediastinal nodal metastasis in non-small cell lung cancer: a meta-analysis. Surgical oncology. 2012;21(3):230-6. www.epistemonikos.org/documents/25c227f72ac0675cf775bbf661c4ef4dfbe690ba

364. Duan YZ, Zhang L, Liu CC, Zhu B, Zhuo WL, Chen ZT. CCND1 G870A polymorphism interaction with cigarette smoking increases lung cancer risk: meta-analyses based on 5008 cases and 5214 controls. Molecular biology reports. 2013;40(7):4625-35. www.epistemonikos.org/documents/25ceb823c4ddee57bc13d6ddf78e416172a8ea4f

365. Zheng CL, Qiu C, Shen MX, Qu X, Zhang TH, Zhang JH, Du JJ. Prognostic impact of elevation of vascular endothelial growth factor family expression in patients with non-small cell lung cancer: an updated meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2015;16(5):1881-95.www.epistemonikos.org/documents/2613a6d6425c3e94853a1da495614a452dfb46ce

366. Kim J.H., Kim H.S., Kim B.J.. MET inhibitors in advanced non-small-cell lung cancer: A metaanalysis and review. Oncotarget. 2017;8(43):75500-75508.www.epistemonikos.org/documents/2619b0f4e29483497fef982fae008d9bea5f1fa5

367. Costa RB, Costa RLB, Talamantes SM, Kaplan JB, Bhave MA, Rademaker A, Miller C, Carneiro BA, Mahalingam D, Chae YK. Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer. Oncotarget. 2018;9(31):22137-22146.www.epistemonikos.org/documents/262a428702bb207cca6e8f733b07374e8ff0227a

368. Yang G., Shu X.-O., Chow W.-H., Zhang X., Li H.-L., Ji B.-T., Cai H., Wu S.-H., Gao Y.-T., Zheng W.. Soy food intake and risk of lung cancer: Evidence from the Shanghai Women's Health Study and a meta-analysis. Cancer Research. 2012; www.epistemonikos.org/documents/2646adf9847ccfb0526db35b998f0b8a92741b12

369. Li W, Tse LA, Wang F. Prognostic value of estrogen receptors mRNA expression in non-small cell lung cancer: A systematic review and meta-analysis. Steroids. 2015;104:129-36. www.epistemonikos.org/documents/264b2c1e491d7d6bd9b885693e24ccaf0370af95

370. Yuan P, Cao JL, Abuduwufuer A, Wang LM, Yuan XS, Lv W, Hu J. Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis. PloS one. 2016;11(1):e0146803. www.epistemonikos.org/documents/26690432e22681a94365935da425d2d982854445

371. Wang Y, Yang H, Li L, Wang H, Zhang C, Yin G, Zhu B. Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis. European journal of cancer (Oxford, England : 1990). 2010;46(4):758-64. www.epistemonikos.org/documents/268e2d1039d7ef18120b9a3af3d1a889871647b7

372. Drodge CS, Ghosh S, Fairchild A. Thoracic reirradiation for lung cancer: a literature review and practical guide. Annals of palliative medicine. 2014;3(2):75-91.www.epistemonikos.org/documents/2713d27e794941a43580061e1284a6099ca6b4c9

373. Wang XB, Li J, Han Y. Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(10):10105-10.www.epistemonikos.org/documents/2759aae27b86f37f5596f307f6054a4e0cc4c796
374. Zhang Y., Ma H., Ding Q., Chen L., Chen Z., Sun S., Wang B., Lv D., Zhang Q., Deng Z., Yu Y.. MLH1 promoter methylation in non-small cell lung cancer: A meta-analysis. International Journal of Clinical and Experimental Medicine. 2016;9(7):13625-13633. www.epistemonikos.org/documents/277c252b7036a80603d39fbb1873fdba23c46272
375. Chung C, Christianson M. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2014;20(1):11-28. www.epistemonikos.org/documents/277f467d52ddbd58a1b415deae8f74f179bd0b5b
376. Bongers M.L., Coupe V.M., Jansma E.P., Smit E.F., Uyl-de Groot C.. Cost-effectiveness of treatment with new agents in advanced non-small-cell lung cancer: A systematic review. Value in Health. 2011;:A451. www.epistemonikos.org/documents/27c66386bfe21ee8e290f8b6899310704065a746
377. Wong K., Victor C., Eng L., Verma S.. The use of epidermal growth factor receptor tyrosine kinase inhibitors in treatment of advanced EGFR wild-type non-small cell lung cancer: A meta-analysis. European Journal of Cancer. 2013;:S825. www.epistemonikos.org/documents/27c6762978dc62093a9a566f09bfd5b1b04dd351
378. Botrel TE, Clark O, Clark L, Paladini L, Faleiros E, Pegoretti B. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis. Lung cancer (Amsterdam, Netherlands). 2011;74(1):89-97.www.epistemonikos.org/documents/27d376a24aec7bb939cd9d058181d70ca2cd7329
379. Zhang Y., Kang S., Fang W., Hong S., Liang W., Yan Y., Qin T., Tang Y., Sheng J., Zhang L.. Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: A meta-analysis. Clinical Lung Cancer. 2015;16(2):144-151. www.epistemonikos.org/documents/27e0ba0ce1c0680deeb4d0e8cff0b4c2de58c389
380. Wang W, Chen Y, Deng J, Zhou J, Zhou Y, Wang S, Zhou J. The prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(10):9769-75.www.epistemonikos.org/documents/27e555f8fd197aa80d1a8120aef20d6cbcea16f1
381. Hamra GB, Laden F, Cohen AJ, Raaschou-Nielsen O, Brauer M, Loomis D. Lung Cancer and Exposure to Nitrogen Dioxide and Traffic: A Systematic Review and Meta-Analysis. Environmental health perspectives. 2015;123(11):1107-1112. www.epistemonikos.org/documents/2815880e40791ac0d3202f53b0e2bfdcefbe65e3
382. Liu YL, Xu Y, Li F, Chen H, Guo SL. CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(5):2651-7.www.epistemonikos.org/documents/2853af68454b605fea1c4ce653f78251e9b185b5
383. Guo R.-R., Xu F.-H., Sun H.-Y.. Docetaxel as a second-line treatment for patients with advanced non small cell lung cancer: A systematic review. Chinese Journal of Evidence-Based Medicine. 2008;8(10):861-868. www.epistemonikos.org/documents/28740d2ecca323466adf071e0d2f2de67408ec96
384. Yifan D, Qun L, Yingshuang H, Xulin L, Jianjun W, Qian M, Yuman Y, Zhaoyang R. Bronchial lavage P 16INK4A gene promoter methylation and lung cancer diagnosis: A meta-analysis. Indian journal of cancer. 2015;52 Suppl 2(6):e96-8. www.epistemonikos.org/documents/2890cc9aaa2fc3e5f0704ed46954ae6266314278
385. Soo R.A., Chen Z., Yan Teng R.S., Tan H.-L., Iacopetta B., Tai B.C., Soong R.. Prognostic significance of immune cells in non-small cell lung cancer: Meta-analysis. Oncotarget.

2018;9(37):24801-24820.
www.epistemonikos.org/documents/28a2e3123edb4937809208158a0100676766c59c

386. Huang LN, Wang DS, Chen YQ, Li W, Hu FD, Gong BL, Zhao CL, Jia W. Meta-analysis for cyclin E in lung cancer survival. Clinica chimica acta; international journal of clinical chemistry. 2012;413(7-8):663-8.
www.epistemonikos.org/documents/28b290c1331d889248f56d492878d85ab6f62f69

387. Ma Z, Dong A, Fan J, Cheng H. Does sleeve lobectomy concomitant with or without pulmonary artery reconstruction (double sleeve) have favorable results for non-small cell lung cancer compared with pneumonectomy? A meta-analysis. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2007;32(1):20-8.
www.epistemonikos.org/documents/28da473a584721fab89081a431d3c9862adcdf48

388. Ma XL, Xiao ZL, Liu L, Liu XX, Nie W, Li P, Chen NY, Wei YQ. Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer. Asian Pacific journal of cancer prevention : APJCP. 2012;13(4):1137-44.
www.epistemonikos.org/documents/29049cbc6a523d25b77fdd052a5d53300372bde5

389. Ma X.-L., Zhang J.-Q., Yang M., Bai G., Zhang L.. Erlotinib in the maintenance therapy of advanced non-small cell lung cancer: a systematic review. Chinese Journal of Cancer Prevention and Treatment. 2014;21(10):786-791.
www.epistemonikos.org/documents/290c681c963ea2805e75c349eb267564734d09eb

390. Holty JE, Kuschner WG, Gould MK. Accuracy of transbronchial needle aspiration for mediastinal staging of non-small cell lung cancer: a meta-analysis. Thorax. 2005;60(11):949-55.
www.epistemonikos.org/documents/293437095c8d5b5cc7bcad6f1a3560b77e0fd67b

391. Li C, Wang C. Current evidences on IL1B polymorphisms and lung cancer susceptibility: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(6):3477-82.
www.epistemonikos.org/documents/2963fdad7b65b6663964b06c9d47548c46d2da56

392. Shen G, Lan Y, Zhang K, Ren P, Jia Z. Comparison of 18F-FDG PET/CT and DWI for detection of mediastinal nodal metastasis in non-small cell lung cancer: A meta-analysis. PloS one. 2017;12(3):e0173104.
www.epistemonikos.org/documents/29678c9d80296489815f4579a7e096c72f420356

393. Zhang X, Lu J, Xu J, Li H, Wang J, Qin Y, Ma P, Wei L, He J. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis. Respirology (Carlton, Vic.). 2013;18(1):131-9.www.epistemonikos.org/documents/297a33cdd361bed899f1808f30c685501236e949

394. Souquet PJ, Chauvin F, Boissel JP, Bernard JP. Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 1995;12 Suppl 1(SUPPL. 1):S147-54.www.epistemonikos.org/documents/29dbcdf48a55df156a6cd4a8bda87b41d829fac3

395. Verma V, Mishra MV, Mehta MP. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. Cancer. 2016;122(10):1483-501.www.epistemonikos.org/documents/29dccaec5f036fa73a727c1065d0a235fb3f1e47

396. Xia H., Shen J., Hu F., Chen S., Huang H., Xu Y., Ma H.. PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients. Clinica Chimica Acta. 2017;469:191-194.
www.epistemonikos.org/documents/2a0211ceaa243d9b97d68816c6dbdbcb55fb6ad4

397. Xu C, Zhou Q, Wu YL. Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis. Journal of hematology & oncology. 2012;5(no pagination):62.
www.epistemonikos.org/documents/2a025f6f3407b68861dfc3c6fcccd7f7895c06d0

398. Li D.-J., Xiao D.. Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: A meta-analysis based on the

PRISMA statement. BMC Cancer. 2017;17(1):501. www.epistemonikos.org/documents/2a12d5274c3a34ec9acf4a14a4efaa46926218bd

399. Jiang AG, Lu HY. k-RAS mutations in non-small cell lung cancer patients treated with TKIs among smokers and non-smokers: a meta-analysis. Contemporary oncology (Poznań, Poland). 2016;20(2):124-9. www.epistemonikos.org/documents/2a1a3d43580efd9fb95add9f9370fc445e649640

400. Chen L, Jin H. MicroRNAs as novel biomarkers in the diagnosis of non-small cell lung cancer: a meta-analysis based on 20 studies. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(9):9119-29. www.epistemonikos.org/documents/2a7bdb029fd46de52fb8f5ca38cfa7621d5afc07

401. Hu X.-J., Jin B., Liu Y.-P., Zhang J., Shi J.-P.. Meta-analysis of maintenance therapy with interferon for small cell lung cancer. Chinese Journal of Evidence-Based Medicine. 2006;6(11):809-814. www.epistemonikos.org/documents/2a7c32dca276c8b83b3e7f23c5ab21bdcd9a4408

402. Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol JL, van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, Fitzgerald P, Aristides M, Schiller JH. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung cancer (Amsterdam, Netherlands). 2005;47(1):69-80.www.epistemonikos.org/documents/2a90bda7ce5401ce75ccd435926177450cbb0379

403. Singh A, Kamal R, Ahamed I, Wagh M, Bihari V, Sathian B, Kesavachandran CN. PAH exposure-associated lung cancer: an updated meta-analysis. Occupational medicine (Oxford, England). 2018;68(4):255-261. www.epistemonikos.org/documents/2a9adbcb42c4f47a54a955e5a2090fc1bd7cd9fd

404. Ochiai S, Nomoto Y, Watanabe Y, Yamashita Y, Toyomasu Y, Kawamura T, Takada A, Noriko None, Sakuma H. The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non-small cell lung cancer: a literature review and pooled analysis. Journal of radiation research. 2016;57(5):449-459. www.epistemonikos.org/documents/2aaa317df6ef2c5da9e2a622df2eedce4dc5a0f6

405. Sharieff W.. Can we predict 2-year survival for radical radiation dosing schedules in advanced non-small cell lung cancer through a meta-analysis based predictive model?. Journal of Clinical Oncology. 2010; www.epistemonikos.org/documents/2ab9e67c0c52c4ac720e81329eeb2165723733bd

406. Tan Y, Chen B, Xu W, Zhao W, Wu J. Clinicopathological significance of CD133 in lung cancer: A meta-analysis. Molecular and clinical oncology. 2014;2(1):111-115.www.epistemonikos.org/documents/2acd45eb1b4e96ebdb4d5dcacaf32b9db8f9e17e

407. Xu YH, Gu LP, Sun YJ, Cheng BJ, Lu S. No significant association between the XRCC3 Thr241Met polymorphism and lung cancer risk: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(2):865-74.www.epistemonikos.org/documents/2ad1930a21d76c4619adee2174d7a9538b42d4ea

408. Toy E, Macbeth F, Coles B, Melville A, Eastwood A. Palliative thoracic radiotherapy for non-small-cell lung cancer: a systematic review. American journal of clinical oncology. 2003;26(2):112-20. www.epistemonikos.org/documents/2afd8f9883d6d2dc55d1fed69382a93f85184313

409. Yang X., Yang L., Dai W., Ye B.. Role of p14ARF and p15INK4B promoter methylation in patients with lung cancer: A systematic meta-analysis. OncoTargets and Therapy. 2016;9:6977-6985. www.epistemonikos.org/documents/2b07ca76cffde564da40ab5436864c82a40244bd

410. Xie ZC, Tang RX, Gao X, Xie QN, Lin JY, Chen G, Li ZY. A meta-analysis and bioinformatics exploration of the diagnostic value and molecular mechanism of miR-193a-5p in lung cancer. Oncology letters. 2018;16(4):4114-4128. www.epistemonikos.org/documents/2b261bf9660b7a9a87b3002e5db0bdf4149128d9

411. Refsgaard B, Frederiksen K. Illness-related emotional experiences of patients living with incurable lung cancer: a qualitative metasynthesis. Cancer nursing. 2013;36(3):221-8. www.epistemonikos.org/documents/2b2e812136fff151dd2d61d6a9d8e59e3ea0f64f
412. Jiang L., He J., Shi X., Shen J., Liang W., Yang C., He J.. Prognosis of synchronous and metachronous multiple primary lung cancers: Systematic review and meta-analysis. Lung Cancer. 2015;87(3):303-310. www.epistemonikos.org/documents/2ba6b8826b0cf426a5ee51f5a26bfe644675dd6c
413. Blumenthal G.M., Karuri S., Khozin S., Kazandjian D., Zhang H., Zhang L., Tang S., Sridhara R., Keegan P., Pazdur R.. Overall response rate (ORR) as a potential surrogate for progression-free survival (PFS): A meta-analysis of metastatic non-small cell lung cancer (mNSCLC) trials submitted to the U.S. Food and Drug Administration (FDA). Journal of Clinical Oncology. 2014; www.epistemonikos.org/documents/2bdf23dd2d20223c5cf6499e8e457be9d4be5670
414. Qiu ZX, Xue F, Shi XF, He X, Ma HN, Chen L, Chen PZ. MGMT Leu84Phe gene polymorphism and lung cancer risk: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(5):4381-7.www.epistemonikos.org/documents/2bec82468f22b211e8aac83c74799ea734d0be9c
415. Wang H., Qian J.. Serum pro-gastrin-releasing peptide in diagnosis of small cell lung cancer: A meta-Analysis. Journal of Cancer Research and Therapeutics. 2016;12(8):C260-C263. www.epistemonikos.org/documents/2bf1abf150c708de07dcab1c3734501d0f737bca
416. Liu J., Huang W., Zhou R., Jia S., Tang W., Luo Y., Zhang J.. Serum/plasma 25-hydroxyvitamin D and risk of lung, breast and prostate cancer: A meta-analysis. International Journal of Clinical and Experimental Medicine. 2016;9(2):2728-2737. www.epistemonikos.org/documents/2bf5ce0c6e0695c4607b549e693df1be8a7bad8a
417. Chen J, Lu Y, Zheng Y. Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials. Drug design, development and therapy. 2015;9:4751-60. www.epistemonikos.org/documents/2c02bbe70c4174f2c69c931223c848aac9e1ba8c
418. Xu CH, Wang Q, Qian Q, Zhan P, Yu LK. CYP1A1 exon7 polymorphism is associated with lung cancer risk among the female population and among smokers: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(6):3901-11.www.epistemonikos.org/documents/2c08ad0b79787ed15564b929ca92fc4ae4eb48e4
419. Kennedy SA, Milovanovic L, Dao D, Farrokhyar F, Midia M. Risk factors for pneumothorax complicating radiofrequency ablation for lung malignancy: a systematic review and meta-analysis. Journal of vascular and interventional radiology : JVIR. 2014;25(11):1671-1681.e1.www.epistemonikos.org/documents/2c096e19a25cfc72801904081e5b3dccbf90ef63
420. Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006;15(5):979-87. www.epistemonikos.org/documents/2c1b6a2fd72c7021e6b6125bb6319c39f5e1de7e
421. Luo W, Wang Z, Tian P, Li W. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials. Journal of cancer research and clinical oncology. 2018;144(10):1851-1859. www.epistemonikos.org/documents/2c3a5d79cf61c3d20992720edb4ed80aed5adb11
422. Luo Z, Wu RR, Lv L, Li P, Zhang LY, Hao QL, Li W. Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review. International journal of clinical and experimental pathology. 2014;7(7):3632-46. www.epistemonikos.org/documents/2c84de457a0c1998f85fcacd39689dd6de600d53
423. Li S., Zhou K., Che G., Yang M., Su J., Shen C., Yu P.. Enhanced recovery programs in lung cancer surgery: Systematic review and meta-analysis of randomized controlled trials. Cancer

Management and Research. 2017;9:657-670. www.epistemonikos.org/documents/2c8804dfb56dd744d40714d10e1c74d69a40556d

424. Lee SH, Choi WJ, Sung SW, Kim YK, Kim CH, Zo JI, Park KJ. Endoscopic cryotherapy of lung and bronchial tumors: a systematic review. The Korean journal of internal medicine. 2011;26(2):137-44. www.epistemonikos.org/documents/2c904917677e1698c3a27adce87f8cfdb5ae758b

425. van der Bij S, Koffijberg H, Lenters V, Portengen L, Moons KG, Heederik D, Vermeulen RC. Lung cancer risk at low cumulative asbestos exposure: meta-regression of the exposure-response relationship. Cancer causes & control : CCC. 2013;24(1):1-12. www.epistemonikos.org/documents/2cb908212ca59d663cf5170b4ab17febf5f5fdf6

426. Dahabreh IJ, Linardou H, Kosmidis P, Bafaloukos D, Murray S. EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2011;22(3):545-52. www.epistemonikos.org/documents/2cc8687824b11a50c52e7c90788c5537b5071d79

427. Yang, Zuyao. Predictive biomarkers of the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in treating advanced non-small cell lung cancer: A systematic review of randomized controlled trials. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2015;76(1-B(E)).www.epistemonikos.org/documents/2ccb0e4d25af06d68624a97d484c73fda1c4eed5

428. Luan H, Ye F, Wu L, Zhou Y, Jiang J. Perioperative blood transfusion adversely affects prognosis after resection of lung cancer: a systematic review and a meta-analysis. BMC surgery. 2014;14(1):34. www.epistemonikos.org/documents/2cd64637d9ed2ffe023ef11f128d28ee3259065d

429. Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J, Kester A, Rutten I, Lambin P. Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer treatment reviews. 2007;33(5):461-73.www.epistemonikos.org/documents/2ce690103963500d7f278335a5136fd3afed50d6

430. Gao G., Ren S., Li A., He Y., Chen X., Li W., Zhou F., Li S., Zhou C.. A meta-analysis of comparing EGFR-TKI with chemotherapy as the second-line treatment of NSCLC patients with wild-type EGFR. Journal of Clinical Oncology. 2013; www.epistemonikos.org/documents/2cf86eaa6fd170f86aae9c247319dcdef6b04a85

431. Zhang XW, Liu W, Jiang HL, Mao B. Chinese Herbal Medicine for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. The American journal of Chinese medicine. 2018;46(5):1-30. www.epistemonikos.org/documents/2cfda8813ff0fe5e077dc6a9b3ca7bb82d722ab4

432. Arruda L.M., Cruz F.M., David W.J., Del Giglio A.. Meta-analysis of EGFR TKI as maintenance therapy in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2014; www.epistemonikos.org/documents/2d088e795a60de34afa7a5a5cbb95354e5118b14

433. Maguire R, Papadopoulou C, Kotronoulas G, Simpson MF, McPhelim J, Irvine L. A systematic review of supportive care needs of people living with lung cancer. European journal of oncology nursing : the official journal of European Oncology Nursing Society. 2013;17(4):449-64.www.epistemonikos.org/documents/2d333fceeb7be46a90c0dad74e7571c18f14b07e

434. Schmidt-Hansen M, Berendse S, Hamilton W, Baldwin DR. Lung cancer in symptomatic patients presenting in primary care: a systematic review of risk prediction tools. The British journal of general practice : the journal of the Royal College of General Practitioners. 2017;67(659):e396-e404.www.epistemonikos.org/documents/2d692ac0a863df2b69b859b93565dd1882bf7fc0

435. Gray EP, Teare MD, Stevens J, Archer R. Risk Prediction Models for Lung Cancer: A Systematic Review. Clinical lung cancer. 2016;17(2):95-106.www.epistemonikos.org/documents/2d7cb0528cea6a3c2d9951a2318e9e74e59af514

436. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. British journal of cancer. 2005;93(7):825-33.www.epistemonikos.org/documents/2d8270fb539f170e8aaa1edfd3e6a2be9f1588ed
437. Wang Y, Li J, Tong L, Zhang J, Zhai A, Xu K, Wei L, Chu M. The prognostic value of miR-21 and miR-155 in non-small-cell lung cancer: a meta-analysis. Japanese journal of clinical oncology. 2013;43(8):813-20. www.epistemonikos.org/documents/2d98a257b48ae19018eb13910c6bd870409fdd9f
438. Cao, Ailing, He, Hailang, Jing, Mengxin, Yu, Beibei, Zhou, Xianmei. Shenfu Injection Adjunct with Platinum-Based Chemotherapy for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review. Evidence-based Complementary & Alternative Medicine (eCAM). 2017;2017(no pagination):1-12.www.epistemonikos.org/documents/2db9bea24f7341fd3fd20ea0e1802339852de03a
439. Gao H, Ding X, Wei D, Cheng P, Su X, Liu H, Aziz F, Wang D, Zhang T. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials. Anti-cancer drugs. 2011;22(9):842-52. www.epistemonikos.org/documents/2df5d48df20befd23b67048aaeab40a2e882e659
440. Fan L, Cai L. [Meta-analysis on the relationship between alcohol consumption and lung cancer risk]. Wei sheng yan jiu = Journal of hygiene research. 2009;38(1):85-9.www.epistemonikos.org/documents/2e36d28ffa5bc2b5e75d6298efacfb181ed1583b
441. Chen X, Liang L, Hu X, Chen Y. Glutathione S-transferase P1 gene Ile105Val polymorphism might be associated with lung cancer risk in the Chinese Han population. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33(6):1973-81.www.epistemonikos.org/documents/2e5bce551d3f030786507ddf727381868c2935ea
442. Tang J.-H., Su F., Xu J.-N., Dong M., An M.-M., Wang R.A.. Diagnosis value of tumor marker: The serum neuron specific enolase of small cell lung cancer in RIA: A systematic review. Chinese Journal of Evidence-Based Medicine. 2009;9(5):531-535. www.epistemonikos.org/documents/2e6e6743477b324f5f5eae6ff53dff720bd158dd
443. Wang F, Xu X, Yang J, Min L, Liang S, Chen Y. Height and lung cancer risk: A meta-analysis of observational studies. PloS one. 2017;12(9):e0185316.www.epistemonikos.org/documents/2e78bc4650f883ef43e22c84f5931a4d9e5dd78a
444. Jiang Y, Bi Z, Li D, Liu Y. [Radiotherapy concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of brain metastases from non small cell lung cancer: a meta-analysis]. Zhonghua yi xue za zhi. 2015;95(5):386-91.www.epistemonikos.org/documents/2e9dec8450ceace434cc86be36baed72c077ba1f
445. Liu C.-Q., Tian D., Wang N., Meng X.-P., Yang J.-D., Li H.-W., Zhao N., Zhao S., Liao F., Cui Y.. Efficacy and safety of amrubicin-based regimen used as first-line for extensive-disease small-cell lung cancer: A meta-analysis of randomized controlled trials. Asia-Pacific Journal of Clinical Oncology. 2018;14(2):e81-e87.www.epistemonikos.org/documents/2eaf67a013f727221c787e233259656636aee663
446. Chen C, Hua H, Han C, Cheng Y, Cheng Y, Wang Z, Bao J. Prognosis value of MGMT promoter methylation for patients with lung cancer: a meta-analysis. International journal of clinical and experimental pathology. 2015;8(9):11560-4. www.epistemonikos.org/documents/2ec7f5354b5aac18eac690a729e31f114444c9b7
447. Kyriakoudi A., Zias N.. Endobronchial ultrasound and lung cancer staging. A systematic review and "how to do it" analysis. Minerva Pneumologica. 2010;49(1):17-23.www.epistemonikos.org/documents/2f26e6b3dac0de7183c3af45983f2bdce5197abf
448. Sidorchuk A, Agardh EE, Aremu O, Hallqvist J, Allebeck P, Moradi T. Socioeconomic differences in lung cancer incidence: a systematic review and meta-analysis. Cancer causes & control : CCC. 2009;20(4):459-71. www.epistemonikos.org/documents/2f3ce52df806c1dc478426237082c34e94823024

449. McVie JG. Non-small cell lung cancer: meta-analysis of efficacy of chemotherapy. Seminars in oncology. 1996;23(3 Suppl 7):12-4.www.epistemonikos.org/documents/2f4d09d6114879a6748051ddeb0c24025320ea51
450. Zhao J, Yorke ED, Li L, Kavanagh BD, Li XA, Das S, Miften M, Rimner A, Campbell J, Xue J, Jackson A, Grimm J, Milano MT, Spring Kong FM. Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies. International journal of radiation oncology, biology, physics. 2016;95(5):1357-66. www.epistemonikos.org/documents/2f58864f2e291d79167c53f817882871e80936a8
451. Liao C, Yu Z, Guo W, Liu Q, Wu Y, Li Y, Bai L. Prognostic value of circulating inflammatory factors in non-small cell lung cancer: a systematic review and meta-analysis. Cancer biomarkers : section A of Disease markers. 2014;14(6):469-81. www.epistemonikos.org/documents/2f5e635ecfac10cda8321d4ee7e5718c7d6bca8c
452. Zhao Q.-T., Yang Y., Xu S., Zhang X.-P., Wang H.-E., Zhang H., Wang Z.-K., Yuan Z., Duan G.-C.. Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7,054 patients. OncoTargets and Therapy. 2015;8:2731-2738. www.epistemonikos.org/documents/2f6e76507bcc5eb261fe07650200dba06ca6f9ed
453. Nakamura H. Systematic review of published studies on safety and efficacy of thoracoscopic and robot-assisted lobectomy for lung cancer. Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia. 2014;20(2):93-8.www.epistemonikos.org/documents/2f7368d9ac3e00e67820ac334e9d72a9be71742a
454. Grossman K, Beasley MB, Braman SS. Hepatoid adenocarcinoma of the lung: Review of a rare form of lung cancer. Respiratory medicine. 2016;119:175-179.www.epistemonikos.org/documents/2f79d963da1a52acff4c289a3de929c555061c0f
455. Deng Z, Yang Y, Huang X, Kuang Y, Qin Z, Wang B, Wang H, Li M. Polymorphisms of TGFβ1T+869C and C-509T with Lung Cancer Risk: A Meta-analysis. Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 2016;25(6):1165-1172.www.epistemonikos.org/documents/2f8b651dce3df90a6dbc9b111447f543f2dbd4ae
456. Tan X, Chen M. Association between Catechol-O-methyltransferase rs4680 (G>A) polymorphism and lung cancer risk. Diagnostic pathology. 2014;9:192.www.epistemonikos.org/documents/2fb4352e8b13f2aa4f45f4e4cde660ad1ef28f9c
457. Zhan P, Suo LJ, Qian Q, Shen XK, Qiu LX, Yu LK, Song Y. Chlamydia pneumoniae infection and lung cancer risk: a meta-analysis. European journal of cancer (Oxford, England : 1990). 2011;47(5):742-7. www.epistemonikos.org/documents/2fc9f4e0078523af4d280a2731f3955afda7828b
458. Zhang T, Zhang DM, Zhao D, Hou XM, Liu XJ, Ling XL, Ma SC. The prognostic value of osteopontin expression in non-small cell lung cancer: a meta-analysis. Journal of molecular histology. 2014;45(5):533-40. www.epistemonikos.org/documents/2fe342fd62d597b0e5343d2ad454388263324bbd
459. Bria E, Cuppone F, Ciccarese M, Nisticò C, Facciolo F, Milella M, Izzo F, Terzoli E, Cognetti F, Giannarelli D. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer treatment reviews. 2006;32(8):583-7.www.epistemonikos.org/documents/2fe593297999f6f6b629a58e01450535e8e669ac
460. Whitson BA, Groth SS, Duval SJ, Swanson SJ, Maddaus MA. Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. The Annals of thoracic surgery. 2008;86(6):2008-16; discussion 2016-8.www.epistemonikos.org/documents/2fed0a8063bd775d253f652f96218a432189a50a
461. Qu J., Wang Y.-N., Xu P., Xiang D.-X., Yang R., Wei W., Qu Q.. Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: A meta-analysis. Oncotarget. 2017;8(20):33961-33971. www.epistemonikos.org/documents/2feffbc51247519f9dda7102a49cd3c85e65f613

462. Wang JJ, Zheng Y, Sun L, Wang L, Yu PB, Li HL, Tian XP, Dong JH, Zhang L, Xu J, Shi W, Ma TY. CYP1A1 Ile462Val polymorphism and susceptibility to lung cancer: a meta-analysis based on 32 studies. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP). 2011;20(6):445-52.www.epistemonikos.org/documents/3032d8cbe015b3ec9daa1342e25a854354fbfb8a

463. Wang HH, Zhang CZ, Zhang BL, Chen J, Zeng XL, Deng L, Meng MB. Sublobar resection is associated with improved outcomes over radiotherapy in the management of high-risk elderly patients with Stage I non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(4):6033-6042.www.epistemonikos.org/documents/305afb76d1a52291499a514976dd6d0afce2cad4

464. Qian H, Wang H, Guan X, Yi Z, Ma F. Adoptive immunotherapy combined chemoradiotherapy for non-small-cell lung cancer: a meta-analysis. Anti-cancer drugs. 2016;27(5):433-8. www.epistemonikos.org/documents/306526329eff8a548df6a3ec75b33003a4eb47e1

465. Jiang M, Li X, Quan X, Li X, Zhou B. Clinically Correlated MicroRNAs in the Diagnosis of Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. BioMed research international. 2018;2018:5930951. www.epistemonikos.org/documents/306752f034912845b82fe15dd14d6af1ff2f57ad

466. Dhanasekaran SM, Balbin OA, Chen G, Nadal E, Kalyana-Sundaram S, Pan J, Veeneman B, Cao X, Malik R, Vats P, Wang R, Huang S, Zhong J, Jing X, Iyer M, Wu YM, Harms PW, Lin J, Reddy R, Brennan C, Palanisamy N, Chang AC, Truini A, Truini M, Robinson DR, Beer DG, Chinnaiyan AM. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nature communications. 2014;5(no pagination):5893.www.epistemonikos.org/documents/30cc43830548c02b8c9a26ce5badddf2f84caa25

467. Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Hockenhull J, Proudlove C, Dundar Y, Richardson M, Dickson R, Mullard A, Marshall E. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Health technology assessment (Winchester, England). 2015;19(47):1-134. www.epistemonikos.org/documents/310aa8ff298b5eca56d1011ecebc391f457dac2c

468. Fan G, Zhang K, Ding J, Li J. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(20):33922-33932. www.epistemonikos.org/documents/3131ba96b5ee23141e9bf3431be90ac76642969f

469. Liu Y., Sun L., Xiong Z.-C., Sun X., Zhang S.-L., Ma J.-T., Han C.-B.. Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFRr-TKIs. OncoTargets and Therapy. 2017;10:2267-2279.www.epistemonikos.org/documents/3159af5ff3a2fb629cfa9bc1d912600f9ce39ca4

470. Lu Q, Li CL. Therapeutic efficacy and safety of Kang-ai injection combined with platinum-based doublet chemotherapy in advanced NSCLC: A meta-analysis. Life sciences. 2018;210:9-19. www.epistemonikos.org/documents/31623b94feef914f42b94409d30c7ebd0dca04e0

471. Chaimani A., Dahabreh I., Linardou H., Cappuzzo F., Papadimitriou C., Kosmidis P., Bafaloukos D., Siannis F., Murray S.. Prognostic significance of EGFR gene copy number gain in NSCLC: A systematic review and meta-analysis. Journal of Thoracic Oncology. 2011;:S1005.www.epistemonikos.org/documents/3192405eca4a5c2e214f4514ac36ad136f6ee323

472. Bozcuk H, Artac M, Ozdogan M. Correlates of benefit from neoadjuvant chemotherapy before radiotherapy in non-small cell lung cancer: a meta-analytical approach with meta-regression analysis. Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 2010;15(1):43-50.www.epistemonikos.org/documents/31a1f4d69b97b9008da8ea47a8547ea892314ee6

473. Murray S., Evangelou E., Linardou H., Dahabreh I.J., Kosmidis P., Bafaloukos D., Ioannidis J.P.A.. Predictive significance of EGFR somatic mutations and Gene copy number in NSCLC patients treated with single agent tyrosine kinase inhibitors: A systematic review and meta-analysis. Journal of Thoracic Oncology. 2010;:S55-S56.www.epistemonikos.org/documents/31d50e40508beaf4ec0c52530075b5521d0bbb10

474. Saso S, Rao C, Ashrafian H, Ghaem-Maghami S, Darzi A, Athanasiou T. Positive pre-resection pleural lavage cytology is associated with increased risk of lung cancer recurrence in patients undergoing surgical resection: a meta-analysis of 4450 patients. Thorax. 2012;67(6):526-32.www.epistemonikos.org/documents/32318acaf5ad8fffebe0907c0a9903937cd825ef

475. Mosallanejad Z., Fakhri Y., Ferrante M., Amirhajeloo L.R., Amanidaz N., Zandsalimi Y., Moradi B., Keramati H.. Relationship between exposure to radon and the risk of lung cancer; Systematic review and meta-analysis updated to 2015. International Journal of Pharmacy and Technology. 2016;8(3):4667-4684.www.epistemonikos.org/documents/32328248c0175d50997394d615fb0b167b8e99a0

476. Hendriks LE, Schoenmaekers J, Zindler JD, Eekers DB, Hoeben A, De Ruysscher DK, Dingemans AM. Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: A systematic review. Cancer treatment reviews. 2015;41(7):634-45.www.epistemonikos.org/documents/323762769bb45a7c25d5deecb7ee38c1669f46cc

477. Li Y, Zhang S, Geng JX, Yu Y. Effects of the cyclin D1 polymorphism on lung cancer risk--a meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2012;13(5):2325-8. www.epistemonikos.org/documents/326166dc19355bb09dc23c7a58e3667a11dfe7ba

478. Wang X, Qin Y, Gu J, Wang F, Jia P, Wang H, Yao Q, Zhu S. [Systematic review of studies of workplace exposure to environmental tobacco smoke and lung cancer risk]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2011;14(4):345-50. www.epistemonikos.org/documents/32b7d0a8655897a3a773d3cb21558688d23e00aa

479. Dai L, Duan F, Wang P, Song C, Wang K, Zhang J. XRCC1 gene polymorphisms and lung cancer susceptibility: a meta-analysis of 44 case-control studies. Molecular biology reports. 2012;39(10):9535-47. www.epistemonikos.org/documents/32bf1d1662ffa34c5a152c894d8a2834ef751063

480. Qin H., Zhang K.-Q., Li W.-H., Hao L.-J., Ruan Z.-H.. Combining whole brain radiotherapy with target drug for non-small cell lung cancer with multiple brain metastases: a systematic review. Chinese Journal of Cancer Prevention and Treatment. 2015;22(4):300-304.www.epistemonikos.org/documents/32c43c5a5972447d3baa38f78b5381d1c5fc26cf

481. Liao CY, Chen JH, Liang JA, Yeh JJ, Kao CH. Meta-analysis study of lymph node staging by 18 F-FDG PET/CT scan in non-small cell lung cancer: comparison of TB and non-TB endemic regions. European journal of radiology. 2012;81(11):3518-23. www.epistemonikos.org/documents/330de51afbd78387e5ed29a8f5f0af3e6db44899

482. Chen Y, Huang Y, Huang Y, Chen J, Wang S, Zhou J. The prognostic value of SOX2 expression in non-small cell lung cancer: a meta-analysis. PloS one. 2013;8(8):e71140.www.epistemonikos.org/documents/334f88e758abcd50c25fd570ecde907d4c27e1b6

483. Feng Z, Ni Y, Dong W, Shen H, Du J. Association of ERCC2/XPD polymorphisms and interaction with tobacco smoking in lung cancer susceptibility: a systemic review and meta-analysis. Molecular biology reports. 2012;39(1):57-69. www.epistemonikos.org/documents/336b3720fdd86a712bf032bbc972d17a8c6a0c3d

484. Fu C, Liu Z, Zhu F, Li S, Jiang L. A meta-analysis: is low-dose computed tomography a superior method for risky lung cancers screening population?. The clinical respiratory journal. 2016;10(3):333-41. www.epistemonikos.org/documents/3374db36cee755becf04beb438b1a5b7e4ea7cc6

485. Lange A, Prenzler A, Frank M, Golpon H, Welte T, von der Schulenburg JM. A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer

(NSCLC). BMC pulmonary medicine. 2014;14(1):192. www.epistemonikos.org/documents/337ca4727de56eeb35ea9dd4db2eb85b8989e2a7

486. Tu J., Wang S., Zhao J., Zhu J., Sheng L., Sheng Y., Chen H., Tian J.. rs833061 and rs699947 on Promoter Gene of Vascular Endothelial Growth Factor (VEGF) and Associated Lung Cancer Susceptibility and Survival: A Meta-Analysis. Medical Science Monitor. 2014;20((Tu J., Junweitu@outlook.com; Wang S.; Zhao J.; Zhu J.; Sheng L.; Sheng Y.; Chen H.; Tian J.) Department of Pneumology, Zhejiang University Jinhua Hospital, Jinhua Municipal Central Hospital, Jinhua, China):2520-2526.www.epistemonikos.org/documents/338ef89bd3cc2066f8680925d3ce95a479259dca

487. Lu S., Cheng Y., Zhou C.-C., Wang J., Yang J.C.H., Zhang P.-H., Zhang X.-Q., Wang X., Orlando M., Wu Y.-L.. Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clinical Lung Cancer. 2016;17(5):103-112. www.epistemonikos.org/documents/33a0fdd4602b68e94e4df2453753fb9243abd49e

488. Van Houtte P., Paesmans M., Choy H., Fournel P., Garrido P., Van Meerbeeck J.P., Berghmans T., Sculier J.P.. Adjuvant or induction chemotherapy for non small cell lung cancer treated with chemoradiotherapy: An invidual data metaanalysis of phase ii trials. Journal of Thoracic Oncology. 2013;:S1009-S1010.www.epistemonikos.org/documents/33aa693cb9bf291c5786a558c6ecde92018b4d15

489. Szumera-Ciećkiewicz A, Olszewski WT, Tysarowski A, Kowalski DM, Głogowski M, Krzakowski M, Siedlecki JA, Wągrodzki M, Prochorec-Sobieszek M. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. International journal of clinical and experimental pathology. 2013;6(12):2800-12. www.epistemonikos.org/documents/33e09e47bfc5036a99c69fc89cf3ab621680a2d5

490. Huang F, Pan B, Wu J, Chen E, Chen L. Relationship between exposure to PM2.5 and lung cancer incidence and mortality: A meta-analysis. Oncotarget. 2017;8(26):43322-43331. www.epistemonikos.org/documents/34010106656d8c0134bd0368a81e36c7c37dd867

491. Brenner DR, Yannitsos DH, Farris MS, Johansson M, Friedenreich CM. Leisure-time physical activity and lung cancer risk: A systematic review and meta-analysis. Lung cancer (Amsterdam, Netherlands). 2016;95:17-27. www.epistemonikos.org/documents/342cf09a4f89e0d1bd6d3f4d0e7d027bb318cd4f

492. Chen YJ, Chen LX, Han MX, Zhang TS, Zhou ZR, Zhong DS. The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease: A PRISMA-Compliant Bayesian Meta-Analysis and Systematic Review. Medicine. 2015;94(36):e1451.www.epistemonikos.org/documents/3444dcf53c25c28510f1935ac04059ec90ebdfcd

493. Meert AP, Paesmans M, Berghmans T, Martin B, Mascaux C, Vallot F, Verdebout JM, Lafitte JJ, Sculier JP. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC cancer. 2001;1(no pagination):5.www.epistemonikos.org/documents/3450eb3c3a4ab19186d8cb364a4c14a66df93102

494. Normando SR, Cruz FM, Del Giglio A. Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer. Anti-cancer drugs. 2015;26(9):995-1003. www.epistemonikos.org/documents/3470a4c04ddc771e28a0f1e27642b0b9ff2d47e8

495. Abouarab AA, Rahouma M, Kamel M, Ghaly G, Mohamed A. Single Versus Multi-Incisional Video-Assisted Thoracic Surgery: A Systematic Review and Meta-analysis. Journal of laparoendoscopic & advanced surgical techniques. Part A. 2018;28(2):174-185. www.epistemonikos.org/documents/349bd23160663c76d5688110faaa935ea0b043db

496. Xiao XY, Wang XD, Zang DY. MMP1-1607 1G/2G polymorphism and lung cancer risk: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental

Biology and Medicine. 2012;33(6):2385-92. www.epistemonikos.org/documents/34b3359cfae118ce66461750fc686327c9dca027

497. Zheng X., Reddy R., Schipper M., Ren Y., Chang A., Lin J., Orringer M., Kong F.. Comparisons of local control and survival of stereotactic body radiation therapy versus surgery for stage I non-small cell lung cancer: A meta-analysis. International Journal of Radiation Oncology Biology Physics. 2012;:S553-S554.www.epistemonikos.org/documents/34bd5ffe08016202fdd64a6969bb4f6a9a339cd3

498. Kurmi O., Arya P., Lam H., Ayres J.. Lung cancer risk of solid fuel smoke: A systematic review and meta-analysis. European Respiratory Journal. 2011;www.epistemonikos.org/documents/34df21e1887ddb5e177e79f3934af72aebf201ad

499. Yang Y, Pang Z, Ding N, Dong W, Ma W, Li Y, Du J, Liu Q. The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. Oncotarget. 2016;7(45):74350-74361. www.epistemonikos.org/documents/34e59e6cbd06bde3435d9b6c4752c366c414f50c

500. Douillard JY, Laporte S, Fossella F, Georgoulias V, Pujol JL, Kubota K, Monnier A, Kudoh S, Rubio JE, Cucherat M. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007;2(10):939-46.www.epistemonikos.org/documents/34e809faddd14f87417a6d71914dbf4c00b5a6dd

501. Wang G, Wang W, Gao W, Lv J, Fang J. Two functional polymorphisms in microRNAs and lung cancer risk: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(3):2693-9. www.epistemonikos.org/documents/34e8819cd5c0f752e2c0a29eb6f4d4b8f8379e9d

502. Deng CJ, Dai FQ, Qian K, Tan QY, Wang RW, Deng B, Zhou JH. Clinical updates of approaches for biopsy of pulmonary lesions based on systematic review. BMC pulmonary medicine. 2018;18(1):146. www.epistemonikos.org/documents/34ea07bbeb78d2809c6c84e201708a89ec3a008e

503. Zhou HF, Feng X, Zheng BS, Qian J, He W. A meta-analysis of the relationship between glutathione S-transferase T1 null/presence gene polymorphism and the risk of lung cancer including 31802 subjects. Molecular biology reports. 2013;40(10):5713-21. www.epistemonikos.org/documents/34ee948ca48954eb9a170fbe5bb127692ffc5a57

504. Popat S., Mellemgaard A., Fahrbach K., Martin A., Rizzo M., Kaiser R., Griebsch I., Reck M.. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: A network meta-analysis. Future Oncology. 2015;11(3):409-420. www.epistemonikos.org/documents/34f4e0f93e2cf44a5daa4a49f84c4ab3a6679aa1

505. Houlston RS. CYP1A1 polymorphisms and lung cancer risk: a meta-analysis. Pharmacogenetics. 2000;10(2):105-14.www.epistemonikos.org/documents/35133e9e18d782b18a338bebe74df38cf8efcba7

506. Khunger M, Jain P, Rakshit S, Pasupuleti V, Hernandez AV, Stevenson J, Pennell NA, Velcheti V. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Clinical lung cancer. 2018;19(3):e335-e348.www.epistemonikos.org/documents/35212322126d0f17b23c894ed30f1c190289c66b

507. Qi WX, Sun YJ, Shen Z, Yao Y. Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials. Journal of chemotherapy (Florence, Italy). 2015;27(1):1973947814Y0000000189. www.epistemonikos.org/documents/35216757b1e0dfcacfc9c1e51982039977aea655

508. Gou Y, Zhang L, Yang Q, Zhang R, Guo H, Jiang L, Yang K, Tian J. [A meta analysis of gemcitabine plus platinum chemotherapy compared with single-agent chemotherapy in the treatment of non-small cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer.

2010;13(3):216-23.www.epistemonikos.org/documents/352fba437909a40b9c4a90c9224ed880292a77ba

509. Ding D., Yu Y., Li Z., Niu X., Lu S.. The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis. OncoTargets and Therapy. 2014;7:387-393.www.epistemonikos.org/documents/3533f1efbf169df2bd60a24266131d95dfbc2743

510. Wang Q, Wang Q, Wang SF, Jiao LJ, Zhang RX, Zhong Y, Zhang J, Xu L. Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. Current oncology (Toronto, Ont.). 2017;24(4):e269-e276.www.epistemonikos.org/documents/353e7ab3be0d5a0b12ba8d9fd43f00c84f596e07

511. Wahidi MM, Govert JA, Goudar RK, Gould MK, McCrory DC, American College of Chest Physicians. Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer? ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):94S-107S.www.epistemonikos.org/documents/3562c93113bb543bba03703930b13b9cc1e6d239

512. Ung YC, Yu E, Falkson C, Haynes AE, Stys-Norman D, Evans WK, Lung Cancer Disease Site Group Of Cancer Care Ontario's Program In Evidence-Based Care. The role of high-dose-rate brachytherapy in the palliation of symptoms in patients with non-small-cell lung cancer: a systematic review. Brachytherapy. 2006;5(3):189-202.www.epistemonikos.org/documents/35694f9e5c050cb5f7227b6f6f629a87b7acc19f

513. Special report: maintenance therapy in advanced non-small-cell lung cancer. Technology Evaluation Center Assessment Program. Executive summary. 2011;26(4):1-3.www.epistemonikos.org/documents/35937157deb78054b0b8a573f53e331e47e46adc

514. Le Chevalier T., Brown A., Fitzgerald P., Aristides M., Natale R., Scagliotti G., Vansteenkiste J., Van Meerbeeck J.L., Rosell R., Rudd R.M., Danson S., Thatcher N., Manegold C., Pujol J.-L., Stahel R., Van Zandvijks N., Gridelli C., Crino L., Schiller J.. A meta-analysis of platinum-based GEMZAR in non-small cell lung cancer (NSCLC). Revue de Pneumologie Clinique. 2003;59(5 I):333-335. www.epistemonikos.org/documents/35a51a670c41ee4b0137138552239563fa89e931

515. Wan Q., Yang Y., Li Y.-L.. Efficacy and safety of PD-1 antibody/PD-L1 antibody versus docetaxel in non-small-cell lung cancer: a Meta-analysis. 中国新药杂志 (Chinese Journal of New Drugs). 2018;27(2):229-235. www.epistemonikos.org/documents/35b91da36de4e8bf0ed7d731632177d56d56af8e

516. Wang YH, Shen XD. Human immunodeficiency virus infection and mortality risk among lung cancer patients: A systematic review and meta-analysis. Medicine. 2018;97(15):e0361. www.epistemonikos.org/documents/35e5c8a027973a90d25b8432ef097fd5750115b5

517. Sasse, E C Sr, Lima, J P, Santos, L V, Sasse, A D Sr. Irinotecan plus platinum analog (IP) compared to etoposide plus platinum analog (EP) in extensive stage small cell lung cancer (ED-SCLC): Systematic review with meta-analysis. Journal of Clinical Oncology. 2009;27:8105-8105.www.epistemonikos.org/documents/360873f084d1fe90210402f6c61fc0ece68d1019

518. Des Guetz G., Uzzan B., Nicolas P., Morere J.. Efficacy and safety of doublet compared to single agent in advanced non small cell lung cancer. A systematic review and meta-analysis. Journal of Thoracic Oncology. 2010;:S82. www.epistemonikos.org/documents/362258afb467c624e824555f93d1c7f31e31efa6

519. Zhou YY, Zhang SM, Cai ZG, Zhang H, Wang L, Xu XP, Wu HB. Myeloperoxidase G463A polymorphism and lung cancer risk in Asians: a pooled analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(5):3035-9.www.epistemonikos.org/documents/3627c4a5fae1b6e003b0a2c3a022e3b036696569

520. Tang J., Ni S., Bian A.. Association between psychological factors and lung cancer in a Chinese population: A meta-analysis. International Journal of Clinical and Experimental Medicine. 2016;9(6):11065-11071. www.epistemonikos.org/documents/362e1296e1e68748c0d9a4177982079e356f8d5a

521. Lou-Qian Z, Rong Y, Ming L, Xin Y, Feng J, Lin X. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis. PloS one. 2013;8(1):e54970. www.epistemonikos.org/documents/36312b7834135b2db40b8e54320473e3d4df1e73
522. Pavia M, Bianco A, Pileggi C, Angelillo IF. Meta-analysis of residential exposure to radon gas and lung cancer. Bulletin of the World Health Organization. 2003;81(10):732-8.www.epistemonikos.org/documents/36491ccb20bd4751dfa8290a4f19440d5366d479
523. Li N, Yang L, Ou W, Zhang L, Zhang SL, Wang SY. Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer. PloS one. 2014;9(7):e102777. www.epistemonikos.org/documents/364c11008503c4257e5cc760a36e2297269dc1c0
524. Marta Pelayo Alvarez, Virginie Westeel, Marcela Cortés-Jofré, Xavier Bonfill Cosp. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database of Systematic Reviews. 2013;11(11):CD001990. www.epistemonikos.org/documents/366a3ce568f75bbe813962d42c393eb54e55b7e7
525. Johnson ES, Choi KM. Lung cancer risk in workers in the meat and poultry industries--a review. Zoonoses and public health. 2012;59(5):303-13.www.epistemonikos.org/documents/366f475699209c8e71fcedd86b1c9a7547f38f24
526. Yang Y, Wang X, Yao Q, Qin L, Xu C. Dairy Product, Calcium Intake and Lung Cancer Risk: A Systematic Review with Meta-Analysis. Scientific reports. 2016;6:20624.www.epistemonikos.org/documents/368306dd9722b5b4ec388ee51962c64b04b76e3b
527. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax. 2001;56(8):628-38. www.epistemonikos.org/documents/36a0be0b492a79f2461bb080f264fcd65ff7b4d8
528. WANG J, GAO J, HE J. [Diagnostic value of ProGRP and NSE for small cell lung cancer: a meta-analysis]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2010;13(12):1094-100. www.epistemonikos.org/documents/36bd94b581c8b6a3ce9886240887217563ff48b6
529. Liu Y, Yuan D, Ye W, Lv T, Song Y. Prognostic value of circulating endothelial cells in non-small cell lung cancer patients: a systematic review and meta-analysis. Translational lung cancer research. 2015;4(5):610-618. www.epistemonikos.org/documents/36d2b1599002895229170280cd18bbba6a982a26
530. Roviello, Giandomenico, Zanotti, Laura, Cappelletti, Maria Rosa, Gobbi, Angela, Senti, Chiara, Generali, Daniele, Bottini, Alberto. No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials. Clinical Lung Cancer. 2016;17(5):334-340. www.epistemonikos.org/documents/3716f5f80819ab81b300fd34c6d6cc7e60082113
531. Xia Y., Chang S., Ye J., Xue J., Shu Y.. Application effect of fast track surgery for patients with lung cancer: A meta-analysis. Chinese Journal of Lung Cancer. 2016;19(12):827-836. www.epistemonikos.org/documents/3721d9cddb00cacb9aca7299a961f0b6b4510d36
532. Bi N., Shedden K., Kong F.S.. A genetic polymorphism in miR-196a2 is associated with increased risk of lung cancer: A meta-analysis. Journal of Thoracic Oncology. 2012;:S220. www.epistemonikos.org/documents/372e0b4f01270faa92d57796a004855f447f9c44
533. Tiago B de Castria, Edina MK da Silva, Aecio FT Gois, Rachel Riera. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2013;8(8):CD009256. www.epistemonikos.org/documents/37699496b0411c5d344ac81484f9384e37a784d7
534. Edwards TQ. Surveillance Imaging Following Curative-Intent Surgery for Non-Small Cell Lung Carcinoma: A Systematic Review. The University of Texas Medical Branch. 2016;www.epistemonikos.org/documents/37dcd769ce27b552c342919cbbc9425e727892c2

535. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(28):4617-25. www.epistemonikos.org/documents/37f7d3e9e8edc3bad0157580e228bccea9456604

536. Youroukou A, Gkiozos I, Kalaitzi Z, Tsalafoutas I, Papalla K, Charpidou A, Kouloulias V. The potential role of brachytherapy in the irradiation of patients with lung cancer: a systematic review. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2017;19(8):1-6. www.epistemonikos.org/documents/3818644c6ac2e7dd8c811aa76a8f544ba1b275d8

537. Guan P, Yin Z, Li X, Wu W, Zhou B. Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. Journal of experimental & clinical cancer research : CR. 2012;31(1):54. www.epistemonikos.org/documents/382fbe7f9052c70ea12e1c2d83646803f23c5bf0

538. Yuan Y, Huang Q, Gu C, Chen H. Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated meta-analysis. Journal of thoracic disease. 2017;9(12):5314-5321. www.epistemonikos.org/documents/38348e0102e01b2f8d6a5c3cfe9b154ceec7c619

539. Ye Z., Zhang X., Luo Y., Li S., Huang L., Li Z., Li P., Chen G.. Prognostic values of vimentin expression and its clinicopathological significance in non-small cell lung cancer: A meta-analysis of observational studies with 4118 cases. PLoS ONE. 2016;11(9):e0163162.www.epistemonikos.org/documents/383748e8266c0bcf7dae300d2ef7a4d828741f26

540. Celik I, Gallicchio L, Boyd K, Lam TK, Matanoski G, Tao X, Shiels M, Hammond E, Chen L, Robinson KA, Caulfield LE, Herman JG, Guallar E, Alberg AJ. Arsenic in drinking water and lung cancer: a systematic review. Environmental research. 2008;108(1):48-55.www.epistemonikos.org/documents/3862ccbfc8d1da65d586e6e98da03a0c57d94d83

541. Lima Netto, José Corrêa. Effectiveness of sublobectomy compared to lobectomy for the treatment of lung cancer of non small cell in the early stages. Proportional meta-analysis of case series. Universidade Estadual Paulista. Faculdade de Medicina de Botucatu for the degree of Doutor. 2013;:63-63.www.epistemonikos.org/documents/3877009d9edaabf921a948b3eeb3848c25a3bed3

542. Verougstraete V, Lison D, Hotz P. Cadmium, lung and prostate cancer: a systematic review of recent epidemiological data. Journal of toxicology and environmental health. Part B, Critical reviews. 2003;6(3):227-55. www.epistemonikos.org/documents/3878c8edfae31ecbb0bfa638ab9cf9df7f3f2271

543. Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong W, Liao Y, Du J. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. European journal of cancer (Oxford, England : 1990). 2013;49(3):604-15. www.epistemonikos.org/documents/38a2f276be168b6caf3c72913c50c5dcedd9628b

544. Zhong A., Xing Y., Pan X., Shi M., Xu H.. Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis. OncoTargets and Therapy. 2015;8:3595-3601. www.epistemonikos.org/documents/38ba0d59349bc26863d7cb56160ef80a612a1f2f

545. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. The New England journal of medicine. 1992;327(23):1618-24. www.epistemonikos.org/documents/38d3fecb26abf1e9c8a16ddc21cc7e0690df6a64

546. Xuan Z.-X., Zhang S., Yuan S.-J., Wang W., Yu J.. Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: A meta-analysis. World Journal of Surgical Oncology. 2016;14(1):237. www.epistemonikos.org/documents/38f35c3372c91e459f1050342b3334b33273e5e1

547. Wang B, Zuo Z, Li F, Yang K, Du M, Gao Y. Gefitinib versus Docetaxel in Treated Non-small-cell Lung Cancer: A Meta-analysis. Open medicine (Warsaw, Poland). 2017;12:86-91. www.epistemonikos.org/documents/38f439d8326c07d82f1ed43722fc65027df09020
548. Bearz A, Berretta M, Tirelli U. Clinical Effectiveness and Cost-Effectiveness of Target Therapies for Adult Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Systematic Review. Current cancer drug targets. 2018;18(5):405-409. www.epistemonikos.org/documents/38f43a5a09e2c28faf8d4b077dccf7864b65d972
549. Fan H., Yu H., Deng H., Chen X.. Transforming Growth Factor-(beta)1 rs1800470 polymorphism is associated with lung cancer rrisk: A meta-analysis. Medical Science Monitor. 2014;20((Fan H.; Yu H., huapengyu@aliyun.com; Deng H.; Chen X.) Department of Respiratory Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, China):2358-2362. www.epistemonikos.org/documents/39008fb15f7f6662270f2f69ed5cc0cab6e7bd31
550. Liu X, Xu F, Wang G, Diao X, Li Y. Kanglaite injection plus chemotherapy versus chemotherapy alone for non-small cell lung cancer patients: A systematic review and meta-analysis. Current therapeutic research, clinical and experimental. 2008;69(5):381-411. www.epistemonikos.org/documents/391bcb8e912ba0f40c76bedd662986d0ad92707a
551. Chen H, Senan S, Nossent EJ, Boldt RG, Warner A, Palma DA, Louie AV. Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review. International journal of radiation oncology, biology, physics. 2017;98(3):622-631.www.epistemonikos.org/documents/392156a9b82bc4dc6f60a3eefe36a4425193bed6
552. Zhu L, Yang Z, Wang S, Tang Y. [Erlotinib in the trentment of Advanced Non-small-cell Lung Cancer: A Systematic Review.]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2009;12(12):1229-36. www.epistemonikos.org/documents/392407b2164bbaf86ec1c8de21ef6b5ee1e5e3b9
553. Jia Z., Yin Z., Guan P., Zhou B.. [The Association between Polymorphisms of XPD and Susceptibility of Lung Cancer: A meta Analysis.]. Chinese Journal of Lung Cancer. 2009;12(10):1079-1084. www.epistemonikos.org/documents/39473084211ea9af9c1491ecc443dcdc556014e1
554. Huang H, Shi Y, Huang J, Wang X, Zhang R, Chen H. Circulating Tumor Cells as a Potential Biomarker in Diagnosis of lung cancer: A Systematic Review and Meta-Analysis. The clinical respiratory journal. 2018;12(2):639-645. www.epistemonikos.org/documents/39561aa966c37b014f7c4fb7ce316c76e76a8197
555. Wang WL, Tang ZH, Xie TT, Xiao BK, Zhang XY, Guo DH, Wang DX, Pei F, Si HY, Zhu M. Efficacy and safety of sorafenib for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. Asian Pacific journal of cancer prevention : APJCP. 2014;15(14):5691-6.www.epistemonikos.org/documents/3964d78664d48fe2ab081766552d748c99ebbd2b
556. Duan L, Hu X, Jin Y, Liu R, You Q. Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis. BMC cancer. 2016;16(1):276. www.epistemonikos.org/documents/396fa1cdfbd89ccdfa249eda287d8c57cda5fdcb
557. Qiao Q, Hu W. The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects. Lung. 2013;191(4):369-77.www.epistemonikos.org/documents/397689e046ec10dd4e66abe1e04782c40f0bb6e3
558. Vinas F, Ben Hassen I, Jabot L, Monnet I, Chouaid C. Delays for diagnosis and treatment of lung cancers: a systematic review. The clinical respiratory journal. 2016;10(3):267-71. www.epistemonikos.org/documents/39a040ece1dc1b1d5919bed14c8f42e95b2b8eeb
559. Salah S, Tanvetyanon T, Abbasi S. Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases. Lung cancer (Amsterdam, Netherlands). 2012;75(1):9-14. www.epistemonikos.org/documents/39f58e940386de0d3a25d93e71588dd208d5af35

560. Nie W, Xue L, Sun G, Ning Y, Zhao X. Interleukin-6 -634C/G polymorphism is associated with lung cancer risk: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(5):4581-7.www.epistemonikos.org/documents/3a164db7b5bb0d2f37378b941db7524c9b464897
561. Ma X., Cao L., Wang X., Liu J., Zhang Q., Zhang L.. Efficacy and safety of ramucircumab in treatment of advanced non-small cell lung cancer: A meta analysis. Chinese Journal of Cancer Biotherapy. 2018;25(5):515-521. www.epistemonikos.org/documents/3a34e5ad08896102a548b833be1a40f69e4af852
562. Zhan B, Lu D, Luo P, Wang B. Prognostic Value of Expression of MicroRNAs in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Clinical laboratory. 2016;62(11):2203-2211. www.epistemonikos.org/documents/3a46f413833c82de884609748c8e05858dc0003a
563. Xiao J, He B, Zou Y, Chen X, Lu X, Xie M, Li W, He S, You S, Chen Q. Prognostic value of decreased FOXP1 protein expression in various tumors: a systematic review and meta-analysis. Scientific reports. 2016;6:30437. www.epistemonikos.org/documents/3a6429b331e04274822cfe68f8c049736151a9c8
564. Lee PN, Forey BA. Indirectly estimated absolute lung cancer mortality rates by smoking status and histological type based on a systematic review. BMC cancer. 2013;13(no pagination):189. www.epistemonikos.org/documents/3a68ebcd9772b63b14fce1d3b6646b6b5e800b8b
565. Yu XJ, Dai WR, Xu Y. Survival Outcome after Stereotactic Body Radiation Therapy and Surgery for Early Stage Non-Small Cell Lung Cancer: A Meta-Analysis. Journal of investigative surgery : the official journal of the Academy of Surgical Research. 2017;:1-8.www.epistemonikos.org/documents/3a9dc17f8fe966526c88d182634c1742987a27b5
566. Yan, X-l, Gu, Y-h. Meta - analysis of Kanglaite Injection Combined with NP Regimen Chemotherapy for Advanced Non - small Cell Lung Cancer. Chinese General Practice. 2013;4:431-435. www.epistemonikos.org/documents/3aa67c69bb51eb46d416dd60f6741fa3044c90b9
567. Rebollo-Aguirre AC, Ramos-Font C, Villegas Portero R, Cook GJ, Llamas Elvira JM, Romero Tabares A. Is FDG-PET suitable for evaluating neoadjuvant therapy in non-small cell lung cancer? Evidence with systematic review of the literature. Journal of surgical oncology. 2010;101(6):486-94.www.epistemonikos.org/documents/3abbabc219320bfb07055bbbb4dabf906ddebe00
568. Bablekos GD, Analitis A, Michaelides SA, Charalabopoulos KA, Tzonou A. Management and postoperative outcome in primary lung cancer and heart disease co-morbidity: a systematic review and meta-analysis. Annals of translational medicine. 2016;4(11):213. www.epistemonikos.org/documents/3acf072f37479d34f9526bc95483689b7c7c13e8
569. Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, Aupérin A, Le Chevalier T, Stephens RJ, Arriagada R, Higgins JP, Johnson DH, Van Meerbeeck J, Parmar MK, Souhami RL, Bergman B, Douillard JY, Dunant A, Endo C, Girling D, Kato H, Keller SM, Kimura H, Knuuttila A, Kodama K, Komaki R, Kris MG, Lad T, Mineo T, Piantadosi S, Rosell R, Scagliotti G, Seymour LK, Shepherd FA, Sylvester R, Tada H, Tanaka F, Torri V, Waller D, Liang Y, for the Non-Small Cell Lung Cancer Collaborative Group. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2015;3(3):CD011430.www.epistemonikos.org/documents/3ad9ae17d4e70d60eeb1ce8cca2cfc9e3061aade
570. Yang H.-B., Xing M., Ma L.-N., Feng L.-X., Yu Z.. Prognostic significance of neutrophil-lymphocyteratio/platelet-lymphocyteratioin lung cancers: A meta-analysis. Oncotarget. 2016;7(47):76769-76778. www.epistemonikos.org/documents/3adb20d53f48bfe9fab58f162aaacbd6cfecbbf3
571. Zhang J, Wu J, He Q, Liang W, He J. The prognostic value of metformin for advanced non-small cell lung cancer: a systematic review and meta-analysis. Translational lung cancer research. 2018;7(3):389-396. www.epistemonikos.org/documents/3af19dc68dbc722ebc25bddf555172d7e0a78a47

572. Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y, Song Y. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer investigation. 2010;28(6):661-9. www.epistemonikos.org/documents/3b11544ab8212ee9aba8ac1e2d5dc30ab694e5f6
573. Ren JH, He WS, Yan GL, Jin M, Yang KY, Wu G. EGFR mutations in non-small-cell lung cancer among smokers and non-smokers: a meta-analysis. Environmental and molecular mutagenesis. 2012;53(1):78-82. www.epistemonikos.org/documents/3b142f832bbb3f77f8b81fae0f511cfa4868d85d
574. Zheng X., Wang K., Xu L., Ye P., Cai S., Lu H., Bao C., Kong J.. The effect of serum lactate dehydrogenase levels on lung cancer prognosis: A meta-analysis. International Journal of Clinical and Experimental Medicine. 2017;10(10):14179-14186. www.epistemonikos.org/documents/3b248f159f85f60fa4f029663e67cce8f56d213a
575. O'Rourke N, Macbeth F. Is concurrent chemoradiation the standard of care for locally advanced non-small cell lung cancer? A review of guidelines and evidence. Clinical oncology (Royal College of Radiologists (Great Britain)). 2010;22(5):347-55. www.epistemonikos.org/documents/3b44a6b2dad3c98a41706ec98090bfd29081c492
576. Deng B, Qian K, Zhou JH, Tan QY, Wang RW. Optimization of Chest Tube Management to Expedite Rehabilitation of Lung Cancer Patients After Video-Assisted Thoracic Surgery: A Meta-Analysis and Systematic Review. World journal of surgery. 2017;41(8):2039-2045.www.epistemonikos.org/documents/3b64a6b0bdcbdf035b43dbc774c95135f1666c6f
577. Luchini C, Veronese N, Nottegar A, Cheng M, Kaneko T, Pilati C, Tabbò F, Stubbs B, Pea A, Bagante F, Demurtas J, Fassan M, Infante M, Cheng L, Scarpa A. Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis. Virchows Archiv : an international journal of pathology. 2018;472(6):939-947. www.epistemonikos.org/documents/3babfe0cc3a7e9f06227acd9c411ee0cd4f4f052
578. Kachuri L, Latifovic L, Liu G, Hung RJ. Systematic review of genetic variation in chromosome 5p15.33 and telomere length as predictive and prognostic biomarkers for lung cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2016;25(12):1537-1549. www.epistemonikos.org/documents/3bbf98f82de7d7965709d73d1d266e729bb0d444
579. Jin F, Qian C, Qing Y, Zhang Z, Wang G, Shan J, Dai N, Li Z, Wang D. Genetic polymorphism of APE1 rs1130409 can contribute to the risk of lung cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(7):6665-71.www.epistemonikos.org/documents/3bc2161b8210650fdc82496b9f7ffc637d647b43
580. Deng L.-B., Li X.-G., Ming W.-D.. Radiofrequency ablation for the treatment of advanced non-small-cell lung cancer: A meta-analysis. Journal of Interventional Radiology (China). 2013;22(12):1000-1006. www.epistemonikos.org/documents/3be28b47cd3fc13e3d2f21254d3a241aca72a3de
581. Mei XD, Su H, Song J, Dong L. Prognostic significance of β-catenin expression in patients with non-small cell lung cancer: a meta-analysis. Bioscience trends. 2013;7(1):42-9. www.epistemonikos.org/documents/3be744b7af3b7f8ad5c0359ac38c60c0d532014d
582. Chen W, Wang Q, Liu M, Ding XB. The association of APE1 Asp148Glu gene polymorphisms and lung cancer risk: an updated meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(4):3597-603.www.epistemonikos.org/documents/3c09e92a2aa9f00be7fb01ca81d121bcec44b5c6
583. Chen S., Flower A., Ritchie A., Liu J., Molassiotis A., He Y., Lewith G.. Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: A systematic review. European Journal of Integrative Medicine. 2010;:179. www.epistemonikos.org/documents/3c7c5297f852bd64575c478b2e017acb7513894b
584. Liang H, Liang W, Zhao L, Chen D, Zhang J, Zhang Y, Tang S, He J. Robotic Versus Video-assisted Lobectomy/Segmentectomy for Lung Cancer: A Meta-analysis. Annals of surgery.

2018;268(2):254-259. www.epistemonikos.org/documents/3c855902120b0c1ec1bfadb7a2a2ca21cca67111

585. Wang Q, Wang M, He X, Gao T, Cao H, Dou W, Tian J. [Meta-analysis on treatment of non-small cell lung cancer with brucea javanica oil emulsion in combination with platinum-contained first-line chemotherapy]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. 2012;37(13):2022-9.www.epistemonikos.org/documents/3cf7cf33ff1e37eee55aa005dea5e0912d6e742d

586. Falkson CB, Vella ET, Yu E, El-Mallah M, Mackenzie R, Ellis PM, Ung YC. Radiotherapy With Curative Intent in Patients With Early-stage, Medically Inoperable, Non-Small-cell Lung Cancer: A Systematic Review. Clinical lung cancer. 2017;18(2):105-121.e5. www.epistemonikos.org/documents/3d106179d631d0b93d89e9df16c301a96bd20139

587. Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010;5(2):260-74. www.epistemonikos.org/documents/3d20221b2ba128559bda5589b7ba7f1c99515405

588. TanTai J, Shen Y, Zhao H. Quantitative assessment of the influence of common variations on 6p21 and lung cancer risk. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(1):689-94. www.epistemonikos.org/documents/3d2b147ea151f893cc1307470ecb12f7fd267004

589. Batista N, Tee J, Sciubba D, Sahgal A, Laufer I, Weber M, Gokaslan Z, Rhines L, Fehlings M, Patel S, Raja Rampersaud Y, Reynolds J, Chou D, Bettegowda C, Clarke M, Fisher C. Emerging and established clinical, histopathological and molecular parametric prognostic factors for metastatic spine disease secondary to lung cancer: Helping surgeons make decisions. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2016;34:15-22.www.epistemonikos.org/documents/3d55b811b1d09562320073c80ffb94a6e67d3c71

590. Coureau G, Salmi LR, Etard C, Sancho-Garnier H, Sauvaget C, Mathoulin-Pélissier S. Low-dose computed tomography screening for lung cancer in populations highly exposed to tobacco: A systematic methodological appraisal of published randomised controlled trials. European journal of cancer (Oxford, England : 1990). 2016;61:146-56.www.epistemonikos.org/documents/3d62d8625c96e72db8cd87978254495371df79a2

591. Hasegawa Y., Kawaguchi T., Kubo A., Ando M., Shiraishi J., Isa S., Tsuji T., Tsujino K., Nakagawa K., Takada M.. Ethnic difference in toxicity in non-small cell lung cancer patients treated with chemotherapy: A systematic review on phase II and III clinical trials. Journal of Clinical Oncology. 2010;www.epistemonikos.org/documents/3d78f570c1f4d7cb8782c83c43e4243197af01ab

592. Li D., Zhu X., Wang H., Qiu M., Li N.. Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis. Journal of Thoracic Disease. 2017;9(2):310-317. www.epistemonikos.org/documents/3d88480452e4714c937abd978f46f7cd8bbc618f

593. Jiang H, Zhao W, Shao W. Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer: meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(8):7383-9.www.epistemonikos.org/documents/3da857adcb0ed247d73f172adb83d624a02dba2a

594. von Meyenfeldt EM, Gooiker GA, van Gijn W, Post PN, van de Velde CJ, Tollenaar RA, Klomp HM, Wouters MW. The relationship between volume or surgeon specialty and outcome in the surgical treatment of lung cancer: a systematic review and meta-analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012;7(7):1170-8. www.epistemonikos.org/documents/3db768252a7940170612e2620b33ac9e3819f462

595. Jia, Y, Lacouture, M E, Su, X, Wu, S. Effect of chemotherapy on the risk of erlotinib-induced skin rash in cancer patients: A meta-analysis. Journal of Clinical Oncology. 2009;27:9573-9573. www.epistemonikos.org/documents/3db941200f15307e18dd4ae646062a81230b6be6

596. Liu Y., Liu Y., Fan Z.-W., Li J., Xu G.-G.. Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib. European Journal of Clinical Pharmacology. 2015;71((Liu Y.; Liu Y.; Fan Z.-W.; Li J.) Department of Respiratory Medicine, Chinese PLA Air Force General Hospital, Beijing, China):541-7. www.epistemonikos.org/documents/3dd555d277af9077b63446575b8e464f53630881

597. Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Current medical research and opinion. 2006;22(3):561-73. www.epistemonikos.org/documents/3dea965041fc38e8a68e25b577bf7599f1c53eb8

598. Palma DA, Senan S, Oberije C, Belderbos J, de Dios NR, Bradley JD, Barriger RB, Moreno-Jiménez M, Kim TH, Ramella S, Everitt S, Rengan R, Marks LB, De Ruyck K, Warner A, Rodrigues G. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. International journal of radiation oncology, biology, physics. 2013;87(4):690-6. www.epistemonikos.org/documents/3deefa4d32a31def10bc4ea0c8549fcd9d45d4bf

599. Xiao, Na, Zhou, Xianmei. Meta-analysis on treatment of non-small cell lung cancer with Xiaoaiping injection in combination with platinum-contained first-line chemotherapy. 2013;(33):3669-3674. www.epistemonikos.org/documents/3e051a22695e86662da738124794b4266a89c88c

600. Zer A, Ding K, Lee SM, Goss GD, Seymour L, Ellis PM, Hackshaw A, Bradbury PA, Han L, O'Callaghan CJ, Tsao MS, Shepherd FA. Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(3):312-23.www.epistemonikos.org/documents/3e0d63e54e5a779dc8e3d740fb5f51949a124b42

601. Zhou C, An H, Hu M, Liu Q, Geng P, Xu J, Sun B, Liu C. The cyclin D1 (CCND1) G870A polymorphism and lung cancer susceptibility: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(6):3831-7.www.epistemonikos.org/documents/3e204cf8b3edcc6991f57c372f4b8a186a5c57de

602. Zhang X.-N., Huang L.. Neoadjuvant chemotherapy followed by surgery versus upfront surgery in non-metastatic non-small cell lung cancer: Systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2017;8(52):90327-90337. www.epistemonikos.org/documents/3e3836e80740be301eb8734e9cf8353bb45f0a28

603. Zhao N. [Meta-analysis of smoking and lung cancer in China: combined analysis of fifteen case-control studies]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 1993;14(6):350-4. www.epistemonikos.org/documents/3e3c38e15f4cce4d454820be933d29726b0c6af6

604. Wang J, Chen J, Chen X, Wang B, Li K, Bi J. Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis. PloS one. 2011;6(12):e28844. www.epistemonikos.org/documents/3e5ff9f2accf57d13663f1411ea7c85964fd06d0

605. Xiao BK, Yang JY, Dong JX, Ji ZS, Si HY, Wang WL, Huang RQ. Meta-analysis of seven randomized control trials to assess the efficacy and toxicity of combining EGFR-TKI with chemotherapy for patients with advanced NSCLC who failed first-line treatment. Asian Pacific journal of cancer prevention : APJCP. 2015;16(7):2915-21.www.epistemonikos.org/documents/3e7390c0e111d6d58a8a7e0b24bde7c59313c5cb

606. Zhao, Qiuling, Xie, Ruixiang, Lin, Shen, You, Xiang, Weng, Xiuhua. Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of

Randomized Clinical Trials. BioMed Research International. 2018;2018:1-9. www.epistemonikos.org/documents/3e80b05144204572695337a245ccb0889326324f

607. Mei J., Xiao Z., Guo C., Pu Q., Ma L., Liu C., Lin F., Liao H., You Z., Liu L.. Prognostic impact of tumor-associated macrophage infiltration in non-small cell lung cancer: A systemic review and meta-analysis. Oncotarget. 2016;7(23):34217-34228. www.epistemonikos.org/documents/3e849a74d05e6ffc4cdbf43ee5a2401cf0615545
608. Chang C.-J., Tu Y.-K., Chen P.-C., Yang H.-Y.. Occupational Exposure to Talc Increases the Risk of Lung Cancer: A Meta-Analysis of Occupational Cohort Studies. Canadian Respiratory Journal. 2017;2017(no pagination):1270608. www.epistemonikos.org/documents/3e9229eae165c79e9d1aa20c1e7c98509e1bcefa
609. Jin J., Hu K., Zhou Y., Li W.. Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis. PLoS ONE. 2017;12(9):e0184412.www.epistemonikos.org/documents/3e977baee606f4b71b3e346b3d5ccd1314df18db
610. Qiu ZX, Zhao S, Li L, Li WM. Prognostic value and clinicopathological significance of epithelial cadherin expression in non-small cell lung cancer. Thoracic cancer. 2015;6(5):589-96. www.epistemonikos.org/documents/3e9899dc3ebdf684dd7d4c9001cddb49e88282f9
611. Toloza EM, Harpole L, Detterbeck F, McCrory DC. Invasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003;123(1 Suppl):157S-166S.www.epistemonikos.org/documents/3ea46a825552e2f54378bce69fe8fa7ec66a2d6d
612. Soo RA, Loh M, Mok TS, Ou SH, Cho BC, Yeo WL, Tenen DG, Soong R. Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011;6(6):1030-8. www.epistemonikos.org/documents/3eb3dee0cdb57abeb6b3288e78182677fc821174
613. Wang H., Wu S., Zhao L., Zhao J., Liu J., Wang Z.. Clinical use of microRNAs as potential non-invasive biomarkers for detecting non-small cell lung cancer: A meta-analysis. Respirology. 2015;20(1):56-65. www.epistemonikos.org/documents/3eb632ff3e1ee121cc240853b5ba0fa717f45c45
614. Yang X, Guo Y, Du Y, Yang J, Li S, Liu S, Li K, Zhang D. Serum microRNA-21 as a diagnostic marker for lung carcinoma: a systematic review and meta-analysis. PloS one. 2014;9(5):e97460. www.epistemonikos.org/documents/3ec38b0cddf5a816b1f5cd5f3f48f68f8b390bef
615. Ye X, Xie L, Chen G, Tang JM, Ben XS. Robotic thoracic surgery versus video-assisted thoracic surgery for lung cancer: a meta-analysis. Interactive cardiovascular and thoracic surgery. 2015;21(4):409-14. www.epistemonikos.org/documents/3ec8dd63d18d0b248eef1e197af56221e55e3390
616. Zhang X., Zhou J.-G., Wu H.-L., Ma H., Jiang Z.-X.. Diagnostic accuracy of PCR for detecting ALK gene rearrangement in NSCLC patients: A systematic review and meta-analysis. Oncotarget. 2017;8(43):75400-75410. www.epistemonikos.org/documents/3ed7b9cd707808bd579be3a2ec2c7b0a56f8cd4b
617. Cheng Z, Shan F, Yang Y, Shi Y, Zhang Z. CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis. BMC medical imaging. 2017;17(1):5. www.epistemonikos.org/documents/3eeb1ba43a7fa2d5bf4fe74a482844f7c913e349
618. Qiang G., Liang C., Xiao F., Yu Q., Wen H., Song Z., Tian Y., Shi B., Guo Y., Liu D.. Prognostic significance of platelet-to-lymphocyte ratio in non-small-cell lung cancer: A meta-analysis. OncoTargets and Therapy. 2016;9:869-876. www.epistemonikos.org/documents/3efd738c5f74796e1f8e9962959cff84c738dd40
619. Ellis PM, Blais N, Soulieres D, Ionescu DN, Kashyap M, Liu G, Melosky B, Reiman T, Romeo P, Shepherd FA, Tsao MS, Leighl NB. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung

Cancer. 2011;6(8):1379-91. www.epistemonikos.org/documents/3f275f495a4ecca503df7e2b3f5ac1869e8b1abf

620. Brenner DR, Boffetta P, Duell EJ, Bickeböller H, Rosenberger A, McCormack V, Muscat JE, Yang P, Wichmann HE, Brueske-Hohlfeld I, Schwartz AG, Cote ML, Tjønneland A, Friis S, Le Marchand L, Zhang ZF, Morgenstern H, Szeszenia-Dabrowska N, Lissowska J, Zaridze D, Rudnai P, Fabianova E, Foretova L, Janout V, Bencko V, Schejbalova M, Brennan P, Mates IN, Lazarus P, Field JK, Raji O, McLaughlin JR, Liu G, Wiencke J, Neri M, Ugolini D, Andrew AS, Lan Q, Hu W, Orlow I, Park BJ, Hung RJ. Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. American journal of epidemiology. 2012;176(7):573-85.www.epistemonikos.org/documents/3f290964d8d40d0a9b3a7c0ef04c0ce9f91f8457
621. Zhang D, Zhang X, Zhao C. Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review. OncoTargets and therapy. 2016;9:3695-704. www.epistemonikos.org/documents/3f40c8fa04285781da5af48863ce2469a94933f7
622. Zhang T, Guo Q, Zhang Y, Liu Z, Zhou S, Xu S. Meta-analysis of adjuvant chemotherapy versus surgery alone in T2aN0 stage IB non-small cell lung cancer. Journal of cancer research and therapeutics. 2018;14(1):139-144. www.epistemonikos.org/documents/3f46f3962aa3bae520eb54b7d06d794a7d02165a
623. Le HQ, Tomenson JA, Warheit DB, Fryzek JP, Golden AP, Ellis ED. A Review and Meta-Analysis of Occupational Titanium Dioxide Exposure and Lung Cancer Mortality. Journal of occupational and environmental medicine. 2018;60(7):356-356. www.epistemonikos.org/documents/3fb4b05c805ae9b441fdde789359d64b8bb284e3
624. Lv ShP, Wang Y, Huang L, Wang F, Zhou JG, Ma H. Meta-Analysis of Serum Gastrin-Releasing Peptide Precursor as a Biomarker for Diagnosis of Small Cell Lung Cancer. Asian Pacific journal of cancer prevention : APJCP. 2017;18(2):391-397. www.epistemonikos.org/documents/3ff675b8a2be332f85de4e6bb3edcea17fc066dd
625. Tan M, Song X, Zhang G, Peng A, Li X, Li M, Liu Y, Wang C. Statins and the risk of lung cancer: a meta-analysis. PloS one. 2013;8(2):e57349.www.epistemonikos.org/documents/400af3c88643677d685cd5edb37ab3e693431d0d
626. Xia Q., Xu J., Chen H., Gao Y., Gong F., Hu L., Yang L.. Association between an elevated level of HMGBI and non-small-cell lung cancer: A meta-analysis and literature review. OncoTargets and Therapy. 2016;9:3917-3923. www.epistemonikos.org/documents/4022cc526cef798323fc827c49c76011b0d93bd5
627. Abdel-Rahman O. Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma: a systematic review. Immunotherapy. 2016;8(12):1383-1391. www.epistemonikos.org/documents/402b657a513e6f510efd4018f9c33af6c394a2de
628. Chen GC, Zhang ZL, Wan Z, Wang L, Weber P, Eggersdorfer M, Qin LQ, Zhang W. Circulating 25-hydroxyvitamin D and risk of lung cancer: a dose-response meta-analysis. Cancer causes & control : CCC. 2015;26(12):1719-28. www.epistemonikos.org/documents/402c503a576e355e58b5033ac835aa68c58da784
629. You W., Liu M., Miao J.-D., Liao Y.-Q., Song Y.-B., Cai D.-K., Gao Y., Peng H.. A network meta-analysis comparing the efficacy and safety of anti-PD-1 with anti-PD-L1 in non-small cell lung cancer. Journal of Cancer. 2018;9(7):1200-1206. www.epistemonikos.org/documents/403a6fcb33e153d374e2ab09739a90f587caef8f
630. Luo H, Qiao L, Liang N, Zhang J. Risk factors for recurrence in patients with resected N1 non-small cell lung cancer - a systematic review and meta-analysis. Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 2015;20(3):791-9. www.epistemonikos.org/documents/404cbdc27d29785a09fd8fe73c3b74912198c5d9
631. Chen LY, Molina-Vila MA, Ruan SY, Su KY, Liao WY, Yu KL, Ho CC, Shih JY, Yu CJ, Yang JC, Rosell R, Yang PC. Coexistence of EGFR T790M mutation and common activating mutations in

pretreatment non-small cell lung cancer: A systematic review and meta-analysis. Lung cancer (Amsterdam, Netherlands). 2016;94:46-53.www.epistemonikos.org/documents/40521328362f6ff2cb79386176283c19276cab5e

632. Tanaka F, Wada H. [Efficacy of postoperative adjuvant therapy for resected non-small cell lung cancer--an evidence-based review]. Gan to kagaku ryoho. Cancer & chemotherapy. 2006;33(3):300-6. www.epistemonikos.org/documents/4067ab249177d38aafee39c231b5b69be0c530ad

633. Jun X.F., Yun F.. The clinical pathological characters and prognosis of FGFR1 gene amplification in non-small cell lung cancer: A meta-analysis. Journal of Clinical Oncology. 2015; www.epistemonikos.org/documents/4069b7fe2114adbedd005ac7b3d5c96bc6f27c09

634. Le Pechoux C., Mauguen A., Schild S.E., Saunders M.I., Turrisi A., Sause W., Ball D., Belani C.P., Zajusz A., Pignon J.P.. Accelerated or hyperfractionated radiotherapy (RT) versus conventional RT in non metastatic lung cancer (LC): Individual patient data (IPD) meta-analysis from 2279 patients (PTS). Journal of Thoracic Oncology. 2010;:S73.www.epistemonikos.org/documents/406d18022349d202145de1b0566359e752362f89

635. Bi N., Shedden K., Zheng X., Wang W., Kong F.. Comparison of the effectiveness of radiofrequency ablation with stereotactic body radiation therapy in inoperable stage I nonsmall cell lung cancer: A systemic review and meta-analysis. International Journal of Radiation Oncology Biology Physics. 2012;:S611-S612.www.epistemonikos.org/documents/406d5b4ad3136a17b1c20b941321890674d005a5

636. He F, Cai L. [Meta analysis of the association between the expression of microRNA-155 and the outcome of patients with lung cancer]. Wei sheng yan jiu = Journal of hygiene research. 2014;43(6):1004-8. www.epistemonikos.org/documents/407b3249df10ed1f771eb840d3bc75f553c5c43f

637. Wang H., Xie F., Hu Z., Chen L.. Elevated expression of CXCR4 and correlation with clinicopathological features and prognosis of non-small cell lung cancer patients: a meta-analysis. Genetics and Molecular Research. 2015;14(4):17893-17903. www.epistemonikos.org/documents/40b5d7f2ae96c66ffd779e11dfcf6a82415c8bec

638. Han S, Hong Y, Liu T, Wu N, Ye Z. The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2018;9(18):14619-14629. www.epistemonikos.org/documents/40c18ad662d29246b107f8ed1e6de95e06c153fb

639. Tian Y.X., Yu M., Li S., Ren X.P., Liu L.H., Shang W.L., Huo S.F., Ren Y.J., Wen H.X., Yang Z., Wei S.H., Xu L.B., Xiong J.. Role of diagnostic significance of serum p53 antibodies in lung cancer: A meta-analysis. Journal of the American Geriatrics Society. 2014;:S378.www.epistemonikos.org/documents/41504ef7688fba8ca74a7f58a9cf60a43219074d

640. Gamble JF, Nicolich MJ, Boffetta P. Lung cancer and diesel exhaust: an updated critical review of the occupational epidemiology literature. Critical reviews in toxicology. 2012;42(7):549-98. www.epistemonikos.org/documents/41e9b3456dae05100423427b8f625789fedd096c

641. Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2010;95(1):32-40.www.epistemonikos.org/documents/420d35d060a71e7831c222bb33579236b4b1eb91

642. Zeng Y, Liu R, Zhang H. [Meta-analysis of association between E-cadherin promoter methylation and lung cancer risk]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2013;16(7):353-8. www.epistemonikos.org/documents/42165ab5a682a450490775246d9e4117ee828805

643. Hubner RA, Riley RD, Billingham LJ, Popat S. Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PloS one. 2011;6(10):e25164. www.epistemonikos.org/documents/423b1d1f35ea338bd86b494c04eb280370ff2cf2

644. Akamatsu H., Mori K., Harada H., Imai H., Ono A., Taira T., Kenmotsu H., Naito T., Murakami H., Takahashi T.. Surrogate markers of survival in locally advanced non-small cell lung cancer: Meta-analysis from randomized trials. Annals of Oncology. 2013;:ix64. www.epistemonikos.org/documents/423e0fc56a193dbe58302df6c901abf96b0b2fba
645. Li Z, Guo H, Lu Y, Hu J, Luo H, Gu W. Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: a systematic review and meta-analysis. OncoTargets and therapy. 2018;11:3697-3703.www.epistemonikos.org/documents/4246f12d5f01bb9579f2eaa183e57109e0b86bc4
646. Uehara Y, Kiyohara C. Alcohol consumption and lung cancer risk among Japanese: a meta-analysis. Fukuoka igaku zasshi = Hukuoka acta medica. 2010;101(5):101-8.www.epistemonikos.org/documents/424b2b3d4eb83b889a460957ddce4de2d7ebe144
647. Armoiry X, Tsertsvadze A, Connock M, Royle P, Melendez-Torres GJ, Souquet PJ, Clarke A. Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis. PloS one. 2018;13(7):e0199575.www.epistemonikos.org/documents/426d468a910adf40d63a15d124c2eea4ee86dda2
648. Sheng Z, Zhang Y. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs. American journal of clinical oncology. 2017;40((Sheng Z.) *Department of Hematology, Weifang Peoplenulls Hospital, Weifang (dagger)Department of Oncology, Lin Yi Peoplenulls Hospital, Linyi, Shandong, China):362-369.www.epistemonikos.org/documents/42859521401f1c3623dee37af4a2ba0f0a61e511
649. Chen X, Cai L. [Meta-analysis of the effects on hormone replacement therapy and oral contraceptives associated with female lung cancer risk]. Wei sheng yan jiu = Journal of hygiene research. 2009;38(6):672-6. www.epistemonikos.org/documents/42d9b435f9ffe0e9ffcbe0ea9971602856bb3a4e
650. Bai L., Yu N., Li Y., Zhang W., Duan X., Guo Y.. The value of 18FDG PET-CT in the diagnosis of mediastinal lymph node metastasis in non-small cell lung cancer: a Meta-analysis. Chinese Journal of Radiology (China). 2016;50(10):752-757. www.epistemonikos.org/documents/42ffd0de472d2f71122bb790b88ace77a971e858
651. Li X.-L., Tang X.-L., Li Y.-P., Li C.-C., Zhang X.-H.. Efficacy and safety of egfr-tkis versus chemotherapy as the first line treatment for patients with advanced non-small cell lung cancer: A systematic review. Chinese Journal of Evidence-Based Medicine. 2016;16(2):191-199.www.epistemonikos.org/documents/435a3fa0b9219e1e65a50b1db535ef736acb7e93
652. Xie S.-S., Li M., Zhou C.-C., Tan M., Lu K., Zhang G.-L., Peng A.-M., Li X., Liu Y., Song X.-L., Wang C.-H.. Prophylactic cranial irradiation may impose a detrimental effect on overall survival of patients with non-small cell lung cancer: A systematic review and meta-analysis of the literature. Respirology. 2014;:172.www.epistemonikos.org/documents/438ebc31bc6fe21caa0d534b530fa5f367610da9
653. Liang HY, Zhou H, Li XL, Yin ZH, Guan P, Zhou BS. Chemo-radiotherapy for advanced non-small cell lung cancer: concurrent or sequential? It's no longer the question: a systematic review. International journal of cancer. Journal international du cancer. 2010;127(3):718-28.www.epistemonikos.org/documents/43a5894dc7dd9956e5f9b3c25283f793dce81ee8
654. Lan X, Lan T, Faxiang Q. Interleukin-10 promoter polymorphism and susceptibility to lung cancer: a systematic review and meta-analysis. International journal of clinical and experimental medicine. 2015;8(9):15317-15328. www.epistemonikos.org/documents/43acb5fb14bb2149b267a1a296597684b63ca816
655. Goss GD, Logan DM, Newman TE, Evans WK. Use of vinorelbine in non-small-cell lung cancer. Provincial Lung Disease Site Group. Cancer prevention & control : CPC = Prévention & contrôle en cancérologie : PCC. 1997;1(1):28-38. www.epistemonikos.org/documents/43c109522bf1cfb239ca0884f03952344499459b

656. Xu C, Chang Z, Wang X, Li L, Qi H, Liu Y. [A meta analysis of doublets versus single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2012;15(6):361-8. www.epistemonikos.org/documents/43d1ca18d8893bca0775e417f337a113deb9b32e
657. Liu Q.-X., Deng X.-F., Zhou D., Li J.-M., Min J.-X., Dai J.-G.. Visceral pleural invasion impacts the prognosis of non-small cell lung cancer: A meta-analysis. European Journal of Surgical Oncology. 2016;42(11):1707-1713. www.epistemonikos.org/documents/43dc1a1c0a1d9d5958e02347a766b8301e27e669
658. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(19):3860-7.www.epistemonikos.org/documents/43feddb14cb336507651282c0169cd44a64944cf
659. Jia Y, Li F, Liu YF, Zhao JP, Leng MM, Chen L. Depression and cancer risk: a systematic review and meta-analysis. Public health. 2017;149:138-148.www.epistemonikos.org/documents/44182016c81adefec8be4fa54793c5b2cc6e212f
660. Puggina A, Broumas A, Ricciardi W, Boccia S. Cost-effectiveness of screening for lung cancer with low-dose computed tomography: a systematic literature review. European journal of public health. 2016;26(1):168-75. www.epistemonikos.org/documents/443797e3d22dfb645a850cbc338c6a5aaa9934d0
661. Zikos E., Sloan E.K., Ediebah D.E., Coens C., Quinten C., Koller M., Van Meerbeeck J., Flechtner H., Martinelli F., Bottomley A.. Health-related quality of life in small-cell lung cancer: A systematic review on methodological issues in randomized controlled trials. European Journal of Cancer. 2011;:S232.www.epistemonikos.org/documents/4437a5a033d526279ca1a455e68be04046a3ae39
662. Yang Y., Shen J., He J., Jiang G.. A meta-analysis of abnormal beta-catenin immunohistochemical expression as a prognostic factor in lung cancer: location is more important. Clinical and Translational Oncology. 2016;18(7):685-692. www.epistemonikos.org/documents/4442eaa5066bdc99538cf127abff1a485aec3cfd
663. Gou Y.-J., He X.-D., Xie D.-X., Yang K.-H., Liu Y.-L., Zhang J.-H.. Meta analysis on CD133 expression and clinical significance in non-small cell lung cancer. Chinese Journal of Tissue Engineering Research. 2013;17(23):4292-4298. www.epistemonikos.org/documents/444c2599ef3b5351342ae524fca7e09e84a45e41
664. Fan X., Xiu Q.. Effect of X-ray repair cross complementing group 1 polymorphisms on the efficacy of platinum-based chemotherapy in patients with nonsmall cell lung cancer. Journal of Cancer Research and Therapeutics. 2015;11(3):571-574. www.epistemonikos.org/documents/446971feebc49877e06c8cf8e2af920627a3b51d
665. He J, Deng L, Na F, Xue J, Gao H, Lu Y. The association between TGF-β1 polymorphisms and radiation pneumonia in lung cancer patients treated with definitive radiotherapy: a meta-analysis. PloS one. 2014;9(3):e91100. www.epistemonikos.org/documents/446e3a300d71f4f7c2969cc242642e00fed1a8df
666. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet (London, England). 1993;342(8862):19-21. www.epistemonikos.org/documents/44806511e44cdd1e35ca989fad0987fd5127e6cd
667. Ludovic Reveiz, José-Ramón Rueda, Andrés Felipe Cardona. Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2012;12(12):CD004284. www.epistemonikos.org/documents/4487c886cfdfabffa0c903717e5ae1e757e99738
668. Zhang X, Ran Y. Prognostic role of elevated platelet count in patients with lung cancer: a systematic review and meta-analysis. International journal of clinical and experimental medicine.

2015;8(4):5379-87. www.epistemonikos.org/documents/44b271ff244db0275168566cd8d92a3d108807ee

669. Rodriguez-Larrad A, Lascurain-Aguirrebena I, Abecia-Inchaurregui LC, Seco J. Perioperative physiotherapy in patients undergoing lung cancer resection. Interactive cardiovascular and thoracic surgery. 2014;19(2):269-81. www.epistemonikos.org/documents/44b800573da1c15a6fdc2a7506c231fdd9bcad2a

670. Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T, Yang JC. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA oncology. 2018;4(2):210-216.www.epistemonikos.org/documents/44bd7705c32ceaff9e3c03dfdf3e4bbfbeb48a20

671. Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, Lee SH, Heo DS. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA. 2014;311(14):1430-7.www.epistemonikos.org/documents/44e2aac3753b50c2ed239fdf7f407276e37b7ced

672. Sadeghi R., Taghizadeh Kermani A., Bagheri R., Shojaei P., Tehranian S.. Accuracy of sentinel node biopsy in the staging of non-small cell lung carcinomas: Systematic review and meta-analysis of the literature. European Journal of Nuclear Medicine and Molecular Imaging. 2012;:S456.www.epistemonikos.org/documents/450c204fa1e6790957009a284f2879401f36b049

673. Xie F.-J., Lu H.-Y., Zheng Q.-Q., Qin J., Gao Y., Zhang Y.-P., Hu X., Mao W.-M.. The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: A meta-analysis. OncoTargets and Therapy. 2016;9:171-181. www.epistemonikos.org/documents/45248742fbe94336eaa183b827feba4557063b40

674. Zhong H., Qian Y., Fang S., Yang L., Li L., Gu W.. HE4 expression in lung cancer, a meta-analysis. Clinica Chimica Acta. 2017;470:109-114.www.epistemonikos.org/documents/45328ae34002adea1d70e9923176ec11cedf910e

675. Lou Y, Li R, Xiong L, Gu A, Shi C, Chu T, Zhang X, Gu P, Zhong H, Wen S, Han B. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(6):3967-79.www.epistemonikos.org/documents/453420ae2ae919f933a8eeaa0bf8e618ed40703f

676. Zhang H, Gao L, Zhang B, Zhang L, Wang C. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysis. Scientific reports. 2016;6:22618. www.epistemonikos.org/documents/4535f258d68140717b0d0bc72df9c5f1f81bda28

677. Li L, Li X, Yin J, Song X, Chen X, Feng J, Gao H, Liu L, Wei S. The high diagnostic accuracy of combined test of thyroid transcription factor 1 and Napsin A to distinguish between lung adenocarcinoma and squamous cell carcinoma: a meta-analysis. PloS one. 2014;9(7):e100837.www.epistemonikos.org/documents/45554e20568ec511cc1935cbbc9e549ad94b18ee

678. Zhao Y., Wang B., Hu K., Wang J., Lu S., Zhang Y., Lu W., Zhao E., Yuan L.. Glutathione S-Transferase (theta)1 polymorphism contributes to lung cancer susceptibility: A Meta-Analysis of 26 case-control studies. Oncology Letters. 2015;9(4):1947-1953. www.epistemonikos.org/documents/45577278079351b7343311f553b092b28272379b

679. Lim E, Harris G, Patel A, Adachi I, Edmonds L, Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009;4(11):1380-8. www.epistemonikos.org/documents/4564993194500c94db32136abf8fdd9b7ff935e5

680. Zhao J., Shi X., Wang T., Ying C., He S., Chen Y.. The Prognostic and Clinicopathological Significance of IGF-1R in NSCLC: a Meta-Analysis. Cellular Physiology and Biochemistry.

2017;43(2):697-704. www.epistemonikos.org/documents/457398150494f20340ff72c05fca0c35a0968e22

681. Xu L., Tang W.. The associations of nucleotide polymorphisms in mir-196a2, mir-146a, mir-149 with lung cancer risk. Cancer Biomarkers. 2015;15(1):57-63.www.epistemonikos.org/documents/4575c90fe8db1853cdc4ae2e267131aa3e3e7ac3

682. Yao YW, Yuan DM, Lü YL, Li YF, Song Y. [Screening of early lung cancer with low-dose computed tomography in high-risk populations: a meta-analysis]. Zhonghua yi xue za zhi. 2011;91(40):2819-23. www.epistemonikos.org/documents/45861ca5f4a67963545c10b27f341002f4c65ba5

683. Li M, Liu X, Zhang L. The relationship of indoor coal use and environmental tobacco smoke exposure with lung cancer in China: A meta-analysis. Journal of cancer research and therapeutics. 2018;14(Supplement):S7-S13. www.epistemonikos.org/documents/458f73369f944b372278dd73fc7b0fafcb35487c

684. Zhang B, Zhu F, Ma X, Tian Y, Cao D, Luo S, Xuan Y, Liu L, Wei Y. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2014;112(2):250-5. www.epistemonikos.org/documents/45967256f6745c1d16944834903f43eb02cdb9d0

685. Khuder SA, Mutgi AB. Effect of smoking cessation on major histologic types of lung cancer. Chest. 2001;120(5):1577-83.www.epistemonikos.org/documents/45aaee05b6ee04e6a20be15ee69ac5c87468c20f

686. Lee WJ, Brennan P, Boffetta P, London SJ, Benhamou S, Rannug A, To-Figueras J, Ingelman-Sundberg M, Shields P, Gaspari L, Taioli E. Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2002;7(3):230-41.www.epistemonikos.org/documents/45bbf49e823681a4811fb8d4700f991a6399ef99

687. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane database of systematic reviews (Online). 2010;5(5):CD007309. www.epistemonikos.org/documents/45bf7abd59cc555aa26dd54412232405abd25f55

688. Gong B, Jiang N, Yan G, Wang S, Deng C, Wei S, Zhao Y. Predictors for Severe Acute Esophagitis in Lung Cancer Patients Treated with chemoradiotherapy: a systematic review. Current medical research and opinion. 2016;32(10):1-33. www.epistemonikos.org/documents/45e09c0ced7bb3fc6d860044768a534aede2652f

689. Zhao Y, Wang S, Aunan K, Seip HM, Hao J. Air pollution and lung cancer risks in China--a meta-analysis. The Science of the total environment. 2006;366(2-3):500-13.www.epistemonikos.org/documents/45ed55b1b2f5f43c63a64f5d2f8836f923c93d46

690. Bongers ML, Coupé VM, Jansma EP, Smit EF, Uyl-de Groot CA. Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. PharmacoEconomics. 2012;30(1):17-34. www.epistemonikos.org/documents/4614ab02e9dee7beff75e8e086a20659bbb94d02

691. Davidson PM, Jiwa M, Digiacomo ML, McGrath SJ, Newton PJ, Durey AJ, Bessarab DC, Thompson SC. The experience of lung cancer in Aboriginal and Torres Strait Islander peoples and what it means for policy, service planning and delivery. Australian health review : a publication of the Australian Hospital Association. 2013;37(1):70-8.www.epistemonikos.org/documents/461befffb038d556b7f2e62abc0976a044d45415

692. Petrelli F., Borgonovo K., Cabiddu M., Cremonesi M., Guarneri P., Lonati V., Barni S.. Anaemia risk with anti-EGFR agents in advanced non small cell lung cancer - A meta-analysis of 10 trials. European Journal of Cancer. 2011;:S631. www.epistemonikos.org/documents/463d23e0bd13404aecd8b0ce8ac24295d571f5ae

693. Zhu L., Jing S., Wang B., Wu K., Shenglin M.A., Zhang S.. Anti-PD-1/PD-L1 Therapy as a Promising Option for Non-Small Cell Lung Cancer: a Single arm Meta-Analysis. Pathology and Oncology Research. 2016;22(2):331-339. www.epistemonikos.org/documents/46a2a297a4721f3e53414466a21a4f0bdcc3cb3d
694. Liu L., Zheng F.. IL-10 -1082A/G, -592C/A, and -819T/C polymorphisms in association with lung cancer susceptibility: A meta-analysis. OncoTargets and Therapy. 2016;9:6083-6091. www.epistemonikos.org/documents/46b8de33b682c481fb67c21ce39eeaed04cd498e
695. Ye Z, Song H, Higgins JP, Pharoah P, Danesh J. Five glutathione s-transferase gene variants in 23,452 cases of lung cancer and 30,397 controls: meta-analysis of 130 studies. PLoS medicine. 2006;3(4):e91. www.epistemonikos.org/documents/46e2ae83eac6be4ab4219754c5b34370d461e7ae
696. Messori A, Trippoli S, Tendi E. G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation. Journal of clinical pharmacy and therapeutics. 1996;21(2):57-63.www.epistemonikos.org/documents/47177feb0f3f29c8b7b41cd533f384831a5828a4
697. Zhao QT, Yang ZX, Yang L, Xing D, Wei JC, Li WY. Diagnostic value of bone-specific alkaline phosphatase in lung carcinoma patients with bone metastases: a meta-analysis. International journal of clinical and experimental medicine. 2015;8(10):17271-80. www.epistemonikos.org/documents/478ea989c258360c0c42bb371f63a2fdaff42769
698. Guetz G.D., Uzzan B., Chouahnia K., Nicolas P., Morere J.F.. Is there a benefit on survival of tyrosine-kinase inhibitors versus chemotherapy in first line in mutated EGFR patients with advanced non-small cell cancer (NSCLC)? A meta-analysis. Journal of Clinical Oncology. 2012;www.epistemonikos.org/documents/47eee79d317441c638017a6ad2a59664f63d4e1b
699. Peng WJ, He Q, Yang JX, Wang BX, Lu MM, Wang S, Wang J. Meta-analysis of association between cytokine gene polymorphisms and lung cancer risk. Molecular biology reports. 2012;39(5):5187-94. www.epistemonikos.org/documents/481049f2919d3824d1fbc413aee9b3dfa83d7a84
700. Zheng H, Wang Z, Shi X, Wang Z. XRCC1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. Lung cancer (Amsterdam, Netherlands). 2009;65(3):268-73. www.epistemonikos.org/documents/48465e015035e6a9724813641848974d3894aac4
701. Gu C, Lu J, Cui T, Lu C, Shi H, Xu W, Yuan X, Yang X, Huang Y, Lu M. Association between MGMT promoter methylation and non-small cell lung cancer: a meta-analysis. PloS one. 2013;8(9):e72633. www.epistemonikos.org/documents/48527c8e9e82dd7752f9b53630ba174f7830cce1
702. Uy C, Lopez J, Trinh-Shevrin C, Kwon SC, Sherman SE, Liang PS. Text Messaging Interventions on Cancer Screening Rates: A Systematic Review. Journal of medical Internet research. 2017;19(8):e296. www.epistemonikos.org/documents/488f86e565366372ec722e0aa5b1f649a09c3392
703. Zhou JG, Tian X, Wang X, Tian JH, Wang Y, Wang F, Zhang Y, Ma H. Treatment on advanced NSCLC: Platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials. Medical oncology (Northwood, London, England). 2015;32(2):471.www.epistemonikos.org/documents/48aa750930831b58bafd887802e45bb63782ecba
704. Zheng C, Yu G, Wang H, Tang A, Geng P, Zhang H, Zhu Z, Li F, Xie X. Meta-analysis of chemotherapy and dendritic cells with cytokine-induced killer cells in the treatment of non-small-cell lung cancer. International journal of clinical and experimental medicine. 2015;8(8):14527-37.www.epistemonikos.org/documents/48b4c72cefa0a5f6f07e62ace7584ecf7e614ba6
705. Wang Q, Ke J, Song Q, Hu W, Lu X, Wang Z, Gong H, Xu T, Chen X, Xu B, Liu C, Sun Y, Gong Y, Yang Y, Zhu Y. The SNP rs931794 in 15q25.1 Is Associated with Lung Cancer Risk: A Hospital-Based Case-Control Study and Meta-Analysis. PloS one.

2015;10(6):e0128201.www.epistemonikos.org/documents/48cb7434f20bc408b82a3a8f6ea384354ed0a5a8

706. Roca E, Gurizzan C, Amoroso V, Vermi W, Ferrari V, Berruti A. Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis. Cancer treatment reviews. 2017;59:117-122.www.epistemonikos.org/documents/48d5cd950650f310f9c3447e045fabceb1452724

707. Usman Ali M, Miller J, Peirson L, Fitzpatrick-Lewis D, Kenny M, Sherifali D, Raina P. Screening for lung cancer: A systematic review and meta-analysis. Preventive medicine. 2016;89:301-14. www.epistemonikos.org/documents/48dc115c8a1b68252ede6dc1a111901b04ff0c17

708. Pignon J.P.. Individual patient data meta-analysis and radiotherapy in head and neck and lung cancer. Radiotherapy and Oncology. 2010;:S54-S55.www.epistemonikos.org/documents/48e4f1643351e03ba2cce0f44a2afa596c716da0

709. Pochesci A., Trenta P., Iacovelli R., Palleschi M., Prete A.A., Magri V., Mosillo C., Pellegrino D., De Benedetto A., Cortesi E.. Reversible epidermal growth factor receptor tyrosine kinases inihibitors (rEGFR-TKIs), erlotinib or gefitinib, compared to chemotherapy (CHT) in previously treated metastatic non small cell lung cancer (NSCLC) patients (PTS): A meta-analysis. Lung Cancer. 2013;:S32-S33. www.epistemonikos.org/documents/48e9330195f7dcb8864234aceb6380f7dcae9d90

710. LI Xiu, HE Ming-sheng. High-dose chemotherapy assisted with autologous peripheral blood stem cell treatment for small cell lung cancer: a meta-analysis. 中国循证医学杂志 (Chinese Journal of Evidence-Based Medicine). 2012;12(1):49-54. www.epistemonikos.org/documents/49067c5cd6642a026f29cf5719448e3c503e58c3

711. Li G, Gao S, Sheng Z, Li B. The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials. Chemotherapy. 2016;61(4):179-189.www.epistemonikos.org/documents/490d38ab245f3ee654f2d41dd6f0a336fe6b5b08

712. Chen Y.J., Chen L.X., Zhong D.S., Wang J., Peng L., Feng X.. First-line chemotherapy for extensive-disease small cell lung cancer: A network meta-analysis. Chinese Journal of Lung Cancer. 2016;19(4):184-191. www.epistemonikos.org/documents/491cf13182526e9869d201d5e81e0be4ed051c9e

713. Sekine I, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N. Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials. Cancer treatment reviews. 2004;30(4):359-68. www.epistemonikos.org/documents/492da79338b3bfbaaefcf05a81db82ab8f9ee34d

714. Zhao Y.-L., Peng X.-X., Wang Y.-D., Cui S.-Q.. Elemene injections for pulmonary cancer: A systematic review. Chinese Journal of Evidence-Based Medicine. 2005;5(3):216-223+228. www.epistemonikos.org/documents/4957aff59bba3d1785e02a615d6e306fd2e5a5ab

715. Wang R., Tang J.-H., Li R., Tang H.-L., An M.-M., Cai Y., Liang B.-B., Zhang G.-Y., Long L.-Y., Chen L.-A.. Diagnostic value of serum neuron specific enolase in small cell lung cancer patients: A systematic review. Chinese Journal of Evidence-Based Medicine. 2008;8(10):846-850.www.epistemonikos.org/documents/497a11ebffb08af80bde08c51ccbb1bef24a002a

716. Cao H, Wang G, Meng L, Shen H, Feng Z, Liu Q, Du J. Association between circulating levels of IGF-1 and IGFBP-3 and lung cancer risk: a meta-analysis. PloS one. 2012;7(11):e49884. www.epistemonikos.org/documents/4985b6d36f5734d0a3c303a7b34fde40e7630b99

717. Qian H., Gao F., Wang H., Ma F.. The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: A meta-analysis of clinical trials. BMC Cancer. 2014;14(1):683. www.epistemonikos.org/documents/49e1c6328ae8732e11671542cf87f9a5807cddae

718. Zhang LQ, Jiang F, Xu L, Wang J, Bai JL, Yin R, Wu YQ, Meng LJ. The Role of Cyclin D1 Expression and Patient's Survival in Non-Small-Cell Lung Cancer: A Systematic Review With Meta-

Analysis. Clinical lung cancer. 2012;13(3):188-95. www.epistemonikos.org/documents/49e2eaed9255841707930ba98f8411adeeaeef0e

719. Slatore CG, Baumann C, Pappas M, Humphrey LL. Smoking behaviors among patients receiving computed tomography for lung cancer screening. Systematic review in support of the U.S. preventive services task force. Annals of the American Thoracic Society. 2014;11(4):619-27.www.epistemonikos.org/documents/4a1b564baa84f8d790d44741ea716ade3a3326f2

720. Abdel-Rahman O, Fouad M. Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis. Expert review of anticancer therapy. 2015;15(4):1-11. www.epistemonikos.org/documents/4a2cff8817df7a8f994cffbd1d718ddc890d2aa6

721. Hong S, Tan M, Wang S, Luo S, Chen Y, Zhang L. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. Journal of cancer research and clinical oncology. 2015;141((Hong S.; Zhang L., zhangli6@mail.sysu.edu.cn) Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China):909-21. www.epistemonikos.org/documents/4a3dff25eefb3ac3f8df13ce3108e00dcccae43e

722. Chen Z, Liu HB, Yu CH, Wang Y, Wang L, Song Y. Diagnostic value of mutation-specific antibodies for immunohistochemical detection of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis. PloS one. 2014;9(9):e105940.www.epistemonikos.org/documents/4a6a0d47207153e102a83d7bae2613890e79232f

723. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA oncology. 2016;2(12):1607-1616. www.epistemonikos.org/documents/4ab0da7edcad357354f5d9d626008f73c2232a46

724. Wang X., Wei T., Tian L., Wang M., Qi Y., Shang Q.. Association between 1195g>A polymorphism of cyclooxygenase-2 gene with lung cancer risk: A meta-analysis. International Journal of Clinical and Experimental Medicine. 2017;10(9):13440-13445. www.epistemonikos.org/documents/4ab7e0a9769d7da1454edf3f58e19de572224457

725. Xu JL, Jin B, Ren ZH, Lou YQ, Zhou ZR, Yang QZ, Han BH. Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. PloS one. 2015;10(7):e0131278. www.epistemonikos.org/documents/4ac02d8920447a9c52eb809afadeb6062bb95b45

726. Li Y, Qiu LX, Shen XK, Lv XJ, Qian XP, Song Y. A meta-analysis of TP53 codon 72 polymorphism and lung cancer risk: evidence from 15,857 subjects. Lung cancer (Amsterdam, Netherlands). 2009;66(1):15-21. www.epistemonikos.org/documents/4af0e7a9d1d0de46644816b7c15294e7d234b1b4

727. Hu YB, Zhang Q, Li HJ, Michot JM, Liu HB, Zhan P, Lv TF, Song Y, written on behalf of the AME Academic Lung Cancer Cooperation Group. Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Translational lung cancer research. 2017;6(Suppl 1):S8-S20.www.epistemonikos.org/documents/4b2b6c6e77b13b1b10d2468dc1b29286f7b5ea88

728. Zhang W, Wei Y, Yu D, Xu J, Peng J. Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis. Medicine. 2018;97(16):e0460. www.epistemonikos.org/documents/4b3f3a9d3dfd70e90e2052fac5f4b55bc680613c

729. Liu Y., Zhang Y., Feng G., Niu Q., Xu S., Yan Y., Li S., Jing M.. Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non-small cell lung cancer: A network meta-analysis. Experimental and Therapeutic Medicine. 2017;14(5):4017-4032.www.epistemonikos.org/documents/4b45b7fe2cec7e2094cb6c5bbadb45a51b16ca52

730. Granger CL, McDonald CF, Parry SM, Oliveira CC, Denehy L. Functional capacity, physical activity and muscle strength assessment of individuals with non-small cell lung cancer: a

systematic review of instruments and their measurement properties. BMC cancer. 2013;13(no pagination):135.www.epistemonikos.org/documents/4b4a55e85facc5389c24c0142f602cd965919229

731. Fakhri Y., Ghahremanfard F., Avazpour M., Moradi M., Amanidaz N., Zandsalimi Y., Moradi B., Amirhajeloo L.R., Keramati H.. Selenium and lung cancer: A systematic review, meta-analysis and meta-regression. International Journal of Pharmacy and Technology. 2016;8(2):13038-13056.www.epistemonikos.org/documents/4b7202847653bcec5c1995ca916ca9061eaa3462

732. Chen J., Wang J., Wu X., Che X., Zou Y., Weng M., Miao Q., Zheng Q.. Meta-analysis for the efficacy of S-1-based regimens as the first-line treatment in Asian chemotherapy-naive patients with advanced non-small-cell lung cancer. Future Oncology. 2017;13(24):2195-2207.www.epistemonikos.org/documents/4b75fd6d9b05696892318b7e97b3b643d6861fd3

733. Lu Q, Luo JB, Feng YF, She Q, Shi ZF. [Jinlong capsule combined with chemoradiotherapy for NSCLC: a Meta-analysis]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. 2015;40(22):4491-6. www.epistemonikos.org/documents/4b844b3cfe251bd5eb282f40128448ca8a34bde1

734. Xu XL, Dan L, Chen W, Zhu SM, Mao WM. Neoadjuvant chemoradiotherapy or chemotherapy followed by surgery is superior to that followed by definitive chemoradiation or radiotherapy in stage IIIA (N2) nonsmall-cell lung cancer: a meta-analysis and system review. OncoTargets and therapy. 2016;9:845-53.www.epistemonikos.org/documents/4b8bd456a1550449912792d2a5f71bcd325cb80b

735. Gao M, Wang Y, Shi Y, Liu D, Liang Y, Yu Y, Zhaobin J, Zhu L, Jin S. The relationship between three well-characterized polymorphisms of the angiotensin converting enzyme gene and lung cancer risk: a case-control study and a meta-analysis. Journal of the renin-angiotensin-aldosterone system : JRAAS. 2012;13(4):455-60.www.epistemonikos.org/documents/4ba5a9cc6c1a5693ffc8d4cc1f013259d735a78f

736. Pellegrino B, Facchinetti F, Bordi P, Silva M, Gnetti L, Tiseo M. Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature. Clinical lung cancer. 2018;19(2):e151-e161. www.epistemonikos.org/documents/4baec606c86982982417b4a27e3f3df633ecfb14

737. Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, Paesmans M, Steels E, Verdebout JM, Sculier JP. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. The European respiratory journal. 2002;20(4):975-81.www.epistemonikos.org/documents/4bc891ee6f369e6d05df89b4c2a32812a02f59c7

738. Deng XF, Jiang L, Liu QX, Zhou D, Hou B, Cui K, Min JX, Dai JG. Lymph node micrometastases are associated with disease recurrence and poor survival for early-stage non-small cell lung cancer patients: a meta-analysis. Journal of cardiothoracic surgery. 2016;11:28.www.epistemonikos.org/documents/4bcf1673792044a087effed0c61fd1018f79df32

739. Zhiwei W, Yuan J, Yihui Y, Xin H, Jingtao C, Lei S, Yongjian D. Ventana immunohistochemistry assay for anaplastic lymphoma kinase gene rearrangement detection in patients with non-small cell lung cancer: A meta-analysis. Thoracic cancer. 2017;8(5):471-476. www.epistemonikos.org/documents/4be5c21505f0d43570361f96b780aaeaf67eae35

740. Xiao S., Kuang S.-C., Zhao X.-J., Long W.-F., Yang J.-J.. Meta-analysis of the relationship between ERCC2/XPD 312 gene polymorphism and lung cancer. 中华肿瘤防治杂志 (Chinese Journal of Cancer Prevention and Treatment). 2016;23(3):203-208. www.epistemonikos.org/documents/4c2eca5f8b1d99f1c2682dc0d03a2528a6848db3

741. Qian HH, Xu TS, Cai XQ, Ji TL, Guo HX. Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: A meta-analysis. Clinica chimica acta; international journal of clinical chemistry. 2015;451(Pt B):208-14. www.epistemonikos.org/documents/4c3744c1552f07a43bb29a92012b0251b39120ef

742. Thein KZ, Yeung SJ, Oo TH. Primary thromboprophylaxis (PTP) in ambulatory patients with lung cancer receiving chemotherapy: A systematic review and meta-analysis of randomized

controlled trials (RCTs). Asia-Pacific journal of clinical oncology. 2018;14(3):210-216.www.epistemonikos.org/documents/4c3b9373f40fa76be582b40b08ea3b06e059494d

743. Xue X, Liu Y, Pan L, Wang Y, Wang K, Zhang M, Wang P, Wang J. Diagnosis of multiple primary lung cancer: a systematic review. The Journal of international medical research. 2013;41(6):1779-87. www.epistemonikos.org/documents/4c3f2adba959997fc7fd5513d2880c13a8f625c0

744. Lipsett M, Campleman S. Occupational exposure to diesel exhaust and lung cancer: a meta-analysis. American journal of public health. 1999;89(7):1009-17.www.epistemonikos.org/documents/4c4c2c092e6d7944487ae0acb4d97ad192ee13b4

745. He WJ, Li WH, Jiang B, Wang YF, Xia YX, Wang L. MicroRNAs level as an initial screening method for early-stage lung cancer: a bivariate diagnostic random-effects meta-analysis. International journal of clinical and experimental medicine. 2015;8(8):12317-26.www.epistemonikos.org/documents/4c5862ba740b2251c5d165c66052a32000c960b8

746. Lv YL, Yuan DM, Wang K, Miao XH, Qian Q, Wei SZ, Zhu XX, Song Y. Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011;6(8):1350-8. www.epistemonikos.org/documents/4c732f9735cb94673b953d7aa4a62aa06b715fc6

747. Sun G, Xue L, Wang M, Zhao X. Lymph node ratio is a prognostic factor for non-small cell lung cancer. Oncotarget. 2015;6(32):33912-8.www.epistemonikos.org/documents/4c80d8c102ea64a2bb13da0e34141ca6414b6c87

748. Chen E, Nguyen J, Cramarossa G, Khan L, Leung A, Lutz S, Chow E. Symptom clusters in patients with lung cancer: a literature review. Expert review of pharmacoeconomics & outcomes research. 2011;11(4):433-9. www.epistemonikos.org/documents/4c83ed843c293103353dd177fc4b772054d119ca

749. Ngamwong Y, Tangamornsuksan W, Lohitnavy O, Chaiyakunapruk N, Scholfield CN, Reisfeld B, Lohitnavy M. Additive Synergism between Asbestos and Smoking in Lung Cancer Risk: A Systematic Review and Meta-Analysis. PloS one. 2015;10(8):e0135798. www.epistemonikos.org/documents/4c8751e6018f1e41c87b1f1b790d212a2a8bda0f

750. Ye XH, Bu ZB, Feng J, Peng L, Liao XB, Zhu XL, Sun XL, Yu HG, Yan DF, Yan SX. Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis. Molecular biology reports. 2014;41(1):373-85. www.epistemonikos.org/documents/4cc162417687a02e3a48a7a2a58d688eded359aa

751. Lin L, Zhao J, Kong N, He Y, Hu J, Huang F, Han J, Cao X. Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors. Oncotarget. 2017;8(34):57379-57385. www.epistemonikos.org/documents/4cc871bba315542a55b1f167a81a8aa923da5821

752. Tomioka K, Saeki K, Obayashi K, Kurumatani N. Risk of Lung Cancer in Workers Exposed to Benzidine and/or Beta-Naphthylamine: A Systematic Review and Meta-Analysis. Journal of epidemiology / Japan Epidemiological Association. 2016;26(9):447-58. www.epistemonikos.org/documents/4cce64f691f13a5450d99fc5cd70ce2b79a71a2e

753. Zeng C, Fan W, Zhang X. RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients--a short report. Cellular oncology (Dordrecht). 2015;38(4):319-25. www.epistemonikos.org/documents/4ce3280980fe8aac58610329e97287a0f0e260fe

754. Han JC, Xu F, Du J, Zhang YJ, Wei YJ, Li HB, Li XD. Serum Osteopontin Levels Correlate with Clinical and Pathological Features in Non-Small Cell Lung Cancer. Analytical and quantitative cytopathology and histopathology. 2015;37(5):295-301. www.epistemonikos.org/documents/4ce9b55a88068cc9642947787a8c80b7d8d98709

755. Wakai K, Matsuo K, Nagata C, Mizoue T, Tanaka K, Tsuji I, Sasazuki S, Shimazu T, Sawada N, Inoue M, Tsugane S, Research Group for the Development and Evaluation of Cancer Prevention

Strategies in Japan. Lung cancer risk and consumption of vegetables and fruit: an evaluation based on a systematic review of epidemiological evidence from Japan. Japanese journal of clinical oncology. 2011;41(5):693-708. www.epistemonikos.org/documents/4d40122fe3096180c761e15ece9cfff362ca2501

756. Li N, Huang HQ, Zhang GS. Association between SOD2 C47T polymorphism and lung cancer susceptibility: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(2):955-9. www.epistemonikos.org/documents/4d5d1a746958add6cde4c3070669c001a3eb8ac8

757. Shen Y, Pang C, Shen K, Wu Y, Li D, Wan C, Liao Z, Yang T, Chen L, Wen F. Diagnostic value of thyroid transcription factor-1 for pleural or other serous metastases of pulmonary adenocarcinoma: a meta-analysis. Scientific reports. 2016;6:19785. www.epistemonikos.org/documents/4d63fad2ea5a10c105f5ff8b9abbdc3014a3a15f

758. Chen E., Zeng Z., Bai B., Zhu J., Song Z.. The prognostic value of CSCs biomarker CD133 in NSCLC: A meta-analysis. Oncotarget. 2016;7(35):56526-56539.www.epistemonikos.org/documents/4db8e11cf2ad8b780f18f08529a69737f7be6ef1

759. Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung cancer (Amsterdam, Netherlands). 2012;78(1):8-15.www.epistemonikos.org/documents/4dbf70c130d3f3581ebea22ecbfbeefea3dee40b

760. Driessen EJ, Peeters ME, Bongers BC, Maas HA, Bootsma GP, van Meeteren NL, Janssen-Heijnen ML. Effects of prehabilitation and rehabilitation including a home-based component on physical fitness, adherence, treatment tolerance, and recovery in patients with non-small cell lung cancer: A systematic review. Critical reviews in oncology/hematology. 2017;114:63-76. www.epistemonikos.org/documents/4debc9ba16c130fd6a5d3e4e4a86861e05f4e5a9

761. Wang L, Zhang X, Liu J, Shen L, Li Z. Tea consumption and lung cancer risk: a meta-analysis of case-control and cohort studies. Nutrition (Burbank, Los Angeles County, Calif.). 2014;30(10):1122-7. www.epistemonikos.org/documents/4dfa981fed1e439f64cd5af3b28d835f7967944f

762. ZHANG Rong-hui, Paerhati • Tayier, ZHANG Jian-qing, YANG Mei, BAI Ge, ZHANG Li. Comparison of platinum-based doublet versus non-platinum single-agent as first line chemotherapy in the elderly with advanced non-small cell lung cancer: a meta-analysis. 中华肿瘤防治杂志 (Chinese Journal of Cancer Prevention and Treatment). 2013;20(15):1194-1199. www.epistemonikos.org/documents/4e1d85bc961904da384ef0f08097c51818dea860

763. Raaschou-Nielsen O, Andersen ZJ, Beelen R, Samoli E, Stafoggia M, Weinmayr G, Hoffmann B, Fischer P, Nieuwenhuijsen MJ, Brunekreef B, Xun WW, Katsouyanni K, Dimakopoulou K, Sommar J, Forsberg B, Modig L, Oudin A, Oftedal B, Schwarze PE, Nafstad P, De Faire U, Pedersen NL, Ostenson CG, Fratiglioni L, Penell J, Korek M, Pershagen G, Eriksen KT, Sørensen M, Tjønneland A, Ellermann T, Eeftens M, Peeters PH, Meliefste K, Wang M, Bueno-de-Mesquita B, Key TJ, de Hoogh K, Concin H, Nagel G, Vilier A, Grioni S, Krogh V, Tsai MY, Ricceri F, Sacerdote C, Galassi C, Migliore E, Ranzi A, Cesaroni G, Badaloni C, Forastiere F, Tamayo I, Amiano P, Dorronsoro M, Trichopoulou A, Bamia C, Vineis P, Hoek G. Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). The lancet oncology. 2013;14(9):813-22. www.epistemonikos.org/documents/4e2d91229a1536f26b7ab2a12059010af32f6901

764. Erren TC, Glende CB, Morfeld P, Piekarski C. Is exposure to silica associated with lung cancer in the absence of silicosis? A meta-analytical approach to an important public health question. International archives of occupational and environmental health. 2009;82(8):997-1004.www.epistemonikos.org/documents/4e45a7fa930debb35ae16f95a69977d6cf54bf06

765. Wang X, Ling L, Su H, Cheng J, Jin L. Aberrant methylation of genes in sputum samples as diagnostic biomarkers for non-small cell lung cancer: a meta-analysis. Asian Pacific journal of

cancer prevention : APJCP. 2014;15(11):4467-74. www.epistemonikos.org/documents/4e74278d991a0e5a5503d24d4e9630271e1241a8

766. Yi Z, Liu B, Guan X, Ma F. Plasma cell-free DNA and survival in non-small-cell lung cancer: A meta-analysis. Molecular and clinical oncology. 2017;7(2):167-172.www.epistemonikos.org/documents/4eb865d45e7f46327889a52a1839b0ed09b422a0

767. Walker J, Sawhney A, Hansen CH, Symeonides S, Martin P, Murray G, Sharpe M. Treatment of depression in people with lung cancer: a systematic review. Lung cancer (Amsterdam, Netherlands). 2013;79(1):46-53. www.epistemonikos.org/documents/4ef8230a924bdd4ec74f55fe2e03d2becaa1bc16

768. Schmidt-Hansen M, Baldwin DR, Hasler E. What is the most effective follow-up model for lung cancer patients? A systematic review. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012;7(5):821-4.www.epistemonikos.org/documents/4f1d679c0040527c6d50c2b2d775457b2daae3f2

769. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(13):2181-90.www.epistemonikos.org/documents/4f29042e943d8a0af2d93e6ac337c9ea25910810

770. Liu S, Wang D, Chen B, Wang Y, Zhao W, Wu J. The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status. Lung cancer (Amsterdam, Netherlands). 2011;73(2):203-10.www.epistemonikos.org/documents/4f420051ecb7a364997882d9ee2de27ef023a9e6

771. Xu S, Yang J, Xu S, Zhu Y, Zhang C, Liu L, Liu H, Dong Y, Teng Z, Xing X. Lymphatic vessel density as a prognostic indicator in Asian NSCLC patients: a meta-analysis. BMC pulmonary medicine. 2018;18(1):128. www.epistemonikos.org/documents/4f47eb63a90971dbe0ac0bd6d5e4a61ca860567c

772. Des Guetz G, Uzzan B, Nicolas P, Valeyre D, Sebbane G, Morere JF. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis. Critical reviews in oncology/hematology. 2012;84(3):340-9.www.epistemonikos.org/documents/4f5ef4b025ebacbe0d73e611f462cdc35ab3204a

773. Zhang W., Yang W.-L., Yang S.-Y., Huo S.-F., Shang W.-L., Du J., Lin X.-L., Bu L.-N.. Diagnostic value of white light bronchoscopy combined with autofluorescence bronchoscopy for early diagnosis of lung cancer: A systematic review. Journal of Xi'an Jiaotong University (Medical Sciences). 2011;32(6):733-738.www.epistemonikos.org/documents/4f66da3862e7997b2c6c265fc37504f165b06d6d

774. Quast E, Williams M, School of Health Sciences, University of South Australia, Australia. Distress with breathing in people with lung cancer: a systematic review. Internet Journal of Allied Health Sciences & Practice. 2009;7(4):1-11. www.epistemonikos.org/documents/4f82b8f79a915d6013078c1e54fad78c148261d3

775. Poghosyan H, Sheldon LK, Leveille SG, Cooley ME. Health-related quality of life after surgical treatment in patients with non-small cell lung cancer: a systematic review. Lung cancer (Amsterdam, Netherlands). 2013;81(1):11-26. www.epistemonikos.org/documents/4f905bf7ccfaa15fc8f5205b508dbc685cf1f1cf

776. Khuder SA, Herial NA, Mutgi AB, Federman DJ. Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis. Chest. 2005;127(3):748-54.www.epistemonikos.org/documents/4f9353585e1557eb9b7df41810b5207175b2f624

777. Zhu N., He J., Zhang S., Chen X.. [A Meta-analysis of Platinum Plus Taxanes Regimen on Treating Advanced Non-small Cell Lung Cancer.]. Chinese Journal of Lung Cancer. 2009;12(8):868-874. www.epistemonikos.org/documents/4f95b2e1a59dd3c2fb4371d5fb8f0db108a27d80

778. Liang Y. An expression meta-analysis of predicted microRNA targets identifies a diagnostic signature for lung cancer. BMC medical genomics. 2008;1:61.www.epistemonikos.org/documents/4f9b6ddda44afd18ea6340c888d429c12af7f2d1
779. Wang ZF, Ren SX, Li W, Gao GH. Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis. BMC cancer. 2018;18(1):148. www.epistemonikos.org/documents/4fc59fb5a2b2e0dee105867c46ca3e7964adcc7c
780. Okawara G, Mackay JA, Evans WK, Ung YC, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Management of unresected stage III non-small cell lung cancer: a systematic review. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006;1(4):377-93. www.epistemonikos.org/documents/501d5e11ffcb5e8e1c8d4a4d443888d97064a471
781. Bradbury P., Sivajohanathan D., Chan A., Kulkarni S., Ung Y., Ellis P.M.. Postoperative Adjuvant Systemic Therapy in Completely Resected Non-Small-Cell Lung Cancer: A Systematic Review. Clinical Lung Cancer. 2017;18(3):259-273.e8. www.epistemonikos.org/documents/50430b3464c94a90b415a0e279ef4331b6912016
782. Duan WX, Hua RX, Yi W, Shen LJ, Jin ZX, Zhao YH, Yi DH, Chen WS, Yu SQ. The association between OGG1 Ser326Cys polymorphism and lung cancer susceptibility: a meta-analysis of 27 studies. PloS one. 2012;7(4):e35970. www.epistemonikos.org/documents/506b2028a1646f0068ae7fa66e84ff794a277e8c
783. Hasegawa Y, Ando M, Kubo A, Isa S, Yamamoto S, Tsujino K, Kurata T, Ou SH, Takada M, Kawaguchi T. Human papilloma virus in non-small cell lung cancer in never smokers: a systematic review of the literature. Lung cancer (Amsterdam, Netherlands). 2014;83(1):8-13.www.epistemonikos.org/documents/50bf4899551b7988d09898a8383cbefd60863630
784. Fan J, Fong T, Xia Z, Zhang J, Luo P. The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis. Cancer medicine. 2018;7(10):4993-5005. www.epistemonikos.org/documents/50c9854e7fc11a5585b1aabb78861226a42acac2
785. Zhang C, Li J, Han Y, Jiang J. A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer. Drug design, development and therapy. 2015;9:3267-78. www.epistemonikos.org/documents/50eed26f3e7470bc999fdb6b47b9a001a1d3cdb7
786. Hamra GB, Guha N, Cohen A, Laden F, Raaschou-Nielsen O, Samet JM, Vineis P, Forastiere F, Saldiva P, Yorifuji T, Loomis D. Outdoor particulate matter exposure and lung cancer: a systematic review and meta-analysis. Environmental health perspectives. 2014;122(9):906-11.www.epistemonikos.org/documents/50fcf15b791b2751c809e84b7ac1ae493addb289
787. Ludovic Reveiz, José-Ramón Rueda, Andrés Felipe Cardona. Chemotherapy for brain metastases from small cell lung cancer. Cochrane Database of Systematic Reviews. 2012;6(6):CD007464. www.epistemonikos.org/documents/510d49774613a8eff762f02bf7d4c3f1d3df4441
788. Yu YW, Wang CP, Han YF, Niu JJ, Zhang YZ, Fang Y. [Meta-analysis on related risk factors regarding lung cancer in non-smoking Chinese women]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2016;37(2):268-72. www.epistemonikos.org/documents/51111067714e754ea4df4406c5a645d7e79d8ae1
789. Pouwels S, Fiddelaers J, Teijink JA, Woorst JF, Siebenga J, Smeenk FW. Preoperative exercise therapy in lung surgery patients: A systematic review. Respiratory medicine. 2015;109(12):1495-504. www.epistemonikos.org/documents/511a3b21de5d8cf23403e63bc66a4bd29b8984ca
790. Chen, D, Xie, X, Gao, Y. Meta-analysis of randomized clinical trials of thalidomide-chemotherapy combination regimen for non-small cell lung cancer patients in China. 中国肿瘤临床 (Chinese Journal of Clinical Oncology). 2012;39(22):1818-1823. www.epistemonikos.org/documents/511d77c39f21b44a691f31b8b6c1deb019e3e978

791. Yu B, Zhu X, Liang Z, Sun Y, Zhao W, Chen K. Clinical usefulness of 18F-FDG PET/CT for the detection of distant metastases in patients with non-small cell lung cancer at initial staging: a meta-analysis. Cancer management and research. 2018;10:1859-1864. www.epistemonikos.org/documents/5131ab8ece3d5a2dff439fc2285e122c9e85152c
792. Katz KA. Topical tretinoin, lung cancer, and lung-related mortality. Archives of dermatology. 2008;144(7):945-6.www.epistemonikos.org/documents/51c1f8cd92d4e572a0fd33a509e7f3901fa6641f
793. Qi WX, Wang Q, Jiang YL, Sun YJ, Tang LN, He AN, Min DL, Lin F, Shen Z, Yao Y. Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data. PloS one. 2013;8(2):e55637.www.epistemonikos.org/documents/51d83b213a087c81d141865f18aaf54315e12ef7
794. Bei L, Xiao-Dong T, Yu-Fang G, Jian-Ping S, Zhao-Yu Y. DNA repair gene XRCC3 Thr241Met polymorphisms and lung cancer risk: A meta-analysis. Bulletin du cancer. 2015;102(4):332-9. www.epistemonikos.org/documents/51f39fdd725bdf142e6a93fef6687ec066ff48e9
795. Liu X, Lin XJ, Wang CP, Yan KK, Zhao LY, An WX, Liu XD. Association between smoking and p53 mutation in lung cancer: a meta-analysis. Clinical oncology (Royal College of Radiologists (Great Britain)). 2014;26(1):18-24. www.epistemonikos.org/documents/51fdefff5c3740a3dba67a739e57383b486b6654
796. Lee C.K., Man J., Lord S., Links M., Gebski V., Mok T., Yang J.C.-H.. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. Journal of Thoracic Oncology. 2017;12(2):403-407. www.epistemonikos.org/documents/52429fb57124dcb284ce757a0b6690337a4570e7
797. Nakamura H, Ando K, Shinmyo T, Morita K, Mochizuki A, Kurimoto N, Tatsunami S. Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis. Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia. 2011;17(5):469-80.www.epistemonikos.org/documents/52aa95ffe79da4462079343c6952fc8528ce8a64
798. Chu D, Nguyen J, Koo K, Zeng L, Bedard G, Lam H, Wong E, Popovic M, Chow E. An Update on the Quality of Life Measurements in Lung Cancer Patients Receiving Palliative Radiotherapy: A Literature Review. World journal of oncology. 2013;4(2):67-73. www.epistemonikos.org/documents/52b95d346c577b1acbde3ed2527b1b0fdcbe9264
799. Yan R., Chi L., Zheng X., Sun R., You J., Ye X.. A meta-analysis of serum p16 gene promoter methylation for diagnosis of nonsmall cell lung cancer. Indian Journal of Cancer. 2015;52(6):e116-e118. www.epistemonikos.org/documents/52e1419f2a5ae44cdae834bc3159d8f3afef2703
800. Hu XY, Zhang W, Hu Y, Zhang Y, Gong R, Liang JY, Liu L. A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban. 2016;36(3):313-20. www.epistemonikos.org/documents/532136c235b2d6e3a409f130909ccf8274a5c3f7
801. Fu Y, Li J, Zhang Y. Polymorphisms in the vitamin D receptor gene and the lung cancer risk. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(2):1323-30. www.epistemonikos.org/documents/5336cd36f3daca4c72528ce9e23fe0a3b2b1aed5
802. Li Y., Cheng T., Chen L., Cheng Q.J., Wan H.Y.. Erlotinib versus chemotherapy (Docetaxel/pemetrexed) as second-line therapy in advanced non-small cell lung cancer: A meta-analysis. International Journal of Clinical and Experimental Medicine. 2017;10(3):4606-4617.www.epistemonikos.org/documents/533ab12b61fbd5b7207fcda06b5d37e5fedb28b2
803. Zhang X.-D., Li Y.-T., Yang S.-Y., Li W.. Meta-analysis on MTHFR polymorphism and lung cancer susceptibility in East Asian populations. Biomedical Reports. 2013;1(3):440-446. www.epistemonikos.org/documents/53791809d9d085bbdd96b4cbdc7bd389501ccd22

804. Wink KC, Roelofs E, Solberg T, Lin L, Simone CB, Jakobi A, Richter C, Lambin P, Troost EG. Particle therapy for non-small cell lung tumors: where do we stand? A systematic review of the literature. Frontiers in oncology. 2014;4(OCT):292. www.epistemonikos.org/documents/53900aac73232399538e1ef52ff458b452913a4a
805. Zhang J, Zhang YL, Ma KX, Qu JM. Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis. Thorax. 2013;68(5):442-50. www.epistemonikos.org/documents/53b4b42b635f69f5e4d39239faaf87bd8be168be
806. Deghaidy AA, Nofal LM, Abd-Elmoneium SE, Mahdy NH. Meta-analysis of survival models of lung cancer. The Journal of the Egyptian Public Health Association. 2005;80(1-2):77-126. www.epistemonikos.org/documents/53ec1b660a5959858019a907c4e3dca1a9a21862
807. Li J, Yang M, Li P, Su Z, Gao P, Zhang J. Idiopathic pulmonary fibrosis will increase the risk of lung cancer. Chinese medical journal. 2014;127(17):3142-9.www.epistemonikos.org/documents/541a0151b08e3f674547b2c7ff26e53a4ca3b2da
808. Peters S, Bexelius C, Munk V, Leighl N. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer treatment reviews. 2016;45:139-62. www.epistemonikos.org/documents/5439727716b8c2ef6a49973c7711052046b05609
809. Mounika P.. Helicobacter pylori Infection and Risk of Lung Cancer: A Meta-Analysis. Lung Cancer International. 2013;2013(no pagination):131869.www.epistemonikos.org/documents/54795376d2147dcc85bbd68061d3ddbac18eb930
810. Sun W, Hu G, Long J, Wang D, Liu G, Hu None. Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis. Current medical research and opinion. 2014;30(10):1-23.www.epistemonikos.org/documents/5481f27f2f98cdfe93869a74f9ae959433a388ce
811. Schütte S, Dietrich D, Montet X, Flahault A. Participation in lung cancer screening programs: are there gender and social differences? A systematic review. Public health reviews. 2018;39:23. www.epistemonikos.org/documents/549062fbe8c38a49e8b90127ac569d0ebc6a164e
812. Demetriou CA, Raaschou-Nielsen O, Loft S, Møller P, Vermeulen R, Palli D, Chadeau-Hyam M, Xun WW, Vineis P. Biomarkers of ambient air pollution and lung cancer: a systematic review. Occupational and environmental medicine. 2012;69(9):619-27. www.epistemonikos.org/documents/54b65aa3dc5097a938575221aa02bf0004f21c1e
813. Granger CL, McDonald CF, Berney S, Chao C, Denehy L. Exercise intervention to improve exercise capacity and health related quality of life for patients with Non-small cell lung cancer: a systematic review. Lung cancer (Amsterdam, Netherlands). 2011;72(2):139-53.www.epistemonikos.org/documents/54b9329e6ac17f22c765c6425b6d1b18a4161573
814. Slatore CG, Sullivan DR, Pappas M, Humphrey LL. Patient-centered outcomes among lung cancer screening recipients with computed tomography: a systematic review. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014;9(7):927-34.www.epistemonikos.org/documents/54c29492ae42554146d12cc5848ac377f0121e86
815. Huang D, Zhou Y. Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: A meta-analysis based on 44 studies. Biomedical reports. 2014;2(4):452-462. www.epistemonikos.org/documents/54c62b15b317a3b9a7be1bac3f986cb049b576d3
816. Sim, Esther HA, Yang, Ian A, Wood-Baker, Richard, Bowman, Rayleen V, Fong, Kwun M. Gefitinib for advanced non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2018;1(1):CD006847. www.epistemonikos.org/documents/54d244f24e23258006757589599f6762fe140018

817. Zhu L, Zhang S, Xu X, Wang B, Wu K, Deng Q, Xia B, Ma S. Increased Biological Effective Dose of Radiation Correlates with Prolonged Survival of Patients with Limited-Stage Small Cell Lung Cancer: A Systematic Review. PloS one. 2016;11(5):e0156494. www.epistemonikos.org/documents/54ffa05133ed9d58fc5a1120c5c8ad72ef899044

818. Lyman GH, Barron RL, Natoli JL, Miller RM. Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. Critical reviews in oncology/hematology. 2012;81(3):296-308.www.epistemonikos.org/documents/5534086ed8667d545537f2f17103781b5165500e

819. Hosgood HD, Berndt SI, Lan Q. GST genotypes and lung cancer susceptibility in Asian populations with indoor air pollution exposures: a meta-analysis. Mutation research. 2007;636(1-3):134-43. www.epistemonikos.org/documents/55bccbc3a710de34f1d61359c8db0b934455591a

820. Madelon Pijls-Johannesma, Dirk K M De Ruysscher, Philippe Lambin, Ruud Houben, Isabelle Rutten, Johan F. Vansteenkiste. Early versus late chest radiotherapy in patients with limited-stage small cell lung cancer. Cochrane Database of Systematic Reviews. 2005;(4):CD004700.www.epistemonikos.org/documents/55c703e74abcb1e32465145d01ada6cbb4124cb2

821. Ma Z, Guo W, Gong T, Niu HJ, Wang RW, Jiang YG. CYP1A2 rs762551 polymorphism contributes to risk of lung cancer: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(3):2253-7.www.epistemonikos.org/documents/55ed50c1b3e1ac9483cdd3a558f82c350d62f13a

822. Geng Y, Shao Y, He W, Hu W, Xu Y, Chen J, Wu C, Jiang J. Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2015;37(4):1560-71.www.epistemonikos.org/documents/56132e41ae9561b1c4c49184b60e770a0cdf9713

823. Mi D, Li Z, Yang K, Cao N, Tian J, Ma B. [Thermo-chemotherapy of GP or TP for advanced non-small cell lung cancer: a systematic review]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2012;15(8):456-64. www.epistemonikos.org/documents/5616cee8ecb0496ba6f56420f60f2d85a96ec001

824. Lima J.P.S.N., Dos Santos L.V., Sasse E.C., Sasse A.D.. Irinotecan compared to etoposide in combination with platinum analog in extensive disease small cell lung cancer: Systematic review and metaanalysis with geographic origin sub-analysis. Journal of Thoracic Oncology. 2011;:S313-S314.www.epistemonikos.org/documents/56271bd007b13012336e368c749181efabbfe313

825. Mell LK, Malik R, Komaki R, Movsas B, Swann RS, Langer C, Antonadou D, Koukourakis M, Mundt AJ. Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis. International journal of radiation oncology, biology, physics. 2007;68(1):111-8.www.epistemonikos.org/documents/563dcc598165f0db2f1d4018cbc8c5af015c3dbe

826. Wang S., Lian X., Sun M., Luo L., Guo L.. Efficacy of compound Kushen injection plus radiotherapy on nonsmall-cell lungcancer: A systematic review and meta-Analysis. Journal of Cancer Research and Therapeutics. 2016;12(4):1298-1306. www.epistemonikos.org/documents/56745fb04e846d890a9b55a81bdfdfcbf6386219

827. Bedetti B, Bertolaccini L, Rocco R, Schmidt J, Solli P, Scarci M. Segmentectomy versus lobectomy for stage I non-small cell lung cancer: a systematic review and meta-analysis. Journal of thoracic disease. 2017;9(6):1615-1623. www.epistemonikos.org/documents/567f7ec57294a821e92eebb9392d51f8233afb3e

828. Lee PN. Systematic review of the epidemiological evidence comparing lung cancer risk in smokers of mentholated and unmentholated cigarettes. BMC pulmonary medicine. 2011;11(no pagination):18. www.epistemonikos.org/documents/56895c45c868232c10250b42741325c32df6bd83

829. Zhang L, Wang S, Che X, Li X. Vitamin D and lung cancer risk: a comprehensive review and meta-analysis. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2015;36(1):299-305.www.epistemonikos.org/documents/568e8899582a619c2ec22de8e885c65432a5a679

830. Wang X., Ding X., Kong D., Zhang L., Guo Y., Ren J., Hu X., Yang J., Gao S.. The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: a meta-analysis. International Journal of Clinical Oncology. 2017;22(2):1-8.www.epistemonikos.org/documents/56a1af34edb3612d18c1cf9102bd091e5871e66c

831. Murray S., Evangelou E., Linardou H., Kosmidis P., Bafaloukos D., Ioannidis J.. Predictive and prognostic significance of somatic mutations in the tyrosine kinase (TK) domain of EGFR in nsclc patients treated with single agent gefitinib: A systematic review and meta-analysis. Annals of Oncology. 2008;:viii105.www.epistemonikos.org/documents/56a5a5bb0fe2ea502730e05c985d1960fc5f8a24

832. Koo HJ, Do KH, Lee JB, Alblushi S, Lee SM. Lung Cancer in Combined Pulmonary Fibrosis and Emphysema: A Systematic Review and Meta-Analysis. PloS one. 2016;11(9):e0161437. www.epistemonikos.org/documents/56c5ffeea46ef16f31cf77e4af7012619365d16b

833. Aguiar P.N., Santoro I.L., Tadokoro H., De Lima Lopes G., Filardi B.A., Oliveira P., Mountzios G., De Mello R.A.. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: A network meta-analysis. Immunotherapy. 2016;8(4):479-488.www.epistemonikos.org/documents/56cf4be4566bc7a42562123e46db8a4024722383

834. Sharkey K., Hatton A., Mileshkin L.. The current status of clinical research for the management of the supportive care needs of lung cancer patients or their families: A systematic review. Asia-Pacific Journal of Clinical Oncology. 2009;:A256. www.epistemonikos.org/documents/56f769570736b96dfcb3b16666da3defe7abc3ca

835. Min Tun N., Nayak A.. Differential effect of erlotinib on survival of patients with non-small cell lung cancer in terms of EGFR status: A meta-analysis. Journal of Clinical Oncology. 2012; www.epistemonikos.org/documents/57056380967ccf989c87fdbe185c60ac422b4e4f

836. Ding N, Pang Z, Shen H, Ni Y, Du J, Liu Q. The Prognostic Value of PLR in Lung Cancer, a Meta-analysis Based on Results from a Large Consecutive Cohort. Scientific reports. 2016;6:34823. www.epistemonikos.org/documents/571402ba47369495dfad2f9a2cd430487937f316

837. Jiang J, Huang L, Liang X, Zhou X, Huang R, Chu Z, Zhan Q. Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Acta oncologica (Stockholm, Sweden). 2011;50(4):582-8.www.epistemonikos.org/documents/57343cae9f9100eb22545f51960864061ede1b6b

838. Ambroise D, Wild P, Moulin JJ. Update of a meta-analysis on lung cancer and welding. Scandinavian journal of work, environment & health. 2006;32(1):22-31.www.epistemonikos.org/documents/574e1218eaadffbf472065e8326eb34e46466545

839. Gu J., Zhou Y., Huang L., Ou W., Wu J., Li S., Xu J., Feng J., Liu B.. TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis. Molecular and Clinical Oncology. 2016;5(6):705-713. www.epistemonikos.org/documents/5764a5b3cce970fa27e3d575ae7bbc61f2bc2a71

840. Pak K, Park S, Cheon GJ, Kang KW, Kim IJ, Lee DS, Kim EE, Chung JK. Update on nodal staging in non-small cell lung cancer with integrated positron emission tomography/computed tomography: a meta-analysis. Annals of nuclear medicine. 2015;29((Pak K., ilikechopin@daum.net; Kim I.-J., injkim@pusan.ac.kr) Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea):409-19.www.epistemonikos.org/documents/576cd2c17e64c2dd16bfdf296598f00e14758459

841. Des Guetz G., Landre T., Nicolas P., Vergnenegre A., Chouaid C.. Anti PD-1 (nivolumab, pembrolizumab) or anti PD-L1 (atezolizumab) versus docetaxel for previously treated patients with

advanced NSCLC: A meta-analysis. ASCO 2016. Published in: Journal of Clinical Oncology. 2016;34(15):e20555.www.epistemonikos.org/documents/57798d3d60a34d241ac4408c9bc213de44a81fe7

842. Luo S, Chen L, Chen X, Xie X. Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases. Oncotarget. 2015;6(18):16725-34. www.epistemonikos.org/documents/581e7a2c792792d440694719f16626bd5c473c56

843. Kim BJ, Kim JH, Kim HS. Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review. Oncotarget. 2017;8(31):51779-51785. www.epistemonikos.org/documents/5836d46e7c203c75949c4e3d008e1de401dc8c58

844. Bao M., Pan Y.-J., Wang R., Li S.-L., Liang J., Yung J.-M., Luo J.. The efficacy of nivolumab for the treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials. International Journal of Clinical and Experimental Medicine. 2017;10(1):153-161.www.epistemonikos.org/documents/5855c960d11baf743ee9f6b2c042a46cb4219a5b

845. Mahar A.L., Fong R., Johnson A.P.. The economic impact of treating advanced lung cancer-a systematic review. Supportive Care in Cancer. 2011;:S290.www.epistemonikos.org/documents/58673b8a852440371f7d69239e4c0c8a7e2a5cac

846. Dubey AK, Gupta U, Jain S. Epidemiology of lung cancer and approaches for its prediction: a systematic review and analysis. Chinese journal of cancer. 2016;35(1):71.www.epistemonikos.org/documents/5877121e2408e8b5d0569a2584046523f3465480

847. Wu T, Xu YH, Ye XL. X-ray repair cross-complementing group 1 Arg194Trp polymorphism is associated with increased risk of lung cancer in Chinese Han population. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(5):2611-5.www.epistemonikos.org/documents/587a72fc7ff2343ccc8b5c06a8c6d3ccc690f8ba

848. Huang L, Dai JM, Fu H. [Comprehensive analysis of asbestos-induced occupational lung cancer and mesothelioma]. Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases. 2013;31(1):19-23.www.epistemonikos.org/documents/58dd1089511e4ad3f7f97c1215cd770f86f7aa96

849. Zhao B, Zhang W, Yu D, Xu J, Wei Y. The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials. Cancer medicine. 2018;7(5):1642-1659. www.epistemonikos.org/documents/58e3b08456cbb7902db576d810294b109344de5d

850. Wan X., Wang J., Cao X.-H., Bao C.-E., Zhou Q.-X., Yang Y.-F.. Does the age affect the efficacy of anti-VEGF agents in advanced non-small-cell lung cancer? A meta-analysis. International Journal of Clinical and Experimental Medicine. 2016;9(8):16157-16163.www.epistemonikos.org/documents/58f828b8e1e4875afcdc4955f45970bdf83f8555

851. Pujol JL, Carestia L, Daurès JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. British journal of cancer. 2000;83(1):8-15.www.epistemonikos.org/documents/591305d8edef19e2b903234b80a30afd5d409d57

852. Song J, Su H, Wang BL, Zhou YY, Guo LL. Fish Consumption and Lung Cancer Risk: Systematic Review and Meta-Analysis. Nutrition and cancer. 2014;66(4):539-49.www.epistemonikos.org/documents/59160135a7f74fb9c6eb3ef1de7c3d239efa932d

853. Zhong C, Liu H, Jiang L, Zhang W, Yao F. Chemotherapy plus best supportive care versus best supportive care in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials. PloS one. 2013;8(3):e58466. www.epistemonikos.org/documents/593f1bcd22b904da4e9e2971bcddd8b69711f0cf

854. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung cancer (Amsterdam, Netherlands). 2007;58(1):95-103. www.epistemonikos.org/documents/5952aa000c306cb78f40bd70909b3176d11746d3

855. Santillan AA, Camargo CA, Colditz GA. A meta-analysis of asthma and risk of lung cancer (United States). Cancer causes & control : CCC. 2003;14(4):327-34.www.epistemonikos.org/documents/595865006ad7b6304a4b85798eb3d573ce7b8378

856. Ruben JD, Ball DL. The efficacy of PET staging for small-cell lung cancer: a systematic review and cost analysis in the Australian setting. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012;7(6):1015-20.www.epistemonikos.org/documents/597f52de078645071050e0b760b3ce1cd898f22e

857. Hasegawa Y., Ando M., Kubo A., Isa S., Yamamoto S., Tsujino K., Kurata T., Ou S.-H.I., Takada M., Koshiol J., Kawaguchi T.. Human papillomavirus in non-small cell lung cancer in never smokers in east Asia: A systematic review of the literature. Journal of Clinical Oncology. 2012;www.epistemonikos.org/documents/5991ac6edcdde3948c2a118e9f3b829d32b732b2

858. Xiong Y., Wang T., Wang M., Zhao J., Li X., Zhang Z., Zhou Y., Liu J., Jia L., Han Y.. Long non-coding RNAs function as novel predictors and targets of non-small cell lung cancer: A systematic review and metaanalysis. Oncotarget. 2018;9(13):11377-11386. www.epistemonikos.org/documents/59a105ebcb2baa111e8f5cf8abd5630195acb5aa

859. He Q., Zhang M., Zhang J., Chen Y., Shen J., Liu Y., Zhong S., Jiang L., Yang C., Zeng Y., Guo M., Chen X., He J., Liang W.. Correlation between epidermal growth factor receptor mutations and nuclear expression of female hormone receptors in non-small cell lung cancer: a meta-analysis. Journal of Thoracic Disease. 2015;7(9):1588-1594.www.epistemonikos.org/documents/59b8480ba2841f87498fcc8f825ebe025c263ae2

860. Nielsen LS, Bælum J, Rasmussen J, Dahl S, Olsen KE, Albin M, Hansen NC, Sherson D. Occupational asbestos exposure and lung cancer--a systematic review of the literature. Archives of environmental & occupational health. 2014;69(4):191-206. www.epistemonikos.org/documents/59f0e08e63d8fbae6f3ee63dfe3acaa70c3fae54

861. Huang L, Zhou JG, Yao WX, Tian X, Lv SP, Zhang TY, Jin SH, Bai YJ, Ma H. Systematic review and meta-analysis of the efficacy of serum neuron-specific enolase for early small cell lung cancer screening. Oncotarget. 2017;8(38):64358-64372. www.epistemonikos.org/documents/59f16459cddd954ec423eb7fb4af0b885fac2ea5

862. Li F., Zhang S.-H., Pang L.-M.. Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer. Oncotarget. 2017;8(49):86816-86827. www.epistemonikos.org/documents/59f3dc4120fc5099bfa5ff09113badf941962314

863. Wang R, Zhang Y, Zhang J, Zhi X. Association of X-ray repair cross-complementing group 1 promoter rs3213245 polymorphism with lung cancer risk. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(3):1739-43.www.epistemonikos.org/documents/59fb736134aeec6c4b1d089f26083ea4b229027f

864. Murray S., Linardou H., Bafaloukos D., Papadimitriou C., Nasioulas G., Kosmidis P.. Technical considerations for somatic EGFR mutational analysis in non-small-cell lung cancer: Recommendations from a systematic review. Forum of Clinical Oncology. 2012;3(2):15-30.www.epistemonikos.org/documents/5a4495666b12f0d3e90e6b42bfc13239e1512850

865. Yang G, Shu XO, Chow WH, Zhang X, Li HL, Ji BT, Cai H, Wu S, Gao YT, Zheng W. Soy food intake and risk of lung cancer: evidence from the Shanghai Women's Health Study and a meta-analysis. American journal of epidemiology. 2012;176(10):846-55. www.epistemonikos.org/documents/5a6fd1468a3b4bcfcb687b4214039a942bb250c6

866. Wei YT, Luo YZ, Feng ZQ, Huang QX, Mo AS, Mo SX. TK1 overexpression is associated with the poor outcomes of lung cancer patients: a systematic review and meta-analysis. Biomarkers in medicine. 2018;12(4):403-413. www.epistemonikos.org/documents/5a96e52d4c9c405f996a1718c135a0b87983e5a6

867. Jiang L., Yang H., He P., Liang W., Zhang J., Li J., Liu Y., He J.. Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry. The American journal of surgical pathology. 2016;40(5):697-703.www.epistemonikos.org/documents/5a97f3ad4316ccd559f8c343665e336554e6e882

868. Zeng L.-M., Yu X.-L., Yu T.-T., Xiao J.-H., Song B., Peng J.-Y.. Efficacy and safety of 125I seed interstitial implantation for lung cancer: A meta-analysis. Chinese Journal of Evidence-Based Medicine. 2015;15(8):957-966. www.epistemonikos.org/documents/5acd9cb2e5706bc676dcc53d8be3ef6756eb56e5

869. Han D, Wang G, Sun L, Ren X, Shang W, Xu L, Li S. Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis. European journal of cancer care. 2017;26(6). www.epistemonikos.org/documents/5ae07607efb8882e940739dca417392f37e859d1

870. Xu W., Jiang X., Xu Z., Ye T., Shi Q.. The Efficacy of Brucea javanica Oil Emulsion Injection as Adjunctive Therapy for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis. Evidence-based Complementary and Alternative Medicine. 2016;2016(no pagination):1-11.www.epistemonikos.org/documents/5afe70a65ed049ebb31ce08c0f4fb818cb5297ba

871. Yi L, Zhang W, Zhang H, Shen J, Zou J, Luo P, Zhang J. Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer. Drug design, development and therapy. 2018;12:2455-2466. www.epistemonikos.org/documents/5b2b77c9ec4fbd92fc0cdff3e20b79071870e7aa

872. Choy H, Gerber DE, Bradley JD, Iyengar P, Monberg M, Treat J, Govindan R, Koustensis A, Barker S, Obasaju C. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: A systematic review of completed and ongoing studies. Lung cancer (Amsterdam, Netherlands). 2015;87(3):232-240. www.epistemonikos.org/documents/5b2dcc1f14fba436db16b64e9f43c20c4490d55a

873. Mokhles S, Macbeth F, Treasure T, Younes RN, Rintoul RC, Fiorentino F, Bogers AJ, Takkenberg JJ. Systematic lymphadenectomy versus sampling of ipsilateral mediastinal lymph-nodes during lobectomy for non-small-cell lung cancer: a systematic review of randomized trials and a meta-analysis. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2017;51(6):1149-1156.www.epistemonikos.org/documents/5b3dfa808bd9240b8fbd230404f9f61cd3efe2ef

874. Ollier M, Chamoux A, Naughton G, Pereira B, Dutheil F. Chest CT Scan Screening for Lung Cancer in Asbestos Occupational Exposure: A Systematic Review and Meta-analysis. Chest. 2014;145(6):1339-46. www.epistemonikos.org/documents/5b5115298619e590e678f05b094b286c9449963e

875. Zheng H, Liu QX, Hou B, Zhou D, Li JM, Lu X, Wu QP, Dai JG. Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis. Oncotarget. 2017;8(34):57356-57364. www.epistemonikos.org/documents/5b6ccd99df8f1a596a5596f89a1148abb109a0b9

876. Zhang X, Shi X, Han B. [Comparison of short-term effect of video-assisted thoracoscopic surgery lobectomy and thoracotomy lobectomy in the treatment of non-small cell lung cancer: a systematic review]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2012;15(7):422-8.www.epistemonikos.org/documents/5b748e1f0bbb9e6d5115b706d6cbd5ba0cae00c8

877. Wang TJ, Zhou BS. Meta-analysis of the potential relationship between exposure to environmental tobacco smoke and lung cancer in nonsmoking Chinese women. Lung cancer (Amsterdam, Netherlands). 1997;16(2-3):145-50. www.epistemonikos.org/documents/5b9461d8e1e9fdb85d73e59c309b7c1371ac27db

878. Pignon J.-P., Stewart L.A., Marino P.. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis. Cancer. 1996;77(11):2413-2414. www.epistemonikos.org/documents/5b9bcbb8dbd59f85a5ee2a05f4905f5011072fa0

879. Qu X, Wang K, Dong W, Shen H, Wang Y, Liu Q, Du J. Association between two CHRNA3 variants and susceptibility of lung cancer: a meta-analysis. Scientific reports. 2016;6:20149. www.epistemonikos.org/documents/5bb8e2f507d2c15da5131d5631d57964efb22caf
880. Lin X, Lu L, Liu L, Wei S, He Y, Chang J, Lian X. Blood lipids profile and lung cancer risk in a meta-analysis of prospective cohort studies. Journal of clinical lipidology. 2017;11(4):1073-1081. www.epistemonikos.org/documents/5bc23a2baf80a53696fe159a019e39ba9fdcd57d
881. Schutte S., Dietrich D., Montet X., Flahault A.. Participation in lung cancer screening programs: Are there gender and social differences? A systematic review. Public Health Reviews. 2018;39(1). www.epistemonikos.org/documents/5bdb3571bd5fb9059f6d0421dee9e3237fdcd3e8
882. Aguiar PN, Santoro IL, Tadokoro H, de Lima Lopes G, Filardi BA, Oliveira P, Castelo-Branco P, Mountzios G, de Mello RA. A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker. Immunotherapy. 2016;8(9):1011-9.www.epistemonikos.org/documents/5bf22e99b07e94079df5f7b68f25d57eb44350ee
883. Wang D.-M., Chen B.-J., Li W.-M., Li J., Chen W.-B.. Risk factors on lung cancer: A meta-analysis. Chinese Journal of Evidence-Based Medicine. 2010;10(12):1446-1449.www.epistemonikos.org/documents/5bfab3400dd791eb5bce52ff20a36b6d6f641655
884. Liu ZB, Shu J, Wang LP, Jin C, Lou ZX. Cytochrome P450 2A6 deletion polymorphism and risk of lung cancer: a meta-analysis. Molecular biology reports. 2013;40(9):5255-9.www.epistemonikos.org/documents/5c06a43d252473cfc54674754e58d281e2b6376c
885. Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. International journal of cancer. 2017;140(12):2805-2819. www.epistemonikos.org/documents/5c42195b2180462904510d7c0e3ea907add458c1
886. Steffens D, Beckenkamp PR, Hancock M, Solomon M, Young J. Preoperative exercise halves the postoperative complication rate in patients with lung cancer: a systematic review of the effect of exercise on complications, length of stay and quality of life in patients with cancer. British journal of sports medicine. 2018;52(5):344.www.epistemonikos.org/documents/5c7a6747a568a35127fd575401703c737c3d59cf
887. Yamamoto H., Takagi H., Goto S., Matsui M., Umemoto T.. A meta-analysis of adjusted and unadjusted observational studies of sleeve lobectomy vs pneumonectomy for non-small cell lung cancer. Thorax. 2011;:A145. www.epistemonikos.org/documents/5c7b2e4a3e5aa113c836811d12ea87b5d755bdf9
888. Ibrahim EM. Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials. Annals of thoracic medicine. 2010;5(3):153-60.www.epistemonikos.org/documents/5c96f5f077882b15432ca45b7d05905c5ec97456
889. Zhang M, Guo H, Zhao S, Wang Y, Yang M, Yu J, Yan Y, Wang Y. Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. Oncotarget. 2016;7(26):39823-39833.www.epistemonikos.org/documents/5c9e5dd5b39689f6ff7fa07362247769be239fd9
890. Qiao G.-L., Qi W.-X., Zheng S.-E., Shen Z., Yao Y.. Association between single nucleotide polymorphism of 309 T/G in murine doubleminute 2 gene and the susceptibility of non-small cell lung cancer: A Meta-analysis. Tumor. 2014;34(1):84-90. www.epistemonikos.org/documents/5cb01be64b269969e7145e177a86726c4e08f7d2
891. De Castria T.B., Castro G., Hoff P.M.. Maintenance chemotherapy (MC) in advanced non-small cell lung cancer (NSCLC): A meta-analysis. Journal of Clinical Oncology. 2014;www.epistemonikos.org/documents/5cba68a66df877ff82db716b9e472e750eca208b
892. Ma G, Deng Y, Jiang H, Li W, Wu Q, Zhou Q. The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis. Clinica chimica acta; international journal of clinical chemistry. 2018;482:101-107.www.epistemonikos.org/documents/5cc8cadbdd415cc14632d0eda7afc88463e84a83

893. Zhao Q.-T., Yuan Z., Zhang H., Zhang X.-P., Wang H.-E., Wang Z.-K., Duan G.-C.. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patients. International Journal of Cancer. 2016;139(1):164-170.www.epistemonikos.org/documents/5ccde6930132e7cda3ae2302586b782a8fba4add
894. Donnadieu N, Paesmans M, Sculier JP. [Chemotherapy of non-small cell bronchial cancers. Meta-analysis of the literature as a function of the extent of the disease]. Revue des maladies respiratoires. 1991;8(2):197-204. www.epistemonikos.org/documents/5cd573b4450d0d38817883952efb132831f652f7
895. Lima JP, dos Santos LV, Sasse EC, Lima CS, Sasse AD. Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010;5(12):1986-93. www.epistemonikos.org/documents/5d7534f8b4aff79a677baa343938dca265e958e5
896. Zhu J, Li W, Zhou J, Chen Y, Zhao C, Zhang T, Peng W, Wang X. The diagnostic value of narrow-band imaging for early and invasive lung cancer: a meta-analysis. Clinics (Sao Paulo, Brazil). 2017;72(7):438-448. www.epistemonikos.org/documents/5da1a02544328c8ce7c4f870d3c33d0b9e161577
897. Chang CH, Chen KY, Young-Xu Y, Kurth T, Orav EJ, Yang PC, Chan KA. The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis. Lung cancer (Amsterdam, Netherlands). 2008;62(2):242-52.www.epistemonikos.org/documents/5dadb83fcd7d46d75ac6cccbed25b2b7eec75fbe
898. Jiang X, Hidru TH, Zhang Z, Bai Y, Kong L, Li X. Evidence of elemene injection combined radiotherapy in lung cancer treatment among patients with brain metastases: A systematic review and meta-analysis. Medicine. 2017;96(21):e6963. www.epistemonikos.org/documents/5db6076703df66c170bbba41ba670dbb3c4a08d0
899. Chen J, Zhao QW, Shi GM, Wang LR. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies. Journal of Zhejiang University. Science. B. 2012;13(11):875-83. www.epistemonikos.org/documents/5dd9ceb75fbd2de85f05314923de9a55c2740910
900. Lin G, Fang F, Yu XJ, Yu L. Meta-analysis of the relationship between p21 Ser31Arg polymorphism and lung cancer susceptibility. Genetics and molecular research : GMR. 2011;10(4):2449-56. www.epistemonikos.org/documents/5de1a739d594dba1f1c475a72375221943229401
901. Alexander M, Burbury K. A systematic review of biomarkers for the prediction of thromboembolism in lung cancer - Results, practical issues and proposed strategies for future risk prediction models. Thrombosis research. 2016;148:63-69. www.epistemonikos.org/documents/5e15b2c06c37cdf920bb5ae46e37044fd6a87be5
902. Huang XP, Zhou WH, Zhang YF. Genetic variations in the IGF-IGFR-IGFBP axis confer susceptibility to lung and esophageal cancer. Genetics and molecular research : GMR. 2014;13(1):2107-19. www.epistemonikos.org/documents/5e18c65078263fa016af30e40d7ecd48f3b8e869
903. Gu J., Ou W., Huang L., Wu J., Li S., Xu J., Feng J., Liu B., Zhou Y.. PTEN expression is associated with the outcome of lung cancer: evidence from a meta-analysis. Minerva medica. 2016;107(5):342-351. www.epistemonikos.org/documents/5e2c80c2926f9989e4fc83419c3feedb4392a633
904. Dickhoff C, Rodriguez Schaap PM, Otten RHJ, Heymans MW, Heineman DJ, Dahele M. Salvage surgery for local recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: a systematic review. Therapeutic advances in medical oncology. 2018;10:1758835918787989.www.epistemonikos.org/documents/5e32b2ffc1086d53d0a7e8061863984bc620c985

905. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Role of preoperative chemotherapy for non-small-cell lung cancer: a meta-analysis. Lung cancer (Amsterdam, Netherlands). 2006;54(3):325-9. www.epistemonikos.org/documents/5e33ab8e8e1303fcb4d0db1cba45e2bbb0681fb0
906. Goulet K, Grignon S. Case report: clozapine given in the context of chemotherapy for lung cancer. Psycho-oncology. 2008;17(5):512-6.www.epistemonikos.org/documents/5e36fa24921182d0330cda6be6e2656ef32f9418
907. Wang X, Zhao H, Lv L, Bao L, Wang X, Han S. Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis. Scientific reports. 2016;6:19239.www.epistemonikos.org/documents/5ea637eb1049fb55406e3946e51721fc00313f44
908. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). American journal of cancer research. 2015;5(9):2892-2911. www.epistemonikos.org/documents/5eb21712e5e7cae3d60d8293d3cc19a91f6b2603
909. Hong C., Mei T., Wang J.. Intercalated combination of chemotherapy and EGFR-TKIs versus chemotherapy alone in the first-line treatment of advanced non-small cell lung cancer: A meta analysis. Chinese Journal of Lung Cancer. 2016;19(12):837-846. www.epistemonikos.org/documents/5ebad370df49e4d39429dd4d0269d22ef77ea03b
910. Raviv Y, Shitrit D, Amital A, Fox B, Rosengarten D, Fruchter O, Bakal I, Kramer MR. Lung cancer in lung transplant recipients: experience of a tertiary hospital and literature review. Lung cancer (Amsterdam, Netherlands). 2011;74(2):280-3. www.epistemonikos.org/documents/5f03ac14208a54f486c1215c37d00294d33eb7d1
911. Fan J., Zhou X., Huang J., Wang X., Che G.. Prognostic roles of PCNA expressions in non-small cell lung cancer: A meta-analysis. International Journal of Clinical and Experimental Medicine. 2016;9(3):5655-5665. www.epistemonikos.org/documents/5f2cc76ed48c5be05b742c1d085abb7be90ed2f6
912. Yang Y, Luo X, Yang N, Feng R, Xian L. The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis. PloS one. 2014;9(11):e111651.www.epistemonikos.org/documents/5f2f2962a282579ccc9bc7e56db306dac5a7db18
913. Cinquini M., Martelli O., Rossi A., Piva S., Farina G., Torri V.. Meta-analysis of published randomized clinical trials (RCTS) comparing platinum/etoposide (PE) versus platinum/topoisomerase 1 inhibitors (PTIS) regimens for extensive-disease small-cell lung cancer (ED-SCLC). Annals of Oncology. 2010;:viii150.www.epistemonikos.org/documents/5f5502ba2120e6a8a0c5c56b7b739b4cbd05c9a3
914. Devine A, Marignol L. Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis. Anticancer research. 2016;36(1):5-12. www.epistemonikos.org/documents/5f6b77e4cf4a55ce4252fd9cef228a52a1f56568
915. Gallicchio L, Boyd K, Matanoski G, Tao XG, Chen L, Lam TK, Shiels M, Hammond E, Robinson KA, Caulfield LE, Herman JG, Guallar E, Alberg AJ. Carotenoids and the risk of developing lung cancer: a systematic review. The American journal of clinical nutrition. 2008;88(2):372-83.www.epistemonikos.org/documents/5f701dde8cc557ad9213e5ef8806c5fce6a2d105
916. Dong S, Du J, Li W, Zhang S, Zhong X, Zhang L. Systematic mediastinal lymphadenectomy or mediastinal lymph node sampling in patients with pathological stage I NSCLC: a meta-analysis. World journal of surgery. 2015;39(2):410-6. www.epistemonikos.org/documents/5f71f1ca66807e540377cadecb418b462809ab86
917. Zhang J., Ma X., Li Y., Song Y., Ma G., Huang J., Zhu C., Liu M.. Microvessel density as a prognostic factor in non-small cell lung cancer: A meta-analysis. International Journal of Clinical

and Experimental Medicine. 2016;9(9):17676-17689. www.epistemonikos.org/documents/5f75070df3d4b781ec3c725d4630989edd101d05

918. Xavier Bonfill Cosp, Consol Serra, Montse Sacristan, Miquel Nogué, Ferran Losa, Jesús Montesinos. Second-line chemotherapy for non-small cell lung cancer. Cochrane database of systematic reviews (Online). 2002;(2):CD002804. www.epistemonikos.org/documents/5f79e9344b3df567affec728c2c3704e42448a23

919. Pijls-Johannesma M, Grutters JP, Verhaegen F, Lambin P, De Ruysscher D. Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review. The oncologist. 2010;15(1):93-103. www.epistemonikos.org/documents/5f834ba4b61ecdef3e9fb012231449daefd6c92b

920. Maziak DE, Markman BR, MacKay JA, Evans WK, Cancer Care Ontario Practice Guidelines Initiative Lung Cancer Disease Site Group. Photodynamic therapy in nonsmall cell lung cancer: a systematic review. The Annals of thoracic surgery. 2004;77(4):1484-91.www.epistemonikos.org/documents/5f8a40a8546174702865255c0cb199bd30dde745

921. Xiao S, Sun S, Long W, Kuang S, Liu Y, Huang H, Zhou J, Zhou Y, Lu X. A meta-analytic review of the association between two common SNPs in miRNAs and lung cancer susceptibility. OncoTargets and therapy. 2018;11:2419-2427. www.epistemonikos.org/documents/5f90e15e59439e8c827d3690ced8d7b7ea02dd29

922. Yu N., Su X., Wang Z., Dai B., Kang J.. Association of Dietary Vitamin A and β-Carotene Intake with the Risk of Lung Cancer: A Meta-Analysis of 19 Publications. Nutrients. 2015;7(11):9309-9324. www.epistemonikos.org/documents/5f91ec06679f1887a29ae8306dcd3ebb27d93990

923. Guo S, Liang Y, Zhou Q. Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/cisplatin as first-line chemotherapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011;6(2):406-8; author reply 408. www.epistemonikos.org/documents/6072c8a930ebbf6ce6a6dfdd5c2345b492061efb

924. Zhang Y, Chen K, Zhang H. [Meta-analysis of risk factors on lung cancer in non-smoking Chinese female]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2001;22(2):119-21. www.epistemonikos.org/documents/608ce5fc2e94d0ef0e115710820763e9a3fd2344

925. Sun Q., Dong M., Chen Y., Zhang J., Qiao J., Guo X.. Prognostic significance of FoxM1 expression in non-small cell lung cancer. Journal of Thoracic Disease. 2016;8(6):1269-1273. www.epistemonikos.org/documents/60a22cbc3e1b80ea38bcb82d63161eb5e18116af

926. Selvaraj G, Wei D, Kaliamurthi S, Keren G. Prognostic Impact of Tissue Inhibitor of Metalloproteinase-1 in Non-Small Cell Lung Cancer: Systematic Review and Meta-Analysis. Current medicinal chemistry. 2018; www.epistemonikos.org/documents/60e7dc69161632f0e04512b0276baba962e9ac6f

927. Liu X, Li Z, Zhang Z, Zhang W, Li W, Xiao Z, Liu H, Jiao H, Wang Y, Li G. Meta-analysis of GSTM1 null genotype and lung cancer risk in Asians. Medical science monitor : international medical journal of experimental and clinical research. 2014;20:1239-45. www.epistemonikos.org/documents/611566220733fd95c11b3cdb32a993a62376db91

928. Petrelli F, Maltese M, Tomasello G, Conti B, Borgonovo K, Cabiddu M, Ghilardi M, Ghidini M, Passalacqua R, Barni S, Brighenti M. Clinical and Molecular Predictors of PD-L1 Expression in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis. Clinical lung cancer. 2018;19(4):315-322.www.epistemonikos.org/documents/6187a87b482005457c0d3180672ec93688c7c3e4

929. Wang S, Zhang Y, Zhang S, Ma S. [Effect of amifostine on locally advanced non-small cell lung cancer patients treated with radiotherapy: a meta-analysis of randomized controlled trials]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2012;15(9):539-44.www.epistemonikos.org/documents/619a3f066e3d5455e935b341d25320068ec48b76

930. Tanvetyanon T, Soares HP, Djulbegovic B, Jacobsen PB, Bepler G. A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007;2(12):1091-7.www.epistemonikos.org/documents/61a523e85361d17987fe457a63fc3c75106dbac2
931. Gu J, Wen Y, Zhu S, Hua F, Zhao H, Xu H, You J, Sun L, Wang W, Chen J, Zhou Q. Association between P(16INK4a) promoter methylation and non-small cell lung cancer: a meta-analysis. PloS one. 2013;8(4):e60107. www.epistemonikos.org/documents/61c7e7bb2b936749cc5679b7706e05ec6dcf4c21
932. Rossi A, Garassino MC, Cinquini M, Sburlati P, Di Maio M, Farina G, Gridelli C, Torri V. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung cancer (Amsterdam, Netherlands). 2010;70(2):119-28. www.epistemonikos.org/documents/621bda30f959e7a6ae5b780c19dce3e703af2eef
933. Qu H, Li R, Liu Z, Zhang J, Luo R. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. International journal of clinical and experimental pathology. 2013;6(11):2644-50. www.epistemonikos.org/documents/6298b3b3a4bc1245b3ed6e3ca72f2b4720e8bced
934. Viani, Gustavo Arruda, Silva, Rondinelli Salvador, Boin, André Campiolo, Ikeda, Veridiana Yuri, Vianna, Bruno Silveira, Santanella, Fernando. Thirty years of prophylactic cranial irradiation in patients with small cell lung cancer: a meta-analysis of randomized clinical trials. J Bras Pneumol. 2012;38(3):372-381.www.epistemonikos.org/documents/62ac5496b905b3b59953643ef1eedc51346fb2f8
935. Lao X, Qin X, Peng Q, Chen Z, Lu Y, Liu Y, Li S. Association of CYP1B1 Leu432Val polymorphism and lung cancer risk: an updated meta-analysis. Lung. 2014;192(5):739-48.www.epistemonikos.org/documents/62c890260abac6fd6a8e3bb74a9a79f0c2d43cb9
936. Zhong H., Zhou R., Feng Y., Zheng G.-X., Liang Y., Zhang J.-Y., Qin X.-Q., Chen W., Wu J.-Q., Zhong Y.-H.. Association of vitamin D receptor gene polymorphism with the risk of lung cancer: A meta-analysis. Journal of Receptors and Signal Transduction. 2014;34(6):500-505.www.epistemonikos.org/documents/62d53124fb2f75ec170f0017e9d3a95fb7cb3e01
937. Harbison C., Stroh C., Lynch T.J., Gandara D.R., O'Byrne K.J., Pirker R., Maier S., Celik I., Weber M.R., Khambata-Ford S.. Patient selection for cetuximab in NSCLC: A systematic review of candidate predictive biomarkers. Journal of Clinical Oncology. 2010;www.epistemonikos.org/documents/62e8ead5e4b2443db9124d37ad444ffaba673952
938. Pujol JL, Barlesi F, Daurès JP. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung cancer (Amsterdam, Netherlands). 2006;51(3):335-45. www.epistemonikos.org/documents/62f5efa4d195b99e5627db82c8192a55771a2e31
939. Chen FF, Zhang D, Wang YL, Xiong B. Video-assisted thoracoscopic surgery lobectomy versus open lobectomy in patients with clinical stage I non-small cell lung cancer: a meta-analysis. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2013;39(9):957-63. www.epistemonikos.org/documents/6301ae2147970c94a8fc67ab10c6bd00fbb27f3e
940. Zhu JC, Yan TD, Morris DL. A systematic review of radiofrequency ablation for lung tumors. Annals of surgical oncology. 2008;15(6):1765-74.www.epistemonikos.org/documents/6308a5b5b50c5e70214f8a93cd0179f3fd232246
941. Zhang W., Hu L., Huang C., Ying J., Zhao N.. Efficacy of EGFR-TKI therapy in patients with brain metastases from non-small-cell lung cancer: A meta-analysis. Tropical Journal of Pharmaceutical Research. 2017;16(11):2761-2772. www.epistemonikos.org/documents/632045913645546136aa91ce20a88307c68bf505
942. Liang W, Wu X, Hong S, Zhang Y, Kang S, Fang W, Qin T, Huang Y, Zhao H, Zhang L. Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses. PloS one.

2014;9(10):e109757.www.epistemonikos.org/documents/634dd3d93b3cb460fbb1e7d2511a33b8ac2f165c

943. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax. 2006;61(2):140-5. www.epistemonikos.org/documents/6358444a56e4b921b311dab22eeebbc5ffe1e067

944. Xu L, Lan H, Su Y, Li J, Wan J. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis. Drug design, development and therapy. 2015;9:2855-65. www.epistemonikos.org/documents/636017f9335981f7c7b4a09ebc5f49207d5cd9ca

945. Xu Y, Fei Y, Zhong W, Zhang L, Zhao J, Li L, Wang M. The Prevalence and clinical characteristics of primary Sjogren's syndrome patients with lung cancer: An analysis of ten cases in China and literature review. Thoracic cancer. 2015;6(4):475-9. www.epistemonikos.org/documents/636469fe4820509b4bdcaaf2536d87f0cfa70129

946. WU Kun-peng, WU Ai-bing, SHEN Xiang, LI Shu-jun, LIANG Ya-hai, YANG Zhi-xiong. Meta-analysis on the association between aspirin risk of lung cancer. 中华肿瘤防治杂志(Chinese Journal of Cancer Prevention and Treatment). 2014;21(1):55-60. www.epistemonikos.org/documents/63697339313616717c62f3246ea51f451ef81ce9

947. Fayerweather W.E.. Meta-analysis of lung cancer in asphalt roofing and paving workers with external adjustment for confounding by coal tar. Journal of Occupational and Environmental Hygiene. 2007;4(SUPPL.1):175-200. www.epistemonikos.org/documents/63a70c20abbfba9ba8701c4cd283408910b02e55

948. Marcela Cortés-Jofré, José-Ramón Rueda, Gilda Corsini-Muñoz, Carolina Fonseca-Cortés, Magali Caraballoso, Xavier Bonfill Cosp. Drugs for preventing lung cancer in healthy people. Cochrane Database of Systematic Reviews. 2012;10(2):CD002141. www.epistemonikos.org/documents/63b7fdee12ddfcf7235b33d5ed9347420c597fe0

949. Xie Y., Qin J., Nan G., Huang S., Wang Z., Su Y.. Coffee consumption and the risk of lung cancer: An updated meta-analysis of epidemiological studies. European Journal of Clinical Nutrition. 2016;70(2):199-206. www.epistemonikos.org/documents/63e8e6341846009f7d18f289c1449bb032a4081d

950. Li SJ, Huang J, Zhou XD, Zhang WB, Lai YT, Che GW. Clinicopathological and prognostic significance of Oct-4 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. Journal of thoracic disease. 2016;8(7):1587-600.www.epistemonikos.org/documents/64140e37d2663e1996b34ec691acf7ee4ee52957

951. Chen B.-Q., Yang H., Hu B.-B., Xue J.-X., Lu Y.. E-cadherin as a prognostic factor in stage I non-small cell lung cancer: A meta-analysis. Chinese Journal of Evidence-Based Medicine. 2016;16(5):517-522. www.epistemonikos.org/documents/643a26f8c746cbe3f70f91a9ba4d27505f6c4f0b

952. Ibrahim EM, Abouelkhair KM, Al-Masri OA, Chaudry NC, Kazkaz GA. Cetuximab-based therapy is effective in chemotherapy-naïve patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Lung. 2011;189(3):193-8.www.epistemonikos.org/documents/645ed63f33a94a5108e620242c309d923fe9e85a

953. Tam K.W., Zhang W., Soh J., Chen M., Sun H., Stastny V., Thu K., Lam W., Gazdar A.. A study of p16 inactivation in lung cancer cell lines and tumor samples with a meta-analysis of the literature. Cancer Research. 2012; www.epistemonikos.org/documents/648a02e7e10a6b424292396583eb1e8e43fbf24d

954. Qi WX, Tang LN, He AN, Shen Z, Lin F, Yao Y. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung. 2012;190(5):477-85. www.epistemonikos.org/documents/648b53b167e79fb33691afad7844af4c1d9d8852

955. Mi D., Ren W., Yang K.. Adoptive immunotherapy with interleukin-2 & induced killer cells in non-small cell lung cancer: A systematic review & meta-analysis. Indian Journal of Medical

Research, Supplement. 2016;143(Supplement):1-10. www.epistemonikos.org/documents/64af2c40567a25c569f70e912268743947015cd2

956. Chouahnia K., Des Guetz G., Uzzan B., Nicolas P., Morere J.F.. Survival benefit from maintenance therapy after first-line chemotherapy in advanced non-small cell lung cancer: A meta-analysis. Journal of Clinical Oncology. 2012; www.epistemonikos.org/documents/64b2f6e473d9cc1b7cd86bf9d82986f8570ea68b

957. Wang M., Cao J.-X., Pan J.-H., Liu Y.-S., Xu B.-L., Li D., Zhang X.-Y., Li J.-L., Liu J.-L., Wang H.-B., Wang Z.-X.. Adoptive immunotherapy of Cytokine-induced killer cell therapy in the treatment of Non-small cell lung cancer. PLoS ONE. 2014;9(11):e112662. www.epistemonikos.org/documents/64bc139ea593e0efcc2464b6a25e5c9bc67a0fc1

958. Bai J, Dai J, Yu H, Shen H, Chen F. Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis. Journal of toxicology and environmental health. Part A. 2009;72(11-12):677-82. www.epistemonikos.org/documents/64c2a3f1f9d1ab3c6d234a8d50ffb6824f6f0a2a

959. Li SJ, Zhou XD, Huang J, Liu J, Tian L, Che GW. A systematic review and meta-analysis-does chronic obstructive pulmonary disease predispose to bronchopleural fistula formation in patients undergoing lung cancer surgery?. Journal of thoracic disease. 2016;8(7):1625-38.www.epistemonikos.org/documents/64e55a51fe777e612bf478f5ca270d78a2c772fd

960. Liang W., He Q., Zhang J., Jiang L., Zhou C., He J.. A bayesian network comparison of different agents or regimens as first-line treatment for advanced EGFR-mutated NSCLC. Journal of Clinical Oncology. 2016; www.epistemonikos.org/documents/6533c2be6e501c89039fbedafd12a8566f2dd695

961. Ren J., He B.Z., Zhang T.S., Lu S.P., Yan T.. Meta-analysis of correlation between the CYP1A2 -3860 G > A polymorphism and lung cancer risk. Genetics and Molecular Research. 2016;15(2). www.epistemonikos.org/documents/6571b012ae640c898e24b112bfbc058e77de2b22

962. Qiu M, Yang X, Hu J, Ding X, Jiang F, Yin R, Xu L. Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis. PloS one. 2013;8(8):e72251. www.epistemonikos.org/documents/657b3dacd4294565c78cc0199fbaa008298eb67e

963. Sebio Garcia R, Yáñez Brage MI, Giménez Moolhuyzen E, Granger CL, Denehy L. Functional and postoperative outcomes after preoperative exercise training in patients with lung cancer: a systematic review and meta-analysis. Interactive cardiovascular and thoracic surgery. 2016;23(3):486-97.www.epistemonikos.org/documents/658e4d6990c7b536e6c8e49e2084cf085febd98e

964. Xing G.-C.. Meta-analysis of the quality of life and near-term efficacy after chemotherapy combined with compound Kushen injection in treating advanced non-small cell lung cancer. Chinese Journal of New Drugs. 2011;20(10):889-894. www.epistemonikos.org/documents/659fc342b799544c95d0016867f6ebe20f938f65

965. Mitchell P, Mok T, Barraclough H, Strizek A, Lew R, van Kooten M. Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: a systematic review. Clinical lung cancer. 2012;13(4):239-51. www.epistemonikos.org/documents/65d9994666e16495a2a2f5e890699b075461d6ba

966. Walling J. Chemotherapy for advanced non-small-cell lung cancer. Respiratory medicine. 1994;88(9):649-57.www.epistemonikos.org/documents/661ceb84d87eb16a1a5459e6cc3c597d7846a656

967. Frödin JE. Lung cancer. Acta oncologica (Stockholm, Sweden). 1996;35 Suppl 7:46-53. www.epistemonikos.org/documents/662fa6b5b2900f192372c5cd301dab16201a10a0

968. Zhang J, Wang HT, Li BG. Prognostic significance of circulating tumor cells in small--cell lung cancer patients: a meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2014;15(19):8429-33. www.epistemonikos.org/documents/668066cbd663df5592a4cf1f019aaa179bd2abcc

969. Chambers SK, Dunn J, Occhipinti S, Hughes S, Baade P, Sinclair S, Aitken J, Youl P, O'Connell DL. A systematic review of the impact of stigma and nihilism on lung cancer outcomes. BMC cancer. 2012;12(no pagination):184. www.epistemonikos.org/documents/668569045115531223 4b9a3e6ac98d3eb7285009
970. Christensen TD, Vad H, Pedersen S, Hvas AM, Wotton R, Naidu B, Larsen TB. Venous thromboembolism in patients undergoing operations for lung cancer: a systematic review. The Annals of thoracic surgery. 2014;97(2):394-400. www.epistemonikos.org/documents/66861fd5756e6a7e83821a8d3d19b4c2a2f03a02
971. Stone WZ, Wymer DC, Canales BK. Fluorodeoxyglucose-positron-emission tomography/computed tomography imaging for adrenal masses in patients with lung cancer: review and diagnostic algorithm. Journal of endourology / Endourological Society. 2014;28(1):104-11.www.epistemonikos.org/documents/669b4d56f06dcc8d8f71779f81ce6e3cbf4b444b
972. Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, Yu LK, Song Y. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009;4(9):1094-103.www.epistemonikos.org/documents/66a846408793b43b8c74e3be83ce815647833c87
973. Zhang Y., Sheng J., Kang S., Fang W., Yan Y., Hu Z., Hong S., Wu X., Qin T., Liang W., Zhang L.. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: A meta-analysis. PLoS ONE. 2014;9(9):e107161.www.epistemonikos.org/documents/66c38ed64570844420967768a582dc3343dd0bcf
974. Peng B, Wang YH, Liu YM, Ma LX. Prognostic significance of the neutrophil to lymphocyte ratio in patients with non-small cell lung cancer: a systemic review and meta-analysis. International journal of clinical and experimental medicine. 2015;8(3):3098-106.www.epistemonikos.org/documents/6700e8ed95a5ca4bcf57cb58547d7f6b47bd577f
975. Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(23):4837-45. www.epistemonikos.org/documents/67449c6e050b54fce64afefef16b4f310f4cf1c7
976. Xiang H., Zhang S., Luo Y., Wu J., Xu J., Fang Z., Li Y.. Meta-analysis of serum gastrin-releasing peptide precursor as a biomarker for prognostic evaluation of small cell lung cancer. International Journal of Clinical and Experimental Medicine. 2018;11(7):6491-6500.www.epistemonikos.org/documents/67467702f6e90943e7cd1628e24058399ea54165
977. Zhou G.-W., Li Q.. The efficacy of vandetanib, a dual inhibitor of VEGFR and EGFR tyrosine kinases in previously treated advanced NSCLC: A meta-analysis of randomized controlled trials. Respirology. 2011;:171-172. www.epistemonikos.org/documents/674e53ee5f57ec955fc420b58249a7f673c46586
978. Amarasena IU, Chatterjee S, Walters JA, Wood-Baker R, Fong KM. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database of Systematic Reviews. 2015;8(8):CD006849. www.epistemonikos.org/documents/67539fbdacd87028b5bfb4afc3ab17cd75c1e320
979. Dawe DE, Christiansen D, Swaminath A, Ellis PM, Rothney J, Rabbani R, Abou-Setta AM, Zarychanski R, Mahmud SM. Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis. Lung cancer (Amsterdam, Netherlands). 2016;99:180-5.www.epistemonikos.org/documents/675664677dbb6a915e2956ff41cf24247d2401e0
980. Andrew P., Jerat S., Valdes M., Lee-Ying R.M., O'Connor S.. Local tumor control and survival outcomes of percutaneous radiofrequency ablation plus post-ablation chemotherapy for

lung tumors in nonsurgical patients: A meta-analysis. Journal of Clinical Oncology. 2013;www.epistemonikos.org/documents/6756e34baf548c7746362ed5c226997bc3eb0de7

981. De Mello R.A., Escriu C., Castelo-Branco P., Cabral P.L., Mountzios G., Lopes G.L., Madureira P.. Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: A network meta-analysis. Oncotarget. 2018;9(14):11805-11815.www.epistemonikos.org/documents/675a8209152102daddf24c9403e53d30c307db56

982. Chen LS, Hung RJ, Baker T, Horton A, Culverhouse R, Saccone N, Cheng I, Deng B, Han Y, Hansen HM, Horsman J, Kim C, Lutz S, Rosenberger A, Aben KK, Andrew AS, Breslau N, Chang SC, Dieffenbach AK, Dienemann H, Frederiksen B, Han J, Hatsukami DK, Johnson EO, Pande M, Wrensch MR, McLaughlin J, Skaug V, van der Heijden HF, Wampfler J, Wenzlaff A, Woll P, Zienolddiny S, Bickeböller H, Brenner H, Duell EJ, Haugen A, Heinrich J, Hokanson JE, Hunter DJ, Kiemeney LA, Lazarus P, Le Marchand L, Liu G, Mayordomo J, Risch A, Schwartz AG, Teare D, Wu X, Wiencke JK, Yang P, Zhang ZF, Spitz MR, Kraft P, Amos CI, Bierut LJ. CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis. Journal of the National Cancer Institute. 2015;107(5).www.epistemonikos.org/documents/67918681cea6c8a44e2175e8a4c5a90c61b9194e

983. Abdel-Rahman O. Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line; a meta-analysis. The clinical respiratory journal. 2018;12(5):1809-1819. www.epistemonikos.org/documents/67e06957e54b5d818eae4b943526add06ab8fc7c

984. Fu X., Feng T., Wu M., Zhang L., Jiang C.. [Relationship between environmental tobacco smoke and lung cancer risk among nonsmokers in China: A meta-analysis]. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. 2015;49(7):644-648.www.epistemonikos.org/documents/67ea70c5421aed22904ad84a7d3f2cca3e0292a6

985. Turner E.J., McCloud P., Germanos P., Dehle F., Norris S., Tan J.. Meta-analysis of progression-free survival as a predictor of overall survival in locally advanced or metastatic non-small cell lung cancer trials. Journal of Clinical Oncology. 2012; www.epistemonikos.org/documents/6897eec7a126d7e4b15da10e70b36cb0a7a13a18

986. Sponsiello-Wang Z, Sanders E, Weitkunat R. Occupational acrylonitrile exposure and lung cancer: a meta-analysis. Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews. 2006;24(2):257-84. www.epistemonikos.org/documents/68f6eff4a78f7b654ff81c17b89ffc738d0b16e5

987. Rossi A., Di Maio M., Chiodini P., Rudd R., Okamoto H., Skarlos D.-V., Frueh M., Qian W., Tamura T., Samantas E., Shibata T., Perrone F., Gallo C., Gridelli C., Martelli O., Lee S.M.. Carboplatin-or cisplatinbased chemotherapy as firstline treatment of small-cell lung cancer (SCLC): The cocis individual patient data metaanalysis. Journal of Thoracic Oncology. 2011;:S312. www.epistemonikos.org/documents/68fb81690f29a1c3a98bb18b2280370ad1d7a5cd

988. Zhang Y, Sun Y, Wang L, Ye T, Pan Y, Hu H, Yu Y, Zhao N, Song Y, Garfield D, Chen H. Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials. OncoTargets and therapy. 2013;6:1771-7.www.epistemonikos.org/documents/6908acdfc564719c76887e30e5136cb3a5e3c884

989. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007;2(9):845-53.www.epistemonikos.org/documents/69290b048179541ba29ffafb96cea52c0ec5f173

990. Zhang C, Huang C, Wang J, Wang X, Li K. Maintenance or Consolidation Therapy for Non--Small-Cell Lung Cancer: A Meta-Analysis Involving 5841 Subjects. Clinical lung cancer. 2015;16(5):e15-23. www.epistemonikos.org/documents/693e366a21b5df81f69452cff071d7b13d16c112

991. Tian X, Wang B, Guo J, Liu X, Zhang T, Liang C, Zhou N, Hou X, Ma Y, Yu H, Chen L, Ren Z, Fan K, Tian Q. The MDM2 T309G polymorphism and risk of lung cancer: an updated meta-analysis of 10186 cases and 14155 controls. Panminerva medica. 2016;58(4):341-348.www.epistemonikos.org/documents/695977528100767e61368ae67fe4c5acfe67276a

992. Li Z, Liu H, Li L. Video-assisted thoracoscopic surgery versus open lobectomy for stage I lung cancer: A meta-analysis of long-term outcomes. Experimental and therapeutic medicine. 2012;3(5):886-892. www.epistemonikos.org/documents/6983e254186e2670d94dfe2419a4e90932509984

993. Wang T, Luo L, Zhou Q. Risk of Pleural Recurrence in Early Stage Lung Cancer Patients after Percutaneous Transthoracic Needle Biopsy: A Meta-analysis. Scientific reports. 2017;7:42762. www.epistemonikos.org/documents/69a7277e1779c7dced18771d677e6dacb41106f9

994. Brody R., Zhang Y., Ballas M., Siddiqui M.K., Gupta P., Barker C., Midha A., Walker J.. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 2017;112:200-215. www.epistemonikos.org/documents/69b62b22a259f0fd62c0db07b8b3ff3a48be1dbe

995. Wheatley-Price P, Blackhall F, Lee SM, Ma C, Ashcroft L, Jitlal M, Qian W, Hackshaw A, Rudd R, Booton R, Danson S, Lorigan P, Thatcher N, Shepherd FA. The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010;21(10):2023-8. www.epistemonikos.org/documents/6a004a1f5dc0372fe705385ed7ff34658452036f

996. Sakamoto J, Teramukai S, Watanabe Y, Hayata Y, Okayasu T, Nakazato H, Ohashi Y. Meta-analysis of Adjuvant Immunochemotherapy Using OK-432 in Patients With Resected Non-Small-Cell Lung Cancer. Journal of immunotherapy : official journal of the Society for Biological Therapy. 2001;24(3):250-256.www.epistemonikos.org/documents/6a54ce6df6eeaf2d72c292b35e64838c366eeb7b

997. Li S, Zhang W, Fan J, Lai Y, Che G. Clinicopathological and prognostic significance of heat shock protein 27 (HSP27) expression in non-small cell lung cancer: a systematic review and meta-analysis. SpringerPlus. 2016;5(1):1165. www.epistemonikos.org/documents/6a827f7a374b0f3f30544e855b93b0a1abf1cb46

998. Stone CJL, Vaid HM, Selvam R, Ashworth A, Robinson A, Digby GC. Multidisciplinary Clinics in Lung Cancer Care: A Systematic Review. Clinical lung cancer. 2018;19(4):323-330.e3. www.epistemonikos.org/documents/6b33db3339352ecd6a4b5e3ae08d33b206a9e70e

999. Pat K, Dooms C, Vansteenkiste J. Systematic review of symptom control and quality of life in studies on chemotherapy for advanced non-small cell lung cancer: how CONSORTed are the data?. Lung cancer (Amsterdam, Netherlands). 2008;62(1):126-38.www.epistemonikos.org/documents/6b5cc19667723473730c4a12e3a0d71898d4075b

1000. Hu X, Pu K, Feng X, Wen S, Fu X, Guo C, He W. Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PloS one. 2016;11(3):e0149247. www.epistemonikos.org/documents/6b601be8e3dd91f2101fd54cc528b6e5c3fd0e78

1001. Pan Z.-K., Ye F., Wu X., An H.-X., Wu J.-X.. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. Journal of Thoracic Disease. 2015;7(3):462-470. www.epistemonikos.org/documents/6b787267e2007e9d6cd6f44e2820623e8b35e003

1002. Zhang P, Zhang Y, Yang H, Li W, Chen X, Long F. Association between EPHX1 rs1051740 and lung cancer susceptibility: a meta-analysis. International journal of clinical and experimental medicine. 2015;8(10):17941-9. www.epistemonikos.org/documents/6b793a34aa74bd8b241ef65f5e209f4555eefffc

1003. Palma D, Lagerwaard F, Rodrigues G, Haasbeek C, Senan S. Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and

systematic review. International journal of radiation oncology, biology, physics. 2012;82(3):1149-56.www.epistemonikos.org/documents/6bb19220c00146b66356d6ce76d84b89350cb63e

1004. Chen C, Xun P, Nishijo M, He K. Cadmium exposure and risk of lung cancer: a meta-analysis of cohort and case-control studies among general and occupational populations. Journal of exposure science & environmental epidemiology. 2016;26(5):437-44. www.epistemonikos.org/documents/6bd23d104990c5953f9ec018110745e0b85b909a

1005. Shim J, Brindle L, Simon M, George S. A systematic review of symptomatic diagnosis of lung cancer. Family practice. 2014;31(2):137-48.www.epistemonikos.org/documents/6be844ad650a96a35ab858886578f89676565c11

1006. Cao JQ, Rodrigues GB, Louie AV, Zaric GS. Systematic review of the cost-effectiveness of positron-emission tomography in staging of non-small-cell lung cancer and management of solitary pulmonary nodules. Clinical lung cancer. 2012;13(3):161-70. www.epistemonikos.org/documents/6bea1529c0510a2383ae0565d6d63f83c0116d55

1007. Rong B, Yang S, Li W, Zhang W, Ming Z. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World journal of surgical oncology. 2012;10(no pagination):170.www.epistemonikos.org/documents/6beb4c30efd56e2e8c2b50a47f8bcb90024dedaa

1008. Li M, Yang X, Chen Y, Yang X, Dai X, Sun F, Zhang L, Zhan C, Feng M, Wang Q. Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis. OncoTargets and therapy. 2017;10:2885-2892.www.epistemonikos.org/documents/6c53258c17a9c2468d193b28b51766b59fa1f201

1009. Xiong Y, Wang T, Wang M, Zhao J, Li X, Zhang Z, Zhou Y, Liu J, Jia L, Han Y. Long non-coding RNAs function as novel predictors and targets of non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2018;9(13):11377-11386. www.epistemonikos.org/documents/6c6108e73cbe045e7671a112c4bb453d0e64cf06

1010. Paramanandam VS, Dunn V. Exercise for the management of cancer-related fatigue in lung cancer: a systematic review. European journal of cancer care. 2015;24(1):4-14.www.epistemonikos.org/documents/6c76a56d8e948464dcb65eeb81989162bcede3c0

1011. Chu Q, Vincent M, Logan D, Mackay JA, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung cancer (Amsterdam, Netherlands). 2005;50(3):355-74.www.epistemonikos.org/documents/6ca77066df4c8d1f6159f1b7d69821792c701f7d

1012. Nie YL, Liu KX, Mao XY, Li YL, Li J, Zhang MM. Effect of injection of brucea javanica oil emulsion plus chemoradiotherapy for lung cancer: a review of clinical evidence. Journal of evidence-based medicine. 2012;5(4):216-25. www.epistemonikos.org/documents/6cf38e599e241ccb61c8bf733747f67f25da8187

1013. He Q., Zhang J., Shen J., Liang W., He J.. A bayesian network meta-analysis of different agents or regimens as second-line treatment for SCLC. Journal of Clinical Oncology. 2016; www.epistemonikos.org/documents/6d0e9cccba15342cd4e4ca2ecda36c4ffa2e72ca

1014. Xu C.-R., Zhou Q., Wu Y.-L.. Meta-analysis of the egfrtki verses chemotherapy for NSCLC patients by different selections. Journal of Thoracic Oncology. 2011;:S1295-S1296.www.epistemonikos.org/documents/6d32ead1fae589b9fa06e35d198ab30eaf77206b

1015. Wang Y., Wang S., Xu S., Qu J., Liu B.. Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: A meta-analysis. PLoS ONE. 2014;9(10):e110617. www.epistemonikos.org/documents/6d47b7bdad8f3b05038b5336b9df98a8713c05a8

1016. Santos FN, de Castria TB, Cruz MR, Riera R. Chemotherapy for advanced non-small cell lung cancer in the elderly population. Cochrane Database of Systematic Reviews.

2015;10(10):CD010463.
www.epistemonikos.org/documents/6d7baf18483cd508273ebb164fe8beb4a7339d36

1017. Kong Q, Li P, Tian Q, Ha MW. Role of MDM2 T309G polymorphism in susceptibility and prognosis of nonsmall cell lung cancer: a meta-analysis. Genetic testing and molecular biomarkers. 2014;18(5):357-65.
www.epistemonikos.org/documents/6dc346a23ea4a113bc51efe0f4e5a67ad01491b7

1018. Pyo J.-S., Kang G., Cho W.J., Choi S.B.. Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: A meta-analysis. Pathology Research and Practice. 2016;212(8):710-716.
www.epistemonikos.org/documents/6dc392ef0611b9f2a55208c40ac5635143281acb

1019. Zhou YY, Hu ZG, Zeng FJ, Han J. Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials. PloS one. 2016;11(3):e0151939.
www.epistemonikos.org/documents/6dfec42c6debb86daa8721fb42b572c1ab2eaaa6

1020. Gopal M, Abdullah SE, Grady JJ, Goodwin JS. Screening for lung cancer with low-dose computed tomography: a systematic review and meta-analysis of the baseline findings of randomized controlled trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010;5(8):1233-9.www.epistemonikos.org/documents/6e07fb31a28c08591223f0f9cbe69c4d62446543

1021. Yang YL, Chen MW, Xian L. Prognostic and clinicopathological significance of downregulated E-cadherin expression in patients with non-small cell lung cancer (NSCLC): a meta-analysis. PloS one. 2014;9(6):e99763.
www.epistemonikos.org/documents/6e13818ffb80a3d283cad1258fb5205d52aaf800

1022. Yang Y., Zhang D., Zhou X., Bao W., Ji Y., Sheng L., Cheng L., Chen Y., Du X., Qiu G.. Prophylactic cranial irradiation in resected small cell lung cancer: A systematic review with meta-analysis. Journal of Cancer. 2018;9(2):433-439.
www.epistemonikos.org/documents/6e19e3b26e09d7d74ee4585eb3d991e5cc140440

1023. Zhang Y., Fang W., Yan Y., Wang M., Kang S., Sheng J., Zhan J., Chen N., Hong S., Yang Y., Ma Y., He D., Qin T., Zhou T., Tang Y., He X., Liang W., Zhang L.. The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis. Medical Oncology. 2015;32(3):61.www.epistemonikos.org/documents/6e3c23b610ec46b26b9c88ac2a26744591a02e05

1024. Zhang X, Zang J, Xu J, Bai C, Qin Y, Liu K, Wu C, Wu M, He Q, Zhang S, Wei L, He J. Maintenance Therapy With Continuous or Switch Strategy in Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis. Chest. 2011;140(1):117-26.
www.epistemonikos.org/documents/6e45f1fd16cf712211f30f2cafe3b13d4a31d925

1025. Gandini S, Massi D, Mandalà M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Critical reviews in oncology/hematology. 2016;100:88-98.
www.epistemonikos.org/documents/6e8841da7226e0a2577636a41c5e954fed8b8518

1026. Cohen BL. Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies. JNCI: Journal of the National Cancer Institute. 1997;89(9):664-665.www.epistemonikos.org/documents/6e8e941491130476732 7406c2abd3d2879a1dc89

1027. Qi WX, Tang LN, He AN, Shen Z, Lin F, Yao Y. Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison. Current medical research and opinion. 2012;28(4):643-50.
www.epistemonikos.org/documents/6eb4d594436bbc5fccda821ec0ef2722b213a732

1028. Gupta R, Dastane AM, McKenna R, Marchevsky AM. The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis. Human pathology. 2009;40(3):356-65.
www.epistemonikos.org/documents/6ef587b8cce4e8ac125bda5066f0762f351b1ab3

1029. Li S, Zhu R, Li D, Li N, Zhu X. Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis. Journal of thoracic disease. 2018;10(6):3701-3713.www.epistemonikos.org/documents/6f491e46e967f0bce6b8afc24f912dfd44e21696
1030. Yin X, Ying J, Li L, Zhang H, Wang H. A meta-analysis of lentinan injection combined with chemotherapy in the treatment of nonsmall cell lung cancer. Indian journal of cancer. 2015;52 Suppl(5):E29-31. www.epistemonikos.org/documents/6f77cad81b9ed254fad3b928aa19a20179258975
1031. Zhang L, Cao F, Wang Y, Wang S, Zhong D. Antiangiogenic agents combined with chemotherapy in the first-line treatment of advanced non-small-cell lung cancer: overall and histology subgroup-specific meta-analysis. Oncology research and treatment. 2014;37(12):710-8.www.epistemonikos.org/documents/6f89344aa3b9fff342e3595b95ff4fe8ae00c206
1032. Yu Y, Lv Q, Zhang B, Lan F, Dai Y. Adjuvant therapy with heparin in patients with lung cancer without indication for anticoagulants: A systematic review of the literature with meta-analysis. Journal of cancer research and therapeutics. 2016;12(Supplement):37-42.www.epistemonikos.org/documents/6f93c1d7aa3d68ea3e1e2a570b9db133558cc155
1033. Zhao YL, Han S, Pu R, Shi LW. The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: a meta-analysis from randomized controlled clinical trials. Indian journal of cancer. 2014;51 Suppl 3(7):e86-91.www.epistemonikos.org/documents/6fa8414451b5c6ce2ff06b9c0d798134b1ae5e9b
1034. Lima JP, dos Santos LV, Sasse EC, Sasse AD. Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis. European journal of cancer (Oxford, England : 1990). 2009;45(4):601-7. www.epistemonikos.org/documents/6fb39d7c83cf038280c316ae7305751bd0f2128c
1035. Watine J. Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review. Scandinavian journal of clinical and laboratory investigation. 2000;60(4):259-73. www.epistemonikos.org/documents/6ff45dcef6818b12d62fd1184c5805c87556df46
1036. Cote ML, Chen W, Smith DW, Benhamou S, Bouchardy C, Butkiewicz D, Fong KM, Gené M, Hirvonen A, Kiyohara C, Larsen JE, Lin P, Raaschou-Nielsen O, Povey AC, Reszka E, Risch A, Schneider J, Schwartz AG, Sorensen M, To-Figueras J, Tokudome S, Pu Y, Yang P, Wenzlaff AS, Wikman H, Taioli E. Meta- and pooled analysis of GSTP1 polymorphism and lung cancer: a HuGE-GSEC review. American journal of epidemiology. 2009;169(7):802-14.www.epistemonikos.org/documents/6ffe1b688a94e45da6ee77901ba98fd4ed34e467
1037. Han S, Woo S, Suh CH, Kim YJ, Oh JS, Lee JJ. A systematic review of the prognostic value of texture analysis in 18F-FDG PET in lung cancer. Annals of nuclear medicine. 2018;32(9):602-610. www.epistemonikos.org/documents/7003540e20cdf5706896b0ede6b9622d3ca303a8
1038. Wang X., Lin H., Liyuan L., Zhang Y., Liu J., Liu Z., Shi H.. A meta-analysis of Kang`ai injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Journal of Cancer Research and Therapeutics. 2015;11(3):558-564. www.epistemonikos.org/documents/70175d1efdecc21fbdba5b264408ac794926b80f
1039. Wen S, Zhou W, Li CM, Hu J, Hu XM, Chen P, Shao GL, Guo WH. Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta-analysis of published studies involving 32 studies. BMC cancer. 2015;15(1):520. www.epistemonikos.org/documents/705874a1ba7982069c9e7f6eb82c69ffc0bf6b8f
1040. Wei DM, Chen WJ, Meng RM, Zhao N, Zhang XY, Liao DY, Chen G. Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients. Respiratory research. 2018;19(1):150.www.epistemonikos.org/documents/705c9a618b390605593cbcbc9ab2a1a5fb4b98d6
1041. Qiu T, Shen Y, Wang MZ, Wang YP, Wang D, Wang ZZ, Jin XF, Wei YC. External suction versus water seal after selective pulmonary resection for lung neoplasm: a systematic review. PloS

one. 2013;8(7):e68087.
www.epistemonikos.org/documents/707534172e1987d55595af3f0445ad29d19c8470

1042. Cao D, Ge W, Wang H, Zhang L, Zheng Y, Zhang J. [Efficacy and safety of rh-endostatin combined with chemotherapy versus chemotherapy alone for advanced NSCLC: a meta-analysis review]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2011;14(5):404-13.www.epistemonikos.org/documents/707b632a9fc8b77baa6b5ee86aeea67c5a7d3e87

1043. Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung cancer (Amsterdam, Netherlands). 2012;76(3):478-85.www.epistemonikos.org/documents/70846ba02b22589fa7e15b6d775bddc4c831103e

1044. OuYang PY, Su Z, Mao YP, Deng W, Xie FY. Combination of EGFR-TKIs and chemotherapy as first-line therapy for advanced NSCLC: a meta-analysis. PloS one. 2013;8(11):e79000.
www.epistemonikos.org/documents/70b53eb7ca2edf877c747441a3aa98ed3fe1f861

1045. Lou X, Zhou J, Ma H, Xu S, He E, Skog S, Wang H. The Half-Life of Serum Thymidine Kinase 1 Concentration Is an Important Tool for Monitoring Surgical Response in Patients with Lung Cancer: A Meta-Analysis. Genetic testing and molecular biomarkers. 2017;21(8):471-478.www.epistemonikos.org/documents/70b5bd919fd4149042767c4d38f7ebcb710d24be

1046. Berman DW, Crump KS. A meta-analysis of asbestos-related cancer risk that addresses fiber size and mineral type. Critical reviews in toxicology. 2008;38 Suppl 1:49-73.www.epistemonikos.org/documents/70cdb1c8a8c73cb9698981fbf571faf79d0ab806

1047. Ge W, Xu H, Yan Y, Cao D. The effects of prophylactic cranial irradiation versus control on survival of patients with extensive-stage small-cell lung cancer: a meta-analysis of 14 trials. Radiation oncology (London, England). 2018;13(1):155.
www.epistemonikos.org/documents/70e7a1f9e26d58b3035f4a271e77676b2bd8d5a0

1048. Mlika M., Dziri C., Zorgati M.M., Khelil M.B., Mezni F.. Liquid biopsy as surrogate to tissue in lung cancer for molecular profiling: A meta-analysis. Current Respiratory Medicine Reviews. 2018;14(1):48-60.
www.epistemonikos.org/documents/71370e63cf366efcf37c05a738951fbfc9ba96ba

1049. Shi W, Zhang W, Sun H, Shao Y. Sleeve lobectomy versus pneumonectomy for non-small cell lung cancer: a meta-analysis. World journal of surgical oncology. 2012;10(no pagination):265.
www.epistemonikos.org/documents/713f025a305637c2d134be418b726f4ad87ea3e4

1050. Li C., Yin Z.-H., Guan P., Li X.-L., Zhou B.-S.. NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and the risk of lung cancer: A meta-analysis. Thoracic Cancer. 2010;1(3):102-108.
www.epistemonikos.org/documents/7162eb2587498118d1c46fc7268442d72147d50b

1051. Bennett BM, Wells JR, Panter C, Yuan Y, Penrod JR. The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature. Frontiers in pharmacology. 2017;8:339.
www.epistemonikos.org/documents/7173206415ab752022cc1c5cb39889eae3bbfb5a

1052. Tsuda T., Babazono A., Yamamoto E., Mino Y., Matsuoka H.. A meta-analysis on the relationship between pneumoconiosis and lung cancer. Journal of Occupational Health. 1997;39(4):285-294.
www.epistemonikos.org/documents/718c6cb44f3e99967a056fcd9213bb24f34481ae

1053. Mehra R, Moore BA, Crothers K, Tetrault J, Fiellin DA. The association between marijuana smoking and lung cancer: a systematic review. Archives of internal medicine. 2006;166(13):1359-67. www.epistemonikos.org/documents/718c7cc25e59bca987849018227a7135f7bca818

1054. Gao G., Zhou X., Huang R., Jiang J., Chu Z., Zhan Q., Liang X.. [A Meta-Analysis of Platinum Plus Gemcitabine or Vinorelbine for Advanced Non-small Cell Lung Cancer.]. Chinese Journal of Lung Cancer. 2009;12(1):38-43.
www.epistemonikos.org/documents/71906eeded6ef84aff00f65c699e834d030ecf81

1055. Liu J., Sheng Z., Zhang Y., Li G.. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A

Meta-Analysis of 30 Randomized Controlled Trials. Targeted Oncology. 2016;11(1):49-58.www.epistemonikos.org/documents/7195cac52b9add1a9c8f79a7331c854df089ca33

1056. Hotta K, Ueoka H, Kiura K, Tabata M, Tanimoto M. An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2004;46(1):61-76. www.epistemonikos.org/documents/71aa2dd5733d0682d2c0a21d02b74473f68e02f3

1057. Fei X.-S., Song Y., Shi Y., Wei S.-Z.. Meta-analysis of expression and significance of COX-2 in NSCLC tissues. Chinese Journal of Cancer Prevention and Treatment. 2009;16(19):1482-1485. www.epistemonikos.org/documents/71d16469db5b868c502a0fa1face49c6691b9909

1058. LU X, YANG X, ZHANG Z, WANG D. [meta-analysis of serum tumor markers in lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2010;13(12):1136-40.www.epistemonikos.org/documents/71e6dbd206ebd8e50f1fd7b017a2ee1f496f1e1b

1059. Alzahouri K, Martinet Y, Briançon S, Guillemin F. Staging practices of primary non-small-cell lung cancer: a literature review. European journal of cancer care. 2006;15(4):348-54. www.epistemonikos.org/documents/71f41c0240b562aee9c3736a809f567c2f6dbf74

1060. He Z., Xia Y., Tang S., Chen Y., Chen L.. Detection of occult tumor cells in regional lymph nodes is associated with poor survival in pN0 non-small cell lung cancer: A meta-analysis. Journal of Thoracic Disease. 2016;8(3):375-385. www.epistemonikos.org/documents/7201c5ef6983a01ad858af69be62d0cf8da8e5da

1061. Xu CA, Chang ZY, Wang XJ, Qi HY. Doublets versus single-agent therapy as first-line therapy for elderly patients with advanced non-small cell lung cancer? A systematic review of randomised controlled trials. International journal of clinical practice. 2013;67(11):1118-27.www.epistemonikos.org/documents/722014ad8c34e12d51912953b6028950a81e5f1b

1062. Yamashita S, Goto T, Mori T, Horio H, Kadota Y, Nagayasu T, Iwasaki A. Video-assisted thoracic surgery for lung cancer: republication of a systematic review and a proposal by the guidelines committee of the Japanese Association for Chest Surgery 2014. General thoracic and cardiovascular surgery. 2014;62(12):701-5.www.epistemonikos.org/documents/726fef23d49fed10a2859ebec9a83502f6a6d339

1063. Li Y, Huang Y, Cao YS, Zeng J, Tong WN, Xu SL, Zhuo AS. Assessment of the association between XRCC1 Arg399Gln polymorphism and lung cancer in Chinese. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(6):3681-5.www.epistemonikos.org/documents/727192f310566e7d567d58770ef417157ef0b511

1064. Rafel Fuentes, Xavier Bonfill Cosp, José Expósito Hernandez. Surgery versus radiosurgery for patients with a solitary brain metastasis from non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2006;(1):CD004840. www.epistemonikos.org/documents/72c25425f0210fbf7ee10158a183c75e90467a63

1065. Yang Y, Xian L. The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(7):6791-9. www.epistemonikos.org/documents/72cfd0beff921d834ba39461262a75894c5c61b5

1066. Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics. 1998;8(3):227-38. www.epistemonikos.org/documents/72eb1639622d25b2b9d70af01b80a21ac97f8cc4

1067. Ni HJ, Pudasaini B, Yuan XT, Li HF, Shi L, Yuan P. Exercise Training for Patients Pre- and Postsurgically Treated for Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis. Integrative cancer therapies. 2017;16(1):63-73. www.epistemonikos.org/documents/72f7b33122502acff07beb25cc775becd525a22a

1068. Wang W, Chen J, Zhao F, Zhang B, Yu H. Lack of association between a functional polymorphism (rs1800796) in the interleukin-6 gene promoter and lung cancer. Diagnostic

pathology. 2014;9:134. www.epistemonikos.org/documents/7322d3eab5cd98f11b3bce7ce49998f9df34ad33

1069. Korte JE, Brennan P, Henley SJ, Boffetta P. Dose-specific meta-analysis and sensitivity analysis of the relation between alcohol consumption and lung cancer risk. American journal of epidemiology. 2002;155(6):496-506. www.epistemonikos.org/documents/7362da40ca400a7c434357d054cca2d6ee9f7643

1070. Zhang X.-H., Li C., Dai C.-F., Zhou B.-S.. Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: A meta-analysis. Thoracic Cancer. 2011;2(3):101-108.www.epistemonikos.org/documents/7371732f2387b518840644a9516633a4020c439b

1071. Hochmuth F., Jochem M., Schlattmann P.. Meta-analysis of aspirin use and risk of lung cancer shows notable results. European Journal of Cancer Prevention. 2016;25(4):259-268. www.epistemonikos.org/documents/738f7aa2791bd129c0c65ca590ffac99f7fda11b

1072. Gao H, Ding X, Wei D, Cheng P, Su X, Liu H, Aziz F, Wang D, Zhang T. Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis. Translational lung cancer research. 2012;1(2):129-44. www.epistemonikos.org/documents/7396bb193f34fba67cdf3e6aa97dc4f2bbb2ef56

1073. Ye S, Li J, Hao K, Yan J, Zhou H. The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis. Scientific reports. 2016;6:35770.www.epistemonikos.org/documents/73998f0154bebfb9ab9a02754fa41806ea5c032b

1074. El Zoghbi M, Salameh P, Stücker I, Brochard P, Delva F, Lacourt A. Absence of multiplicative interactions between occupational lung carcinogens and tobacco smoking: a systematic review involving asbestos, crystalline silica and diesel engine exhaust emissions. BMC public health. 2017;17(1):156.www.epistemonikos.org/documents/73aa5f39b4545f12febcf467201a6941c4ad273c

1075. Zaïr ZM, Singer DR. Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis. Pharmacogenomics. 2016;17(9):1089-112. www.epistemonikos.org/documents/73e03d8d1ea8b291c79782f775b92a47ea5f582c

1076. Collaud S., Fadel E., Schirren J., Yokomise H., Bolukbas S., Dartevelle P., Keshavjee S., Waddell T.K., De Perrot M.. En bloc resection of pulmonary sulcus non-small cell lung cancer invading the spine: A systematic review and pooled analysis. Journal of Clinical Oncology. 2013;www.epistemonikos.org/documents/74378766ce02cec88ba0b0f006b102242504e029

1077. Zhao S, Gao F, Zhang Y, Zhang Z, Zhang L. Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis. International journal of cancer. 2018;142(8):1676-1688.www.epistemonikos.org/documents/744c6effb08f2cdcacbf475c4153b5f3d1d251f5

1078. Chen X.-P., Xu W.-H., Xu D.-F., Xie X.-H., Yao J., Fu S.-M.. GSTM1 polymorphisms and lung cancer risk in the Chinese population: a meta-analysis based on 47 studies. Asian Pacific journal of cancer prevention : APJCP. 2014;15(18):7741-7746. www.epistemonikos.org/documents/74519c9424fafdc3403e1d21897716968cf26b62

1079. Tie Y., Ma X., Zhu C., Mao Y., Shen K., Wei X., Chen Y., Zheng H.. Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials. International Journal of Cancer. 2017;140(4):948-958. www.epistemonikos.org/documents/748e0e9c745ce9eb52137a2c1685a9927b541d3a

1080. Mitchell MD, Aggarwal C, Tsou AY, Torigian DA, Treadwell JR. Imaging for the Pretreatment Staging of Small cell Lung Cancer: A Systematic Review. Academic radiology. 2016;23(8):1047-56. www.epistemonikos.org/documents/74bb8736d51cb1d1b80d3716f2b5daedce03a6d2

1081. Wang J, Cai Y. Matrix metalloproteinase 2 polymorphisms and expression in lung cancer: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33(6):1819-28. www.epistemonikos.org/documents/74fa7dc048d031424cf0969164df2b2b5e013fc4

1082. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, Scherpereel A, Mascaux C, Moreau M, Roelandts M, Alard S, Meert AP, Patz EF, Lafitte JJ, Sculier JP, European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2008;3(1):6-12. www.epistemonikos.org/documents/750f81e5f4b802755967c4fc6ecb92f47cc9e8d4

1083. Ma L., Xiang J.. Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer: A meta-analysis. Thoracic Cancer. 2016;7(4):442-451. www.epistemonikos.org/documents/75314d1dd1ab93493c248f8b5a6751865752396d

1084. Wu LM, Xu JR, Hua J, Gu HY, Chen J, Haacke EM, Hu J. Can diffusion-weighted imaging be used as a reliable sequence in the detection of malignant pulmonary nodules and masses?. Magnetic resonance imaging. 2013;31(2):235-46. www.epistemonikos.org/documents/754274078c96d3f2979e139cd074f828075da106

1085. Owonikoko T.K., Behera M., Chen Z., Bhimani C., Curran W.J., Khuri F.R., Ramalingam S.S.. Meta-analysis of second line chemotherapy efficacy in sensitive and refractory small cell lung cancer (SCLC) patients. Journal of Thoracic Oncology. 2010;:S551-S552.www.epistemonikos.org/documents/75472378f720678b6a5e1be93b12399af97af68c

1086. Yang ZY, Mao C, Zheng DY, Tang JL. Predictive biomarkers for EGFR tyrosine kinase inhibitors in treatment of advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Hong Kong medical journal = Xianggang yi xue za zhi. 2018;24 Suppl 4(4):34-37.www.epistemonikos.org/documents/754bde1806d67d87d16fe94ceb974d76ad749cef

1087. Lou Y, Li R, Zhang Y, Zhong R, Pei J, Xiong L, Zhang X, Han B. XPA gene rs1800975 single nucleotide polymorphism and lung cancer risk: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(7):6607-17.www.epistemonikos.org/documents/754c1d31770ecb49eee2be83912d11ae43f583c2

1088. Selvaraj G, Kaliamurthi S, Chandra Kaushik A, Khan A, Wei YK, Cho WC, Gu K, Wei DQ. Identification of target gene and prognostic evaluation for lung adenocarcinoma using gene expression meta-analysis, network analysis and neural network algorithms. Journal of biomedical informatics. 2018;86:120-134.www.epistemonikos.org/documents/756865dea497afbf8824afb28485d513d782ea06

1089. Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, Lee JH, Yang JC, Zhao M, Zhou C, Lee JK, Lee SH, Lee JY, Ahn MJ, Tan TJ, Tan DS, Tan EH, Ong ST, Lim WT. A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. Oncotarget. 2017;8(25):41474-41486.www.epistemonikos.org/documents/75698246225c0da0a3a39ff8652c6d8114ed2887

1090. Kim JH, Kim HS, Kim BJ. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. Oncotarget. 2017;8(29):48248-48252. www.epistemonikos.org/documents/757bec4480a9ad0362396aea834cc8a48b051992

1091. Collins J, Noble S, Chester J, Coles B, Byrne A. The assessment and impact of sarcopenia in lung cancer: a systematic literature review. BMJ open.

2014;4(1):e003697.www.epistemonikos.org/documents/75b0a89b67e06f40170dbdd7433ebd8feb07017c

1092. Tian X, Tian Y, Ma P, Sui C, Meng F, Li Y, Fu L, Jiang T, Wang Y, Jiang Y. Association between the XRCC3 C241T polymorphism and lung cancer risk in the Asian population. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(5):2589-97.www.epistemonikos.org/documents/75ef8118fe6a54727b3f71630212a49ef08f12c5

1093. Sanguedolce F, Loizzi D, Sollitto F, Di Bisceglie M, Lucarelli G, Carrieri G, Bufo P, Cormio L. Bladder Metastases from Lung Cancer: Clinical and Pathological Implications: A Systematic Review. Oncology. 2017;92(3):125-134. www.epistemonikos.org/documents/75fdbc8425998ecfd191b6df637b3e7c3c5ed3ab

1094. Geng P, Yao J, Zhu Y. hOGG1 Ser326Cys polymorphism and lung cancer susceptibility: a meta-analysis. Molecular biology reports. 2014;41(4):2299-306.www.epistemonikos.org/documents/7626b17fa837eef385a69697cf82f5cf3429edfb

1095. Pujol J., Lynch T.J., Rosell R., Butts C.A., Shepherd F.A., Thatcher N., Vansteenkiste J., Manegold C., Groos J., Pirker R.. A meta-analysis of four randomized phase II/III trials adding cetuximab to platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC). European Journal of Cancer, Supplement. 2009;:508. www.epistemonikos.org/documents/7650f6dc21dbe147b6253fcbdeb7dbd5de849c84

1096. Wang Q, Hu DF, Rui Y, Jiang AB, Liu ZL, Huang LN. Prognosis value of HIF-1α expression in patients with non-small cell lung cancer. Gene. 2014;541(2):69-74.www.epistemonikos.org/documents/765a91bf8d9e405d187fab277ba7bb3cbb9acfda

1097. An J, Lv W. Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: A meta-analysis. Thoracic cancer. 2018;9(5):606-612. www.epistemonikos.org/documents/766c52b1b37e6e0a62be167022dcf64c32b17a13

1098. Fan J., Xia Z., Zhang X., Chen Y., Qian R., Liu S., You D., Zhang J., Luo P.. The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: A systematic review and meta-analysis. OncoTargets and Therapy. 2018;11:1105-1115. www.epistemonikos.org/documents/7678840452d31851b2b8234f79453fb700e8da19

1099. Fan Y, Xu X, Xie C. EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data. OncoTargets and therapy. 2014;7:2075-84. www.epistemonikos.org/documents/76a7aa1e66861807964b31c967236d5a2be50853

1100. Yin Y, Wang J, Wang X, Gu L, Pei H, Kuai S, Zhang Y, Shang Z. Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: A meta-analysis. Clinics (São Paulo, Brazil). 2015;70(7):524-30. www.epistemonikos.org/documents/76ab403f263749bb84f3be42f0be76d46e2d6d60

1101. Gupta A., Majumder K., Arora N., Mayo H.G., Singh P.P., Beg M.S., Hughes R., Singh S., Johnson D.H.. Premorbid body mass index and mortality in patients with lung cancer: A systematic review and meta-analysis. Lung Cancer. 2016;102:49-59. www.epistemonikos.org/documents/76e688f26ab3768551fd4b02be26bed59d535874

1102. Xiao Z., Cao C., Mei J., Liao H., Yan T., Liu L.. Should tumor with direct adjacent lobe invasion (Tdali) be assigned to T2 or T3 in non-small cell lung cancer: A meta-analysis. Journal of Thoracic Disease. 2016;8(8):1956-1965. www.epistemonikos.org/documents/7700821861587858e1a31157b4b80dc8ba0a0480

1103. Tong M, Wang J, Jiang N, Pan H, Li D. Correlation between p-STAT3 overexpression and prognosis in lung cancer: A systematic review and meta-analysis. PloS one. 2017;12(8):e0182282. www.epistemonikos.org/documents/771eb332977aa5cdf6d45eab53c90f45f439b145

1104. Cui C, Sun X, Zhang J, Han D, Gu J. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis. Journal of cancer research and therapeutics. 2014;10 Suppl(7):C131-4. www.epistemonikos.org/documents/77241cb80411cbcef5ed2cdc732393896ce4476b

1105. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. Radiology. 1999;213(2):530-6. www.epistemonikos.org/documents/77366fc3069554a38e33af4cebdc6b69bb70023b

1106. Feng Y.-Y., Wang X.-S., Yang R.-J., Yang J.-Q., Hu X.-C., Wang W., Liu Y.-X., Kong D.-J., Zhang L., Zhang G.-P.. A meta-analysis evaluating stereotactic radiotherapy combined with WBRT versus SRT alone for the NSCLC patients with brain metastases. International Journal of Clinical and Experimental Medicine. 2017;10(1):675-683.www.epistemonikos.org/documents/774262ff0b94435ea3b8ea83fa56f814148544e7

1107. Wu Y, Shi H, Jiang M, Qiu M, Jia K, Cao T, Shang Y, Shi L, Jiang K, Wu H. The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety. International journal of cancer. 2017;141(12):2562-2570.www.epistemonikos.org/documents/7772a000440e0c11fe440200066e15c69d5a80d4

1108. Paech DC, Weston AR, Pavlakis N, Gill A, Rajan N, Barraclough H, Fitzgerald B, Van Kooten M. A systematic review of the interobserver variability for histology in the differentiation between squamous and nonsquamous non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011;6(1):55-63. www.epistemonikos.org/documents/777d8eceb87089fcf7f9a450ea5bb6c67b951105

1109. Rossi A., Garassino M.C., Sburlati P., Cinquini M., Gridelli C., Farina G., Torri V.. Maintenance or consolidation therapy in small cell lung cancer (SCLC): A systematic review and meta-analysis. Annals of Oncology. 2008;:viii118-viii119. www.epistemonikos.org/documents/7780571072e21881fc0ffe048582d33d8c2af9c6

1110. Chien C.R., Wang P.H.. The role of biomarkers in lung cancer screening: A systematic review and meta-analysis. Value in Health. 2012;:A63.www.epistemonikos.org/documents/77fb01e9211350866481afce2aa1135eeecb5ebd

1111. Zhuang J, Yu Y, Li Z, Lu S. Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis. Oncotarget. 2017;8(32):53675-53683. www.epistemonikos.org/documents/7801a6faf1c4233f3361006a604280635ef7b67b

1112. Mahar A.L., Fong R., Johnson A.. The economic impact of treating early lung cancer: A systematic review. Value in Health. 2011;:A440.www.epistemonikos.org/documents/7805198cd9d45a4c469f7d1b1a67363e09b393dc

1113. Zhang C, Liu J, Tong J, Sun X, Song S, Huang G. 18F-FDG-PET evaluation of pathological tumour response to neoadjuvant therapy in patients with NSCLC. Nuclear medicine communications. 2013;34(1):71-7. www.epistemonikos.org/documents/780d5b5537c29f5efc5272a9d1e3e7996441ad1a

1114. Abdel-Rahman O., Elhalawani H.. Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: A comparative meta-analysis. Future Oncology. 2015;11(7):1109-1122. www.epistemonikos.org/documents/7819b58e30535874509d30df487d66b0fdae68b2

1115. ZENG Lin-miao, ZHENG Hai-lun, PENG Jin-yun, XIAO Jian-hong, PAN Wei-piao, WU Dong-mei. Effectiveness and Safety of Kanglaite Combined with Gemcitabine for Advanced Non-small Cell Lung Cancer: A Meta-Analysis. 中国循证医学杂志 (Chinese Journal of Evidence-Based Medicine). 2014;07(2014):827-834.www.epistemonikos.org/documents/78592ee2e3ece039c80666382245b167d258fa58

1116. Zheng FF, Zhang ZY, Dai YP, Liang YY, Deng CH, Tao Y. Metastasis to the penis in a patient with adenocarcinoma of lung, case report and literature review. Medical oncology (Northwood, London, England). 2009;26(2):228-32. www.epistemonikos.org/documents/78780fac47cde8cb1b09a97d3097251799862c1d

1117. Yu W, Jiang X, Bai T, Lv X, Chang F. Association between +936 C>T gene polymorphism of vascular endothelial growth factor and lung cancer: a meta-analysis. Cancer biomarkers : section

A of Disease markers. 2014;14(6):483-92. www.epistemonikos.org/documents/78874332b14aa162f889f04a0c5c1a4bc32e5bc3

1118. An N., Zhang Y., Niu H., Li Z., Cai J., Zhao Q., Li Q.. EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression. Medicine. 2016;95(50):e5601. www.epistemonikos.org/documents/789311f33d5b8e8d2d95fb1e3d34f92a6b1bdf4b

1119. Han RX, Liu X, Pan P, Jia YJ, Yu JC. Effectiveness and safety of chemotherapy combined with dendritic cells co-cultured with cytokine-induced killer cells in the treatment of advanced non-small-cell lung cancer: a systematic review and meta-analysis. PloS one. 2014;9(9):e108958.www.epistemonikos.org/documents/789fc481fef95ae7e5d22ba15d9520c456f018a0

1120. Armstrong B, Hutchinson E, Unwin J, Fletcher T. Lung cancer risk after exposure to polycyclic aromatic hydrocarbons: a review and meta-analysis. Environmental health perspectives. 2004;112(9):970-8. www.epistemonikos.org/documents/78af51ad8608e83f10100b34f1aa263547098380

1121. Claassens L, van Meerbeeck J, Coens C, Quinten C, Ghislain I, Sloan EK, Wang XS, Velikova G, Bottomley A. Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(15):2104-20. www.epistemonikos.org/documents/78afd98be6fad55790b10d1ca35983f83f74e640

1122. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003;123(1 Suppl):137S-146S.www.epistemonikos.org/documents/78c241eff2d8b8802e1de5b762b786a076f466a2

1123. Yu DP, Cheng X, Liu ZD, Xu SF. Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review. Oncology letters. 2017;14(2):1568-1580. www.epistemonikos.org/documents/78d886516332d551f763cd29bd52100f94dc3711

1124. Liu Y, Qi M, Hou S, Shao L, Zhang J, Li Y, Liu Q. Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials. Medicine. 2017;96(43):e8345. www.epistemonikos.org/documents/791d11a3e653a43b64989311be8e6cf3565374d6

1125. Gao Y., Gao F., Hu T.-T., Li G., Sui Y.-X.. Combined effects of glutathione S-transferase M1 and T1 polymorphisms on risk of lung cancer: Evidence from a metaanalysis. Oncotarget. 2017;8(17):28135-28143. www.epistemonikos.org/documents/795a4c65bb882c91f7323985796d3f7d61724104

1126. He H, Zhou X, Wang Q, Zhao Y. Does the couse of astragalus-containing chinese herbal prescriptions and radiotherapy benefit to non-small-cell lung cancer treatment: a meta-analysis of randomized trials. Evidence-based complementary and alternative medicine : eCAM. 2013;2013(no pagination):426207.www.epistemonikos.org/documents/795e3939bad957b0668584b00b9eeea16a3f6b4c

1127. Liu B, Yuan M, Sun Y, Cheng Z, Zhang Z, Hou S, Wang X, Liu J. Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2018;9(10):9480-9488.www.epistemonikos.org/documents/79974a601219f13b7104bdae8dd6022e7913146c

1128. Zhang T, Yuan S, Wang Z, Zhang Q, Zhao P, Shan L. [Bevacizumab combined with chemotherapy for advanced non-small cell lung cancer: a meta-analysis]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2013;16(2):82-90. www.epistemonikos.org/documents/799ad1e3b8c94d9b2ec9eb791be52f4d6a1f0558

1129. Bezjak A, Rumble RB, Rodrigues G, Hope A, Warde P, Members of the IMRT Indications Expert Panel. Intensity-modulated radiotherapy in the treatment of lung cancer. Clinical oncology (Royal College of Radiologists (Great Britain)). 2012;24(7):508-20. www.epistemonikos.org/documents/79a1618718c3847a367af0bb00429c2b80be102f

1130. Wong K.M., Victor C., Eng L., Verma S.. The use of epidermal growth factor receptor tyrosine kinase inhibitors in treatment of advanced EGFR wild-type non-small cell lung cancer: A meta-analysis study. Journal of Thoracic Oncology. 2013;:S1184. www.epistemonikos.org/documents/79a91cb2c3d2c5f4a082f41e22337aad1d80e8c7

1131. Paz-Ares L., Zimmermann A., Ciuleanu T.-E., Bunn P.A., Antonio B.S., Denne J., Iturria N., John W.J., Scagliotti G.V.. Meta-analysis examining impact of age on pemetrexed (pem) efficacy for the treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2014;www.epistemonikos.org/documents/79d01e2977e5108280b0cc4680eb82eab0c09d23

1132. Brown T, Pilkington G, Boland A, Oyee J, Tudur Smith C, Dundar Y, Richards E, Yang R, Dickson R. Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review. Health technology assessment (Winchester, England). 2013;17(6):1-99.www.epistemonikos.org/documents/79d36ce66e2eb2bf86bb7b3996012ca24089722f

1133. Berghmans T, Paesmans M, Meert AP, Mascaux C, Lothaire P, Lafitte JJ, Sculier JP. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung cancer (Amsterdam, Netherlands). 2005;49(1):13-23.www.epistemonikos.org/documents/79ddbc70f3383ab4a3b124d4156ae58ccc48c71a

1134. Liu WJ, Zeng XT, Qin HF, Gao HJ, Bi WJ, Liu XQ. Whole brain radiotherapy plus chemotherapy in the treatment of brain metastases from lung cancer: a meta-analysis of 19 randomized controlled trails. Asian Pacific journal of cancer prevention : APJCP. 2012;13(7):3253-8.www.epistemonikos.org/documents/79e3d5a3e3066cc897ec31e32fa7051c42cc8d9d

1135. Taylor R, Najafi F, Dobson A. Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. International journal of epidemiology. 2007;36(5):1048-59. www.epistemonikos.org/documents/79ef1ea28e1541bb02f284a9a27edd4d65fe7154

1136. Standfield L, Weston AR, Barraclough H, Van Kooten M, Pavlakis N. Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence. Respirology (Carlton, Vic.). 2011;16(8):1210-20. www.epistemonikos.org/documents/79f01c67fea4aa7a85a86de0f7f4256867c708d8

1137. van Baardwijk A, Tomé WA, van Elmpt W, Bentzen SM, Reymen B, Wanders R, Houben R, Ollers M, Lambin P, De Ruysscher D. Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2012;105(2):145-9. www.epistemonikos.org/documents/7a07f0c4876949f400abafcced3af7149980b8ab

1138. Liu ZB, Wang LP, Shu J, Jin C, Lou ZX. Methylenetetrahydrofolate reductase 677TT genotype might be associated with an increased lung cancer risk in Asians. Gene. 2013;515(1):214-9. www.epistemonikos.org/documents/7a36d5f9ee2e6f87788abeb194d2e723b523f093

1139. Guo Z, Zhao C, Wang Z. MicroRNAs as ideal biomarkers for the diagnosis of lung cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(10):10395-407. www.epistemonikos.org/documents/7a509d77bc7c1cf246303909afca7d23b4bffc56

1140. Schmidt-Hansen M, Baldwin DR, Hasler E, Zamora J, Abraira V, Roqué I, Figuls M. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2014;11(11):CD009519.www.epistemonikos.org/documents/7a7e4eb8beb8312e36026736d945f1fdc1f86b9e

1141. Senthi S, Haasbeek CJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2013;106(3):276-82.www.epistemonikos.org/documents/7ac2503bb6eef6f2198a7cb837ecf580c3fcee76

1142. Ravenel JG. Evidence-based imaging in lung cancer: a systematic review. Journal of thoracic imaging. 2012;27(5):315-24.www.epistemonikos.org/documents/7ad2d93bcae7410c859125f342b838999afdee70

1143. Chemotherapy for non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2000;(2):CD002139.www.epistemonikos.org/documents/7b181e766960699df0da0b29344c31e36431def1

1144. Yu N, Zhang Q, Liu Q, Yang J, Zhang S. A meta-analysis: microRNAs' prognostic function in patients with nonsmall cell lung cancer. Cancer medicine. 2017;6(9):2098-2105.www.epistemonikos.org/documents/7b32491c33433cda5bf330e220328329c2f32a43

1145. Hamaji M., Ali S.O., Burt B.M.. A Meta-Analysis of Resected Metachronous Second Non-Small Cell Lung Cancer. Annals of Thoracic Surgery. 2015;99((Hamaji M., mhamaji@kuhp.kyoto-u.ac.jp) Department of Thoracic Surgery, Kyoto University Hospital, Shogoin, Sakyo-ku, Kyoto, Japan):1470-8.www.epistemonikos.org/documents/7b343311bcdf81caadf6a5eddbd2b01d0db60cb8

1146. Owonikoko TK, Behera M, Chen Z, Bhimani C, Curran WJ, Khuri FR, Ramalingam SS. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012;7(5):866-72.www.epistemonikos.org/documents/7b3f4f632172b5c06a5b9a2cbd9964b04f30d0af

1147. Chee Khoon Lee, Davies, Lucy, Yi-Long Wu, Tetsuya Mitsudomi, Akira Inoue, Rosell, Rafael, Caicun Zhou, Kazuhiko Nakagawa, Thongprasert, Sumitra, Masahiro Fukuoka, Lord, Sally, Marschner, Ian, Yu-Kang Tu, Gralla, Richard J., Gebski, Val, Mok, Tony, Yang, James Chih-Hsin, Lee, Chee Khoon, Wu, Yi-Long, Mitsudomi, Tetsuya. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. JNCI: Journal of the National Cancer Institute. 2017;109(6):1-9. www.epistemonikos.org/documents/7b6c58eab6bc8f4907a631fc80d86bf3044bd848

1148. Black C, de Verteuil R, Walker S, Ayres J, Boland A, Bagust A, Waugh N. Population screening for lung cancer using computed tomography, is there evidence of clinical effectiveness? A systematic review of the literature. Thorax. 2007;62(2):131-8. www.epistemonikos.org/documents/7b8fb531f6f7bee039e2e8b280577d8578184d10

1149. Alimujiang S, Zhang T, Han ZG, Yuan SF, Wang Q, Yu TT, Shan L. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Versus Placebo as Maintenance Therapy for Advanced Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials. Asian Pacific journal of cancer prevention : APJCP. 2013;14(4):2413-9.www.epistemonikos.org/documents/7b9c7aed3c0dda2e900d952b24c083bba5f21bdc

1150. Shepherd, F A, Douillard, J, Fukuoka, M, Saijo, N, Kim, S, Cufer, T, Sellers, M V, Armour, A A, Kim, E S. Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. Journal of Clinical Oncology. 2009;27:8011-8011.www.epistemonikos.org/documents/7bda7fcfadd01a65c0879fcf812ae958ad7e3c50

1151. Qin H, Wang C, Jiang Y, Zhang X, Zhang Y, Ruan Z. Patients with single brain metastasis from non-small cell lung cancer equally benefit from stereotactic radiosurgery and surgery: a systematic review. Medical science monitor : international medical journal of experimental and clinical research. 2015;21((Qin H.; Wang C.; Zhang X.; Ruan Z.) Department of Oncology, Southwest Hospital, Third Military Medical University, Chongqing, China):144-52.www.epistemonikos.org/documents/7bde6796664ac3edede91a630d468063555395c9

1152. Huang Y.-H.J., Zhang Z.-F., Tashkin D.P., Feng B., Straif K., Hashibe M.. An epidemiologic review of marijuana and cancer: An update. Cancer Epidemiology Biomarkers and Prevention. 2015;24(1):15-31. www.epistemonikos.org/documents/7be0aba56f9c35ecf2c98e85bef82ff8390c4e38

1153. Roth JA, Carlson JJ. Prognostic Role of ERCC1 in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Clinical lung cancer. 2011;12(6):393-401.www.epistemonikos.org/documents/7c2b3f335632ad1289f20acc0c042406ff9b9222
1154. Zhang X, Guo M, Fan J, Lv Z, Huang Q, Han J, Wu F, Hu G, Xu J, Jin Y. Prognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysis. Cancer biomarkers : section A of Disease markers. 2016;16(3):415-23. www.epistemonikos.org/documents/7c59431b2ae2000ab691f5cd557a812d1e36da83
1155. Xu W., Jin C., Dai X., Lv X.. A meta-analysis of erlotinib versus docetaxel for advanced nonsmall-cell lung cancer with poor prognosis. Indian Journal of Cancer. 2015;52(5):e12-e16. www.epistemonikos.org/documents/7c63d06def88c3e60beeabecd0384602a19e3ece
1156. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clinical oncology (Royal College of Radiologists (Great Britain)). 2002;14(5):338-51. www.epistemonikos.org/documents/7c720f135961c421f2155a487af8647a7b1cf4c2
1157. Wao H, Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Systematic reviews. 2013;2(1):10. www.epistemonikos.org/documents/7ca4dc13f4bddf7fd0d55bf33553fdb4dd57f139
1158. Fritz H., Seely D., Kennedy D., Dean F., Sagar S.. Vitamin A and lung cancer: A systematic review. Journal of the Society for Integrative Oncology. 2010;:203.www.epistemonikos.org/documents/7caa8102bb7b87f7bcf54a2f35fae9671ac16316
1159. Mollberg NM, Bennette C, Howell E, Backhus L, Devine B, Ferguson MK. Lymphovascular invasion as a prognostic indicator in stage I non-small cell lung cancer: a systematic review and meta-analysis. The Annals of thoracic surgery. 2014;97(3):965-71. www.epistemonikos.org/documents/7cb6ba74044be8405610157537309df8f2109911
1160. Tweedie RL, Scott DJ, Biggerstaff BJ, Mengersen KL. Bayesian meta-analysis, with application to studies of ETS and lung cancer. Lung cancer (Amsterdam, Netherlands). 1996;14 Suppl 1(SUPPL. 1):S171-94. www.epistemonikos.org/documents/7cc88f9faec48546a5b901e955998e7f5f59d926
1161. Mao X., Zhang Y., Xie F., Zheng X., Sun J.. Can peripheral blood be used as surrogate in detecting epidermal growth factor receptor mutation status in advanced non-small cell lung cancer patients? A meta-analysis. Oncotarget. 2017;8(44):78057-78067. www.epistemonikos.org/documents/7d29b962ac5f5521cb9a9a7e4248a86fec989030
1162. Gong L, Wu D, Zou J, Chen J, Chen L, Chen Y, Ni C, Yuan H. Prognostic impact of serum and tissue MMP-9 in non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(14):18458-68. www.epistemonikos.org/documents/7d2b84e01ea6d0d0ee28353eba3d84bd4970102a
1163. Poinen-Rughooputh S., Rughooputh M.S., Guo Y., Rong Y., Chen W.. Occupational exposure to silica dust and risk of lung cancer: an updated meta-analysis of epidemiological studies. BMC public health. 2016;16(1):1137. www.epistemonikos.org/documents/7e0d26d8320d15646b2861e41d49025aa7d2db66
1164. Fan L, Fan K. Lung cancer screening CT-based coronary artery calcification in predicting cardiovascular events: A systematic review and meta-analysis. Medicine. 2018;97(20):e10461. www.epistemonikos.org/documents/7e11c88fe98bae12fb933e00401ff8ecb7e5e267
1165. Jin ZY, Han RQ, Liu AM, Wang XS, Wu M, Zhang ZF, Zhao JK. [A Meta-analysis on tea drinking and the risk of lung cancer in Chinese population]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2012;33(8):857-61. www.epistemonikos.org/documents/7e4715b5383509147bb1f7a65eb035312c031fb1
1166. Zhang M, Li G, Wang Y, Wang Y, Zhao S, Haihong P, Zhao H, Wang Y. PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Scientific reports. 2017;7(1):10255. www.epistemonikos.org/documents/7e5b3b750717a9e252d12777cbd867674bd4d53d

1167. Tanvetyanon T, Finley DJ, Fabian T, Riquet M, Voltolini L, Kocaturk C, Fulp WJ, Cerfolio RJ, Park BJ, Robinson LA. Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013;24(4):889-94. www.epistemonikos.org/documents/7ebfb8b8e5a6c6c6d206b3a13407a032a3061b29

1168. Sun Y, Li Z, Li J, Li Z, Han J. A Healthy Dietary Pattern Reduces Lung Cancer Risk: A Systematic Review and Meta-Analysis. Nutrients. 2016;8(3):134.www.epistemonikos.org/documents/7efe4c6ba84eb6e58cea0b59b16ccadc5b8b75ae

1169. Zhou B, Wu F, Yuan L, Miao Z, Zhu S. Is Huachansu Beneficial in Treating Advanced Non-Small-Cell Lung Cancer? Evidence from a Meta-Analysis of Its Efficacy Combined with Chemotherapy. Evidence-based complementary and alternative medicine : eCAM. 2015;2015(no pagination):408145.www.epistemonikos.org/documents/7f051cfd123904de3f994716d0c510a03583446a

1170. Tian J., Zhang Q., Wang X.. Proton and Carbon ion for stage I non-small cell lung cancer: A meta analysis. Radiotherapy and Oncology. 2016;:S583-S584.www.epistemonikos.org/documents/7f1a924f05f7396e3c071f8e5b7877da01ab0e9b

1171. Wang N, Mengersen K, Kimlin M, Zhou M, Tong S, Fang L, Wang B, Hu W. Lung cancer and particulate pollution: A critical review of spatial and temporal analysis evidence. Environmental research. 2018;164:585-596. www.epistemonikos.org/documents/7f27385a4dd06e5f5df92c4d68f88ea399b9c953

1172. Soo RA, Chen Z, Yan Teng RS, Tan HL, Iacopetta B, Tai BC, Soong R. Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis. Oncotarget. 2018;9(37):24801-24820. www.epistemonikos.org/documents/7f33d84e451f4822805228d063607fd2cad53680

1173. Raymakers AJ, Mayo J, Lam S, FitzGerald JM, Whitehurst DG, Lynd LD. Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review. Applied health economics and health policy. 2016;14(4):409-18.www.epistemonikos.org/documents/7f3630ad7ce104d95f6ae66e879e5afea5043a95

1174. Kiyohara C, Ohno Y. Sex differences in lung cancer susceptibility: a review. Gender medicine. 2010;7(5):381-401.www.epistemonikos.org/documents/7f4610e01d5773196d3ffbf60a02eb6a38f9f86a

1175. Aupérin A, Le Péchoux C, Pignon JP, Koning C, Jeremic B, Clamon G, Einhorn L, Ball D, Trovo MG, Groen HJ, Bonner JA, Le Chevalier T, Arriagada R, Meta-Analysis of Cisplatin/carboplatin based Concomitant Chemotherapy in non-small cell Lung Cancer (MAC3-LC) Group. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2006;17(3):473-83. www.epistemonikos.org/documents/7f4d243c45ef20a6c717626960c8a1c7f47ea4d0

1176. Zhong S, Wu Y, Yan X, Tang J, Zhao J. Metformin use and survival of lung cancer patients: Meta-analysis findings. Indian journal of cancer. 2017;54(1):63-67.www.epistemonikos.org/documents/7f55608f8935185490a97e310ad04f0649452a8f

1177. Singh N, Kulkarni P, Aggarwal AN, Rai Mittal B, Gupta N, Behera D, Gupta A. Choroidal metastasis as a presenting manifestation of lung cancer: a report of 3 cases and systematic review of the literature. Medicine. 2012;91(4):179-94. www.epistemonikos.org/documents/7f69e82c2e4d7e08bff3b385545b39eccbbb1648

1178. Xiao Z, Wang CQ, Zhou MH, Li NN, Liu SY, He YJ, Wang YZ, Feng JH, Yao XS, Chen L, Ma B, Yu S, Zeng XT, Li CW, Ding J. Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials. International immunopharmacology. 2018;61:363-375.www.epistemonikos.org/documents/7f8cac3463a62a530661578794c585dbf2be6075

1179. Dearden S., Stevens J., Wu Y.-L., Blowers D.. Mutation mapping in non-small cell lung cancer; a meta-analysis by geography and histology (MUTMAP). Annals of Oncology. 2012;:xi47. www.epistemonikos.org/documents/7f911e5b41ff822e5d0b649046810cdab68331a6

1180. Noh J, Sohn J, Cho J, Kang DR, Joo S, Kim C, Shin DC. Residential radon and environmental burden of disease among Non-smokers. Annals of occupational and environmental medicine. 2016;28:12. www.epistemonikos.org/documents/7f99e3dab67c69e7f48df4d12142992faa0e716c

1181. Chen P.-F., He X.-F., Huang G.-H., Wang W., Qiu Z.-H.. Association Between the CYP1B1 Polymorphisms and Lung Cancer Risk: A Meta-Analysis. Technology in Cancer Research and Treatment. 2016;15(5):NP73-NP82. www.epistemonikos.org/documents/7fb166ee0c8948fc5f279c305e8c913d74de3c90

1182. Huang Y, Liu X, Kuang X, Liao D. CYP2D6 T188C variant is associated with lung cancer risk in the Chinese population. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(4):2189-93. www.epistemonikos.org/documents/7fb8a71ae5dd61b33e8b0b9e164ca55d23d56943

1183. Watine J. Laboratory variables as additional staging parameters in patients with small-cell lung carcinoma. A systematic review. Clinical chemistry and laboratory medicine. 1999;37(10):931-8. www.epistemonikos.org/documents/8008dbaf39d161c40945524d15b7cd82fa4d2724

1184. Li S., Fan J., Zhou J., Ren Y., Shen C., Che G.. Residual disease at the bronchial stump is positively associated with the risk of bronchoplerual fistula in patients undergoing lung cancer surgery: A meta-analysis. Interactive Cardiovascular and Thoracic Surgery. 2016;22(3):327-335.www.epistemonikos.org/documents/801210cbc3b71082bfd2244b8210af35c8928e56

1185. Gao X., Dong R., Liang Y., Hao G., Liu Z.. Venenum bufonis injection combined with chemotherapy in the treatment of non-small cell lung carcinoma: A meta-analysis. Anti-Tumor Pharmacy. 2013;3(6):467-470. www.epistemonikos.org/documents/80581f1d415bc94775eddd9716e54723c7d774ca

1186. Wang H, Liu Z. Genetic association of BSF2 polymorphism and susceptibility to lung cancer. Cell biochemistry and biophysics. 2014;70(3):1887-91.www.epistemonikos.org/documents/80724f6049aef49628d14de793981e8a94286884

1187. Pan W., Yang Y., Zhu H., Zhang Y., Zhou R., Sun X.. KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies. Oncotarget. 2016;7(7):8373-8388. www.epistemonikos.org/documents/808ed79fdc6d488455ce81c8e6487920aae1caa8

1188. Kouranos V., Vassias A., Dimopoulos G., Syrigos K.. Antibiotic prophylaxis in chemotherapy-induced neutropenia in lung cancer patients. European Respiratory Journal. 2011;www.epistemonikos.org/documents/80d87786a1919a9f6f5b2dca3dd03e5e0cbfba60

1189. Cardoso, Renata Carvalho, Carlo, Marysia Mara Rodrigues do Prado De. Fatigue in Lung Cancer Patients: a Systematic Review of Literature. Rev. bras. cancerol. 2013;59(4):575-582. www.epistemonikos.org/documents/80fa86f3121edaf45b1780af0b5450397910c046

1190. Xue Y., Jiang Y., Jin S., Li Y.. Association between cooking oil fume exposure and lung cancer among Chinese nonsmoking women: A meta-analysis. OncoTargets and Therapy. 2016;9:2987-2992. www.epistemonikos.org/documents/80fea3aa81e5a1fa0198c0788b1395bf3610e6e9

1191. Granger CL, Connolly B, Denehy L, Hart N, Antippa P, Lin KY, Parry SM. Understanding factors influencing physical activity and exercise in lung cancer: a systematic review. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2017;25(3):983-999.www.epistemonikos.org/documents/81023d8e843e6f87d6cbebe8730e21354a3c469d

1192. Liu X, Yang Q, Xi Y, Yu K, Wang W, Zhao X, Kou X. Kanglaite injection combined with chemotherapy versus chemotherapy alone in the treatment of advanced non-small cell lung

carcinoma. Journal of cancer research and therapeutics. 2014;10 Suppl 1(5):46-51. www.epistemonikos.org/documents/8109ef6273b9d3f4a3f2d3cffdf7b145a74dda78

1193. Slatore CG, Au DH, Gould MK, American Thoracic Society Disparities in Healthcare Group. An official American Thoracic Society systematic review: Insurance status and disparities in lung cancer practices and outcomes. American journal of respiratory and critical care medicine. 2010;182(9):1195-205.www.epistemonikos.org/documents/810e7641ab3fa0dbd235f0970196c1779d69e36e

1194. Steuer CE, Behera M, Ernani V, Higgins KA, Saba NF, Shin DM, Pakkala S, Pillai RN, Owonikoko TK, Curran WJ, Belani CP, Khuri FR, Ramalingam SS. Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review. JAMA oncology. 2017;3(8):1120-1129. www.epistemonikos.org/documents/8129e18864ef196e50f7570271d32cca6c040b4f

1195. Zhang Y, Liu C. The interaction between smoking and GSTM1 variant on lung cancer in the Chinese population. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(1):395-401. www.epistemonikos.org/documents/81331f9caff21adb3ecb4942f33e61f8775e69cb

1196. Shen ZT, Wu XH, Li B, Shen JS, Wang Z, Li J, Zhu XX. CYP2E1 Rsa I/Pst I polymorphism and lung cancer susceptibility: A meta-analysis involving 10,947 subjects. Journal of cellular and molecular medicine. 2018;22(7):3703. www.epistemonikos.org/documents/813c0f7689691a6a3f978f96a3cd206a72e037f8

1197. Yan B., Zhang W., Jiang L.-Y., Qin W.-X., Wang X.. Reduced E-cadherin expression is a prognostic biomarker of non-small cell lung cancer: A meta-analysis based on 2395 subjects. International Journal of Clinical and Experimental Medicine. 2014;7(11):4352-4356.www.epistemonikos.org/documents/81448bec01fa66ab1f1a6cc6cf9c5056b545325e

1198. Berghmans T., Paesmans M., Meert A.-P., Tiseo M., Sculier J.-P.. Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis. European Respiratory Journal. 2013;www.epistemonikos.org/documents/8182cce4ccbaa6e70606dd7e9d83fcfa92b6acf1

1199. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Survival following lobectomy vs limited resection for stage I lung cancer: a meta-analysis. British journal of cancer. 2005;92(6):1033-7. www.epistemonikos.org/documents/821048193f0dcc955eb4339ee94e13846e6f802c

1200. Yang D, Dai R, Zhang Q, Fang P. Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review. Saudi journal of biological sciences. 2018;25(5):888-894. www.epistemonikos.org/documents/821c6821d4d6f6d632ae70c2336e55572d482c31

1201. Wang X, Liu H, Shen Y, Li W, Chen Y, Wang H. Low-dose computed tomography (LDCT) versus other cancer screenings in early diagnosis of lung cancer: A meta-analysis. Medicine. 2018;97(27):e11233. www.epistemonikos.org/documents/8233025480cc8d9d747c6f62784e26491c44d2f9

1202. Strauch LS, Eriksen RØ, Sandgaard M, Kristensen TS, Nielsen MB, Lauridsen CA. Assessing Tumor Response to Treatment in Patients with Lung Cancer Using Dynamic Contrast-Enhanced CT. Diagnostics (Basel, Switzerland). 2016;6(3). www.epistemonikos.org/documents/82370e2dcb1eb1d9bd2f8145045e0d8a35593409

1203. Wang D.-y., Li Z., Yang K.-h., Tian J.-h., Zhang Q.-n., Wang X.-h.. Radiotherapy combined with hyperthermia for locally-advanced non-small cell lung cancer: A systematic review. Chinese Journal of Evidence-Based Medicine. 2012;12(10):1203-1208. www.epistemonikos.org/documents/82410241732a7ef402ad20b504b7b6584d58dd9e

1204. Gao X., Liu W., Li Y., Wang J., Zhang K., Jia T.. Outcomes of surgical treatment for isolated adrenal metastasis in non-small cell lung cancer: A systematic review and pooled analysis. Journal of Thoracic Oncology. 2013;:S526. www.epistemonikos.org/documents/8250872ea6f2f7a80f17278ba6f2f713dae5377c

1205. Fan L, Feng Y, Wan H, Shi G, Niu W. Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis. PloS one. 2014;9(6):e100866. www.epistemonikos.org/documents/8283f6f0fe8f67c94226bda4c3247c39d80c98f9

1206. Le Marchand L, Guo C, Benhamou S, Bouchardy C, Cascorbi I, Clapper ML, Garte S, Haugen A, Ingelman-Sundberg M, Kihara M, Rannug A, Ryberg D, Stücker I, Sugimura H, Taioli E. Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer causes & control : CCC. 2003;14(4):339-46.www.epistemonikos.org/documents/82b959c255af3842cd5ae2c6ef2f652357200bd6

1207. Sheng J, Yang YP, Zhao YY, Qin T, Hu ZH, Zhou T, Zhang YX, Hong SD, Ma YX, Zhao HY, Huang Y, Zhang L. The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials. Medicine. 2015;94(34):e1400.www.epistemonikos.org/documents/82b9c444f7db6e8b4f38a460ad28078fa419febd

1208. Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clinical drug investigation. 2010;30(4):229-41. www.epistemonikos.org/documents/82bd413e7d942225f57dd0fa0e5e3b3179cb3616

1209. Chu D., Nguyen J., Koo K., Zeng L., Bedard G., Lam H., Wong E., Popovic M., Chow E.. An update of the quality of life measurements in advanced lung cancer patients receiving palliative radiotherapy: A literature review. Supportive Care in Cancer. 2013;:S134.www.epistemonikos.org/documents/82c390c9f96a0394c630cec0139beb57266d82f6

1210. Wu J, Hong D, Zhang X, Lu X, Miao J. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. Scientific reports. 2017;7:44173. www.epistemonikos.org/documents/82c40a87e23662a95a1b833284e88ac10eb261ff

1211. Kong C, Guo WJ, Zha WW, Zhu XZ, Huang SF, Zhang YW, Xu JH, He X. A new index comparable to BED for evaluating the biological efficacy of hypofractionated radiotherapy schemes on early stage non-small cell lung cancer: analysis of data from the literature. Lung cancer (Amsterdam, Netherlands). 2014;84(1):7-12.www.epistemonikos.org/documents/82f31470d666a2605adee86bf019ff48b8da42f5

1212. Duan P., Quan C., Hu C., Zhang J., Xie F., Hu X., Yu Z., Gao B., Liu Z., Zheng H., Liu C., Wang C., Yu T., Qi S., Fu W., Kourouma A., Yang K.. Nonlinear dose-response relationship between radon exposure and the risk of lung cancer: Evidence from a meta-analysis of published observational studies. European Journal of Cancer Prevention. 2015;24((Duan P.; Quan C.; Hu C.; Zhang J.; Xie F.; Hu X.; Yu Z.; Gao B.; Liu Z.; Zheng H.; Liu C.; Wang C.; Yu T.; Qi S.; Fu W.; Kourouma A.; Yang K.)):267-77.www.epistemonikos.org/documents/8307ff3f58ce40c7dfce8541b513e63cf05b1c35

1213. Blinman P, Alam M, Duric V, McLachlan SA, Stockler MR. Patients' preferences for chemotherapy in non-small-cell lung cancer: a systematic review. Lung cancer (Amsterdam, Netherlands). 2010;69(2):141-7. www.epistemonikos.org/documents/831757dd79b4c3c484f636fd3cf085375aa47554

1214. Hotta K, Kiura K, Fujiwara Y, Takigawa N, Hisamoto A, Ichihara E, Tabata M, Tanimoto M. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. PloS one. 2011;6(11):e26646.www.epistemonikos.org/documents/8370eda68b457c52883fe8f414b0da83e7748482

1215. Rueda, José-Ramón, Solà, Ivan, Pascual, Antonio, Subirana Casacuberta, Mireia. Non-invasive interventions for improving well-being and quality of life in patients with lung cancer. Cochrane database of systematic reviews (Online). 2011;9(9):CD004282. www.epistemonikos.org/documents/83b2b59a01ebcb9b34539e2497aae660fff5e8ee

1216. Yang X, Qiu MT, Hu JW, Wang XX, Jiang F, Yin R, Xu L. GSTT1 null genotype contributes to lung cancer risk in asian populations: a meta-analysis of 23 studies. PloS one. 2013;8(4):e62181. www.epistemonikos.org/documents/83cfde8d82291ad003e1b0f39c8bc82c46a13fc0
1217. Feng X, Dong CQ, Shi JJ, Zhou HF, He W, Zheng BS. Lack of association of glutathione S-transferase M3 gene polymorphism with the susceptibility of lung cancer. Asian Pacific journal of cancer prevention : APJCP. 2012;13(9):4465-8. www.epistemonikos.org/documents/83dad5d3d04afb8b36e651c477847df6d28cf4c3
1218. Huang Y, Hu Q, Deng Z, Hang Y, Wang J, Wang K. MicroRNAs in body fluids as biomarkers for non-small cell lung cancer: a systematic review. Technology in cancer research & treatment. 2014;13(3):277-87. www.epistemonikos.org/documents/83db7e378afa9a422aa8e6506360259a77d35955
1219. Fry JS, Hamling JS, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating FEV1 decline to lung cancer risk. BMC cancer. 2012;12(no pagination):498. www.epistemonikos.org/documents/83ef6eaef2784c1fea339c9df6efbcfc4395ee7a
1220. Zhang T., Xu J., Ma J., Cai S., Wu C., Liu Y.. A meta-analysis of randomized clinical trials (RCTs) on epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) for advanced non-small cell lung cancer (NSCLC). Value in Health. 2014;:A68. www.epistemonikos.org/documents/84055bceefccd6b9aa6171eb71db5c3f57ce4384
1221. Liu J., Li S., Li H., Zhang S., Liu Y., Ma L., Liu X., Cheng Y.. The efficacy of combination of EGFR TKIs and chemotherapy versus EGFR TKIs monotherapy for first-line treatment of NSCLC with EGFR mutation: A Meta-analysis. Tumor. 2018;38(4):361-370. www.epistemonikos.org/documents/8431110e0ead39e6bb4496e9c4df655f29f1a6c1
1222. Liu Z.-L., Huang L.-N., Wang B., Liu J.-Z., Liu W.-W.. Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: A meta-analysis. Chinese Journal of Evidence-Based Medicine. 2016;16(5):557-563.www.epistemonikos.org/documents/844737efbbd7ccc2674072c2a2703e7732bcfafc
1223. Medical Advisory Secretariat. Epidermal growth factor receptor (EGFR) genetic testing for prediction of response to EGFR-targeted (TKI) drugs in patients with advanced non-small-cell lung cancer: an evidence-based analysis. 2010;:1-48. www.epistemonikos.org/documents/844a425b4dd5afdf0a8c08bb0b2ef709b66bd38f
1224. Wang T, Luo L, Huang H, Yu J, Pan C, Cai X, Hu B, Yin X. Perioperative blood transfusion is associated with worse clinical outcomes in resected lung cancer. The Annals of thoracic surgery. 2014;97(5):1827-37. www.epistemonikos.org/documents/84908ee4226a77e574f03c07d3e8bb3bc5fda1cd
1225. Zhang Y, Zhang Z, Huang X, Kang S, Chen G, Wu M, Miao S, Huang Y, Zhao H, Zhang L. Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials. Clinical lung cancer. 2017;18(5):e333-e340.www.epistemonikos.org/documents/84b5e752437f31c4fa55b5540927164ef44deea2
1226. Qiu M., Wang J., Xu Y., Ding X., Li M., Jiang F., Xu L., Yin R.. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: A meta-analysis. Cancer Epidemiology Biomarkers and Prevention. 2015;24(1):206-212. www.epistemonikos.org/documents/84f6b705feeef24abc20e2dc09535d59cc5bb490
1227. Moretti F., D'Antona P., Finardi E., Barbetta M., Dominioni L., Poli A., Gini E., Noonan D.M., Imperatori A., Rotolo N., Cattoni M., Campomenosi P.. Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer. Oncotarget. 2017;8(55):94980-94996.www.epistemonikos.org/documents/8504ad721e7a33533b4680f4006f587c99dd59d1
1228. Bucknell NW, Hardcastle N, Bressel M, Hofman MS, Kron T, Ball D, Siva S. Functional lung imaging in radiation therapy for lung cancer: A systematic review and meta-analysis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2018;129(2):196-208.www.epistemonikos.org/documents/852d829d284c262d855495f35798ea88d7220b64

1229. Li X, Wang H, Lin W, Xu Q. Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials. Current medical research and opinion. 2014;30(11):2295-304.www.epistemonikos.org/documents/85337a85ad48d4dd3baedd3fa8dcdb74c66e73e0

1230. Jiang J, Liang X, Zhou X, Huang R, Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2007;57(3):348-58. www.epistemonikos.org/documents/85351b7ca071386df7ceceb40981323f685147d0

1231. Ni X, Xu N, Wang Q. Meta-Analysis and Systematic Review in Environmental Tobacco Smoke Risk of Female Lung Cancer by Research Type. International journal of environmental research and public health. 2018;15(7). www.epistemonikos.org/documents/8539a0fce43ef476e95867590ffd076168b2466a

1232. Zhu Q, Hu H, Weng DS, Zhang XF, Chen CL, Zhou ZQ, Tang Y, Xia JC. Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC. BMC cancer. 2017;17(1):412.www.epistemonikos.org/documents/854989346837fa8c5f9f342cb136a0fe87ab7a23

1233. Wang T, Yan T, Ma S, Wang K, Wang J, Song J, He W, Bai J, Jin L. The efficacy and safety of preoperative chemotherapy for patients with nonsmall cell lung cancer: A meta-analysis. Indian journal of cancer. 2017;54(1):223-227. www.epistemonikos.org/documents/8561afbd57436b4bf7c95dac13d8a307dd6487a0

1234. Nie W, Tao X, Wei H, Chen WS, Li B. The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis. Oncotarget. 2015;6(28):25696-700. www.epistemonikos.org/documents/8568169d8bd344a9fd77c7bc3d819140d6b9c52b

1235. Zhong S., Ma T., Chen L., Chen W., Lv M., Zhang X., Zhao J.. Physical Activity and Risk of Lung Cancer: A Meta-analysis. Clinical Journal of Sport Medicine. 2016;26(3):173-181. www.epistemonikos.org/documents/8589e3a2cd9f4274818eeaf4983c9cc50dfc64b8

1236. Yang S, Cui M, Li HY, Zhao YK, Gao YH, Zhu HY. Meta-analysis of the effectiveness of Chinese and Western integrative medicine on medium and advanced lung cancer. Chinese journal of integrative medicine. 2012;18(11):862-7. www.epistemonikos.org/documents/85a61be85e8e798c593506b27ed43d785045a78a

1237. Galarraga V, Boffetta P. Coffee Drinking and Risk of Lung Cancer-A Meta-Analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2016;25(6):951-7.www.epistemonikos.org/documents/85a9d629d0478c1f3326cc17fdf3c14ba2e31dea

1238. Lorigan P, Radford J, Howell A, Thatcher N, Cancer Research UK, Department of Medical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK, paul.lorigan@man.ac.uk. Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. Lancet Oncology. 2005;6(10):773-779.www.epistemonikos.org/documents/85dbfc5d5c60d1b80e610ff382819da428b48ac2

1239. Liu HZ, Peng J, Zheng F, Wang CH, Han MJ. Lack of assocation of glutathione S-transferase T1 gene null and susceptibility to lung cancer in china: a meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2013;14(12):7215-9. www.epistemonikos.org/documents/85f60eac594033fc6422217e1079935660573a86

1240. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA : the journal of the American Medical Association. 2012;307(22):2418-29.www.epistemonikos.org/documents/864089da8eb9afe95a1a1ff2c90291c89b8ed503

1241. Sun J, Garfield DH, Lam B, Yan J, Gu A, Shen J, Han B. The value of autofluorescence bronchoscopy combined with white light bronchoscopy compared with white light alone in the

diagnosis of intraepithelial neoplasia and invasive lung cancer: a meta-analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011;6(8):1336-44.
www.epistemonikos.org/documents/8656c217686b9033f80e112346b6bdd0194545e8

1242. Dong G.-T., Wu X.-H., Guo W., Li Z., Qi X., Zhou Z., Hou W.. Shenyi capsules as an adjuvant treatment for NSCLC: a systematic review and Meta-analysis of randomized controlled trials. 中国新药杂志 (Chinese Journal of New Drugs). 2017;26(14):1683-1695.
www.epistemonikos.org/documents/868d9b99f14238f7ffea37aaebf21c7027c007ba

1243. Huang J., Zhang Y., Sheng J., Zhang H., Fang W., Zhan J., Zhou T., Chen Y., Liu L., Zhang L.. The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: A meta-analysis of prospective clinical trials. OncoTargets and Therapy. 2016;9:5867-5874.www.epistemonikos.org/documents/869b498cb983f0d60dcce3492de4a1442d7190d3

1244. Zhan P, Wang Q, Qian Q, Yu LK. XRCC3 Thr241Met gene polymorphisms and lung cancer risk: a meta-analysis. Journal of experimental & clinical cancer research : CR. 2013;32:1.
www.epistemonikos.org/documents/86c4e272c1c98b957ff9a455d120b22c7afa8eab

1245. Chang X.-J., Wang Z.-T., Yang L.. Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis. Molecular and Clinical Oncology. 2016;5(2):271-278.www.epistemonikos.org/documents/86c86b9173fd508db510fc8983fa87f79c6fb4a1

1246. Yan TD, Black D, Bannon PG, McCaughan BC. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(15):2553-62.
www.epistemonikos.org/documents/86d35e3530a7fcd5e8698c66053ac0cdf6d5e46d

1247. Gao G, Ren S, Li A, Xu J, Xu Q, Su C, Guo J, Deng Q, Zhou C. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. International journal of cancer. Journal international du cancer. 2012;131(5):E822-9.
www.epistemonikos.org/documents/86e5bffe748b485a0c74458395056f90fd5a7c25

1248. Han J.-C., Li X.-D., Du J., Xu F., Wei Y.-J., Li H.-B., Zhang Y.-J.. Elevated matrix metalloproteinase-7 expression promotes metastasis in human lung carcinoma. World Journal of Surgical Oncology. 2015;13(1):5.
www.epistemonikos.org/documents/873675c24c4f1ffcac99efb40a74e901645cf337

1249. Fenske D.C., Price G.L., Hess L.M., John W.J., Kim E.S.. Systematic Review of Brain Metastases in Patients With Non-Small-Cell Lung Cancer in the United States, European Union, and Japan. Clinical Lung Cancer. 2017;18(6):607-614.
www.epistemonikos.org/documents/87720f16bc1dd97ba45bcb824eb975a52e5dcbe6

1250. Alam N, Darling G, Evans WK, Mackay JA, Shepherd FA, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Adjuvant chemotherapy for completely resected non-small cell lung cancer: a systematic review. Critical reviews in oncology/hematology. 2006;58(2):146-55.www.epistemonikos.org/documents/87813b2addba8197754bb0b624ae6e2f308da40b

1251. Jiang T, Zhai C, Su C, Ren S, Zhou C. The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysis. Lung cancer (Amsterdam, Netherlands). 2016;100:63-70.
www.epistemonikos.org/documents/878798c70854a1c040a7aefdf33a365998563ea3

1252. Sun F, Sun H, Zheng X, Yang G, Gong N, Zhou H, Wang S, Cheng Z, Ma H. Angiotensin-converting Enzyme Inhibitors Decrease the Incidence of Radiation-induced Pneumonitis Among Lung Cancer Patients: A Systematic Review and Meta-analysis. Journal of Cancer. 2018;9(12):2123-2131.www.epistemonikos.org/documents/87a0bfa3c44352ca9730adf67b45432fac062996

1253. Al Feghali KA, Ballout RA, Khamis AM, Akl EA, Geara FB. Prophylactic Cranial Irradiation in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in oncology. 2018;8:115. www.epistemonikos.org/documents/87b398a87508a68ec13d7cf38af892d3e319c786

1254. Yang Y, Xian L. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(4):2905-21.www.epistemonikos.org/documents/87b75d5300bdfbeab0405bad06df114cb9241034

1255. Liu D.-S., Zhou C.-X., Song Z.-G., Zhang G.-Z.. Risk factors for radiation pneumonitis after radiotherapy in lung cancer patients: A systematic review and meta-analysis. International Journal of Clinical and Experimental Medicine. 2016;9(2):3247-3264. www.epistemonikos.org/documents/87b81024d45d687cedf32e1e773c355b86680b68

1256. Zhou Y, Wang Y, Ju X, Lan J, Zou H, Li S, Qi Y, Jia W, Hu J, Liang W, Zhang W, Pang L, Li F. Clinicopathological significance of ALDH1A1 in lung, colorectal, and breast cancers: a meta-analysis. Biomarkers in medicine. 2015;9(8):777-90. www.epistemonikos.org/documents/87f17236fd4fbf28b10a4f579c48192d9e1656c1

1257. Goulart B.H.L., Sullivan S.D., Garrison L.P., Ramsey S., Martins R., Patrick D.. Systematic review of the impact of chemotherapy on patient reported outcomes in advanced non-small-cell lung cancer. Value in Health. 2009;:A499. www.epistemonikos.org/documents/88493eb259d016f59945ffc57bb5532e8c157126

1258. Burotto M, Manasanch EE, Wilkerson J, Fojo T. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. The oncologist. 2015;20(4):400-10. www.epistemonikos.org/documents/88812db77577b7a8c1a50705a59e1809f1628fee

1259. JIANG Jin, WANG Xiao-jing, ZHANG Lu, LIN Oiao, CHEN Miao, TIAN Jin-hui. Pemetrexed versus docetaxel for advanced non-small-cell lung cancer: a meta-analysis. 中国循证医学杂志 (Chinese Journal of Evidence-Based Medicine). 2011;11(8):960-964. www.epistemonikos.org/documents/8885adf52644042890799d3bbf8cafc1d13fc3b8

1260. Zou JH, An L, Chen S, Ren LQ. XPA A23G polymorphism and lung cancer risk: a meta-analysis. Molecular biology reports. 2012;39(2):1435-40.www.epistemonikos.org/documents/88891d35407806efbb3d3bac8f06356ed3474e82

1261. Tang W., Li R., Tan J., Yu Y., Zhao L., Li X., Jiang S., Liu R., Wang K.. Methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to lung cancer as well as response to chemotherapy: A meta-analysis based on 31 studies. International Journal of Clinical and Experimental Medicine. 2016;9(8):16403-16413.www.epistemonikos.org/documents/888e503d765b5b7ec294672342a6dcaea25a32cf

1262. Chen D, Zhang LQ, Huang JF, Liu K, Chuai ZR, Yang Z, Wang YX, Shi DC, Liu Q, Huang Q, Fu WL. BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis. PloS one. 2014;9(6):e101354. www.epistemonikos.org/documents/889bedae2f8743ffc00ee40480655ef6d278d043

1263. Wang Z., Yang L., An T., Zhao J., Bai H., Duan J., Wu M., Zhuo M., Wang Y., Wang J.. [The Association between EGFR Gene Amplification and the Prognosis in Non-small Cell Lung Cancer: A meta-analysis.]. Chinese Journal of Lung Cancer. 2009;12(12):1247-1254.www.epistemonikos.org/documents/88a6be07886a6f17823d283566f76a214b56b662

1264. Hsieh CC, Hsiao FH. The effects of supportive care interventions on depressive symptoms among patients with lung cancer: A metaanalysis of randomized controlled studies. Palliative & supportive care. 2017;15(6):710-723. www.epistemonikos.org/documents/88f71be1dadb283eee56037a8bfc0c5312f41cbd

1265. Xu Y., Li B., Xu X., Chen Q., Yu X., Mao W.. Is there a survival benefit in patients with stage iiia(n2) non-small cell lung cancer under neoadjuvant chemotherapy and/or radiotherapy followed

by surgery administration: A systematic review and meta-analysis. Journal of Thoracic Oncology. 2013;:S138.www.epistemonikos.org/documents/8902086ec822f7d43a198b91455c4613f28063ff

1266. Zheng M.-H., Sun H.-T., Xu J.-G., Yang G., Huo L.-M., Zhang P., Tian J.-H., Yang K.-H.. Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis. BioMed Research International. 2016;2016(no pagination):5807346.www.epistemonikos.org/documents/892b512f57714ae84f039e4fc15516f6306f181e

1267. Santos M., Lefeuvre D., Le Teuff G., Bourgier C., Le Pechoux C., Soria J., Pignon J., Deutsch E.. Meta analysis of toxicities in phase I or II trials studying the use of target therapy (TT) combined to radiotherapy in patients with locally advanced non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2012;:S234-S235.www.epistemonikos.org/documents/895c54098aada98c15093fc0e42ce590bf164c8d

1268. Schmidt-Hansen M, Page R, Hasler E. The effect of preoperative smoking cessation or preoperative pulmonary rehabilitation on outcomes after lung cancer surgery: a systematic review. Clinical lung cancer. 2013;14(2):96-102. www.epistemonikos.org/documents/8962c4c906d7b556331558a7c2b7726544a8d4de

1269. Chen J.-Y., Cheng Y.-N., Han L., Wei F., Yu W.-W., Zhang X.-W., Cao S., Yu J.-P.. Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis. Cancer Biology and Medicine. 2015;12(2):126-139.www.epistemonikos.org/documents/896beb6ecec6fef5883d2ad8b1be0c93517478dc

1270. Créquit P, Chaimani A, Yavchitz A, Attiche N, Cadranel J, Trinquart L, Ravaud P. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis. BMC medicine. 2017;15(1):193.www.epistemonikos.org/documents/89ba49f5dc2971ef37cc898bf33f3679a011d934

1271. Al-Saleh K, Quinton C, Ellis PM. Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis. Current oncology (Toronto, Ont.). 2012;19(1):e9-e15. www.epistemonikos.org/documents/89e0109624cfde6d7f37de60cf7b5339d7cff88f

1272. Hamaji M., Lee H.-S., Kawaguchi A., Burt B.M.. Overall Survival Following Thoracoscopic vs Open Lobectomy for Early-stage Non-small Cell Lung Cancer: A Meta-analysis. Seminars in Thoracic and Cardiovascular Surgery. 2017;29(1):104-112. www.epistemonikos.org/documents/89f5d34c7da61a8d6848f21ddc17512f21b37085

1273. Liu X, Xu F, Wang G, Diao X, Li Y. Kanglaite injection plus chemotherapy versus chemotherapy alone for non--small cell lung cancer patients: a systematic review and meta-analysis. Current Therapeutic Research. 2008;69(5):381-411. www.epistemonikos.org/documents/8a0064cd3f7510c3ce790436b775d9cf031ee201

1274. Grossi F, Aita M, Defferrari C, Rosetti F, Brianti A, Fasola G, Vinante O, Pronzato P, Pappagallo G. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. The oncologist. 2009;14(5):497-510.www.epistemonikos.org/documents/8a15c52edb6865882f6c0c77289573c2dad3d5fe

1275. Chen L., Zhao P., Cao K., Jin L., Xu R., Tang X.. Efficacy and safety of immune checkpoint inhibitors in the treatment of non-small cell lung cancer: A meta-analysis. Journal of Mind and Behavior. 2018;38(8):780-791. www.epistemonikos.org/documents/8a1a4d90404af3cdff0959a1547dafafd84f07fd

1276. Liu Y, Ren Z, Wang J, Zhang S. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: Systematic review and meta analysis. Thoracic cancer. 2016;7(4):406-414.www.epistemonikos.org/documents/8a211ead77bfddb4bc0b183707db1a0b45562078

1277. Yu D, Shi J, Sun T, Du X, Liu L, Zhang X, Lu C, Tang X, Li M, Xiao L, Zhang Z, Yuan Q, Yang M. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33(3):877-84. www.epistemonikos.org/documents/8a33255f1f6a3c3ec41c3289ce49cd90b5ca6b7a

1278. Ganguli A, Wiegand P, Gao X, Carter JA, Botteman MF, Ray S. The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2013;22(5):1015-26.www.epistemonikos.org/documents/8a575bf5213c25b101a7fee349f18e609f72cceb

1279. Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C, Meert AP, Steels E, Vallot F, Verdebout JM, Lafitte JJ, Sculier JP. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. British journal of cancer. 2003;89(1):55-64.www.epistemonikos.org/documents/8a62bdff77a3f6ecf5739aaf643e014c08369404

1280. Jiang L, Yang KH, Guan QL, Mi DH, Wang J. Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials. Internal medicine journal. 2012;42(12):1297-309.www.epistemonikos.org/documents/8a669a984f178851324ebe312828b9905a34cdea

1281. Zhang Y., Qin Q., Li B., Wang J., Zhang K.. Magnetic resonance imaging for N staging in non-small cell lung cancer: A systematic review and meta-analysis. Thoracic Cancer. 2015;6(2):123-132. www.epistemonikos.org/documents/8a76ab9a2dcdd884f16952fe58f9f6f01b139362

1282. Kim JH, Kim HS, Kim BJ. Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a metaanalysis. Oncotarget. 2017;8(54):93149-93155. www.epistemonikos.org/documents/8a9c0a8337279a5c5256636ed4a053d90452502e

1283. Davies J, Patel M, Gridelli C, de Marinis F, Waterkamp D, McCusker ME. Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies. PloS one. 2017;12(4):e0175679.www.epistemonikos.org/documents/8abe23a8df8978b42cc4f710c020e40f52f7f63d

1284. Wu GX, Raz DJ, Brown L, Sun V. Psychological Burden Associated With Lung Cancer Screening: A Systematic Review. Clinical lung cancer. 2016;17(5):315-324.www.epistemonikos.org/documents/8ac80c897eb0c0e673f8546e3aa7b2d6d68af4a6

1285. Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and risk of lung cancer-Systematic review and meta-analysis. Maturitas. 2010;65(3):198-204.www.epistemonikos.org/documents/8ad86eda11cd13c8c696268ce57f95a8559ab213

1286. Rodrigues G, Lock M, D'Souza D, Yu E, Van Dyk J. Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer--a systematic review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2004;71(2):127-38.www.epistemonikos.org/documents/8b02a57f96c6b543a4636c02ec49eb340ed551b5

1287. Li S., Fan J., Liu J., Zhou J., Ren Y., Shen C., Che G.. Neoadjuvant therapy and risk of bronchopleural fistula after lung cancer surgery: A systematic meta-analysis of 14 912 patients. Japanese Journal of Clinical Oncology. 2016;46(6):534-546. www.epistemonikos.org/documents/8b279862553bb15fab34687d5812b599f01f86e6

1288. Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung cancer (Amsterdam, Netherlands). 2013;82(2):197-203. www.epistemonikos.org/documents/8b49a33b54d3872004e9fc9a860bd02162fa3126

1289. Wang M, Cao JX, Liu YS, Xu BL, Li D, Zhang XY, Li JL, Liu JL, Wang HB, Wang ZX. Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis. BMJ open. 2015;5(4):e006321. www.epistemonikos.org/documents/8b4f266f30019fa01c4c4d2837e75f877b622881

1290. Ramos Hernández C, Mouronte-Roibás C, Barros-Dios JM, Fernández-Villar A, Ruano-Ravina A. Deletion of GSTM1 and GSTT1 genes and lung cancer survival: a systematic review. Tumori. 2017;103(4):0. www.epistemonikos.org/documents/8bb21f0ffce2d9a65dc2d9532b224ac66b692596

1291. Botrel T.E.A., Clark O., Clark L.G.O., Paladini L., Faleiros E., Pegoretti B.. Efficacy of the combination bevacizumab plus chemotherapy (BET-CT) compared to ct alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review (SR) and meta-analysis (MA). Value in Health. 2010;:A239.www.epistemonikos.org/documents/8bf2121758f671d182d225a4e21b545578ded7b8

1292. Zhang Z, Wang T, Zhang J, Cai X, Pan C, Long Y, Chen J, Zhou C, Yin X. Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysis. PloS one. 2014;9(8):e106053. www.epistemonikos.org/documents/8bf5ce34a68a8db661a80d0f7eff8b34140fb800

1293. Jiang, Jin, Wang, Xiaojing, Tian, Jinhui, Li, Lun, Lin, Qiao. Thymosin plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials. Thoracic Cancer. 2011;2(4):213-220. www.epistemonikos.org/documents/8c01033c464f2f36965e659dbc6425b7841cc02e

1294. Han B, Yang L, Wang X, Yao L. Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review. OncoTargets and therapy. 2018;11:2121-2129.www.epistemonikos.org/documents/8c1239f1d50fa289896d8816fe39e396b0d3eeef

1295. Zheng J., Bai X., Hong C., Gao H., Li X.. Meta-analysis of the incidence and risk of arterial and venous thromboembolic events associated with anti-EGFR agents in non-small-cell lung cancer patients. Expert Review of Clinical Pharmacology. 2016;9(10):1389-1395.www.epistemonikos.org/documents/8c1e7e42bc3cb5e8c8ad3e3653d558d45a1aa155

1296. Peng T.-R., Tsai F.-P., Wu T.-W.. Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials. International Immunopharmacology. 2017;49:85-94. www.epistemonikos.org/documents/8c232d9a5cc5ff4c1e1f2af2a5f86e6bfb11c807

1297. Zeng XT, Xia LY, Zhang YG, Li S, Leng WD, Kwong JS. Periodontal Disease and Incident Lung Cancer Risk: A Meta-Analysis of Cohort Studies. Journal of periodontology. 2016;87(10):1158-64. www.epistemonikos.org/documents/8c2f5c88ff64368c86f5c911ff14857ac31f062d

1298. Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Sculier JP. Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung cancer (Amsterdam, Netherlands). 2002;37(2):115-23.www.epistemonikos.org/documents/8c32d3b5a618a53e8c853636d0cd67abdeb0e688

1299. Jiang Q., Jiang G., Wang Y.-X.. Meta-analysis of correlation between ERCC1 expression and efficacy of platinum-based chemotherapy in non-small cell lung cancer patients. Chinese Journal of Cancer Prevention and Treatment. 2012;19(2):123-126+133. www.epistemonikos.org/documents/8c3448e4b04295a92f064fb019b4bd59774ed830

1300. Kuo TT, Chen PL, Shih CC, Chen IM. Endovascular stenting for end-stage lung cancer patients with superior vena cava syndrome post first-line treatments - A single-center experience and literature review. Journal of the Chinese Medical Association : JCMA. 2017;80(8):482-486.www.epistemonikos.org/documents/8c55a993d4871ce7b7b25fd51b39d90c9ebfc6d2

1301. Zhang L., Li M., Yin R., Zhang Q., Xu L.. Comparison of the oncologic outcomes of anatomic segmentectomy and lobectomy for early-stage non-small cell lung cancer. Annals of Thoracic Surgery. 2015;99(2):728-737. www.epistemonikos.org/documents/8c7c6588f50665ae7c2811bf13f4d06cf0d19b9b

1302. Wang W, Yan H, Zhang Q, Song W, Li H, Xu J. Evaluating the association of polymorphisms in the HAP1 gene with lung cancer risk: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(11):10825-31.www.epistemonikos.org/documents/8ca8d90e65ec32f1713540692336d0620a158f08

1303. He J, Shen J, Yang C, Jiang L, Liang W, Shi X, Xu X, He J. Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis. Medicine. 2015;94(22):e903. www.epistemonikos.org/documents/8cd49bfe9fea217cb4ebbaa54b836765274c38fa

1304. Zhang LL, Cao FF, Wang Y, Meng FL, Zhang Y, Zhong DS, Zhou QH. The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2015;17(5):371-7. www.epistemonikos.org/documents/8cd895f69f822b552df43e46f1ae310aeb84fc07

1305. Yawen, Z, Runmei, L, Feng, W, Liang,L, Xinwei, Z, Xiubao, R.. [A meta-analysis of adoptive immunotherapy combined with chemo/radio therapy in the treatment of non-small cell lung cancer]. 中国肿瘤生物治疗杂志 (Chinese Journal of Cancer Biotherapy). 2013;20(4):461-467.www.epistemonikos.org/documents/8cdcdcb9c345a076c8a27cdc282e2db1219e7276

1306. Pyo JS, Kang G, Sohn JH. ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis. The International journal of biological markers. 2016;31(4):0. www.epistemonikos.org/documents/8cf6c6eab140d47c4fac51a403560249ecad4266

1307. Meert AP, Martin B, Paesmans M, Berghmans T, Mascaux C, Verdebout JM, Delmotte P, Lafitte JJ, Sculier JP. The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. British journal of cancer. 2003;89(6):959-65.www.epistemonikos.org/documents/8cfc933ccf3a112f562ba95da550c5b19fc674aa

1308. Rakovitch E, Tsao M, Ung Y, Pignol JP, Cheung P, Chow E. Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: a meta-analysis. International journal of radiation oncology, biology, physics. 2004;58(1):196-203.www.epistemonikos.org/documents/8d18d893ccef7071005fd679d8d17b5dcf1c3313

1309. Jing W., Li N., Wang Y., Liu X., Liao S., Chai H., Tu J.. The prognostic significance of long noncoding RNAs in non-small cell lung cancer: A meta-analysis. Oncotarget. 2017;8(3):3957-3968. www.epistemonikos.org/documents/8d7ff28827ff0ec37d58c775e0c6dbfd7a922ad2

1310. Salvo N, Hadi S, Napolskikh J, Goh P, Sinclair E, Chow E. Quality of life measurement in cancer patients receiving palliative radiotherapy for symptomatic lung cancer: a literature review. Current oncology (Toronto, Ont.). 2009;16(2):16-28. www.epistemonikos.org/documents/8dccb82f7b88a1b89edbeb52a931726de2bed7b0

1311. Wang Y, Yang H, Li L, Wang H. Glutathione S-transferase T1 gene deletion polymorphism and lung cancer risk in Chinese population: a meta-analysis. Cancer epidemiology. 2010;34(5):593-7. www.epistemonikos.org/documents/8e0f7b7dd084497c690614cffb48800829f93619

1312. Zhang Q, Dai HH, Dong HY, Sun CT, Yang Z, Han JQ. EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: a meta-analysis. Lung cancer (Amsterdam, Netherlands). 2014;85(3):339-45. www.epistemonikos.org/documents/8e25d0e129e5b9a3fa767ffa298d418012b49526

1313. Bouazza YB, Chiairi I, El Kharbouchi O, De Backer L, Vanhoutte G, Janssens A, Van Meerbeeck JP. Patient-reported outcome measures (PROMs) in the management of lung cancer: A

systematic review. Lung cancer (Amsterdam, Netherlands). 2017;113:140-151.www.epistemonikos.org/documents/8e38361b092a6cb55ecdebe1ed18489105dea29d

1314. Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, Hill SR, Ward RL. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. The Lancet. Oncology. 2006;7(9):741-6.www.epistemonikos.org/documents/8e3a34a81c8c91ec3d8c48a9d294511ff242456f

1315. Jiang J, Li L, Wang X, Tian J, Wang Q, Lin Q. [A meta-analysis of pemetrexed plus platinum chemotherapy versus gemcitabine plus platinum chemotherapy for advanced non-small cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2011;14(1):43-8.www.epistemonikos.org/documents/8e502301c3a36a7c8b9c5f8a5687f8ef3e325565

1316. Kulkarni S, Vella ET, Coakley N, Cheng S, Gregg R, Ung YC, Ellis PM. The Use of Systemic Treatment in the Maintenance of Patients with Non-Small Cell Lung Cancer: A Systematic Review. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(7):989-1002.www.epistemonikos.org/documents/8e7a7b15d19c989de286a20c1fe289d6604565ac

1317. Dai Y.-L., Chen C.-H., Yang C.-T., Chen K.-H., Chiang M.-C., Tang S.-T.. A Meta-Analysis of Changes and Determinants of Quality of Life in Advanced Non-Small Cell Lung Cancer Patients undergoing Chemotherapy. Journal of Cancer Research and Practice. 2015;2(3):224-233.www.epistemonikos.org/documents/8eb753d957e7eead3cf426a6accc61556f36d3da

1318. Yang J, Pyo JS, Kang G. Clinicopathological significance and diagnostic approach of ROS1 rearrangement in non-small cell lung cancer: a meta-analysis: ROS1 in non-small cell lung cancer. The International journal of biological markers. 2018;:1724600818772194.www.epistemonikos.org/documents/8ece04075c1b43eb51842283581d433e439dd4f9

1319. Ye X.-H., Song L., Peng L., Bu Z., Yan S.-X., Feng J., Zhu X.-L., Liao X.-B., Yu X.-L., Yan D.. Association between the CYP2E1 polymorphisms and lung cancer risk: a meta-analysis. Molecular Genetics and Genomics. 2015;290((Ye X.-H.; Peng L.; Yan S.-X., yansenxiang@yeah.net; Zhu X.-L.; Liao X.-B.; Yan D.) Department of Radiotherapy, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China):545-58. www.epistemonikos.org/documents/8edd1e0fcbf5e63e1fd953407458da6eaf2156ea

1320. Miao XH, Yao YW, Yuan DM, Lv YL, Zhan P, Lv TF, Liu HB, Song Y. Prognostic value of the ratio of ground glass opacity on computed tomography in small lung adenocarcinoma: A meta-analysis. Journal of thoracic disease. 2012;4(3):265-71. www.epistemonikos.org/documents/8ef1a636743252c04dbb32b6799f8d27f4e46771

1321. Breen D, Barlési F. The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2008;33(5):805-11.www.epistemonikos.org/documents/8f096eabc268214c3379bfc990d6be356290f173

1322. Chen X, Liu L, Guo Z, Liang W, He J, Huang L, Deng Q, Tang H, Pan H, Guo M, Liu Y, He Q, He J. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis. Cancer chemotherapy and pharmacology. 2017;79(6):1109-1117.www.epistemonikos.org/documents/8f2effcbe6e03c1b671433b4066255bdd8b76466

1323. Guo B, Cen H, Tan X, Liu W, Ke Q. Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures. PloS one. 2014;9(6):e99399. www.epistemonikos.org/documents/8f65a60a98db618e3bf86786c6217fc4705468a1

1324. Chang CY, Chang SJ, Chang SC, Yuan MK. The value of positron emission tomography in early detection of lung cancer in high-risk population: a systematic review. The clinical respiratory journal. 2013;7(1):1-6. www.epistemonikos.org/documents/8f6cca7b0b00f1a4e291e7bbfb927ce345b5686d

1325. Bozcuk H, Abali H, Coskun S, Lung Cancer Committee of Turkish Oncology Group. The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer:

a metaregression analysis. World journal of surgical oncology. 2012;10(1):161.www.epistemonikos.org/documents/8f77883d79a44242a0edb7c4ea7df9a1108c7884

1326. Le Pechoux C., Mauguen A., Baumann M., Schild S.E., Parmar M., Turrisi A.T., Sause W., Ball D., Belani C.P., Behrendt K., Pignon J.-P.. Evaluation of modified fractionation radiotherapy effect in non metastatic lung cancer: An updated individual patients data meta-analysis on 10 randomized trials and 2685 patients. Journal of Thoracic Oncology. 2011;:S432-S433. www.epistemonikos.org/documents/8f8e155728996286143bc0409642b6063dc2d7a6

1327. de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110(8):1654-64. www.epistemonikos.org/documents/8fdaa5a81be10159adfc50178aecba118e6b5f18

1328. Van Houtte P., Paesmans M., Garrido P., Choy H., Fournel P., Van Meerbeeck J.P., Berghmans T., Sculier J.P.. An invidual data metaanalysis of phase II trials of adjuvant or induction chemotherapy for NSCLC treated with chemoRT. Radiotherapy and Oncology. 2014;:S23.www.epistemonikos.org/documents/8ff0e361a7300af79771115b63f5d754eb9e66ca

1329. Li S., Zhu R., Li D., Li N., Zhu X.. Prognostic factors of oligometastatic non-small cell lung cancer: A meta-analysis. Journal of Thoracic Disease. 2018;10(6):3701-3713.www.epistemonikos.org/documents/901444fcb2a045da29168dec52e4e29a1360892c

1330. Cavalheri V, Granger C. Preoperative exercise training for patients with non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2017;6:CD012020.www.epistemonikos.org/documents/905fe6bcba7d3d82c103413f173a059c176311af

1331. Ying M, Zhu X, Chen K, Sha Z, Chen L. Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis. Journal of cancer research and clinical oncology. 2015;141(8):1427-39.www.epistemonikos.org/documents/9081ee4f51318834a4bb643853139e9e529d6330

1332. Zhang JW, Zhao YY, Guo Y, Xue C, Hu ZH, Huang Y, Zhao HY, Zhang J, Wu X, Fang WF, Ma YX, Zhang L. The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer. Chinese journal of cancer. 2014;33(2):105-14.www.epistemonikos.org/documents/908d495c8d6fdae9d7d6902ed6931de6a0397ba8

1333. Sheng Z, Zhang Y. EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer. Medical oncology (Northwood, London, England). 2015;32(1):420. www.epistemonikos.org/documents/909132aab13aead7c21725dc4b1e310ca04b6852

1334. Marchevsky AM, Gupta R, Kusuanco D, Mirocha J, McKenna RJ. The presence of isolated tumor cells and micrometastases in the intrathoracic lymph nodes of patients with lung cancer is not associated with decreased survival. Human pathology. 2010;41(11):1536-43.www.epistemonikos.org/documents/90dcfeedfc9490e02c916dde42f2542fb09f603e

1335. Bae JM, Kim EH. Hormonal Replacement Therapy and the Risk of Lung Cancer in Women: An Adaptive Meta-analysis of Cohort Studies. Journal of preventive medicine and public health = Yebang Ŭihakhoe chi. 2015;48(6):280-6. www.epistemonikos.org/documents/90dea07859332933b0ee7fe3db083d3cef2402cd

1336. Lin H, Lu Y, Gu T, Wang J. Influence of nodal status on the surgical outcome for bronchongenic carcinoma involving the carina: a systematic review and meta-analysis. Minerva chirurgica. 2018;73(5):497-504. www.epistemonikos.org/documents/9111f6266c227b5ac5e08b73bfe99b830bf47605

1337. Durieux V., Coureau M., Meert A.-P., Berghmans T., Sculier J.-P.. Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature. Lung Cancer. 2017;106:102-109. www.epistemonikos.org/documents/91200d0b7e9d27a4d38f137bd12880114646b1fe

1338. Cui J, Cai X, Zhu M, Liu T, Zhao N. The efficacy of bevacizumab compared with other targeted drugs for patients with advanced NSCLC: a meta-analysis from 30 randomized controlled

clinical trials. PloS one. 2013;8(4):e62038. www.epistemonikos.org/documents/9141fe5909661379e6f8f6644a62a1658ca16eca

1339. He W, Cheng M. [Meta-analysis on effectiveness and safety of traditional Chinese medicine combined with first-generation EGFR-TKI in treating advanced non-small cell lung cancer]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. 2017;42(13):2591-2598.www.epistemonikos.org/documents/91575d632b1739ba4d671a2578a444738e591ac9

1340. Sehgal IS, Dhooria S, Aggarwal AN, Behera D, Agarwal R. Endosonography Versus Mediastinoscopy in Mediastinal Staging of Lung Cancer: Systematic Review and Meta-Analysis. The Annals of thoracic surgery. 2016;102(5):1747-1755. www.epistemonikos.org/documents/919d23a652cf4b69749ff8bf69301c944c9cede4

1341. Lima AB, Macedo LT, Sasse AD. Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PloS one. 2011;6(8):e22681. www.epistemonikos.org/documents/91b1ea16d5f51e8b4175efae351584ce62c34164

1342. Zhu L, Cao H, Zhang T, Shen H, Dong W, Wang L, Du J. The Effect of Diabetes Mellitus on Lung Cancer Prognosis: A PRISMA-compliant Meta-analysis of Cohort Studies. Medicine. 2016;95(17):e3528. www.epistemonikos.org/documents/91c13bf465e25e522b3ae0587bae21ac566ad9f1

1343. Jin Y.-X., Jiang G.-N., Zheng H., Duan L., Ding J.-A.. Common genetic variants on 3q28 contribute to non-small cell lung cancer susceptibility: evidence from 10 case-control studies. Molecular Genetics and Genomics. 2015;290((Jin Y.-X.; Jiang G.-N., gening_jiang@126.com; Zheng H.; Duan L.; Ding J.-A.) Department of Thoracic Surgery, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai, China):573-84. www.epistemonikos.org/documents/91e99eac8334abc890d4ca6a0ae2fa13d950121c

1344. Zheng Q.-L., Zhang H.-Q., Zhang C., Xu G.. Association between Thr241Met polymorphism in XRCC3 gene and the risk of lung cancer in Chinese population: A meta-analysis. Chinese Journal of Evidence-Based Medicine. 2013;13(9):1080-1083. www.epistemonikos.org/documents/920576622e15caf1e81fb800125d1813a6a983ce

1345. Chi A, Chen H, Wen S, Yan H, Liao Z. Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2017;123(3):346-354.www.epistemonikos.org/documents/921e70666b16901836be31ebc1d8cacd64315d32

1346. Zhang T, Xie J, Arai S, Wang L, Shi X, Shi N, Ma F, Chen S, Huang L, Yang L, Ma W, Zhang B, Han W, Xia J, Chen H, Zhang Y. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget. 2016;7(45):73068-73079.www.epistemonikos.org/documents/92312a41fa2cffa67424d79733ee77a60d1f5af7

1347. Liang Y, Deng J, Xiong Y, Wang S, Xiong W. Genetic association between ERCC5 rs17655 polymorphism and lung cancer risk: evidence based on a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(6):5613-8.www.epistemonikos.org/documents/92409c263d15f7dd0a2f31f2eb2422bd1feb1652

1348. Silvestri GA, Littenberg B, Colice GL. The clinical evaluation for detecting metastatic lung cancer. A meta-analysis. American journal of respiratory and critical care medicine. 1995;152(1):225-30. www.epistemonikos.org/documents/924cfee205458628131ec0e6ab6d34a8d9e8f4ca

1349. Forrest LF, Adams J, Wareham H, Rubin G, White M. Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis. PLoS medicine. 2013;10(2):e1001376. www.epistemonikos.org/documents/9256529bda2d848f88d6f42fb3cac527a6258512

1350. Nie SP, Chen H, Zhuang MQ, Lu M. Anti-diabetic medications do not influence risk of lung cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2014;15(16):6863-9. www.epistemonikos.org/documents/928b3117a129c9863affe1a5475e170a59edfcdf

1351. Xu W., Li R., Jin X., Tan J., Wang K.. Comparative survival analysis of the treatment options for TKI resistant advanced non-small cell lung cancer (NSCLC) patients: A meta-analysis. International Journal of Clinical and Experimental Medicine. 2016;9(9):17822-17831.www.epistemonikos.org/documents/92a8b873cde387ce7c0e562eea419df22da615d7

1352. Tang H.-M., Tu X., Xiong F., Luo Q., Su F.-L., Su Z.-Q., Zhang Q.-Y., Cai Q.-Q.. Cisplatin versus other platinum combined with etoposide in treatment of small cell lung cancer: A meta-analysis. Chinese Journal of Evidence-Based Medicine. 2015;15(4):452-457. www.epistemonikos.org/documents/92ba6b00de2ae24ef6302d3d7a551738edf54085

1353. Lu S, Yu Y, Chen Z, Ye X, Li Z, Niu X. Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies. Lung. 2015;193(5):805-14. www.epistemonikos.org/documents/92bb9e1ec64f6db34691c1043ad07eba32a7495f

1354. Wu Y., Hou Q.. Systemic lupus erythematous increased lung cancer risk: Evidence from a meta-analysis. Journal of Cancer Research and Therapeutics. 2016;12(2):721-724.www.epistemonikos.org/documents/92dcc1e25298b1176f2416d8f5df4f99427e2cba

1355. Buffart LM, Singh AS, van Loon EC, Vermeulen HI, Brug J, Chinapaw MJ. Physical activity and the risk of developing lung cancer among smokers: a meta-analysis. Journal of science and medicine in sport / Sports Medicine Australia. 2014;17(1):67-71. www.epistemonikos.org/documents/9321ad0327f093855a7089de19cfcb6da60528a5

1356. Chen Y, Yu Z, Zhang B, Chang Z, Wang H, Liu Z. CRR9p polymorphism as a protective factor for lung cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(10):9557-62. www.epistemonikos.org/documents/9331f08e7a0b5d526a5abd2bb74eca7446c4a2dc

1357. Huggenberger IK, Andersen JS. Predictive value of the official cancer alarm symptoms in general practice - a systematic review. Danish medical journal. 2015;62(5).www.epistemonikos.org/documents/93536da58347860a25973aae43b8b865d76707ff

1358. Deng H.-Y., Wang Y.-C., Ni P.-Z., Li G., Yang X.-Y., Lin Y.-D., Liu L.-X.. Radiotherapy, lobectomy or sublobar resection? A meta-analysis of the choices for treating stage I non-small-cell lung cancer. European Journal of Cardio-thoracic Surgery. 2017;51(2):203-210.www.epistemonikos.org/documents/9362ff3c79af574edfbc45ee0904ccd97592f897

1359. Zhang HL, Ruan L, Zheng LM, Whyte D, Tzeng CM, Zhou XW. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung cancer (Amsterdam, Netherlands). 2012;77(1):9-15.www.epistemonikos.org/documents/938215b752637b80724bba6b9da231997995154d

1360. Zhao J., Xia Y., Kaminski J., Hao Z., Mott F., Campbell J., Sadek R., Kong F.-M.. Treatment-related death during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A meta-analysis of randomized studies. PLoS ONE. 2016;11(6):e0157455.www.epistemonikos.org/documents/938c2590cedca058e434c12c8c1b9e971bb4c13a

1361. Jiang JW, Liang XH, Zhou XL, Huang RF. [A meta-analysis of the curative effects of carboplatin-based and cisplatin-based chemotherapeutic regimens on advance non-small cell lung cancer]. Zhonghua yi xue za zhi. 2006;86(37):2615-20. www.epistemonikos.org/documents/9395b674f324e266d60265a4f334a6055ddc2f0f

1362. Chen R, Khatri P, Mazur PK, Polin M, Zheng Y, Vaka D, Hoang CD, Shrager J, Xu Y, Vicent S, Butte AJ, Sweet-Cordero EA. A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma. Cancer research. 2014;74(10):2892-902.www.epistemonikos.org/documents/939610599c4df4b9674ea0096ea13c8a5fb029e9

1363. Bakalos G, Miligkos M, Doxani C, Mpoulimari I, Rodopoulou P, Zintzaras E. Assessing the relative effectiveness and tolerability of treatments in small cell lung cancer: a network meta-analysis. Cancer epidemiology. 2013;37(5):675-82. www.epistemonikos.org/documents/939df27ea7fe0a09d163e18e564b1b1701da17ba

1364. Liu Y.-F., Yang S.-Y., Shang W.-L., Zhang W., Huo S.-F., Bu L.-N., Rong B.-X., Nan Y.-D., Tian Y.-X.. Meta-analysis on the diagnostic value of CYFRA21-1 in early non-small cell lung cancer. Journal of Xi'an Jiaotong University (Medical Sciences). 2011;32(1):34-37.www.epistemonikos.org/documents/93b1b69e9005783a2d269dfa7c96cdd2018b0042

1365. Zhao J., Sadek R.F., Albasheer A., Hao Z., Mott F., Kong F.-M.. Treatment-related deaths after concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: A meta-analysis of randomized studies. Journal of Clinical Oncology. 2014; www.epistemonikos.org/documents/93c0c9e6bb3194bce4553fd672e30e87c1db9123

1366. Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010;16(1):291-303.www.epistemonikos.org/documents/93f962492b9d627c938837ad0a2aa7f54e10a63b

1367. Ge W, Cao DD, Wang HM, Jie FF, Zheng YF, Chen Y. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2011;12(10):2705-11. www.epistemonikos.org/documents/9431317f6859ff4053e2f3cd7a73330f22292eb1

1368. Yang X, Li M, Yang X, Zhao M, Huang Y, Dai X, Jiang T, Feng M, Zhan C, Wang Q. Uniport versus multiport video-assisted thoracoscopic surgery in the perioperative treatment of patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis. Journal of thoracic disease. 2018;10(4):2186-2195.www.epistemonikos.org/documents/948f37d7e33a173a9a483d3d9ad07221a85085aa

1369. Schmutz E., Sitter H.. Meta-analysis of survival under adjuvant chemotherapy in non-small cell lung cancer. Langenbeck's Archives of Surgery. 2011;:900.www.epistemonikos.org/documents/949993a8c9de65eba74e6f53140beb940ead2147

1370. Vestergaard HH, Christensen MR, Lassen UN. A systematic review of targeted agents for non-small cell lung cancer. Acta oncologica (Stockholm, Sweden). 2018;57(2):1-11.www.epistemonikos.org/documents/94a28433b9410970a2d408ffac0d073d9fad6e77

1371. Bai Y., Duan J.-L.. Pemetrexed alone versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer: A systematic review. Chinese Journal of New Drugs. 2011;20(19):1926-1934. www.epistemonikos.org/documents/94d01f13dc42c803d297c87a0b6e7af8f44a0770

1372. Vale C.L., Burdett S., Fisher D.J., Navani N., Parmar M.K.B., Copas A.J., Tierney J.F.. Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials. Clinical Lung Cancer. 2015;16((Vale C.L., Claire.Vale@ucl.ac.uk; Burdett S.; Fisher D.J.; Parmar M.K.B.; Copas A.J.; Tierney J.F.) MRC Clinical Trials Unit at UCL, London, United Kingdom):173-182.e4.www.epistemonikos.org/documents/94d5dae77b10cab1c5619d2490922b7c09dcda7c

1373. Hu J, Pan J, Luo ZG. MMP1 rs1799750 single nucleotide polymorphism and lung cancer risk: a meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2012;13(12):5981-4. www.epistemonikos.org/documents/94eeecdc03f3e6a1a19f9dfbe0e6553e8b89e043

1374. Behera M, Owonikoko TK, Chen Z, Kono SA, Khuri FR, Belani CP, Ramalingam SS. Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis. Lung cancer (Amsterdam, Netherlands). 2012;77(2):331-8. www.epistemonikos.org/documents/94f435f37967ab9b8b61f6a2a3db9c952d614d41

1375. Li M, Zhang Q, Fu P, Li P, Peng A, Zhang G, Song X, Tan M, Li X, Liu Y, Wu Y, Fan S, Wang C. Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. PloS one. 2012;7(5):e37229.www.epistemonikos.org/documents/94ffcd6df3c937782ce4c91069f122f0f061c447

1376. Lu Y, Lemon W, Liu PY, Yi Y, Morrison C, Yang P, Sun Z, Szoke J, Gerald WL, Watson M, Govindan R, You M. A gene expression signature predicts survival of patients with stage I non-

small cell lung cancer. PLoS medicine. 2006;3(12):e467. www.epistemonikos.org/documents/957ae14ab0c011b8713bba844940fff6331b098b

1377. Gao X.-L., Fu T., Zhang K.-W., Li Y., Zhang K.-J., Jia T., Liu H., Liu W.. Outcomes of surgical treatment for patients with non-small-cell lung cancer complicated with isolated adrenal metastasis: A systematic review and pooled analysis. Journal of Jilin University Medicine Edition. 2014;40(2):345-350.www.epistemonikos.org/documents/95a83fc6f06ae2f9c2f2becd5bd49d1296940b2a

1378. Zhou JG, Tian X, Cheng L, Zhou Q, Liu Y, Zhang Y, Bai YJ, Ma H. The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis. Medicine. 2015;94(40):e1719.www.epistemonikos.org/documents/95c663e9ed70ab558901422f98032cf47acc6b53

1379. Moreland SS. Nutrition screening and counseling in adults with lung cancer: a systematic review of the evidence. Clinical journal of oncology nursing. 2010;14(5):609-14.www.epistemonikos.org/documents/95d5979ce78bc66d12b033a07606b9555e477e62

1380. Gu X, Ma C, Yuan D, Song Y. Circulating soluble intercellular adhesion molecule-1 in lung cancer: a systematic review. Translational lung cancer research. 2012;1(1):36-44.www.epistemonikos.org/documents/95df4423a1ef5c06007c5bf42467ea5eab061bf7

1381. Bria E, Gralla RJ, Raftopoulos H, Cuppone F, Milella M, Sperduti I, Carlini P, Terzoli E, Cognetti F, Giannarelli D. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. Lung cancer (Amsterdam, Netherlands). 2009;63(1):50-7.www.epistemonikos.org/documents/95f023a680fd5568a14eadfaf06d6410ded47c73

1382. Liu Y, Huang C, Liu H, Chen Y, Li S. Sublobectomy versus lobectomy for stage IA (T1a) non-small-cell lung cancer: a meta-analysis study. World journal of surgical oncology. 2014;12(1):138. www.epistemonikos.org/documents/95f7ef92ba799f70c347ecf765917268890ec2e5

1383. Han C, Ma J, Zhao J, Zhou Y, Jing W, Zou H. EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysis. Cancer investigation. 2011;29(9):626-34.www.epistemonikos.org/documents/95fe691cf1d51b4f1c55a9a0309e2f9878c4dbe1

1384. Luszczynska A, Pawlowska I, Cieslak R, Knoll N, Scholz U. Social support and quality of life among lung cancer patients: a systematic review. Psycho-oncology. 2013;22(10):2160-8. www.epistemonikos.org/documents/961f66ad0c455a239ff6049f5ee4d279af7c19a7

1385. Noble J, Ellis PM, Mackay JA, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006;1(9):1042-58. www.epistemonikos.org/documents/962dea8a86f5f247302ba3084cc29d60a51d0a57

1386. Lu X, Ke J, Luo X, Zhu Y, Zou L, Li H, Zhu B, Xiong Z, Chen W, Deng L, Lou J, Wang X, Zhang Y, Wang Z, Miao X, Cheng L. The SNP rs402710 in 5p15.33 is associated with lung cancer risk: a replication study in Chinese population and a meta-analysis. PloS one. 2013;8(10):e76252.www.epistemonikos.org/documents/9649905150a1543acbaf880fc9516727340ec9e6

1387. Wu R, Jiang Y, Wu Q, Li Q, Cheng D, Xu L, Zhang C, Zhang M, Ye L. Diagnostic value of microRNA-21 in the diagnosis of lung cancer: evidence from a meta-analysis involving 11 studies. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(9):8829-36.www.epistemonikos.org/documents/9679f8d9639a3e74cdb3485e9e1b1d60aade81ee

1388. Liu HB, Wu Y, Lv TF, Yao YW, Xiao YY, Yuan DM, Song Y. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung

cancer: a systematic review and meta-analysis. PloS one. 2013;8(1):e55128. www.epistemonikos.org/documents/967f707b3a5da8122f07f88ee3d46bc62d908bb7

1389. Smith BM, Pinto L, Ezer N, Sverzellati N, Muro S, Schwartzman K. Emphysema detected on computed tomography and risk of lung cancer: a systematic review and meta-analysis. Lung cancer (Amsterdam, Netherlands). 2012;77(1):58-63. www.epistemonikos.org/documents/96900e4ea88205fd3952c1b05dc40d2949307a5b

1390. Cruz, M C, Tan, M. Epidermal growth factor receptor inhibitors as second-line treatment in advanced non-small cell lung cancer: A meta-analysis. Journal of Clinical Oncology. 2009;27:7597-7597. www.epistemonikos.org/documents/96a4ebb37f5c11d02c27b725d33f16121931e49d

1391. Liu J., Dong M., Sun X., Xing L.. Prognostic value of 18F-FDG PET uptake in surgically resected non-small cell lung cancer: A systemic review and metaanalysis. Journal of Nuclear Medicine. 2015; www.epistemonikos.org/documents/96aebfb3aa3060d56cff79601fc9ad48a91ca990

1392. Liu J, Yang Q, Lan Y, Wang M. [Expression of human telomerase in lung cancer:A meta-analysis of diagnostic test]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2001;4(4):299-302. www.epistemonikos.org/documents/96d4f1aff4f839361e8d884e751cc3e5749f4fc8

1393. Jiang T., Min W., Li Y., Yue Z., Wu C., Zhou C.. Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: An update meta-analysis. Cancer Medicine. 2016;5(6):1055-1065. www.epistemonikos.org/documents/96eedbf8436ef1c2b3ac1247701d558bbefa88b1

1394. Shan F, Zhang B, Sun L, Xie L, Shen M, Ruan S. The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. BioMed research international. 2018;2018:5839081.www.epistemonikos.org/documents/9716137f3691880677b231852a6f5e314288fea7

1395. Steuer C., Behera M., Higgins K.A., Saba N., Shin D., Pakkala S., Pillai R., Owonikoko T.K., Curran W.J., Belani C.P., Khuri F., Ramalingam S.S.. A systematic review of carboplatin-paclitaxel versus cisplatin-etoposide concurrent with thoracic radiation for stage III NSCLC patients. Journal of Thoracic Oncology. 2015;:S212.www.epistemonikos.org/documents/979e4266426d4aae81be3ed571c9dde3f925ed24

1396. Leong TL, Loveland PM, Gorelik A, Irving L, Steinfort DP. Preoperative Staging by EBUS in cN0/N1 Lung Cancer: Systematic Review and Meta-Analysis. Journal of bronchology & interventional pulmonology. 2019;26(3):155-165. www.epistemonikos.org/documents/97a54f0ee5d90cb3cc27c41465e48a565177ea60

1397. Wu Y, Liu H, Shi X, Song Y. Can EGFR mutations in plasma or serum be predictive markers of non-small-cell lung cancer? A meta-analysis. Lung cancer (Amsterdam, Netherlands). 2015;88(3):246-53. www.epistemonikos.org/documents/97c382b3715a1c0d88796cb8a74a6dea850a6ffe

1398. Wang S, Lan X, Tan S, Wang S, Li Y. P53 codon 72 Arg/Pro polymorphism and lung cancer risk in Asians: an updated meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(5):2511-20.www.epistemonikos.org/documents/97ca4df1dcc2bfd3b4d7fde6c844ec1236fde266

1399. Liu T, Xie CB, Ma WJ, Chen WQ. Association between CYP2A6 genetic polymorphisms and lung cancer: a meta-analysis of case-control studies. Environmental and molecular mutagenesis. 2013;54(2):133-40. www.epistemonikos.org/documents/97d8ed949b64da69931dd30ea36787363883d36b

1400. Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents. Journal of cancer research and clinical oncology. 2013;139(1):25-38.www.epistemonikos.org/documents/98004a1543c42493366cdaddfc17c95590e7178f

1401. Liu Y., Song X.L., Zhang G.L., Peng A.M., Fu P.F., Li P., Tan M., Li X., Li M., Wang C.H.. Lack of association between IL-6 -174G>C polymorphism and lung cancer: A meta-analysis. Genetics and Molecular Research. 2015;14(1):163-169. www.epistemonikos.org/documents/9807e927676f17fbd628424f1af5cf3954c3948b

1402. Wang S, Wang Z. EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysis. International journal of clinical and experimental medicine. 2014;7(8):1967-78. www.epistemonikos.org/documents/9814c03647b97c46e98d3853baadaf62cb2c60d5

1403. Qi W.-X., Fu S., Zhang Q., Guo X.-M.. Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: A meta-Analysis of 17 phase III randomized controlled trials. Current Medical Research and Opinion. 2015;31(1):25-33.www.epistemonikos.org/documents/984c7a09b820bc4c246b8ffadf176c6cb7e4839c

1404. Lee PN, Forey BA, Coombs KJ. Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. BMC cancer. 2012;12(no pagination):385. www.epistemonikos.org/documents/984df634a23399d895b6bb9f35eb3d413359fcc4

1405. Hu P, Wong PT, Zhou Q, Sheng L, Niu W, Chen S, Xu M, Lin Y. Clinical relevance of the multidrug resistance-associated protein 1 gene in non-small cell lung cancer: A systematic review and meta-analysis. Oncology reports. 2018;40(5):3078-3091. www.epistemonikos.org/documents/985704610aac732c736ae0722d06677af76ea948

1406. Rotshild V, Azoulay L, Zarifeh M, Masarwa R, Hirsh-Raccah B, Perlman A, Muszkat M, Matok I. The Risk for Lung Cancer Incidence with Calcium Channel Blockers: A Systematic Review and Meta-Analysis of Observational Studies. Drug safety. 2018;41(6):555-564.www.epistemonikos.org/documents/986063daf2d1a5c463fd83e6c6d9f7ffe5e6eb8a

1407. Cao C, Chandrakumar D, Gupta S, Yan TD, Tian DH. Could less be more?-A systematic review and meta-analysis of sublobar resections versus lobectomy for non-small cell lung cancer according to patient selection. Lung cancer (Amsterdam, Netherlands). 2015;89(2):121-32.www.epistemonikos.org/documents/9870eafbb8f93b76c7ae4c0aa4e52f5274298acc

1408. Meng D, Zhou Z, Wang Y, Wang L, Lv W, Hu J. Lymphadenectomy for clinical early-stage non-small-cell lung cancer: a systematic review and meta-analysis. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2016;50(4):597-604.www.epistemonikos.org/documents/9874871fe907acd1aa87594d09107f50ddeb25b7

1409. Gui XH, Qiu LX, Zhang HF, Zhang DP, Zhong WZ, Li J, Xiao YL. MDM2 309 T/G polymorphism is associated with lung cancer risk among Asians. European journal of cancer (Oxford, England : 1990). 2009;45(11):2023-6. www.epistemonikos.org/documents/987b03e6d51aa772d040e4b2115010f237126f08

1410. McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, Gao J, Lieb W, Shieh K, Colford JM. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(3):419-30. www.epistemonikos.org/documents/98a164987e8d84a40ecd90de952f4a3cf40f1f63

1411. Yang J, Jiao S. Increased lung cancer risk associated with the TERT rs2736100 polymorphism: an updated meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(6):5763-9. www.epistemonikos.org/documents/98b93db070443530ee898d0431769803db463982

1412. Zhang Q, Jin H, Wang L, Xin B, Zhang J, Zhou Y, Sheng S. Lung cancer risk and genetic variants in East Asians: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(6):5173-9.www.epistemonikos.org/documents/98bb43dd44547ad06d8a71c9f4da5bd197ac8bbc

1413. Boffetta P, Trédaniel J, Greco A. Risk of childhood cancer and adult lung cancer after childhood exposure to passive smoke: A meta-analysis. Environmental health perspectives.

2000;108(1):73-82. www.epistemonikos.org/documents/98cfbe141afde4d922a4d1fb075bbb4580864c4c

1414. Zhang LQ, Wang J, Jiang F, Xu L, Liu FY, Yin R. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PloS one. 2012;7(3):e34100. www.epistemonikos.org/documents/98f12445e529ff2d7db9ec75e7ddda782f5a3b23

1415. Pan G, Ke S, Zhao J. Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Targeted oncology. 2013;8(2):107-16.www.epistemonikos.org/documents/990a5b52326cd9e372f1c0336d0c11bb20066ab7

1416. Gridelli C, Shepherd FA. Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest. 2005;128(2):947-57.www.epistemonikos.org/documents/99130d12223d64ef96178f90d6acdb344092283d

1417. Huang G, Cai S, Wang W, Zhang Q, Liu A. Association between XRCC1 and XRCC3 polymorphisms with lung cancer risk: a meta-analysis from case-control studies. PloS one. 2013;8(8):e68457. www.epistemonikos.org/documents/993e116edefc1c26b619940a68afb0f095c482c2

1418. Li B, Huang X, Fu L. Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis. OncoTargets and therapy. 2018;11:3691-3696. www.epistemonikos.org/documents/9964c41d9849df8014a2f60dc393c4a20b6314d9

1419. Muralidaran A, Detterbeck FC, Boffa DJ, Wang Z, Kim AW. Long-term survival after lung resection for non-small cell lung cancer with circulatory bypass: a systematic review. The Journal of thoracic and cardiovascular surgery. 2011;142(5):1137-42. www.epistemonikos.org/documents/996a686cddffadb2143bb5baaceeec551316376b

1420. Xie Z.-C., Tang R.-X., Gao X., Xie Q.-N., Lin J.-Y., Chen G., Li Z.-Y.. A meta-analysis and bioinformatics exploration of the diagnostic value and molecular mechanism of miR-193a-5p in lung cancer. Oncology Letters. 2018;16(4):4114-4128. www.epistemonikos.org/documents/9970d7fb5e740242bcf1e1b05ae74a29cd1a235e

1421. Zhao QT, Guo T, Wang HE, Zhang XP, Zhang H, Wang ZK, Yuan Z, Duan GC. Diagnostic value of SHOX2 DNA methylation in lung cancer: a meta-analysis. OncoTargets and therapy. 2015;8:3433-3439. www.epistemonikos.org/documents/997eddff1065546828f892290d96ea54375947a9

1422. Zhang YF, Lu J, Yu FF, Gao HF, Zhou YH. Polyunsaturated fatty acid intake and risk of lung cancer: a meta-analysis of prospective studies. PloS one. 2014;9(6):e99637.www.epistemonikos.org/documents/9990b33b3a1bd5b9b667a6a4569aaa11c199fa89

1423. Jin B., Liu Y.-P., Shi J., Liu J., Zhang J., Shi J.-P.. Meta-analysis of induction chemotherapy combined with interferon in advanced non-small cell lung cancer. Chinese Journal of Evidence-Based Medicine. 2006;6(5):370-375. www.epistemonikos.org/documents/99c2eb2ede6aa1c16b6e3606de09451a29419b28

1424. Yu Q, Guo Q, Chen L, Liu S. Clinicopathological significance and potential drug targeting of CDH1 in lung cancer: a meta-analysis and literature review. Drug design, development and therapy. 2015;9:2171-8. www.epistemonikos.org/documents/99d714a2e6ff7e5fd64af52f52a8620567ae0c88

1425. Xu XW, Yuan ZZ, Hu WH, Wang XK. [Meta-analysis on elemene injection combined with cisplatin chemotherapeutics in treatment of non-small cell lung cancer]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. 2013;38(9):1430-7.www.epistemonikos.org/documents/99f01e848b8be7af469fbb78d8dabd2c45a33df4

1426. Mohan HK, Miles KA. Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2009;50(3):376-81.www.epistemonikos.org/documents/9a2986901153d3dae222476bad2239554dcce849

1427. Wang J, Zou ZH, Xia HL, He JX, Zhong NS, Tao AL. Strengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trials. PloS one. 2012;7(3):e32695. www.epistemonikos.org/documents/9a2d60e396a214b7e6795272f81c06452d58168a

1428. Sun DS, Hu LK, Cai Y, Li XM, Ye L, Hou HY, Wang CH, Jiang YH. A systematic review of risk factors for brain metastases and value of prophylactic cranial irradiation in non-small cell lung cancer. Asian Pacific journal of cancer prevention : APJCP. 2014;15(3):1233-9.www.epistemonikos.org/documents/9a30c67cf98dc4eeb49aad8c09508853da3b014d

1429. Wu Q, Luo W, Zhao Y, Xu F, Zhou Q. The utility of 18F-FDG PET/CT for the diagnosis of adrenal metastasis in lung cancer: a PRISMA-compliant meta-analysis. Nuclear medicine communications. 2017;38(12):1117-1124. www.epistemonikos.org/documents/9a33b3247663781d7e5dcb0e7abe9b5debedc59a

1430. Oakley-Girvan I, Davis SW. Breath based volatile organic compounds in the detection of breast, lung, and colorectal cancers: A systematic review. Cancer biomarkers : section A of Disease markers. 2017;21(1):29-39. www.epistemonikos.org/documents/9a45d049ef86ef87006ae34890a94ab7c5bf549b

1431. Laporte S., Squifflet P., Baroux N., Fossella F., Georgoulias V., Pujol J.-L., Douillard J.-Y., Kudoh S., Pignon J.-P., Quinaux E., Buyse M.. Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. BMJ Open. 2013;3(3).www.epistemonikos.org/documents/9a4a4391f1e59a0f834cc8ae09ce7ac18e83946b

1432. Yu SN, Liu GF, Li XF, Fu BH, Dong LX, Zhang SH. Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis. Journal of cellular biochemistry. 2017;118(12):4782-4791.www.epistemonikos.org/documents/9a4b25e5048c5acd49382c4ec3bb9d556bf67ea9

1433. Higginson I.. Chemotherapy in non-small cell lung cancer. Quality of life was ignored in meta-analysis. BMJ (Clinical research ed.). 1996;312(7025):249.www.epistemonikos.org/documents/9a519660a87b7f12bf1cc4148f9c5b3391634a50

1434. Li S., Pan B., Li T., Xie F., Wang H.. Correlation between expression of programmed cell death-ligand 1 protein and prognosis of lung cancer: A Meta-analysis. Journal of Jilin University Medicine Edition. 2015;41(5):969-973. www.epistemonikos.org/documents/9a61451f5edcf1794f5e89a1960c4e50005721a4

1435. Yin M, Yan J, Voutsina A, Tibaldi C, Christiani DC, Heist RS, Rosell R, Booton R, Wei Q. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung cancer (Amsterdam, Netherlands). 2011;72(3):370-7.www.epistemonikos.org/documents/9a92ab40d691dbcd2e41768448fd6e3615dde0a2

1436. Ge X, Guan W, Han F, Guo X, Jin Z. Comparison of Endobronchial Ultrasound-Guided Fine Needle Aspiration and Video-Assisted Mediastinoscopy for Mediastinal Staging of Lung Cancer. Lung. 2015;193(5):757-66. www.epistemonikos.org/documents/9aaa3920bedf99f975cfd2177e343e9b696fc41d

1437. ZHANG Zhen-hua, HONG Jin-chuan, CHEN Zhi-jin, MEI Qi-bing. Systematic review of mannatide injection in the treatment of non-small cell lung cancer. 中国新药杂志 (Chinese Journal of New Drugs). 2012;21(24):2917-2923. www.epistemonikos.org/documents/9ab9a9e7910f87ab76fdb4f203b2279a894237ee

1438. Gu B., Gao W.C., Chu H.J., Gao J., Fu Z., Ding H., Lv J.J., Wu Q.Q.. Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis. Medicine (United States). 2016;95(48):e3752. www.epistemonikos.org/documents/9adc368f896bb0373b264c83f198a7ff653ea175

1439. Shen G., Jia Z., Deng H.. Apparent diffusion coefficient values of diffusion-weighted imaging for distinguishing focal pulmonary lesions and characterizing the subtype of lung cancer: a meta-analysis. European Radiology. 2016;26(2):556-566. www.epistemonikos.org/documents/9aeb76be051d60c9894d5578b71781290fd6ffcc
1440. Sjögren B, Hansen KS, Kjuus H, Persson PG. Exposure to stainless steel welding fumes and lung cancer: a meta-analysis. Occupational and environmental medicine. 1994;51(5):335-6. www.epistemonikos.org/documents/9b3270a0ec1674e8fa78c1739d33683ca730c584
1441. Fuentes HE, Oramas DM, Paz LH, Casanegra AI, Mansfield AS, Tafur AJ. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer. Thrombosis research. 2017;154:28-34. www.epistemonikos.org/documents/9b399242baf382b5520dc8edc14b98fd3e483c59
1442. Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung cancer (Amsterdam, Netherlands). 2001;31(2-3):139-48.www.epistemonikos.org/documents/9b4869f6f8da72be0760968772d21e131ad2d006
1443. Yu P.P., Shiao S.P., Suarez M.. A meta-analysis of lifestyle factors with MPO and GSTM1 human genes in lung cancer prevention. Cancer Research. 2014;74(19).www.epistemonikos.org/documents/9b5fe9ced49e70e393b0650f7ac34e46751d3a70
1444. Yan X, Jiao SC. [Roles of Tumor-infiltrating Lymphocytes in Non-small Cell Lung Cancer Recurrence and Metastasis:A Meta Analysis]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae. 2015;37(4):406-14. www.epistemonikos.org/documents/9b672bb0271af60d4af5b8c3832ff9d174b96792
1445. Wu XM, Chen Y, Shao Y, Zhou XL, Tang WR. Association between cigarette smoking and RASSF1A gene promoter hypermethylation in lung cancer patients: a meta- analysis. Asian Pacific journal of cancer prevention : APJCP. 2014;15(19):8451-4. www.epistemonikos.org/documents/9b836bbb73b292fae328eb9d4735dfe0604392af
1446. Guo H, Zhang R, Yang Q, Zhang L, Yang K, Tian J. [A Systematic Review of Erlotinib for Advanced Non-small Cell Lung Cancer.]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2009;12(12):1260-5. www.epistemonikos.org/documents/9b8aa51b1de5689355c8b0385accbf120d5e2a1d
1447. Zhu YJ, Zhang HB, Liu YH, Bai JP, Li Y, Liu LR, Qu YC, Qu X, Chen X. Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer. Oncology letters. 2017;14(1):655-664. www.epistemonikos.org/documents/9b98dfa3c75e3d42a2b5f79e84797f4497a9af6d
1448. Xu Y., Zhang Y., Wang Z., Chen N., Zhou J., Liu L.. The role of serum angiopoietin-2 levels in progression and prognosis of lung cancer. Medicine (United States). 2017;96(37). www.epistemonikos.org/documents/9b9fb08b4d999f8b23b54dabccd65d42e75b58ad
1449. Zhao Y, Zeng J, Zhang Y, Lu S, Zhao E, Huang Z, Lu W. GSTM1 polymorphism and lung cancer risk among East Asian populations: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(7):6493-500.www.epistemonikos.org/documents/9bb7b9599a852e6a793ffb6bd6eb6b4a31045e51
1450. Chen L, Zhuo D, Chen J, Yuan H. XRCC1 polymorphisms and lung cancer risk in Caucasian populations: a meta-analysis. International journal of clinical and experimental medicine. 2015;8(9):14969-76. www.epistemonikos.org/documents/9bf6aa747e838784d8733a33ad221eb5f50261eb
1451. Wei S, Chen M, Chen N, Liu L. Feasibility and safety of robot-assisted thoracic surgery for lung lobectomy in patients with non-small cell lung cancer: a systematic review and meta-analysis. World journal of surgical oncology. 2017;15(1):98. www.epistemonikos.org/documents/9c03553eabb427fff23b06a9135096d77214abb3
1452. Xu J, Yin Z, Gao W, Liu L, Wang R, Huang P, Yin Y, Liu P, Yu R, Shu Y. Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk. Clinical lung cancer. 2012;13(1):44-51. www.epistemonikos.org/documents/9c2afaabffb2a2b33826708519de0ad53af69c5a

1453. Pamoukdjian F, Bouillet T, Lévy V, Soussan M, Zelek L, Paillaud E. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review. Clinical nutrition (Edinburgh, Scotland). 2018;37(4):1101-1113. www.epistemonikos.org/documents/9c532d66dc1614e6db22f0577d75de7d32003265

1454. Passiglia F., Galvano A., Rizzo S., Incorvaia L., Listi A., Bazan V., Russo A.. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab. International Journal of Cancer. 2018;142(6):1277-1284.www.epistemonikos.org/documents/9c6245549849c4482552d85a2f902d9b99692583

1455. Huang C, Ma L, Li D. Association between myeloperoxidase G-463A polymorphism and lung cancer risk. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(1):475-81. www.epistemonikos.org/documents/9c70d90870c7ea522ec20c8d5179eb50b80ac567

1456. Garassino MC, Borgonovo K, Rossi A, Mancuso A, Martelli O, Tinazzi A, Di Cosimo S, La Verde N, Sburlati P, Bianchi C, Farina G, Torri V. Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer research. 2009;29(7):2691-701.www.epistemonikos.org/documents/9c9528c29014494b5087a380b0f401852a64a730

1457. Ji YN, Wang Q, Suo LJ. CYP1A1 Ile462Val polymorphism contributes to lung cancer susceptibility among lung squamous carcinoma and smokers: a meta-analysis. PloS one. 2012;7(8):e43397. www.epistemonikos.org/documents/9cad7a18b53d263588712674baff3a3e867d7e1e

1458. Liao SH, Liu WZ, Liu T, Sun Y, Feng X, Zhou HF. Potential signaling pathway of hypoxia-inducible factor in lung cancer and its gene polymorphism with lung cancer risk. Journal of receptor and signal transduction research. 2015;35(4):233-7. www.epistemonikos.org/documents/9cdb771c6e704ac4c09dd13ca286c9dfb0563701

1459. Zhang B, Zhu W, Yang P, Liu T, Jiang M, He ZN, Zhang SX, Chen WQ, Chen W. Cigarette smoking and p16INK4α gene promoter hypermethylation in non-small cell lung carcinoma patients: a meta-analysis. PloS one. 2011;6(12):e28882. www.epistemonikos.org/documents/9ceb4685564832a06cacac637d7252245837c8b7

1460. Li H, Hao X, Zhang W, Wei Q, Chen K. The hOGG1 Ser326Cys polymorphism and lung cancer risk: a meta-analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008;17(7):1739-45.www.epistemonikos.org/documents/9cf832db71a56e7673083c4ca8f20f21e2c860fc

1461. Cao C., Zhang Y.-M., Wang R., Sun S.-F., Chen Z.-B., Ma H.-Y., Yu Y.-M., Ding Q.-L., Shu L.-H., Deng Z.-C.. Meta analysis: Excision repair cross complementation group 1 polymorphisms and lung cancer risk: A meta-analysis. Chinese Medical Journal. 2011;124(14):2203-2208.www.epistemonikos.org/documents/9d150be6b445ddd9003bdc60887896bf87de24ad

1462. Sakib N, Li N, Zhu X, Li D, Li Y, Wang H. Effect of postoperative radiotherapy on outcome in resectable stage IIIA-N2 non-small-cell lung cancer: an updated meta-analysis. Nuclear medicine communications. 2018;39(1):51-59. www.epistemonikos.org/documents/9d2ec44b6af6de51d9e89a5a8574d04a51a16280

1463. Jazieh AR, Al Sudairy R, Abu-Shraie N, Al Suwairi W, Ferwana M, Murad MH. Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review. Annals of thoracic medicine. 2013;8(4):204-8. www.epistemonikos.org/documents/9d3337565f1c4b36725b6724b4782b3f243157d9

1464. Zhang Q., Wei G., Wu X., Luo Y.. Note of clarification of data in the meta-analysis of evidences on XPC polymorphisms and lung cancer susceptibility. Tumor Biology. 2014;35(8):7287-91. www.epistemonikos.org/documents/9d5b593c5a1013c0491ec75f42c9859a5914ee30

1465. Matikas A, Georgoulias V, Kotsakis A. The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update. Expert review of respiratory medicine. 2016;10(11):1-13. www.epistemonikos.org/documents/9d6810794dd98c2759cfba98d3e4a51f4a1ab1e5

1466. Zhu J, Hua RX, Jiang J, Zhao LQ, Sun X, Luan J, Lang Y, Sun Y, Shang K, Peng S, Ma J. Association studies of ERCC1 polymorphisms with lung cancer susceptibility: a systematic review and meta-analysis. PloS one. 2014;9(5):e97616. www.epistemonikos.org/documents/9d6e723fafb5700b153279451cf8ce58024ce802

1467. Paesmans M, Garcia C, Wong CY, Patz EF, Komaki R, Eschmann S, Govindan R, Vansteenkiste J, Meert AP, de Jong WK, Altorki NK, Higashi K, Van Baardwijk A, Borst GR, Ameye L, Lafitte JJ, Berghmans T, Flamen P, Rami-Porta R, Sculier JP. Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. The European respiratory journal. 2015;46(6):1751-61.www.epistemonikos.org/documents/9d85a178d0a368082fba95be573ad37089c1efc6

1468. Arriagada R, Pignon JP, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B. Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients. Anticancer research. 1994;14(1B):333-5.www.epistemonikos.org/documents/9d87014154f943a01eef35d34f5a29cf8828b2ee

1469. Alongi F, Ragusa P, Montemaggi P, Bona CM. Combining independent studies of diagnostic fluorodeoxyglucose positron-emission tomography and computed tomography in mediastinal lymph node staging for non-small cell lung cancer. Tumori. 2006;92(4):327-33.www.epistemonikos.org/documents/9d97c932ee21840b670004f2f906573edbf281dc

1470. Pilkington G, Boland A, Brown T, Oyee J, Bagust A, Dickson R. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. Thorax. 2015;70(4):359-367. www.epistemonikos.org/documents/9d9a0925fee903966de8741b20612ffc53153cc5

1471. Wang N., Yang D., Ji B., Li J.Y.. Angiotensin-converting enzyme insertion/deletion gene polymorphism and lung cancer risk: A meta-analysis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System. 2015;16(1):189-194. www.epistemonikos.org/documents/9daeb48d7953cbbc9ed4b5c35b923dffac69ec3a

1472. Wang T., Zhang L., Tian P.U., Tian S.. Identification of differentially-expressed genes between early-stage adenocarcinoma and squamous cell carcinoma lung cancer using meta-analysis methods. Oncology Letters. 2017;13(5):3314-3322. www.epistemonikos.org/documents/9e15ed99c8b5c38dc07177c21b70c520900bd762

1473. Ball H, Moore S, Leary A. A systematic literature review comparing the psychological care needs of patients with mesothelioma and advanced lung cancer. European journal of oncology nursing : the official journal of European Oncology Nursing Society. 2016;25:62-67.www.epistemonikos.org/documents/9e1bb71a5c7d98c0ae546ab3fa36c318903f52be

1474. Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, Yu LK, Song Y. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Medical oncology (Northwood, London, England). 2011;28(1):315-21.www.epistemonikos.org/documents/9e48444b31145b12e9964a68cfb50254a057a072

1475. Huang X, Wang J, Chen Q, Jiang J. Mediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: a systematic review and meta-analysis. PloS one. 2014;9(10):e109979. www.epistemonikos.org/documents/9e4eef8ba38e6799c2374ffae19d14891ed894ed

1476. Akl EA, van Doormaal FF, Barba M, Kamath G, Kim SY, Kuipers S, Middeldorp S, Yosuico V, Dickinson HO, Schünemann HJ. Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. Journal of experimental & clinical cancer research : CR. 2008;27(1):4.www.epistemonikos.org/documents/9e5f572ac6f8edfc41f03d568eeef8ab9bdb0319

1477. Guo L, Liu S, Zhang S, Chen Q, Zhang M, Quan P, Sun X. Human papillomavirus infection as a prognostic marker for lung adenocarcinoma: a systematic review and meta-analysis.

Oncotarget. 2017;8(21):34507-34515. www.epistemonikos.org/documents/9e87d26236f166bf227acdc45fc92e55cfa1b106

1478. Tan Z., Shen W.. Prognostic role of B7-H4 in patients with non-small cell lung cancer: A meta-analysis. Oncotarget. 2017;8(16):27137-27144.www.epistemonikos.org/documents/9e8acfe2fc1c47366dbb6df41d5a46ec2070eb49

1479. Quintans JS, Antoniolli AR, Onofre FM, Onofre AS. Detection of lung cancer using multiple genetic markers--a systematic review. Diagnostic cytopathology. 2013;41(9):834-42. www.epistemonikos.org/documents/9ea6615a8a57bf226397008386f88e385997ca15

1480. Shao Y., Ma L., Ma B., Tian J.-H., Yang K.-H.. Weekly versus three weekly regimens of taxanes for non-small cell lung cancer: A systematic review. Chinese Journal of Evidence-Based Medicine. 2010;10(5):602-608. www.epistemonikos.org/documents/9ed81c7ca785781908b1f67d083fb10106160223

1481. Wasswa-Kintu S, Gan WQ, Man SF, Pare PD, Sin DD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax. 2005;60(7):570-5. www.epistemonikos.org/documents/9efddbfd9a5281dc094e25b9efc65335b6a8efc6

1482. Peng B., Wang Y.-H., Huang Z., Feng S.-J., Wang Y.-S.. Prognostic significance of Osteopontin in patients with lung cancer: A meta-analysis. International Journal of Clinical and Experimental Medicine. 2014;7(12):4616-4626. www.epistemonikos.org/documents/9f33f2763a5e5b33b0ef3347252c81eaf8d0bdd1

1483. Xu TP, Zhu CH, Zhang J, Xia R, Wu FL, Han L, Shen H, Liu LX, Shu YQ. MicroRNA-155 expression has prognostic value in patients with non-small cell lung cancer and digestive system carcinomas. Asian Pacific journal of cancer prevention : APJCP. 2013;14(12):7085-90.www.epistemonikos.org/documents/9f3db1d73772bb4d65e2689afb57b8062e8e41a8

1484. He Y., Li W., Gong H.. Diagnostic efficacy of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for recurrent lung cancer: A meta-analysis. American Journal of Respiratory and Critical Care Medicine. 2013;www.epistemonikos.org/documents/9f3e15eb7343cbda361b5209db05ba2ec9256402

1485. Blinman P., Alam M., McLachlan S., Duric V., Stockler M.. Patients' preferences for chemotherapy in Non-Small-Cell Lung Cancer (NSCLC): A systematic review. Asia-Pacific Journal of Clinical Oncology. 2009;:A167. www.epistemonikos.org/documents/9f7533da4d69ad2d0a6315a1378e778eee41e3db

1486. Cheng D, Downey RJ, Kernstine K, Stanbridge R, Shennib H, Wolf R, Ohtsuka T, Schmid R, Waller D, Fernando H, Yim A, Martin J. Video-assisted thoracic surgery in lung cancer resection: a meta-analysis and systematic review of controlled trials. Innovations (Philadelphia, Pa.). 2007;2(6):261-92.www.epistemonikos.org/documents/9f80658bcfcbe8b37baf55b9f40d041239366a7e

1487. Xu YP, Li B, Xu XL, Mao WM. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis. Medicine. 2015;94(23):e879.www.epistemonikos.org/documents/9f8777ed10806886d84dfdf42d88235594688a40

1488. Yu H., Zhang A.. Gefitinib and docetaxel for the treatment of non-small cell lung cancer: A meta-analysis. International Journal of Clinical and Experimental Medicine. 2016;9(11):21057-21065. www.epistemonikos.org/documents/9f92f79d973f9cea0ecefcd5ba446ecd750b28f5

1489. Liu C, Yin Q, Hu J, Li L, Zhang Y, Wang Y. A meta-analysis of evidences on XPC polymorphisms and lung cancer susceptibility. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(2):1205-13.www.epistemonikos.org/documents/9fa093f3370126f1a554e858be200ed000993119

1490. Neuberger J, Allen A. Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies. Journal of the National Cancer Institute. 1997;89(9):663-4; author reply 664-5. www.epistemonikos.org/documents/9fb1d46862cfbc65095fb0a4a00396810eeea772

1491. Ambroggi M, Biasini C, Toscani I, Orlandi E, Berte R, Mazzari M, Cavanna L. Can early palliative care with anticancer treatment improve overall survival and patient-related outcomes in advanced lung cancer patients? A review of the literature. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2018;26(9):2945-2953. www.epistemonikos.org/documents/9fcb6004395710559b9a0f886a7879ad4aad20e3

1492. Qi WX, Tang LN, He AN, Shen Z, Yao Y. Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis. Journal of cancer research and clinical oncology. 2012;138(5):745-51.www.epistemonikos.org/documents/a00d7bcc96deb69ec5d556a3a632c59638804159

1493. Knez L, Sodja E, Kern I, Košnik M, Cufer T. Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: a systematic review. Lung cancer (Amsterdam, Netherlands). 2011;72(3):271-9. www.epistemonikos.org/documents/a04f9edd516f22b9f73038df2e9e0fdb05785aaf

1494. Thatcher N., Pujol J., Lynch Jr T.J., Rosell R., Butts C.A., Shepherd F.A., Vansteenkiste J., De Blas B., Groos J., Pirker R.. Chemotherapy (CT) plus cetuximab as 1st-line treatment for advanced non-small cell lung cancer (NSCLC): Meta-analysis of individual patient data. Annals of Oncology. 2010;:viii146-viii147.www.epistemonikos.org/documents/a052bd778f09b85e29ac3517879547c9ed7d3e9b

1495. Ramos-Esquivel A, van der Laat A, Rojas-Vigott R, Juárez M, Corrales-Rodríguez L. Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. ESMO open. 2017;2(3):e000236.www.epistemonikos.org/documents/a05c008c20c293be6d8dc9d71fa31f6aee75ab7f

1496. Ying M, Zhu XX, Zhao Y, Li DH, Chen LH. KRAS Mutation as a Biomarker for Survival in Patients with Non-Small Cell Lung Cancer, A Meta-Analysis of 12 Randomized Trials. Asian Pacific journal of cancer prevention : APJCP. 2015;16(10):4439-45. www.epistemonikos.org/documents/a06ede32f687be4ecc0488aad258d6ac804bbd3b

1497. Martinasek MP, McGrogan JB, Maysonet A. A Systematic Review of the Respiratory Effects of Inhalational Marijuana. Respiratory care. 2016;61(11):1543-1551.www.epistemonikos.org/documents/a073ed933458f6ae3e59fff8777fe5780ce3cd2d

1498. Ellis P.M., Vella E.T., Ung Y.C.. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review. Clinical Lung Cancer. 2017;18(5):444-459.e1. www.epistemonikos.org/documents/a073f50ea4e59466a8093de72e8b60ba62bfb2cd

1499. Murphy M, Stordal B. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2011;14(3):177-90.www.epistemonikos.org/documents/a0cf459521162ea99eefd46f15a8638ea52acdaf

1500. Logan DM, Lochrin CA, Darling G, Eady A, Newman TE, Evans WK. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group. Cancer prevention & control : CPC = Prévention & contrôle en cancérologie : PCC. 1998;1(5):366-78.www.epistemonikos.org/documents/a0f7d1acde7ca9b94e9622bd1a3f620d021b2792

1501. Seto T.. Meta-analysis about cisplatin versus carboplatin in advanced non-small cell lung cancer. Japanese Journal of Lung Cancer. 2002;42(7):789-795.www.epistemonikos.org/documents/a100f334e7cb8ed45e502b1928d416728b2eb195

1502. Ma L, Zhan P, Liu Y, Zhou Z, Zhu Q, Miu Y, Wang X, Jin J, Li Q, Lv T, Song Y. Prognostic value of the expression of estrogen receptor β in patients with non-small cell lung cancer: a meta-analysis. Translational lung cancer research. 2016;5(2):202-7. www.epistemonikos.org/documents/a117389ed79eaad1e90cb52f8aec8e898def3e57

1503. Payne C, Larkin PJ, McIlfatrick S, Dunwoody L, Gracey JH. Exercise and nutrition interventions in advanced lung cancer: a systematic review. Current oncology (Toronto, Ont.). 2013;20(4):e321-37. www.epistemonikos.org/documents/a11aacf61ba5e191f6d5f346da484a737b7f4a6c
1504. Zhao N, Zhang XC, Yan HH, Yang JJ, Wu YL. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. Lung cancer (Amsterdam, Netherlands). 2014;85(1):66-73.www.epistemonikos.org/documents/a11fdbf9c1d54114f88507f3466bbce906a577bf
1505. Xie H, Yao H, Huo Y, Li N, Cheng Y. Association between TNF-α gene 308G>A polymorphism and lung cancer risk: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(10):9693-9.www.epistemonikos.org/documents/a1381726c31fb0d9ae7be48d8b8aa0f67a8a986d
1506. Cao LL, Song X, Pei L, Liu L, Wang H, Jia M. Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis. Medicine. 2017;96(31):e7663. www.epistemonikos.org/documents/a196aee8e3aefca4ab19a31840068c2a9f449a9d
1507. Tian J, Luo Y, Xiang J, Tang J. Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis. Journal of neuro-oncology. 2017;135(2):217-227.www.epistemonikos.org/documents/a19787267599dca85ea2ac90a1290ccd54bdb2e3
1508. Wang L., Zhang Q., Tang L., Wei F., Nie W.-W., Chen L.-B., Guan X.-X.. Systematic review of the relationship between genetic polymorphism of p73 4G14C-4A14T and the susceptibility to lung cancer. Chinese Journal of Cancer Prevention and Treatment. 2011;18(20):1585-1589.www.epistemonikos.org/documents/a1a780c46e121a70baa574742a9fbcacd3c26c5b
1509. Zhan P, Qian Q, Yu LK. Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. Journal of thoracic disease. 2013;5(1):40-7. www.epistemonikos.org/documents/a1c10c25279e58d62652b8359f486351b35ee0fc
1510. Kim J, Cho J, Lee MH, Lim JH. Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis. Scientific reports. 2018;8(1):11738. www.epistemonikos.org/documents/a20c9e4ea77a90696808714b821bcccd101e5491
1511. Huncharek M, McGarry R. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. The oncologist. 2004;9(6):665-72. www.epistemonikos.org/documents/a2284c6d9f082bfcbb653721854c107b857e5968
1512. Yu X., Li Y., Yu Y., Lei J., Wan G., Cao F.. Associations between FAS rs2234767 and FASL rs763110 polymorphisms and the risk of lung cancer: A meta-analysis of 39,736 subjects. OncoTargets and Therapy. 2016;9:2049-2056. www.epistemonikos.org/documents/a2326c6d3f80016cbb0320836367a4c67f8eef28
1513. Stroh M, Green M, Cha E, Zhang N, Wada R, Jin J. Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer. Cancer chemotherapy and pharmacology. 2016;77(3):485-94. www.epistemonikos.org/documents/a247290adca85f0582e548893911ef55d6d9ad4a
1514. Liu Y, Yu S, Liu S, Cao H, Ma R, Wu J, Feng J. Comparison of nedaplatin-based versus cisplatin-based chemotherapy for advanced non-small cell lung cancer among East Asian populations: A meta-analysis. Scientific reports. 2015;5:10516. www.epistemonikos.org/documents/a258f08c05a128e949abce67e936398ccf61271b
1515. Wei D, Peng JJ, Gao H, Zhang T, Tan Y, Hu YH. ALDH1 Expression and the Prognosis of Lung Cancer: A Systematic Review and Meta-Analysis. Heart, lung & circulation. 2015;24(8):780-8. www.epistemonikos.org/documents/a2596495d4a35bd1e18111362952297c6f946b55

1516. Cargnin S, Canonico PL, Genazzani AA, Terrazzino S. Quantitative analysis of circulating cell-free DNA for correlation with lung cancer survival: a systematic review and meta-analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017;12(1):43-53.www.epistemonikos.org/documents/a25e492dca6cf5bf1d94cde7efd9ece30394f8d1

1517. Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Molecular biology reports. 2012;39(6):6933-42. www.epistemonikos.org/documents/a262a18efd7e4fd0540af411410d75164e0601fd

1518. Montazeri Z, Nyiraneza C, El-Katerji H, Little J. Waterpipe smoking and cancer: systematic review and meta-analysis. Tobacco control. 2017;26(1):92-97.www.epistemonikos.org/documents/a2950c0aa348d66f9b936cdb52d0815c01c519b4

1519. Bhowmik A., Nath S., Das S., Ghosh S.K., Choudhury Y.. ATM rs189037 (G > A) polymorphism and risk of lung cancer and head and neck cancer: A meta-analysis. Meta Gene. 2015;6:42-48. www.epistemonikos.org/documents/a2a3408ac0090a010cb7c6ff8082ed1b995d2f0a

1520. Xu L.-Y., Wang K., Li W.-J., Guo Y.-L., Kong J.-L.. Effect of endotoxin exposure on lung cancer risk in cotton textile mills and agriculture: A meta-analysis. Translational Cancer Research. 2016;5(3):250-264. www.epistemonikos.org/documents/a2a531b1405f0fa8532cc2f2223f94d38b6f1acc

1521. Wang J, Xu H, Zhou S, Wang D, Zhu L, Hou J, Tang J, Zhao J, Zhong S. Body mass index and mortality in lung cancer patients: a systematic review and meta-analysis. European journal of clinical nutrition. 2018;72(1):4-17. www.epistemonikos.org/documents/a2bdb9411dfebd73b88fde858a88b3510e0a8374

1522. Li L, Wu D, Yu Q, Li L, Wu P. Prognostic value of FOXM1 in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(19):32298-32308.www.epistemonikos.org/documents/a2cfa00bf711f3a613598225e7663c23d21b28b9

1523. MA, YE Lin, CHEN, Liang Liang. Systematic review on Yanshu injection plus NP for terminal NSCLC. Chinese Journal of Cancer Prevention and Treatment. 2011;18(20).www.epistemonikos.org/documents/a2da36e20f39958e6e0e79008aebe8f6a56d0ca9

1524. Sommer MS, Staerkind MEB, Christensen J, Vibe-Petersen J, Larsen KR, Holst Pedersen J, Langberg H. Effect of postsurgical rehabilitation programmes in patients operated for lung cancer: A systematic review and meta-analysis. Journal of rehabilitation medicine. 2018;50(3):236-245.www.epistemonikos.org/documents/a2de25feced42d6fc507a61f7a8403dd3500c80c

1525. Shen G, Bian G, Yu H, Gao M, Kang D, Shen G, Hu S. Comparison between cisplatin plus vinorelbine and cisplatin plus docetaxel in the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials. Molecular and clinical oncology. 2014;2(1):146-150.www.epistemonikos.org/documents/a2de35911058ad74add2759b6fe4a217dbf92235

1526. Tang J, Tang S, Liu J, Wu Q, Wan L, Xu Q. Genetic risk of lung cancer associated with a single nucleotide polymorphism from EXO1: a meta analysis. International journal of clinical and experimental medicine. 2015;8(7):11132-8. www.epistemonikos.org/documents/a313ea8cdc3c77a349cc12da51321b14a4930c2e

1527. Qiu ZX, Zhang K, Qiu XS, Zhou M, Li WM. The prognostic value of phosphorylated AKT expression in non-small cell lung cancer: a meta-analysis. PloS one. 2013;8(12):e81451. www.epistemonikos.org/documents/a32740d7f23249ae7c13b3bcdd34391fdd67cebc

1528. Campbell L, Blackhall F, Thatcher N. Gefitinib for the treatment of non-small-cell lung cancer. Expert opinion on pharmacotherapy. 2010;11(8):1343-57.www.epistemonikos.org/documents/a32f4d7e99f28929d9a491690d3f3ba12ec36ae4

1529. Williams M, Liu ZW, Hunter A, Macbeth F. An updated systematic review of lung chemo-radiotherapy using a new evidence aggregation method. Lung cancer (Amsterdam, Netherlands).

2015;87(3):290-5. www.epistemonikos.org/documents/a353aba04e50ebd02809f5d343c3b7db2c199a82

1530. Luo Q, Wang Z, Li S, Zhou J. Efficacy of different monotherapies in second-line treatment for small cell lung cancer: a meta-analysis of randomized controlled trials. International journal of clinical and experimental medicine. 2015;8(10):19689-700. www.epistemonikos.org/documents/a364da70a7717c17ef2589c166ca4d7b1ada27b5

1531. Zheng Z, Pan TC, Li J, Chen T, Song DW, Yi J. [Meta-analysis of relationship between lymph node micrometastasis and prognosis in stage I non-small cell lung cancer patients]. Ai zheng = Aizheng = Chinese journal of cancer. 2004;23(2):185-8. www.epistemonikos.org/documents/a37b1f7fc51b2c141c21dbb4828c1706ae3c047b

1532. Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer management and research. 2014;6:437-49.www.epistemonikos.org/documents/a38cf28982b492b9efcbe0fb4cd2334c92d6e94c

1533. Kowalewski M., Lewandowska M.A., Zolna L., Chrzastek A., Wnuk P., Dancewicz M., Bella M., Blawat P., Szczesny T., Kowalewski J.. Optimal strategy to prevent atrial fibrillation in patients undergoing pulmonary resection for lung cancer. Network meta-analysis. Journal of Thoracic Oncology. 2015;:S558.www.epistemonikos.org/documents/a3be64d862d55bf321dddc7e172bfc09a08a0342

1534. Lamm SH, Ferdosi H, Dissen EK, Li J, Ahn J. A Systematic Review and Meta-Regression Analysis of Lung Cancer Risk and Inorganic Arsenic in Drinking Water. International journal of environmental research and public health. 2015;12(12):15498-515. www.epistemonikos.org/documents/a3c37e9a7f3b68c806a129e643eb3672d817c0d6

1535. Xiao Z., Liang R., Wang C.-Q., Xu S., Li N., He Y., Tang F., Chen L., Ma H.. Can Aidi injection alleviate the toxicity and improve the clinical efficacy of radiotherapy in lung cancer? A meta-analysis of 16 randomized controlled trials following the PRISMA guidelines. Medicine (United States). 2016;95(35):e4517.www.epistemonikos.org/documents/a3c9679a2accd333ac98db3823cdaf48ecd3f5eb

1536. Liu X, Lin Q, Fu C, Liu C, Zhu F, Liu Z, Li S, Jiang L. Association between XPA gene rs1800975 polymorphism and susceptibility to lung cancer: a meta-analysis. The clinical respiratory journal. 2018;12(2):448-458. www.epistemonikos.org/documents/a3d15b8d76e67d7b57792bb8a2a2afe8094efa97

1537. Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis. PloS one. 2016;11(1):e0146195.www.epistemonikos.org/documents/a42e34de2e6fe646970b683b4c982270fafc966d

1538. Kiss N., Krishnasamy M., Isenring E.. The effect of dietary counselling and/or oral supplements in lung cancer patients undergoing chemotherapy and/or radiotherapy: A systematic review. Asia-Pacific Journal of Clinical Oncology. 2012;:348. www.epistemonikos.org/documents/a496a33cb6b298bad744a8e107548f5978ef64a2

1539. Behera M., Owonikoko T.K., Gal A.A., Steuer C.E., Kim S., Pillai R.N., Khuri F.R., Ramalingam S.S., Sica G.L.. Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. Clinical Lung Cancer. 2016;17(5):57-64.www.epistemonikos.org/documents/a4b8f852fba6064a720f567cf8cd8b6f96e22f39

1540. Cao C, Gupta S, Chandrakumar D, Tian DH, Black D, Yan TD. Meta-analysis of intentional sublobar resections versus lobectomy for early stage non-small cell lung cancer. Annals of cardiothoracic surgery. 2014;3(2):134-41. www.epistemonikos.org/documents/a4c366c6c55df57cecc6619b9f59c610baed0439

1541. Koning CC, Wouterse SJ, Daams JG, Uitterhoeve LL, van den Heuvel MM, Belderbos JS. Toxicity of concurrent radiochemotherapy for locally advanced non-small-cell lung cancer: a

systematic review of the literature. Clinical lung cancer. 2013;14(5):481-7. www.epistemonikos.org/documents/a4d5d68084795bd884431fe3c4a28913ede691eb

1542. Rossi A, Chiodini P, Sun JM, O'Brien ME, von Plessen C, Barata F, Park K, Popat S, Bergman B, Parente B, Gallo C, Gridelli C, Perrone F, Di Maio M. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. The Lancet. Oncology. 2014;15(11):1254-62. www.epistemonikos.org/documents/a502736c2d38bd7f3869ad7c6c8e039a187d53c0

1543. Sheng, Lei, Li, Yan, Chen, Jian-Peng. Disodium Cantharidinate and Vitamin B6 Injection plus Chemotherapy for Non-Small Cell Lung Cancer: A Systematic Review. 中国循证医学杂志 (Chinese Journal of Evidence-Based Medicine). 2012;12(5):589-595. www.epistemonikos.org/documents/a51ff4843f742d910402c924689c7905ba5a0a35

1544. Muthu V, Sehgal IS, Dhooria S, Aggarwal AN, Agarwal R. Efficacy of endosonographic procedures in mediastinal re-staging of lung cancer after neoadjuvant therapy: A systematic review and diagnostic accuracy meta-analysis. Chest. 2018;154(1):99-109.www.epistemonikos.org/documents/a52732710985b6525e97869ccacb7cee5a329a99

1545. Hua-Feng X, Yue-Ming W, Hong L, Junyi D. A meta-analysis of the association between Chlamydia pneumoniae infection and lung cancer risk. Indian journal of cancer. 2015;52 Suppl 2(6):e112-5. www.epistemonikos.org/documents/a53579c7259657bf88aa536bb985b3b089671e93

1546. Nieder C, Pawinski A, Andratschke NH. Combined radio- and chemotherapy for non-small cell lung cancer: systematic review of landmark studies based on acquired citations. Frontiers in oncology. 2013;3(no pagination):176. www.epistemonikos.org/documents/a571d409206425c3f3eb3b6990ed579131389a6c

1547. Seigneurin A, Field JK, Gachet A, Duffy SW. A systematic review of the characteristics associated with recall rates, detection rates and positive predictive values of computed tomography screening for lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014;25(4):781-91.www.epistemonikos.org/documents/a57db15e759fbab0b2251e691a577708241e5b71

1548. Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, Früh M, Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli O, Lee SM. Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(14):1692-8.www.epistemonikos.org/documents/a5b49e72bdb2abe7fb6e7be283967b32fc392d10

1549. Wang M, Ma X, Guo L, Xia F. Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. Drug design, development and therapy. 2017;11:2851-2860. www.epistemonikos.org/documents/a5d8aad68b98aec9c8a3f34928f3dd9feeb7ad73

1550. Soon Y.Y., Stockler M.R., Askie L., Boyer M.J.. An updated systematic review and meta-analysis of randomized controlled trials on duration of chemotherapy for advanced non-small cell lung cancer. Journal of Clinical Oncology. 2014; www.epistemonikos.org/documents/a5fb969081cc584f238d0929ad466b85a694b4d3

1551. Li C, Wu W, Chen N, Song H, Lu T, Yang Z, Wang Z, Zhou J, Liu L. Clinical characteristics and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema: a systematic review and meta-analysis of 13 studies. Journal of thoracic disease. 2017;9(12):5322-5334.www.epistemonikos.org/documents/a651a61b784e1ae1be73491563717c76ed189510

1552. Zhou G.-W., Li Q.. Dual targeting vegfr and EGFR signaling pathways may not be superior to targeting EGFR signaling pathway alone in previously treated advanced NSCLC: A metaanalysis of randomized controlled trials. Respirology. 2011;:189. www.epistemonikos.org/documents/a6797fd4e9ffa5e6c1fe297c6b3c257283c942e0

1553. Zhou GW, Xiong Y, Chen S, Xia F, Li Q, Hu J. Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials.

Medicine. 2016;95(35):e4611. www.epistemonikos.org/documents/a67e3d023bd639247e4819604f79868741c827ae

1554. Jiang H, Zhang H, Hu X, Ma J. A meta-analysis of Shenqi Fuzheng combined with radiation in the treatment of nonsmall cell lung cancer. Journal of cancer research and therapeutics. 2015;11 Suppl 1(5):C101-3. www.epistemonikos.org/documents/a699589d2b07711442fadc54e79177a14cbf0236

1555. Zhao Y, Zheng R, Li J, Lin F, Liu L. Loss of phosphatase and tensin homolog expression correlates with clinicopathological features of non-small cell lung cancer patients and its impact on survival: A systematic review and meta-analysis. Thoracic cancer. 2017;8(3):203-213.www.epistemonikos.org/documents/a69be95f196ef4a4580baf1f654165c3519dbf79

1556. Yang H, Wang H, Zhang C, Tong Z. The accuracy of microRNA-210 in diagnosing lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(39):63283-63293.www.epistemonikos.org/documents/a6a63f05535e5a8eaf9b03a54e443a759ca1a573

1557. Zhong H, Feng Y, Zheng GX, Liang Y, Zhang JY, Zheng BS, Feng X. A meta-analysis of the association between glutathione S-transferase P1 gene polymorphism and the risk of adenocarcinomas of lung cancer. Cancer biomarkers : section A of Disease markers. 2013;13(1):29-35.www.epistemonikos.org/documents/a705bab0de0515941722591eefb9f495bd57058f

1558. Xu Y, Gao P, Lv X, Zhang L, Li W, Zhang J. A meta-analysis of the relationship between ataxia-telangiectasia mutated gene polymorphisms and lung cancer susceptibility. Pathology, research and practice. 2017;213(9):1152-1159. www.epistemonikos.org/documents/a7100ea32c5eedaefd94049473c88105e082a15c

1559. Han Y., Shi K., Zhou S.-J., Yu D.-P., Liu Z.-D.. The clinicopathological significance of hMLH1 hypermethylation in non-small-cell lung cancer: A meta-analysis and literature review. OncoTargets and Therapy. 2016;9:5081-5090. www.epistemonikos.org/documents/a725651e474ec4cf72ca6c5e1215bff81c83f7ac

1560. Biaoxue R, Shuanying Y, Wei L, Wei Z, Zongjuan M. Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients. Current medical research and opinion. 2012;28(10):1699-708.www.epistemonikos.org/documents/a72b8af4b9079ad83c51a079c4abe3bc9e989d36

1561. Belda-Sanchís J, Serra-Mitjans M, Iglesias Sentis M, Rami R. Surgical sealant for preventing air leaks after pulmonary resections in patients with lung cancer. Cochrane database of systematic reviews (Online). 2010;(1):CD003051. www.epistemonikos.org/documents/a7448462c04f7be38273efbf7e7d314b8b8d7292

1562. Li D., Zhu X., Wang H., Li N.. Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis. European Journal of Surgical Oncology. 2017;43(7):1372-1379. www.epistemonikos.org/documents/a766ac0b4fc25dfa664e81d0e26c5479d205bd40

1563. Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, He AN, Yao Y. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2012;13(10):5177-82. www.epistemonikos.org/documents/a76cfd513e80069866182d9efe134ba0f9ddbb67

1564. Vansteenkiste J., Glaspy J., Henry D., Ludwig H., Pirker R., Tomita D., Collins H., Crawford J.. Benefits and risks of using erythropoiesisstimulating agents (ESAS) in nonsmall cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients: results from study-level and patient-level meta-analyses of controlled esa trials in lung cancer. Journal of Thoracic Oncology. 2011;:S645-S646. www.epistemonikos.org/documents/a786250f54ae1cc36af2d0f569de4c9af7100933

1565. Labarca G, Folch E, Jantz M, Mehta HJ, Majid A, Fernandez-Bussy S. Adequacy of Samples Obtained by EBUS-TBNA for Molecular Analysis in Patients with Non-Small Cell Lung Cancer: Systematic Review and Meta-Analysis. Annals of the American Thoracic Society.

2018;15(10):1205-1216.www.epistemonikos.org/documents/a7bfab8a99acff73ee63cf7b4b7dacd9f30664d2

1566. Xiao Z, Wang C, Zhou R, Hu S, Yi N, Feng J, Zhou M, Liu S, Chen L, Ding J, Gong Q, Tang F, Li X. Can Aidi injection improve overall survival in patients with non-small cell lung cancer? A systematic review and meta-analysis of 25 randomized controlled trials. Complementary therapies in medicine. 2018;37:50-60.www.epistemonikos.org/documents/a7e475bced3766647a603db86c0553beb0dc4f4a

1567. Lester JF, MacBeth FR, Coles B. Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small-cell lung cancer: a Cochrane Review. International journal of radiation oncology, biology, physics. 2005;63(3):690-4.www.epistemonikos.org/documents/a80780de1ae74080907de17bcaee464a0ee1fe2f

1568. Duan P, Hu C, Quan C, Yi X, Zhou W, Yuan M, Yu T, Kourouma A, Yang K. Body mass index and risk of lung cancer: Systematic review and dose-response meta-analysis. Scientific reports. 2015;5:16938. www.epistemonikos.org/documents/a8355fa642d655713c1cd43d3eecc7f797f37c74

1569. Xu Y., Gu L., Cheng B., Lu S.. Meta-analysis of stat3 and p-stat3 expression and survival in non-small-cell lung cancer. Journal of Thoracic Oncology. 2013;:S783.www.epistemonikos.org/documents/a845e35dd8f6af4fc6c8fdc991fd8432d7b3a9d9

1570. Gu J, Hua F, Zhong D, Chen J, Liu H, Zhou Q. [Systematic review of the relationship between family history of lung cancer and lung cancer risk]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2010;13(3):224-9. www.epistemonikos.org/documents/a84a37e01dde7ef0a2907d50ef9305a4879d2f0f

1571. Dai S, Mao C, Jiang L, Wang G, Cheng H. P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Human genetics. 2009;125(5-6):633-8. www.epistemonikos.org/documents/a85e2fd2d3da441f6279e084f31de2feb8ecc679

1572. Ma Q.-G., Deng J.-J., Qiao Y., Zhou Y.J.. CEA for the diagnosis of NSCLC in Chinese patients: A systematic review. Chinese Journal of Evidence-Based Medicine. 2011;11(10):1140-1143. www.epistemonikos.org/documents/a8757cc6d0ab1a9534cd2a973e5e1cf2c3ab7592

1573. Jing X, Huang C, Zhou H, Li C, Fan L, Chen J, Zhang G, Liu Y, Cui Z, Qi D, Ma J. Association between serum C-reactive protein value and prognosis of patients with non-small cell lung cancer: a meta-analysis. International journal of clinical and experimental medicine. 2015;8(7):10633-9.www.epistemonikos.org/documents/a89990ab7a29aa395dc92f48343f499df2949384

1574. Haasbeek CJ, Senan S, Smit EF, Paul MA, Slotman BJ, Lagerwaard FJ. Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. The oncologist. 2008;13(3):309-19. www.epistemonikos.org/documents/a8cc29fe83c664c3137d51c7ebf684e5c0416454

1575. Tian C., Tang L.-N., Qi W.-X., Lin F., Li H.-T., Yao Y.. Multitargeted antiangiogenic tyrosine kinase inhibitors in combination with chemotherapy in patients with advanced non-small cell lung cancer: A Meta-analysis. Tumor. 2013;33(9):786-794. www.epistemonikos.org/documents/a8f320fd9e2cd760e6fb204100a349751cece692

1576. Ku GY, Haaland BA, de Lima Lopes G. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. Lung cancer (Amsterdam, Netherlands). 2011;74(3):469-73. www.epistemonikos.org/documents/a90909a0b8c662a280daa7f9f6eb9fbe649ff137

1577. Zhang W., Li J., Li R., Zhang Y., Han M., Ma W.. Efficacy and safety of iodine-125 radioactive seeds brachytherapy for advanced non-small cell lung cancer-A meta-analysis. Brachytherapy. 2018;17(2):439-448. www.epistemonikos.org/documents/a90c56fe59fd42d032a595d1adbaf8889a6e3fd5

1578. Zhao X, Feng Z, Wang G, Pang H, Wang M. Ceritinib Alone for Crizotinib-naive Versus Crizotinib-pretreated for Management of Anaplastic Lymphoma Kinase-rearrangement Non-Small-cell Lung Cancer: A Systematic Review. Clinical lung cancer. 2018;19(6):e945-e956.www.epistemonikos.org/documents/a95f0c49e7529078c0406d887f4fedcd7d6dba0c

1579. Moulin JJ. A meta-analysis of epidemiologic studies of lung cancer in welders. Scandinavian journal of work, environment & health. 1997;23(2):104-13.www.epistemonikos.org/documents/a965b1f3ae2ed2bc8ce2d34a97201cc2b56434d3

1580. Wang C.-M., Ling Z.-G., Wu Y.-B., Cai S.-Q., Tang Z.-M., Wu C., Chen Y.-Q.. Prognostic value of pleural lavage cytology in patients with lung cancer resection: An updated meta-analysis. PLoS ONE. 2016;11(7):e0157518. www.epistemonikos.org/documents/a96d69ab139d1cc282a8185a0874041e7c7ba1e8

1581. Tian G, Li N, Li G. [Dosimetric comparing between protons beam and photons beam for lung cancer radiotherapy: a meta-analysis]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2013;16(5):252-60. www.epistemonikos.org/documents/a9ae77db2f0454e0c39477f21196948030e052bb

1582. Birim O, Kappetein AP, Stijnen T, Bogers AJ. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. The Annals of thoracic surgery. 2005;79(1):375-82.www.epistemonikos.org/documents/a9b8e5194419b0d13463f1e6bd6e5e65c40e340c

1583. Li X., Tang X., Li Y., Zhang Y., Sun X.. Sequential combination of chemotherapy with EGFR-TKI as the first-line treatment for unselected patients with advanced non-small cell lung cancer: Systematic review of randomized controlled trials. Value in Health. 2014;17(7):A733.www.epistemonikos.org/documents/a9e58585d3af87b08dceddcb603c381fd7ac31a

1584. Mi D.-H., Li Z., Yang K.-H., Tian J.-H., Wang D.-Y.. HRCT for non-small cell lung cancer: A meta-analysis. Chinese Journal of Evidence-Based Medicine. 2011;11(11):1262-1267. www.epistemonikos.org/documents/aa0fe433308697de70663bde3c06bea29fa7edde

1585. Taioli E, Benhamou S, Bouchardy C, Cascorbi I, Cajas-Salazar N, Dally H, Fong KM, Larsen JE, Le Marchand L, London SJ, Risch A, Spitz MR, Stucker I, Weinshenker B, Wu X, Yang P. Myeloperoxidase G-463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis. Genetics in medicine : official journal of the American College of Medical Genetics. 2007;9(2):67-73. www.epistemonikos.org/documents/aa1e2041d489644faa37f4e443a035b06105ebff

1586. Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PloS one. 2011;6(3):e17479.www.epistemonikos.org/documents/aa2a5ac6569f2602bb7ace1e0b5789316260ad62

1587. Zhang J, Liu J, Chen J, Li X, Wu Y, Chen H, Wu W, Zhang K, Gu L. Angiotensin receptor blockers (ARBs) reduce the risk of lung cancer: a systematic review and meta-analysis. International journal of clinical and experimental medicine. 2015;8(8):12656-60.www.epistemonikos.org/documents/aa2b15522fc577423f5c0582970d93f1af6e0f99

1588. Bae JM, Kim EH. Human papillomavirus infection and risk of lung cancer in never-smokers and women, an 'adaptive' meta-analysis. Epidemiology and health. 2015;37:e2015052. www.epistemonikos.org/documents/aa2fb6c85ae181134520f92f589a26f011609b15

1589. Zhu H, Zhang S. Body mass index and lung cancer risk in never smokers: a meta-analysis. BMC cancer. 2018;18(1):635.www.epistemonikos.org/documents/aa60e96a45532267c44f6260266b4f23c2b8248d

1590. Jiang L, Liang W, Shen J, Chen X, Shi X, He J, Yang C, He J. The Impact of Visceral Pleural Invasion In Node-negative Non-small-cell Lung cancer: A Systematic Review and Meta-analysis. Chest. 2015;148(4):903-11. www.epistemonikos.org/documents/aa6402d6ff28003bf4e9bce25d58a9681b1a1dab

1591. Liu Y, Gu X, Lin Q, Tian T, Shao L, Yuan C, Zhang B, Fan K. Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta-analysis. International journal of clinical and experimental medicine. 2015;8(8):12765-73. www.epistemonikos.org/documents/aa6a47e818a3238cf985b9a82dcca451184c5276

1592. Sheng J, Yang Y, Ma Y, Yang B, Zhang Y, Kang S, Zhou T, Hong S, Qin T, Hu Z, Fang W, Huang Y, Zhang L. The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysis. PloS one. 2015;10(6):e0127306. www.epistemonikos.org/documents/aab171f854138d14e3fee3659f3324e93d5555b0

1593. Cavalheri V, Tahirah F, Nonoyama M, Jenkins S, Hill K. Exercise training for people following lung resection for non-small cell lung cancer - a Cochrane systematic review. Cancer treatment reviews. 2014;40(4):585-94. www.epistemonikos.org/documents/aac53bd257032addc8061f076d035530749b5b2c

1594. Guo XT, Wang JF, Zhang LY, Xu GQ. Quantitative assessment of the effects of MMP-2 polymorphisms on lung carcinoma risk. Asian Pacific journal of cancer prevention : APJCP. 2012;13(6):2853-6. www.epistemonikos.org/documents/aad4e1d759cf6fbf8b167a619de8e0742c89ae99

1595. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, Minken A, Wanders R, Lutgens L, Hochstenbag M, Boersma L, Wouters B, Lammering G, Vansteenkiste J, Lambin P. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(7):1057-63.www.epistemonikos.org/documents/aaf799b0ce8119994185650da60f7af21c5e7de1

1596. Chen G.-X., Wang M.-H., Zheng T., Tang G.-C., Han F.-G., Tu G.-J.. Diffusion-weighted magnetic resonance imaging for the detection of metastatic lymph nodes in patients with lung cancer: A meta-analysis. Molecular and Clinical Oncology. 2017;6(3):344-354.www.epistemonikos.org/documents/aaf81d404d993b326038e921cb03874dd1fd7cef

1597. Des Guetz G., Uzzan B., Chouahnia K., Nicolas P., Perol M., Morere J.F.. Is there a benefit to maintenance therapy after first line chemotherapy in advanced non-small cell lung cancer - A systematic review with meta-analysis. European Journal of Cancer. 2011;:S593.www.epistemonikos.org/documents/ab10b3cf5311d51b454673e3d8442a747e87ee03

1598. Papadopoulos D, Papadoudis A, Kiagia M, Syrigos K. Nonpharmacologic Interventions for Improving Sleep Disturbances In Patients with Lung Cancer: A Systematic Review and Meta-Analysis. Journal of pain and symptom management. 2018;55(5):1364-1381.e5.www.epistemonikos.org/documents/ab1291036ee17b71dd8bf0e251efcab0efaaeba7

1599. Zhang J, Yang F, Li B, Li H, Liu J, Huang W, Wang D, Yi Y, Wang J. Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. International journal of radiation oncology, biology, physics. 2011;81(4):e305-16.www.epistemonikos.org/documents/ab3edefd52e2f7e4f603d605cb1efee3a5f7a1eb

1600. Luo Z, Wu R, Jiang Y, Qiu Z, Chen W, Li W. Overexpression of estrogen receptor beta is a prognostic marker in non-small cell lung cancer: a meta-analysis. International journal of clinical and experimental medicine. 2015;8(6):8686-97. www.epistemonikos.org/documents/ab4e6419f8945ef00759e2933d1e448b41794d2b

1601. de Cabanyes Candela S, Detterbeck FC. A systematic review of restaging after induction therapy for stage IIIa lung cancer: prediction of pathologic stage. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010;5(3):389-98.www.epistemonikos.org/documents/ab8267675705c0aaea14319fb8942bb783f1570b

1602. Wang X, Hao LR, Yue K. The TP53 codon 72 Pro/Pro genotype may be associated with an increased lung cancer risk in North China: an updated meta-analysis. International journal of clinical and experimental medicine. 2015;8(3):3120-6. www.epistemonikos.org/documents/ab99ccaf652116d497476409f5171de040b3ee16

1603. Bellows B.K., Dahal A., Agarwal N.. Risk of death at one year in patients with non-small cell lung cancer (NSCLC) treated with cisplatin regimens: An indirect comparison meta-analysis based on renal eligibility criteria. Value in Health. 2013;:A131. www.epistemonikos.org/documents/aba0be0a9cb846be2b92f188b15db68474627c35

1604. Sandler A, Hirsh V, Reck M, von Pawel J, Akerley W, Johnson DH. An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. Lung cancer (Amsterdam, Netherlands). 2012;78(1):1-7.www.epistemonikos.org/documents/aba33d1e46b5162508a280add700462b9d52f557

1605. Guo SX, Jian Y, Chen YL, Cai Y, Zhang QY, Tou FF. Neoadjuvant Chemoradiotherapy vesus Chemotherapy alone Followed by Surgery for Resectable Stage III Non-Small-Cell Lung Cancer: a Meta-Analysis. Scientific reports. 2016;6:34388. www.epistemonikos.org/documents/aba3d96fa87275dccab03db2a372e11d8031c541

1606. Batson S, Mitchell SA, Windisch R, Damonte E, Munk VC, Reguart N. Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. OncoTargets and therapy. 2017;10:2473-2482.www.epistemonikos.org/documents/abb7cbef6a07967e18629fcedf0c009ddf5d3cad

1607. Cheng S, Evans WK, Stys-Norman D, Shepherd FA, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007;2(4):348-54. www.epistemonikos.org/documents/abe63482ab4903d892e8d31a37c3974105e65b57

1608. Tan LE, A M R, Lim CS. Association of chronic obstructive pulmonary disease and postresection lung cancer survival: a systematic review and meta-analysis. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2017;65(2):342-352.www.epistemonikos.org/documents/abeeadc8f4919ef94f0d32ab215fb74076e4db5c

1609. Zhang X, Qin Y, Li H, Bai C, Zhu T, Xu J, Wu C, Wu M, Wang C, Song H, Wei L, He J. Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2011;12(11):2857-63.www.epistemonikos.org/documents/ac02da71279f66f3d75015b8c21ebf316c47db60

1610. Chen S, Zhang J, Wang R, Luo X, Chen H. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung cancer (Amsterdam, Netherlands). 2010;70(1):63-70.www.epistemonikos.org/documents/ac052a195a296d916cd1a458308d63762157f63f

1611. Liu H., Ma H.F., Chen Y.K.. Association between GSTM1 polymorphisms and lung cancer: An updated meta-analysis. Genetics and Molecular Research. 2015;14(1):1385-1392.www.epistemonikos.org/documents/ac511866aa5fdb865459617be37c9c71d1cb3f18

1612. Wang J, Gu LJ, Fu CX, Cao Z, Chen QY. Endostar combined with chemotherapy compared with chemotherapy alone in the treatment of nonsmall lung carcinoma: A meta-analysis based on Chinese patients. Indian journal of cancer. 2014;51 Suppl 3(7):e106-9.www.epistemonikos.org/documents/ac69cf1852657f9509d97760cca392cdcdd6b7a2

1613. Li Y, Jin G, Su D. Comparison of Gadolinium-enhanced MRI and 18FDG PET/PET-CT for the diagnosis of brain metastases in lung cancer patients: A meta-analysis of 5 prospective studies. Oncotarget. 2017;8(22):35743-35749. www.epistemonikos.org/documents/ac75879b776f42bf7de660383a93b82385d88b84

1614. He W., Long J., Xian L., Pang F., Su L., Wei S., Wei B., Hu Y.. MDM2 SNP309 polymorphism is associated with lung cancer risk in women: A meta-analysis using METAGEN. Experimental and Therapeutic Medicine. 2012;4(4):569-576. www.epistemonikos.org/documents/ac9952a6c5d53a8355d10e224fbf59d9bfdd66b9

1615. Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung cancer (Amsterdam, Netherlands). 2008;59(1):1-11. www.epistemonikos.org/documents/acb0b35712fab1f46a06366d32b5f9e8542e22a0

1616. Di Maio M, Perrone F, Chiodini P, Gallo C, Camps C, Schuette W, Quoix E, Tsai CM, Gridelli C. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(11):1377-82. www.epistemonikos.org/documents/acbbde941a5e16818e205ad634d2ea17480ef116

1617. Nicolucci A., Grilli R., Alexanian A.A., Apolone G., Torri V., Liberati A.. Quality, evolution, and clinical implications of randomized, controlled trials on the treatment of lung cancer. A lost opportunity for meta-analysis. Journal of the American Medical Association. 1989;262(15):2101-2107.www.epistemonikos.org/documents/acfe323fede55f088c84fa91d8cd7a01a469dee3

1618. Wang C, Lu X, Lyu Z, Bi N, Wang L. Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis. Lung cancer (Amsterdam, Netherlands). 2018;122:94-99. www.epistemonikos.org/documents/ad5bcd1278525d617006acdd05b9dc38fdcba1c1

1619. Wang S, Wang Q, Tian J, Zhou Z, Jiao L, Fu Y, Chen S, Zhang J, Xu L. Meta-analysis comparing doublet and single cytotoxic agent therapy as first-line treatment in elderly patients with advanced nonsmall-cell lung cancer. The Journal of international medical research. 2015;43(6):727-737.www.epistemonikos.org/documents/ad7d486e009b8e2a387f36523fec7757491e7503

1620. Chen G, Wang J, Hong X, Chai Z, Li Q. Dietary vitamin E intake could reduce the risk of lung cancer: evidence from a meta-analysis. International journal of clinical and experimental medicine. 2015;8(4):6631-7. www.epistemonikos.org/documents/ad9413b83a24506acaca7aa295adbde231435203

1621. Wu LM, Xu JR, Gu HY, Hua J, Chen J, Zhang W, Haacke EM, Hu J. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better?. The Journal of surgical research. 2012;178(1):304-14. www.epistemonikos.org/documents/ad953e495298ba82ee0652ef2297a10ee96d5942

1622. Wu W, Yin ZH, Guan P, Ren YW, Zhou BS. Association of oral contraceptives use and lung cancer risk among women: an updated meta-analysis based on cohort and case-control studies. Asian Pacific journal of cancer prevention : APJCP. 2014;15(3):1205-10. www.epistemonikos.org/documents/ade5c652d8959e11fc2cc924572fa09de019961e

1623. Yan H, Li Q, Wang W, Zhen H, Cao B. Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients. Scientific reports. 2015;5:15355. www.epistemonikos.org/documents/adfcd16da137d2e03e97d56ea85ed9c8c1b29991

1624. Hu H, Lin WQ, Zhu Q, Yang XW, Wang HD, Kuang YK. Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis. Oncotarget. 2016;7(49):81090-81098.www.epistemonikos.org/documents/ae10c24d15d965b22ab42f6808c96a5a5e85c44b

1625. Raphael J., Chan K., Karim S., Kerbel R., Lam H., Santos K.D., Saluja R., Verma S.. Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials. Clinical Lung Cancer. 2017;18(4):345-353.e5. www.epistemonikos.org/documents/ae363771117fd0c783f5382f79e4bc71744097f4

1626. Des Guetz G., Uzzan B., Nicolas P., Kader C., Perret G., Sebbane G., Morere J.F.. Comparison of efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis. Journal of Clinical Oncology. 2010;www.epistemonikos.org/documents/aea3e11cadc60607ad5abb80cc6e86e5970a2824

1627. Nakashima K, Horita N, Nagai K, Manabe S, Murakami S, Ota E, Kaneko T. Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma. Journal of thoracic oncology : official

publication of the International Association for the Study of Lung Cancer. 2016;11(9):1574-85.www.epistemonikos.org/documents/aed3cc2a795de55b28e6aa8c845a40e712ce4cfc

1628. Wang JY, Cai Y. X-ray repair cross-complementing group 1 codon 399 polymorphism and lung cancer risk: an updated meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(1):411-8. www.epistemonikos.org/documents/af01bf33a8767bc5cd7c53ac877539cfe10dbe67

1629. Lenters V, Vermeulen R, Dogger S, Stayner L, Portengen L, Burdorf A, Heederik D. A meta-analysis of asbestos and lung cancer: is better quality exposure assessment associated with steeper slopes of the exposure-response relationships?. Environmental health perspectives. 2011;119(11):1547-55.www.epistemonikos.org/documents/af043b3b9d066bef7b940b9161aff9aa95b27195

1630. Zhao L., Li W., Zhang H., Hou N., Guo L., Gao Q.. Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: A pooled analysis of randomized controlled trials. OncoTargets and Therapy. 2015;8:2775-2781. www.epistemonikos.org/documents/af46c041aaafc56b9ec764c90b9085612e7a347c

1631. Liu ZL, Wang Q, Wang M, Wang B, Huang LN. Low molecular weight heparin in treating patients with lung cancer received chemotherapy: A meta-analysis. Journal of cancer research and therapeutics. 2018;14(Supplement):S437-S443. www.epistemonikos.org/documents/af48b5a8a52a5af9c9f5c1a00b4a6b803f9e1dc1

1632. Lilenbaum RC, Langenberg P, Dickersin K. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival. Cancer. 1998;82(1):116-26. www.epistemonikos.org/documents/af6fa3d7c334716b5e3a2b72de60b511d908b96f

1633. Fritz H, Kennedy DA, Ishii M, Fergusson D, Fernandes R, Cooley K, Seely D. Polysaccharide K and Coriolus versicolor Extracts for Lung Cancer: A Systematic Review. Integrative cancer therapies. 2015;14(3):201-11. www.epistemonikos.org/documents/af7dd17fb1fc2fb482c2cc914489dbf8ea7b60bc

1634. Tan X, Wang Y, Shi L, Xian L, Guo J, Liang G, Chen M. Polymorphism of ERCC2 Asp312Asn with lung cancer risk: evidence from 20,101 subjects. Genetic testing and molecular biomarkers. 2014;18(1):50-6. www.epistemonikos.org/documents/af7f881c2ceb0dcf9bd18853c708e1aed8780919

1635. Sedrakyan A, Van Der Meulen J, O'Byrne K, Prendiville J, Hill J, Treasure T. Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. The Journal of thoracic and cardiovascular surgery. 2004;128(3):414-9. www.epistemonikos.org/documents/afa37aac8c78fedce279614ba07dcfc5897d8ad7

1636. Dai P., Li J., Ma X.-P., Huang J., Meng J.-J., Gong P.. Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: A meta-analysis. OncoTargets and Therapy. 2018;11:721-730. www.epistemonikos.org/documents/afeded5a1d0192b24b8983d13567ebf4520df906

1637. Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, Burcoveanu D, Fukuoka M, Besse B, Pignon JP, on behalf of the meta-analysis of bevacizumab in advanced NSCLC collaborative group. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013;24(1):20-30.www.epistemonikos.org/documents/b00953e00a20380f245c147d4dfeaebb467cd2d7

1638. Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. European journal of clinical pharmacology. 1997;51(5):389-93. www.epistemonikos.org/documents/b02a698b9b646b26d1e9df6d0d2efab8df38250d

1639. Collaud S, Fadel E, Schirren J, Yokomise H, Bolukbas S, Dartevelle P, Keshavjee S, Waddell TK, de Perrot M. En Bloc Resection of Pulmonary Sulcus Non-Small Cell Lung Cancer Invading the

Spine: A Systematic Literature Review and Pooled Data Analysis. Annals of surgery. 2015;262(1):184-8.www.epistemonikos.org/documents/b03412a77d7066428fab10c3e449cbcd09790790

1640. Feld R, Sridhar SS, Shepherd FA, Mackay JA, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006;1(4):367-76. www.epistemonikos.org/documents/b0357e97a69f65edd3bb04975e7251da50184421

1641. Qin Q, Zhang C, Yang X, Zhu H, Yang B, Cai J, Cheng H, Ma J, Lu J, Zhan L, Liu J, Liu Z, Xu L, Sun X. Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies. PloS one. 2013;8(11):e79864.www.epistemonikos.org/documents/b05514501816a0760a386db69e2dfc8713054ecd

1642. Barnes, Hayley, See, Katharine, Barnett, Stephen, Manser, Renée. Surgery for limited-stage small-cell lung cancer. Cochrane Database of Systematic Reviews. 2017;4(4):CD011917. www.epistemonikos.org/documents/b07aadca8bdeebcf648bc6aeed7bdb96c890029e

1643. Zhu L, Chen S, Ma S, Zhang S. Glasgow prognostic score predicts prognosis of non-small cell lung cancer: a meta-analysis. SpringerPlus. 2016;5:439.www.epistemonikos.org/documents/b07cf503f2dddac5ec0288f014f01c63a738bcac

1644. Jia M., Feng W., Kang S., Zhang Y., Shen J., Jiang L., Wang W., Guo Z., Peng G., Chen G., He J., Liang W.. Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis. Journal of Thoracic Disease. 2015;7(3):455-461.www.epistemonikos.org/documents/b07de819707cb4f0d8218f5607bd1bafc5c05204

1645. Eijgelshoven I., Verduyn S.C., Bhatti T., Bexelius C., Jansen J.P.. Cost-effectiveness of first-line treatment of advanced metastatic non small cell lung cancer-A systematic review of economic models. Value in Health. 2013;:A414-A415. www.epistemonikos.org/documents/b0933ee693c1f8ea14f6dc6f9448c46cf90a1ad7

1646. Nawrot TS, Martens DS, Hara A, Plusquin M, Vangronsveld J, Roels HA, Staessen JA. Association of total cancer and lung cancer with environmental exposure to cadmium: the meta-analytical evidence. Cancer causes & control : CCC. 2015;26(9):1281-8. www.epistemonikos.org/documents/b0bc21dbf4f642ed32a5f45f7391df4df137c43e

1647. Zhang L, Jin TB, Gao Y, Wang HJ, Yang H, Feng T, Chen C, Kang LL, Chen C. Meta-analysis of the association between the rs8034191 polymorphism in AGPHD1 and lung cancer risk. Asian Pacific journal of cancer prevention : APJCP. 2015;16(7):2713-7. www.epistemonikos.org/documents/b0f6bd21a6a7314dfa14648bfb202358d17eb977

1648. Wang L, Cheng J, Gao J, Wang J, Liu X, Xiong L. Association between the NBS1 Glu185Gln polymorphism and lung cancer risk: a systemic review and meta-analysis. Molecular biology reports. 2013;40(3):2711-5. www.epistemonikos.org/documents/b110852096bb174f9eac35fe63173cd5f4d34698

1649. Ashworth AB, Senan S, Palma DA, Riquet M, Chan Ahn Y, Ricardi U, Congedo MT, Gomez DR, Wright GM, Melloni G, Milano MT, Sole CV, De Pas TM, Carter DL, Warner AJ, Rodrigues GB. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clinical lung cancer. 2014;15(5):346-55. www.epistemonikos.org/documents/b11fcc18413cfde39e0264a7461eb1a4d160578b

1650. Wang B., Lv F., Zhao L., Du M., Gao S.. Video-assisted thoracoscope versus video-assisted mini-thoracotomy for non-small cell lung cancer: A meta-analysis. Chinese Journal of Lung Cancer. 2017;20(5):303-311. www.epistemonikos.org/documents/b1266a89b7f96b34550ed199d0e634f6fee50c9a

1651. Zhong L, Goldberg MS, Parent ME, Hanley JA. Exposure to environmental tobacco smoke and the risk of lung cancer: a meta-analysis. Lung cancer (Amsterdam, Netherlands). 2000;27(1):3-18. www.epistemonikos.org/documents/b126a2ebb793453aed1ebf01d5f9a8b16cf6b772

1652. You W, Liu M, Miao JD, Liao YQ, Song YB, Cai DK, Gao Y, Peng H. A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer. Journal of Cancer. 2018;9(7):1200-1206. www.epistemonikos.org/documents/b12cae888bb59a558fd6286953dbffacc557fd29

1653. Postoperative radiotherapy for non-small cell lung cancer. PORT Meta-analysis Trialists Group. Cochrane database of systematic reviews (Online). 2000;:CD002142.www.epistemonikos.org/documents/b138a3eaeb040975228745213129 7c502a2377a6

1654. Zhu D, Wang Y, Wang L, Chen J, Byanju S, Zhang H, Liao M. Prognostic value of the maximum standardized uptake value of pre-treatment primary lesions in small-cell lung cancer on 18F-FDG PET/CT: a meta-analysis. Acta radiologica (Stockholm, Sweden : 1987). 2018;59(9):284185117745907.www.epistemonikos.org/documents/b13ea320a0ced2c50475a1051536bb8f991f4855

1655. Liao QB, Guo JQ, Zheng XY, Zhou ZF, Li H, Lai XY, Ye JF. Test performance of sputum microRNAs for lung cancer: a meta-analysis. Genetic testing and molecular biomarkers. 2014;18(8):562-7. www.epistemonikos.org/documents/b15ef5f46c0c93bdb81fceaab288158ea97c5d13

1656. Ma W, Xu M, Liu Y, Liu H, Huang J, Zhu Y, Ji LJ, Qi X. Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials. International journal of cancer. Journal international du cancer. 2015;137(2):409-19.www.epistemonikos.org/documents/b16884e57a08768fcbfd59c9a88c82a24c519397

1657. Ren W, Mi D, Yang K, Cao N, Tian J, Li Z, Ma B. The expression of hypoxia-inducible factor-1α and its clinical significance in lung cancer: a systematic review and meta-analysis. Swiss medical weekly. 2013;143(no pagination):w13855. www.epistemonikos.org/documents/b16af1fa6dc5e954b26da01c41eb45b4bad36799

1658. Burdett, Sarah, Rydzewska, Larysa, Tierney, Jayne, Fisher, David, Parmar, Mahesh KB, Arriagada, Rodrigo, Pignon, Jean Pierre, Le Pechoux, Cecile. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2016;10(10):CD002142.www.epistemonikos.org/documents/b1712095576e10c85ded18cb95c80b2a84ee6476

1659. Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, Lafitte JJ, Sculier JP. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. British journal of cancer. 2004;91(12):2018-25. www.epistemonikos.org/documents/b1871fa9fa03e4627f9ff54f754328aa17b4c67f

1660. Tan X, Xian L, Chen X, Shi L, Wang Y, Guo J, Liang G, Zhao Z, Chen M. Association between ERCC2 Lys751Gln polymorphism and lung cancer risk: a meta-analysis involving 23,370 subjects. Twin research and human genetics : the official journal of the International Society for Twin Studies. 2014;17(2):99-107.www.epistemonikos.org/documents/b1a696732932c80dbc664e75a6ea56f0db0665f4

1661. Schild S.E., Foster N., Meyers J.P., Ross H.J., Stella P.J., Garces Y.I., Olivier K.R., Molina J.R., Past L.R., Adjei A.A.. Prophylactic cranial irradiation(PCI) in small cell lung cancer(SCLC): Findings from a north central cancer treatment group (NCCTG) metaanalysis. Journal of Thoracic Oncology. 2011;:S643.www.epistemonikos.org/documents/b1c02741c27ae3696a3256f91ad2ef90677aeabe

1662. Yin ZB, Hua RX, Li JH, Sun C, Zhu JH, Su X, Ji C, Xiang Q, Hua ZM. Smoking and hOGG1 Ser326Cys polymorphism contribute to lung cancer risk: evidence from a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

2014;35(2):1609-18.www.epistemonikos.org/documents/b1c686196f380d11c65335bab27cd4b03f827ae3

1663. Choma D, Daurès JP, Quantin X, Pujol JL. Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data. British journal of cancer. 2001;85(1):14-22. www.epistemonikos.org/documents/b1c960e7eee1d029123d35cd00c3798e152a7939

1664. Wu YT, Li X, Liu ZL, Xu Z, Dai W, Zhang K, Wu JS, Arshad B, Wu KN, Kong LQ. Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis. PloS one. 2017;12(6):e0179680. www.epistemonikos.org/documents/b1d3a2547b4b2d25d4fdefc910e7c951bdb0dbe8

1665. Oh SW, Myung SK, Park JY, Lee CM, Kwon HT, Korean Meta-analysis (KORMA) Study Group. Aspirin use and risk for lung cancer: a meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2011;22(11):2456-65. www.epistemonikos.org/documents/b1f3ba4e33675776d4af9bd92b4bcd1b1b8ddd6e

1666. Zhang ZJ, Bi Y, Li S, Zhang Q, Zhao G, Guo Y, Song Q. Reduced Risk of Lung Cancer With Metformin Therapy in Diabetic Patients: A Systematic Review and Meta-Analysis. American journal of epidemiology. 2014;180(1):11-4. www.epistemonikos.org/documents/b1fde9b1cb807597d87e50d91e36bc33d201619d

1667. Qiu MT, Ding XX, Hu JW, Tian HY, Yin R, Xu L. Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials. Cancer chemotherapy and pharmacology. 2012;70(6):861-73.www.epistemonikos.org/documents/b234ad82bcbf0cfdf628c9247024499fd6fc0f3a

1668. Zhao H, Gu J, Hua F, Xu H, Li L, Yang B, Han Y, Liu S, Hong S. [A meta-analysis of the timing of chest radiotherapy in patients with limited-stage small cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2010;13(9):892-7. www.epistemonikos.org/documents/b23d9bf2a074fe4fa20b932a8e8b4b4db7abbf3a

1669. Bai H, Qian JL, Han BH. S100A4 is an independent prognostic factor for patients with lung cancer: a meta-analysis. Genetic testing and molecular biomarkers. 2014;18(5):371-4. www.epistemonikos.org/documents/b25e812df00b6e9f717ed730c95a1054689800fe

1670. Wang Z., Yang H., Luo S., Liu B., Zhang N., Li L., Zhou S., Shen R., Xie X.. Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: A meta-analysis. Lung Cancer. 2017;112:1-9. www.epistemonikos.org/documents/b2679f0f1192406262beadb646ce0d09a26918c4

1671. Liao K, Bi ZF, He Y, Liu YM. [Whole brain radiation therapy plus temozolomide in the treatment of brain metastases from non small cell lung cancer: a meta-analysis]. Zhonghua yi xue za zhi. 2012;92(45):3199-203. www.epistemonikos.org/documents/b2adbd6a658bed804f0ba73a89030a4e0931e6b5

1672. Jin Y, Sun Y, Shi X, Zhao J, Shi L, Hong W, Yu X. Meta-analysis to assess the efficacy and toxicity of docetaxel-based doublet compared with docetaxel alone for patients with advanced NSCLC who failed first-line treatment. Clinical therapeutics. 2014;36(12):1980-90.www.epistemonikos.org/documents/b2eb4690c06a3550bdf946d85c010e46aecdf892

1673. Mitchell ED, Pickwell-Smith B, Macleod U. Risk factors for emergency presentation with lung and colorectal cancers: a systematic review. BMJ open. 2015;5(4):e006965.www.epistemonikos.org/documents/b30bd8e08c1cf88e03477e890556447039440e97

1674. Huang J, Gu T, Ying J. A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer. International journal of clinical oncology. 2017;22(6):1015-1025. www.epistemonikos.org/documents/b31ad10087148f2553a6c3684fab28d260b5c260

1675. Houlston RS. Glutathione S-transferase M1 status and lung cancer risk: a meta-analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1999;8(8):675-82.www.epistemonikos.org/documents/b349ce53cbf57ff2305c923bb37df540b4ac79b6

1676. Thompson E, Solà I, Subirana M. Non-invasive interventions for improving well-being and quality of life in patients with lung cancer--a systematic review of the evidence. Lung cancer (Amsterdam, Netherlands). 2005;50(2):163-76. www.epistemonikos.org/documents/b35dc3e707add6266061646be6d2a6f1fc429364

1677. Komiya T., Palla S.L., Wang F., Perez R.P., Huang C.H.. Infrequent chemoradiation-induced acute esophagitis in the Asian population: A meta-analysis of published clinical trials for unresectable stage III non-small cell lung cancer. Thoracic Cancer. 2014;5(6):565-569.www.epistemonikos.org/documents/b362960b0e202e6eed5570979b816ba157a92c37

1678. Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Ardine M, Barni S. Platinum rechallenge in patients with advanced NSCLC: a pooled analysis. Lung cancer (Amsterdam, Netherlands). 2013;81(3):337-42. www.epistemonikos.org/documents/b382c326c12a79a4f9e241667d887ff820b9d77a

1679. Lam TK, Gallicchio L, Lindsley K, Shiels M, Hammond E, Tao XG, Chen L, Robinson KA, Caulfield LE, Herman JG, Guallar E, Alberg AJ. Cruciferous vegetable consumption and lung cancer risk: a systematic review. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009;18(1):184-95. www.epistemonikos.org/documents/b3930a375e6992b08225dcc7f68d37e0922277f8

1680. Tang J., Zhang H., Yan J., Shao R.. Indirect comparison of the efficacy and safety of gefitinib and cetuximab-based therapy in patients with advanced non-small-cell lung cancer. Molecular and Clinical Oncology. 2015;3(1):145-150. www.epistemonikos.org/documents/b3a63b38bd9e7f49e7bbddec4cd63f844561c0d4

1681. Lee J.-W., Kim W., Min B.-I., Baek S.K., Cho S.-H.. Traditional herbal medicine as an adjuvant treatment for non-small-cell lung cancer: A systematic review and meta-analysis. European Journal of Integrative Medicine. 2015;7(6):577-585. www.epistemonikos.org/documents/b3b1aac7c27f431b598491dfaef635be10bcbb48

1682. Zhao S, He JL, Qiu ZX, Chen NY, Luo Z, Chen BJ, Li WM. Prognostic value of CD44 variant exon 6 expression in non-small cell lung cancer: a meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2014;15(16):6761-6. www.epistemonikos.org/documents/b4009a515d7a87abad07067eed2054f9c2fdea31

1683. Li H., Ma B., Wang D., Li M., Yuan S.. Association between survivin gene -31G/C and 9194A/G polymorphisms and lung cancer susceptibility: Meta-analysis of six studies. International Journal of Clinical and Experimental Medicine. 2017;10(3):4360-4367. www.epistemonikos.org/documents/b40607c63c8539162e4ee83153f1503698d3cce0

1684. Ma H, Tian X, Zeng XT, Zhang Y, Wang Y, Wang F, Zhou JG. The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis. Medicine. 2016;95(2):e2495.www.epistemonikos.org/documents/b411273956e75a1c2d43c0d01ed47052280a2db0

1685. JafariNezhad A, YektaKooshali MH. Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. PloS one. 2018;13(8):e0202360.www.epistemonikos.org/documents/b418459484ab80c1dd9552609a19c042b153aae7

1686. Griffiths K.E., Young J.. Disparities in lung cancer: A systematic literature review. Asia-Pacific Journal of Clinical Oncology. 2011;:168.www.epistemonikos.org/documents/b484bec79f216d9d84d028df4c91a66f55ad620b

1687. Abdel-Rahman O.. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. Critical Reviews in Oncology/Hematology. 2016;101:75-85. www.epistemonikos.org/documents/b49e4b51f105d097db6acb182b766fe8b55c0bdd

1688. Liang Y, Guo S, Zhou Q. Prognostic value of matrix metalloproteinase-7 expression in patients with non-small cell lung cancer. Tumour biology : the journal of the International Society

for Oncodevelopmental Biology and Medicine. 2014;35(4):3717-24.www.epistemonikos.org/documents/b4bc08077fc5e091dc3467f34f58e79cc4dd0365

1689. Ma G., Zhang J., Yin L., Jiang H., Zhang W., Song Y., Liu M.. The prognostic role of pretreatment epidermal growth factor receptor T790M mutation in advanced non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Oncotarget. 2017;8(31):50941-50948.www.epistemonikos.org/documents/b4ca19e10d71fdbdb7afca271d2a4df35dab4182

1690. Maguire R, Kotronoulas G, Papadopoulou C, Simpson MF, McPhelim J, Irvine L. Patient-reported outcome measures for the identification of supportive care needs in people with lung cancer: are we there yet?. Cancer nursing. 2013;36(4):E1-17. www.epistemonikos.org/documents/b4cb0a715a6748e60adb375b98ec73ee6ff2248e

1691. Meert AP, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout JM, Lafitte JJ, Mascaux C, Sculier JP. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. British journal of cancer. 2002;87(7):694-701.www.epistemonikos.org/documents/b4cd82ba4dd9000e65d0eb099fbd5cf484f0c7ff

1692. Zhai K, Ding J, Shi HZ. HPV and lung cancer risk: A meta-analysis. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2015;63((Zhai K., kan_zhai@sina.com; Ding J., ding201cy@sina.com; Shi H.-Z., shihuanzhong@sina.com) Medical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China):84-90. www.epistemonikos.org/documents/b4ceb2ff440f5f3c0e7d4b9f95e302adf181e247

1693. Li J, Sasane M, Zhao J, Horton VG, Zhang P, Ricculli ML, Zhou ZY, Signorovitch J. Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis. Advances in therapy. 2018;35(7):1035-1048.www.epistemonikos.org/documents/b4f123f042519ca7a9428617a5b183369174e15e

1694. Shen G, Hu S, Deng H, Jia Z. Diagnostic value of dual time-point 18 F-FDG PET/CT versus single time-point imaging for detection of mediastinal nodal metastasis in non-small cell lung cancer patients: a meta-analysis. Acta radiologica (Stockholm, Sweden : 1987). 2015;56(6):681-7.www.epistemonikos.org/documents/b5147981b7e629c1d1ec0da3695c751305a3e936

1695. Raymakers AJ, McCormick N, Marra CA, Fitzgerald JM, Sin D, Lynd LD. Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review. Respirology (Carlton, Vic.). 2017;22(1):61-70. www.epistemonikos.org/documents/b51cab2731e66dc937b05c49d331aba4ae07c4ee

1696. Ansari J, Nagabhushan N, Syed R, Bomanji J, Bacon CM, Lee SM. Small cell lung cancer associated with anti-Hu paraneoplastic sensory neuropathy and peripheral nerve microvasculitis: case report and literature review. Clinical oncology (Royal College of Radiologists (Great Britain)). 2004;16(1):71-6.www.epistemonikos.org/documents/b52b62730374fbd039dae6864d09a6f812534520

1697. Wang T, Ma L. [Pooled Analysis of the Trials of Erlotinib Monotherapy for Epidermal Growth Factor Receptor (EGFR)-mutant Advanced Non-small Cell Lung Cancer.]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2009;12(12):1237-41. www.epistemonikos.org/documents/b531ad3de6ad6e5920fa9d7a35ce1fcadd06c589

1698. Yang Y, Xie Y, Xian L. Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis. Journal of experimental & clinical cancer research : CR. 2013;32(1):15.www.epistemonikos.org/documents/b54fc6fc5ce93f370782042a9018845dbe27d2b8

1699. Tassinari D, Scarpi E, Sartori S, Drudi F, Castellani C, Carloni F, Tombesi P, Lazzari-Agli L. Noninferiority trials in second-line treatments of nonsmall cell lung cancer: a systematic review of literature with meta-analysis of phase III randomized clinical trials. American journal of clinical oncology. 2012;35(6):593-9.www.epistemonikos.org/documents/b55091fa9953f8248a76d0c6fdae1ffea469e73c

1700. Zhang H., Zheng C., Tang A.. Zhenqi Fuzheng combined with chemotherapy for advanced stage lung cancer: A meta analysis. International Journal of Clinical and Experimental Medicine. 2016;9(7):13493-13500. www.epistemonikos.org/documents/b57222c44def24733ec47b3e001ecdffd063da49

1701. Bronte G, Rolfo C, Passiglia F, Rizzo S, Gil-Bazo I, Fiorentino E, Cajozzo M, Van Meerbeeck JP, Lequaglie C, Santini D, Pauwels P, Russo A. What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. Critical reviews in oncology/hematology. 2015;95(3):306-17.www.epistemonikos.org/documents/b579f1cc724df043c7f3fe9e5d95f5934526dc9e

1702. Mundt KA, Dell LD, Crawford L, Sax SN, Boffetta P. Cancer Risk Associated with Exposure to Bitumen and Bitumen Fumes: An Updated Systematic Review and Meta-Analysis. Journal of occupational and environmental medicine. 2018;60(1):6-54. www.epistemonikos.org/documents/b5b64017960736f5589ea5f71148e0a0660ce87e

1703. Bagia M., Houghton B., Brown C., Boyer M., Millward M., Stockler M.. Maintenance chemotherapy in extensive small cell lung cancer (ESCLC): A meta analysis of randomised trials. Journal of Thoracic Oncology. 2011;:S6-S7. www.epistemonikos.org/documents/b5b723bf036694bd65217163124d4b291d364588

1704. Liu J, Huang W, Zhou R, Jia S, Tang W, Luo Y, Zhang J. Bisphosphonates in the Treatment of Patients With Metastatic Breast, Lung, and Prostate Cancer: A Meta-Analysis. Medicine. 2015;94(46):e2014. www.epistemonikos.org/documents/b5c9d1fe1b5232ef32eff1921cd256e159459e29

1705. Zhang L., Gao S., He J.. The role of maintenance therapy in the treatment of elderly non-small-cell lung cancer patients: A meta-analysis of randomized controlled trials. Drug Design, Development and Therapy. 2017;11:3435-3440. www.epistemonikos.org/documents/b5f150a840fba956f6f352b39ade53d9a82f38be

1706. Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, Zakher B, Fu R, Slatore CG. Screening for lung cancer with low-dose computed tomography: a systematic review to update the U.S. Preventive Services Task Force recommendation. Annals of internal medicine. 2013;159(6):411-20.www.epistemonikos.org/documents/b62d810e8d1bf05e3cb7dd84122d36635af626c6

1707. Mei C, Deng W, Zhou Q. [The association of XPD G312A polymorphism with lung cancer risk: a meta-analysis]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2010;13(5):526-32. www.epistemonikos.org/documents/b63000574ea8b0a30c5d5fc1a133502e09d31f66

1708. Wang L, Song Y, Wu GN, Yuan DM. Association of the metformin with the risk of lung cancer: a meta-analysis. Translational lung cancer research. 2013;2(4):259-63.www.epistemonikos.org/documents/b639d2a7b813fdc73b0c3cea649918f3ea91e4fd

1709. Sullivan D.R., Pappas M., Humphrey L.L., Slatore C.G.. Populations and individuals: A systematic review of the psychosocial impact of lung cancer screening with computed tomography on patients. American Journal of Respiratory and Critical Care Medicine. 2014;www.epistemonikos.org/documents/b661ed1f0e9c2d05401e07577c2ec1972d9ce29c

1710. Palma D., Lagerwaard F., Rodrigues G., Haasbeek C., Senan S.. Treatment of stage I NSCLC in patients with severe COPD: Stereotactic radiotherapy outcomes and systematic review. Journal of Thoracic Oncology. 2010;:S510. www.epistemonikos.org/documents/b6623bee5c76a82191d548279ed9d3c560ae50a3

1711. Zhang YF, Zhou L, Zhang HW, Hou AJ, Gao HF, Zhou YH. Association between folate intake and the risk of lung cancer: a dose-response meta-analysis of prospective studies. PloS one. 2014;9(4):e93465. www.epistemonikos.org/documents/b682261d9631029f04ae3dbe1d10ecb3c81cbce4

1712. Ma XL, Liu L, Liu XX, Li Y, Deng L, Xiao ZL, Liu YT, Shi HS, Wei YQ. Prognostic role of microRNA-21 in non-small cell lung cancer: a meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2012;13(5):2329-34. www.epistemonikos.org/documents/b69fd9b4f00786ef419d7d649f759e3357c653e7

1713. Zhu L, Liu J, Ma S, Zhang S. Long Noncoding RNA MALAT-1 Can Predict Metastasis and a Poor Prognosis: a Meta-Analysis. Pathology oncology research : POR. 2015;21(4):1259-64. www.epistemonikos.org/documents/b6a1f0a573c015b9fa08f0e9a50dda0ec618d881

1714. Chen X, Liu Y, Røe OD, Qian Y, Guo R, Zhu L, Yin Y, Shu Y. Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. PloS one. 2013;8(3):e59314. www.epistemonikos.org/documents/b6d44e2b8a9900465676bcbeaa7c4113a8d2cdb2

1715. Hou B., Deng X.-F., Zhou D., Liu Q.-X., Dai J.-G.. Segmentectomy versus wedge resection for the treatment of high-risk operable patients with stage i non-small cell lung cancer: A meta-analysis. Therapeutic Advances in Respiratory Disease. 2016;10(5):435-443.www.epistemonikos.org/documents/b70d539c25ad1b50fd149874d24da9e4cace4332

1716. Xu Y., Chen N., Wang Z., Zhang Y., Mei J., Liu C., Liu L.. Should primary tumor be resected for non-small cell lung cancer with malignant pleural disease unexpectedly found during operation?-a systemic review and meta-analysis. Journal of Thoracic Disease. 2016;8(10):2843-2852.www.epistemonikos.org/documents/b71b60564255877adca35e5e3da6593a7e411596

1717. Coory M, Gkolia P, Yang IA, Bowman RV, Fong KM. Systematic review of multidisciplinary teams in the management of lung cancer. Lung cancer (Amsterdam, Netherlands). 2008;60(1):14-21. www.epistemonikos.org/documents/b71c3baf5593be5d0289c1b9442d9e545ede561b

1718. Claassens, L, van Meerbeeck, J, Coens, C, Quinten, C, Wang, X S, Velikova, G, Bottomley, A. Health-related quality of life (HRQOL) in non-small cell lung cancer (NSCLC): An update of a systematic review on methodological issues in randomized controlled trials (RCTs). Journal of Clinical Oncology. 2009;27:9604-9604.www.epistemonikos.org/documents/b72890a1f1e8e8412b174b23a69f17dd682590ae

1719. Dai Y, Han B, Shen J, Qi D, Jiang L, Gu J, Chu T, Dong Y, Shi H. [Preoperative induction chemotherapy for resectable stage IIIA non-small-cell lung cancer: a meta-analysis of 13 double-blind, randomized clinical trials.]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2008;11(3):398-405.www.epistemonikos.org/documents/b79e8f8677e5324d505586e8b1a6f59cdaeea38c

1720. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies. Expert review of anticancer therapy. 2012;12(10):1299-312.www.epistemonikos.org/documents/b7bfcbe5b314eeb9e49f9c32cacc2fd07efa46c2

1721. Wang B, Peng XX, Sun R, Li J, Zhan XR, Wu LJ, Wang SL, Xie T. Systematic review of β-elemene injection as adjunctive treatment for lung cancer. Chinese journal of integrative medicine. 2012;18(11):813-23. www.epistemonikos.org/documents/b7c2563e218e13119ededfe724a2f7014424d253

1722. Xiao HQ, Tian RH, Zhang ZH, Du KQ, Ni YM. Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis. OncoTargets and therapy. 2016;9:1471-6.www.epistemonikos.org/documents/b7daeeb12ba66c049f67fcafd46857f1b46b35ac

1723. Freudenheim JL, Ritz J, Smith-Warner SA, Albanes D, Bandera EV, van den Brandt PA, Colditz G, Feskanich D, Goldbohm RA, Harnack L, Miller AB, Rimm E, Rohan TE, Sellers TA, Virtamo J, Willett WC, Hunter DJ. Alcohol consumption and risk of lung cancer: a pooled analysis of cohort studies. The American journal of clinical nutrition. 2005;82(3):657-67. www.epistemonikos.org/documents/b7edd9b744ad631c4448faa8aca33959ea97a33a

1724. Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, O'Brien M, Schild SE, Parmar M, Tierney JF, Le Pechoux C, Michiels S, Surrogate Lung Project Collaborative Group. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. The lancet oncology. 2013;14(7):619-26.www.epistemonikos.org/documents/b8073d5efc77438ff6c0708ad307ffedceb7e5d4

1725. Behera M., Pillai R.N., Owonikoko T.K., Kim S., Chen Z., Saba N.F., Belani C.P., Khuri F.R., Ramalingam S.S.. Bevacizumab in combination with taxane versus non-taxane-containing regimens for advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC): A systematic review. Journal of Clinical Oncology. 2013;www.epistemonikos.org/documents/b8205ae2c7c56de8f6f745a3db20e9c97a609ed2

1726. Huang H., Wang T., Hu B., Pan C.. Visceral Pleural Invasion Remains a Size-Independent Prognostic Factor in Stage I Non-Small Cell Lung Cancer. Annals of Thoracic Surgery. 2015;99((Huang H.) Department of Anesthesiology, Sichuan Cancer Hospital, Chengdu, People's Republic of China):1130-9.www.epistemonikos.org/documents/b82265bb5dd01306ba87302bbeedd04198083ee0

1727. Xu W, Zhou Y, Hang X, Shen D. Current evidence on the relationship between CYP1B1 polymorphisms and lung cancer risk: a meta-analysis. Molecular biology reports. 2012;39(3):2821-9. www.epistemonikos.org/documents/b822e28f43bdd278e854b1c95c9f235c5acea8a9

1728. Chu GCW, Lazare K, Sullivan F. Serum and blood based biomarkers for lung cancer screening: a systematic review. BMC cancer. 2018;18(1):181.www.epistemonikos.org/documents/b85d4de89d285d97b208cfb60de01814bf518fc6

1729. Ellis P.M., Blais N., Soulieres D., Ionescu D.N., Liu G., Melosky B., Reiman T., Shepherd F.A., Tsao M., Leighl N.B.. A systematic review and consensus recommendations on the use of biomarkers in the treatment of non-small cell lung carcinoma (NSCLC). Annals of Oncology. 2010;:viii131.www.epistemonikos.org/documents/b86ceb6021989e4f64040e3fd2f25358f979fb54

1730. Maruti S.S., Dawn Flick E., Houweling L., Van Herk-Sukel M.P.P., Dong W.. Incidence of brain metastases and hemorrhage among lung cancer patients: A systematic Review. Pharmacoepidemiology and Drug Safety. 2010;:S258-S259. www.epistemonikos.org/documents/b8799eaee8f19d06fabc1378a7fec5a56ba36264

1731. Zhang X, Li Y, Li H, Qin Y, Bai C, Xu F, Zhu T, Xu J, Wu M, Wang C, Wei L, He J. Combined EGFR and VEGFR versus single EGFR signaling pathways inhibition therapy for NSCLC: a systematic review and meta-analysis. PloS one. 2012;7(8):e40178. www.epistemonikos.org/documents/b88966ad2e37f6163dfc55872bf385ea879be5a4

1732. Jiang J, Liang X, Zhou X, Huang L, Huang R, Chu Z, Zhan Q. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010;5(6):867-73. www.epistemonikos.org/documents/b8fe7edba5fea2bba96dcd0f2ff56b77b394b8f8

1733. Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2010;94(1):1-11.www.epistemonikos.org/documents/b91051dc948fc36ee204515a38b30752505acb5e

1734. Wang YD, Yang HY, Liu J, Wang HY. Updated meta-analysis of the association between CYP2E1 RsaI/PstI polymorphisms and lung cancer risk in Chinese population. Asian Pacific journal of cancer prevention : APJCP. 2014;15(13):5411-6. www.epistemonikos.org/documents/b968f2d285eeed29ead60cfdc2b928ff742c843c

1735. Ma JT, Zheng JH, Han CB, Guo QY. Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer. Cancer science. 2014;105(8):1015-22. www.epistemonikos.org/documents/b99405ec0d683887abe4876b0a811c4a17bfb754

1736. Warkentin M.T., Morris D., Bebb G., Brenner D.R.. The role of DNA repair capacity in lung cancer risk among never-smokers: A systematic review of epidemiologic studies. Cancer Treatment and Research Communications. 2017;13:13-24. www.epistemonikos.org/documents/b998cdfd949bd9becf9d04b6aa550bdf592cc7c7

1737. Kiyohara C, Takayama K, Nakanishi Y. Lung Cancer Susceptibility and hOGG1 Ser326Cys Polymorphism: A Meta-Analysis. Cancers. 2010;2(4):1813-29.www.epistemonikos.org/documents/b9a0cce7cded67c20ba6711fec85fd96ee5a5294

1738. Yuan X, Wu H, Xu H, Han N, Chu Q, Yu S, Chen Y, Wu K. Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis. Scientific reports. 2015;5:10338. www.epistemonikos.org/documents/b9bb63e6686aa69a90d97c6b6b8d1692dc179995

1739. Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q. Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials. International journal of clinical oncology. 2013;18(6):1005-13.www.epistemonikos.org/documents/b9c2a37498915d926185d0679b1a702d21544c3a

1740. Révész D, Engelhardt EG, Tamminga JJ, Schramel FMNH, Onwuteaka-Philipsen BD, van de Garde EMW, Steyerberg EW, Jansma EP, De Vet HCW, Coupé VMH. Decision support systems for incurable non-small cell lung cancer: a systematic review. BMC medical informatics and decision making. 2017;17(1):144.www.epistemonikos.org/documents/b9e4557771440ead1ad2e9773474ea61324bb3fb

1741. Cooper M.R., Chim H., Chan H., Durand C.. Ceritinib: A New Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer. Annals of Pharmacotherapy. 2015;49(1):107-112.www.epistemonikos.org/documents/b9ea5c8f57c13358cde12aa6417a63a1b03e48a8

1742. Xin Y, Guo W, Yang CS, Huang Q, Zhang P, Zhang LZ, Jiang G. Meta-analysis of whole-brain radiotherapy plus temozolomide compared with whole-brain radiotherapy for the treatment of brain metastases from non-small-cell lung cancer. Cancer medicine. 2018;7(4):981-990.www.epistemonikos.org/documents/ba03d9724a32c66501848715158c40c513598fd3

1743. Brea TP, Raviña AR, Villamor JMC, Gómez AG, de Alegría AM, Valdés L. Use of Magnetic Resonance Imaging for N-Staging in Patients with Non-Small Cell Lung Cancer. A Systematic Review. Archivos de bronconeumologia. 2019;55(1):9-16. www.epistemonikos.org/documents/ba2021a8eeee26cc1b07d13b7a846f28ebf6c869

1744. Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. The oncologist. 2017;22(4):470-479. www.epistemonikos.org/documents/ba3c6b22ef2eea27ce2da99ba6876908be5b6531

1745. De Ruysscher D., Paris E., Le Pechoux C., Turrisi A.T., Pang H., Murray N., Lebeau B., Takada M., Skarlos D.-V., Blackstock A., O'Brien M.E.R., Spiro S.. A meta-analysis of randomised trials using individual patient data on the timing of chest radiotherapy in patients with limited stage small cell lung cancer. Journal of Thoracic Oncology. 2011;:S641-S642. www.epistemonikos.org/documents/ba4a8f1a5cdf1fcd94e1037c49babb4735414f82

1746. Hu S.-L., Zhao W.-G., Shen G., Wang F.. Endostar plus chemotherapy for non small cell lung cancer: A systematic review. Chinese Journal of Evidence-Based Medicine. 2011;11(10):1144-1150. www.epistemonikos.org/documents/ba6e904239a7e29774857ca81d9f468215688176

1747. Horita N, Yamamoto M, Sato T, Tsukahara T, Nagakura H, Tashiro K, Shibata Y, Watanabe H, Nagai K, Nakashima K, Ushio R, Ikeda M, Kobayashi N, Shinkai M, Kudo M, Kaneko T. Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients. Scientific reports. 2016;6:18999.www.epistemonikos.org/documents/ba6fead30386150a15256682492bed7c66e7097d

1748. Liu H, Liang Y, Liao H, Li L, Wang H. Association of p73 G4C14-to-A4T14 polymorphism with lung cancer risk. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(9):9311-6. www.epistemonikos.org/documents/ba7da4a700534fca42c374aff60fe28cbad23207

1749. Shang W.-L., Zhang H.-P., Yang S.-Y., Zhang W., Huo S.-F., Liu Y.-F.. Role of low-dose spiral CT scan in lung cancer screening: A meta-analysis. Journal of Xi'an Jiaotong University (Medical

Sciences). 2011;32(1):38-42+68. www.epistemonikos.org/documents/ba809094a3528270985e310f3aa3b93cf2bbd786

1750. Chen H, Louie AV, Boldt RG, Rodrigues GB, Palma DA, Senan S. Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer: A Systematic Review. Clinical lung cancer. 2016;17(5):141-149. www.epistemonikos.org/documents/bac5c0992a2bffc87456a5f2060e46a146714768

1751. Li L, Wan C, Wen FQ. Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis. Genetics and molecular research : GMR. 2014;13(2):3772-86. www.epistemonikos.org/documents/bae65a608286d6fcf4bd73194efd27bad3dcb2ee

1752. Xiao M, Chen L, Wu X, Wen F. The association between the rs6495309 polymorphism in CHRNA3 gene and lung cancer risk in Chinese: a meta-analysis. Scientific reports. 2014;4:6372. www.epistemonikos.org/documents/baf2405ad7495c072162a85578fd18139e1bb2c8

1753. Lesueur P, Martel-Laffay I, Escande A, Kissel M, Locher C, Gervais R, Schott R, Vergnenegre A, Chouaid C. Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review. Expert review of anticancer therapy. 2018;18(11):1-7.www.epistemonikos.org/documents/bb01e52ec81551031f98d1a5415cadb7395ea5da

1754. Huang T, Li J, Zhang C, Hong Q, Jiang D, Ye M, Duan S. Distinguishing Lung Adenocarcinoma from Lung Squamous Cell Carcinoma by Two Hypomethylated and Three Hypermethylated Genes: A Meta-Analysis. PloS one. 2016;11(2):e0149088. www.epistemonikos.org/documents/bb11b114d3cade62ef79589a2b7f40830cc67d14

1755. Tian Y., Liu Q., Chu Q., Chen Y., Wu K.. Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers. Oncotarget. 2017;8(37):62330-62338. www.epistemonikos.org/documents/bb184295fee798c0d30a91d0ea515cbf9e358e0a

1756. Dai WM, Yang B, Chu XY, Wang YQ, Zhao M, Chen L, Zhang GQ. Association between folate intake, serum folate levels and the risk of lung cancer: a systematic review and meta-analysis. Chinese medical journal. 2013;126(10):1957-64. www.epistemonikos.org/documents/bb5104883839261176249359749ffb83b0c550bd

1757. Ding G, Xu W, Hua H, Huang Q, Liang H, Ni Y, Ding Z. Comprehensive assessment of the association between DNA repair gene XRCC3 rs861539 C/T polymorphism and lung cancer risk. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(5):2521-7.www.epistemonikos.org/documents/bb5fc9be15cebe93b925f776fcb0cd18190e4b1b

1758. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis. 2003;18(4):377-85.www.epistemonikos.org/documents/bb8f1661100c5d51965b7610eb230a1ec5e4549a

1759. Tassinari D, Scarpi E, Sartori S, Tamburini E, Santelmo C, Tombesi P, Lazzari-Agli L. Second-Line Treatments in Non-small Cell Lung Cancer: A Systematic Review of Literature and Metaanalysis of Randomized Clinical Trials. Chest. 2009;135(6):1596-609.www.epistemonikos.org/documents/bb9938ca4d4b42836136d86395b61a4e5ebd3242

1760. Zhu L, Yang Z, Wang S, Tang Y. [Kanglaite for Treating Advanced Non-small-cell Lung Cancer: A Systematic Review.]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2009;12(3):208-15. www.epistemonikos.org/documents/bbd880621a515dc8ed3d4ba623c89a800f6be95c

1761. Min L, Wang F, Liang S, Yang J, Xu X. Menopausal status and the risk of lung cancer in women: A PRISMA-compliant meta-analysis. Medicine. 2017;96(26):e7065.www.epistemonikos.org/documents/bc2c2474c255c047deb32d07486b867d64c098b5

1762. Wang F, Zhou J, Zhang Y, Wang Y, Cheng L, Bai Y, Ma H. The Value of MicroRNA-155 as a Prognostic Factor for Survival in Non-Small Cell Lung Cancer: A Meta-Analysis. PloS one.

2015;10(8):e0136889. www.epistemonikos.org/documents/bc2e0788c91eee1657f7260a0324a872b99152dd

1763. Zikos E., Ghislain I., Ediebah D.E., Quinten C., Van Meerbeeck J., Stupp R., Koller M., Flechtner H., Sprangers M.A.G., Bottomley A.. Health-related quality of life in small-cell lung cancer: A systematic review on reporting of methodological and clinical issues in randomized controlled trials. European Journal of Cancer. 2013;:S270.www.epistemonikos.org/documents/bc357b032ee0cf9a2fda51acd2f699ca57cc4268

1764. Li C, Sun Y, Pan Y, Wang Q, Yang S, Chen H. Gemcitabine plus paclitaxel versus carboplatin plus either gemcitabine or paclitaxel in advanced non-small-cell lung cancer: a literature-based meta-analysis. Lung. 2010;188(5):359-64. www.epistemonikos.org/documents/bc621aecb9ea777b8f5d19ab55c7a27093ec9e2e

1765. Oberheim N.A.B., Kesari S., Scott B.. A meta-analysis of survival in leptomeningeal metastasis in melanoma, lung, and gastrointestinal carcinoma. Neuro-Oncology. 2013;:iii124. www.epistemonikos.org/documents/bccb99fe6fc84197e1e6770cab9cc74d28f72292

1766. Timofeeva M.N., Brennan P., Landi M.T., Rafnar T., Houlston R., Hung R., Amos C.I.. Meta-analysis of genome-wide associations studies of lung cancer. Genetic Epidemiology. 2012;:146-147. www.epistemonikos.org/documents/bd1452915b1cca2b1436295c36f57cd17ad8218b

1767. Wang M, Wang G, Ma H, Shan B. Crizotinib versus chemotherapy on ALK-positive NSCLC : a systematic review of efficacy and safety. Current cancer drug targets. 2019;19(1):41-49. www.epistemonikos.org/documents/bd3355e36a482081fe14f3024b0562eb6726c440

1768. Jin J., Zhan P., Katoh M., Kobayashi S.S., Phan K., Qian H., Li H., Wang X., Song Y.. Prognostic significance of beta-catenin expression in patients with non-small cell lung cancer: A meta-analysis. Translational Lung Cancer Research. 2017;6(1):97-108. www.epistemonikos.org/documents/bd3939aad7ba1859d2020277e0521cc9e45a9884

1769. Li X.-M., Yu X.-W., Yuan Y., Pu M.-Z., Zhang H.-X., Wang K.-J., Han X.-D.. Glutathione S-transferase P1, gene-gene interaction, and lung cancer susceptibility in the Chinese population: An updated meta-analysis and review. Journal of Cancer Research and Therapeutics. 2015;11(3):565-570.www.epistemonikos.org/documents/bd41e5a33a2420d5caad5f1e77ea3906f713be06

1770. Chen L, Wang Y, Liu F, Xu L, Peng F, Zhao N, Fu B, Zhu Z, Shi Y, Liu J, Wu R, Wang C, Yao S, Li Y. A systematic review and meta-analysis: Association between MGMT hypermethylation and the clinicopathological characteristics of non-small-cell lung carcinoma. Scientific reports. 2018;8(1):1439.www.epistemonikos.org/documents/bd65e396414f576d207639b5040d235f24ae4d70

1771. Ma JY, Yan HJ, Gu W. Association between BIM deletion polymorphism and clinical outcome of EGFR-mutated NSCLC patient with EGFR-TKI therapy: A meta-analysis. Journal of cancer research and therapeutics. 2015;11(2):397-402. www.epistemonikos.org/documents/bd77efda6140195795355f17419b839ef0040789

1772. Dong M., Liu J., Sun X., Xing L.. The prognostic significance of SUVmax on 18F-FDG PET/CT in early-stage non-small cell lung cancer after SBRT: A meta-analysis. International Journal of Radiation Oncology Biology Physics. 2015;:S157. www.epistemonikos.org/documents/bd9facdf4fd9b147335c40d8cb4a016d6c405d90

1773. Zhang R, Ying K, Shi L, Zhang L, Zhou L. Combined endobronchial and endoscopic ultrasound-guided fine needle aspiration for mediastinal lymph node staging of lung cancer: A meta-analysis. European journal of cancer (Oxford, England : 1990). 2013;49(8):1860-7.www.epistemonikos.org/documents/be0c3ab76f138e4e848e9a8d088d20fa254e568b

1774. Shikata S, Takemura Y. Secondhand smoke exposure and risk of lung cancer in Japan: a systematic review and meta-analysis of epidemiologic studies. Japanese journal of clinical oncology. 2017;47(3):282. www.epistemonikos.org/documents/be16756f8ea775a71ae5474b08b37558f0c1f40c

1775. Kathiresan G, Clement RF, Sankaranarayanan MT. Dyspnea in lung cancer patients: a systematic review. Lung Cancer (Auckland, N.Z.). 2010;1:141-150.www.epistemonikos.org/documents/be264f0499a34e3db93e3f78e39cc07d7ccf7499

1776. Yang WS, Wong MY, Vogtmann E, Tang RQ, Xie L, Yang YS, Wu QJ, Zhang W, Xiang YB. Meat consumption and risk of lung cancer: evidence from observational studies. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012;23(12):3163-70.www.epistemonikos.org/documents/be5eac6a07a72b6e28771323f620606ec027ddd9

1777. Burdett S., Stewart L., Auperin A., Pignon J.-P.. Chemotherapy in non-small-cell lung cancer: an update of an individual patient data meta-analysis. Journal of Clinical Oncology. 2005;23(4):924-925. www.epistemonikos.org/documents/be65bc215054d03902aa047ad59cc805c616c389

1778. Lipworth L, La Vecchia C, Bosetti C, McLaughlin JK, International Epidemiology Institute, Rockville, MD 20850, loren@iei.us. Occupational exposure to rock wool and glass wool and risk of cancers of the lung and the head and neck: a systematic review and meta-analysis. Journal of Occupational & Environmental Medicine. 2009;51(9):1075-1087. www.epistemonikos.org/documents/be6d72674065cba86068f59d85c367ecbd0bdc64

1779. Zheng T, Li D, He Z, Feng S, Zhao S. Prognostic and clinicopathological significance of Beclin-1 in non-small-cell lung cancer: a meta-analysis. OncoTargets and therapy. 2018;11:4167-4175. www.epistemonikos.org/documents/be7786b8f70ed716c2d38f87083288781711cf32

1780. Wang J, Liu Q, Yuan S, Xie W, Liu Y, Xiang Y, Wu N, Wu L, Ma X, Cai T, Zhang Y, Sun Z, Li Y. Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies. Scientific reports. 2017;7(1):8371.www.epistemonikos.org/documents/beb54170ad92e29a8302fbfed9ac19925d7228ae

1781. Luce S, Paesmans M, Berghmans T, Castaigne C, Sotiriou C, Vermylen P, Sculier JP. [Critical review of the randomized trials assessing the role of adjuvant thoracic irradiation and chemotherapy in the treatment of limited-stage small cell lung cancer]. Revue des maladies respiratoires. 1998;15(5):633-41.www.epistemonikos.org/documents/bec1def390b4ad3b533da60d73d7f51b22ebb0ca

1782. Zhou F., Wan J.-T., Tan X.-G., Chen Z.-L., He J.. Meta-analysis of the association between the polymorphism of Thr241Met in DNA damage repair gene XRCC3 and lung cancer susceptibility. Chinese Journal of Cancer Prevention and Treatment. 2011;18(3):161-164+172.www.epistemonikos.org/documents/becea5c158865674fb49ce4aff80599765a8cf85

1783. Fung MC, Sakata T, Ishiguro H, Adachi S. [Gemcitabine-based chemotherapy for non-small cell lung cancer (NSCLC)--a review of 30 randomized trials]. Gan to kagaku ryoho. Cancer & chemotherapy. 2002;29(9):1583-96. www.epistemonikos.org/documents/bee083ecea844a511f4587db437abeef1b683be5

1784. Xu T., Jin Z., Yuan Y., Wei H., Xu X., He S., Chen S., Hou W., Guo Q., Hua B.. Ginsenoside Rg3 Serves as an Adjuvant Chemotherapeutic Agent and VEGF Inhibitor in the Treatment of Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review. Evidence-based Complementary and Alternative Medicine. 2016;2016(no pagination):1-14. www.epistemonikos.org/documents/bf28402aace5cd6bbbf736605500b52bf5c3c0fe

1785. Shen G, Ma H, Liu B, Ren P, Kuang A. Diagnostic Performance of DWI With Multiple Parameters for Assessment and Characterization of Pulmonary Lesions: A Meta-Analysis. AJR. American journal of roentgenology. 2018;210(1):1-10. www.epistemonikos.org/documents/bf500f55c17ff15c5276db9bab468297e3ab3078

1786. Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis. Lung cancer (Amsterdam, Netherlands). 2018;123:76-82. www.epistemonikos.org/documents/bf555ab173b1e66ea02b043f3b85d99306415d07

1787. Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte JJ, Mascaux C, Meert AP, Roelandts M, Scherpereel A, Terrones Munoz V, Sculier JP, European Lung Cancer Working Party, and on behalf of the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010;5(5):612-9. www.epistemonikos.org/documents/bf6db2d0cfadea1f48f5dc78221ac42c2564c467

1788. Lou Y., Li R., Zhang X., Zhong R., Pei J., Xiong L., Han B.. XPA gene RS1800975 single nucleotide polymorphism and lung cancer risk: A metaanalysis. Journal of Thoracic Oncology. 2013;:S1291. www.epistemonikos.org/documents/bf763df60b76943db51534ddea1e60ebdcc21302

1789. Delmotte P, Martin B, Paesmans M, Berghmans T, Mascaux C, Meert AP, Steels E, Verdebout JM, Lafitte JJ, Sculier JP. [VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis]. Revue des maladies respiratoires. 2002;19(5 Pt 1):577-84.www.epistemonikos.org/documents/bf7ff9f552d961e938ebef5b72420eb3a27fc91e

1790. Kiss NK, Krishnasamy M, Isenring EA. The effect of nutrition intervention in lung cancer patients undergoing chemotherapy and/or radiotherapy: a systematic review. Nutrition and cancer. 2014;66(1):47-56. www.epistemonikos.org/documents/bf8194608f49186e123ef123213cd054b4d1cd7f

1791. Li W, Ma G, Wu Q, Deng Y, Liu Y, Wang J. Prognostic value of lymphocyte-to-monocyte ratio among Asian lung cancer patients: a systematic review and meta-analysis. Oncotarget. 2017;8(66):110606-110613. www.epistemonikos.org/documents/bf9c4479ea5bc71f87af6b371f2a1ee9aca553df

1792. Yan BD, Cong XF, Zhao SS, Ren M, Liu ZL, Li Z, Chen C, Yang L. Efficacy and safety of antigen-specific immunotherapy in the treatment of patients with non-small-cell lung cancer: a systematic review and meta-analysis. Current cancer drug targets. 2019;19(3):199-209.www.epistemonikos.org/documents/bfb5fcc3c5c4d92b058188b305a680151d181124

1793. Palma D.A., Senan S., Tsujino K., Barriger R.B., Rengan R., Moreno M., Bradley J.D., Hyun Kim T., Marks L.B., Rodrigues G.. Predicting symptomatic radiation pneumonitis after concurrent chemoradiotherapy for non-small cell lung cancer: Results of an international individual patient data meta-analysis. Journal of Thoracic Oncology. 2012;:S267.www.epistemonikos.org/documents/bfd9dd898c7c87aba4fc1681eb89ed98c87731cb

1794. Chen P, Wang L, Liu B, Zhang HZ, Liu HC, Zou Z. EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. European journal of clinical pharmacology. 2011;67(3):235-43. www.epistemonikos.org/documents/bff66b94ad6492476dc1faaba33a61bc9e8dccc4

1795. Lu H, Fang L, Wang X, Cai J, Mao W. A meta-analysis of randomized controlled trials comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/carboplatin chemotherapy for limited-disease small-cell lung cancer. Molecular and clinical oncology. 2014;2(5):805-810.www.epistemonikos.org/documents/c00534b5a2e62f3d9affba7bd42326a33493663c

1796. Xie F, Sun Q, Wu S, Xie X, Liu Z. Nucleotide excision repair gene ERCC1 19007T>C polymorphism contributes to lung cancer susceptibility: a meta-analysis. Genetic testing and molecular biomarkers. 2014;18(8):591-5. www.epistemonikos.org/documents/c057d71cba8c5e6f1a9957b75fb48ddbd9cee155

1797. Xia L., Yin Z., Li X., Ren Y., Zhang H., Zhao Y., Zhou B.. Genetic polymorphisms in pre-miRNAs predict the survival of non-small-cell lung cancer in Chinese population: A cohort study and a meta-analysis. Oncotarget. 2017;8(44):77963-77974. www.epistemonikos.org/documents/c05fcdf075a76e9e7eed4ae01cd1dc1baced22d0

1798. Dimou A, Non L, Chae YK, Tester WJ, Syrigos KN. MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis. PloS one. 2014;9(9):e107677. www.epistemonikos.org/documents/c075ec354b994c597b17c977616c61aa36bbb2d9

1799. Zu-Yao Yang, Li Liu, Chen Mao, Xin-Yin Wu, Ya-Fang Huang, Xue-Feng Hu, Jin-Ling Tang. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2014;11(11):CD009948.www.epistemonikos.org/documents/c07d6b1bda92492775e5ca5946371726c2d20a18

1800. Liang W., Zhang Y., Kang S., Pan H., Shao W., Deng Q., Shi X., Wang W., He J.. Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis. Journal of Thoracic Disease. 2014;6(9):1239-1250.www.epistemonikos.org/documents/c0a291754ac339ddfbf73393ea31f3f51bdd869c

1801. Li S, Lai Y, Fan J, Shen C, Che G. Clinicopathological and prognostic significance of Nestin expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. Clinical and experimental medicine. 2017;17(2):1-14. www.epistemonikos.org/documents/c0b208b59cf09c18360c96cd54a085544216bba5

1802. Zhang XJ, Sun JG, Sun J, Ming H, Wang XX, Wu L, Chen ZT. Prediction of radiation pneumonitis in lung cancer patients: a systematic review. Journal of cancer research and clinical oncology. 2012;138(12):2103-16. www.epistemonikos.org/documents/c10d765459adef82c329f66f39e2f86c01b641c6

1803. Liu H, Li HY, Chen HJ, Huang YJ, Zhang S, Wang J. EPHX1 A139G polymorphism and lung cancer risk: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(1):155-63. www.epistemonikos.org/documents/c1132a1b4e806f3e032390fcba6cfb2fed4ee0f7

1804. Frood R, Prestwich R, Tsoumpas C, Murray P, Franks K, Scarsbrook A. Effectiveness of Respiratory-gated Positron Emission Tomography/Computed Tomography for Radiotherapy Planning in Patients with Lung Carcinoma - A Systematic Review. Clinical oncology (Royal College of Radiologists (Great Britain)). 2018;30(4):225-232.www.epistemonikos.org/documents/c1389596109326b20967985c4d6bb812c60cb125

1805. Hu Y, Shen J, Liu R, Feng Z, Zhang C, Ling L, Chen L. Prognostic value of pretreatment prognostic nutritional index in non-small cell lung cancer: A systematic review and meta-analysis. The International journal of biological markers. 2018;33(4):1724600818799876.www.epistemonikos.org/documents/c145bf9c98db1626a4e56db246151e8253493dc9

1806. Zhang J.H., Wen Q.L., Yang C., Li A.L., Liu Y., Li X.S.. XRCC3 T241M polymorphism and lung cancer risk in the han Chinese population: A meta-analysis. Genetics and Molecular Research. 2014;13(4):9505-9513. www.epistemonikos.org/documents/c1471267874c32014108dda6c53d884c096a1031

1807. Gao G, Chu H, Zhao L, Gui T, Xu Q, Shi J. A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2012;76(3):380-6.www.epistemonikos.org/documents/c16297b0f499707c37e53c0f0597460aa802d2e1

1808. Li Q., Wu T., Jing L., Li M.-J., Tian T., Ruan Z.-P., Liang X., Nan K.-J., Liu Z.-Y., Yao Y., Guo H.. Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC): A meta-analysis of 7 randomized controlled trials. Medicine (United States). 2017;96(13):e6412.www.epistemonikos.org/documents/c172dd496d07aac522bd44ea3d60b8aadaba7fd7

1809. Korevaar DA, Crombag LM, Cohen JF, Spijker R, Bossuyt PM, Annema JT. Added value of combined endobronchial and oesophageal endosonography for mediastinal nodal staging in lung

cancer: a systematic review and meta-analysis. The Lancet. Respiratory medicine. 2016;4(12):960-968.www.epistemonikos.org/documents/c1833be123446bfa15746b78516295764f942882

1810. Okawara G, Ung YC, Markman BR, Mackay JA, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline. Lung cancer (Amsterdam, Netherlands). 2004;44(1):1-11. www.epistemonikos.org/documents/c18612c1b89126c5ee0d0ef4bc1a5ca1c9e7059d

1811. Wang XF, Zhu YT, Wang JJ, Zeng DX, Mu CY, Chen YB, Lei W, Zhu YH, Huang JA. The prognostic value of interleukin-17 in lung cancer: A systematic review with meta-analysis based on Chinese patients. PloS one. 2017;12(9):e0185168. www.epistemonikos.org/documents/c195349bf5fa18f1aa881d2219d5e4d727560ca5

1812. Li Q, Liu F, Zhang Y, Fu L, Wang C, Chen X, Guan S, Meng X. Association of SOX2 and Nestin DNA amplification and protein expression with clinical features and overall survival in non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget. 2016;7(23):34520-34531.www.epistemonikos.org/documents/c197c33569a880973752d767490368fb8faf2d8e

1813. Qi WX, Tang LN, He AN, Shen Z, Yao Y. The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials. Lung. 2011;189(6):437-43. www.epistemonikos.org/documents/c19bbae8884cfd2c2bfefe110a2a79008876a990

1814. Amir GJ, Lehmann HP. After Detection:: The Improved Accuracy of Lung Cancer Assessment Using Radiologic Computer-aided Diagnosis. Academic radiology. 2016;23(2):186-91. www.epistemonikos.org/documents/c1af143d7c8037b93eec5b80ee5a39a6576e8cc0

1815. Ito M, Horita N, Nagashima A, Kaneko T. Carboplatin plus pemetrexed for the elderly incurable chemo-naive nonsquamous non-small cell lung cancer: Meta-analysis. Asia-Pacific journal of clinical oncology. 2019;15(2):e3-e10. www.epistemonikos.org/documents/c1bd60b8b55b74cf17ec663f380551347aca98e3

1816. Paracha N, Abdulla A, MacGilchrist KS. Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients. Health and quality of life outcomes. 2018;16(1):179. www.epistemonikos.org/documents/c1efbc53586ae7d25a932f05b8f85654f7f55499

1817. Moon EK, Son M, Jin YW, Park S, Lee WJ. Variations of lung cancer risk from asbestos exposure: impact on estimation of population attributable fraction. Industrial health. 2013;51(1):128-33. www.epistemonikos.org/documents/c20d2b5a1388868b4f602df52772c786433d2b74

1818. Tong S, Qin Z, Wan M, Zhang L, Cui Y, Yao Y. Induction chemoradiotherapy versus induction chemotherapy for potentially resectable stage IIIA (N2) non-small cell lung cancer: a systematic review and meta-analysis. Journal of thoracic disease. 2018;10(4):2428-2436.www.epistemonikos.org/documents/c22fb66080cf12abfbf90605eab7f2b5195021d2

1819. Feng Q, Zhang H, Dong Z, Zhou Y, Ma J. Circulating 25-hydroxyvitamin D and lung cancer risk and survival: A dose-response meta-analysis of prospective cohort studies. Medicine. 2017;96(45):e8613. www.epistemonikos.org/documents/c23325b033c36acbc180d948468d388f78c7de22

1820. Chen Y.-Y., Wang L.-W., Wang S.-Y., Wu B.-B., Wang Z.-M., Chen F.-F., Xiong B.. Meta-analysis of postoperative adjuvant chemotherapy without radiotherapy in early stage non-small cell lung cancer. OncoTargets and Therapy. 2015;8:2033-2043. www.epistemonikos.org/documents/c237244710629c997b5a02c72bbc1aa0b2620aa3

1821. Bagia M., Houghton B., Brown C., Millward M., Boyer M., Stockler M.. Maintenance chemotherapy in extensive small cell lung cancer (ESCLC): A meta analysis of randomised trials. Asia-Pacific Journal of Clinical Oncology. 2010;:207. www.epistemonikos.org/documents/c27ea186ce841d84715f9d903da382767b4e23c7

1822. Luo X, Lamsal LP, Xu WJ, Lu J, Lu YJ, Shen Y, Guan Q. Genetic variant in CLPTM1L confers reduced risk of lung cancer: a replication study in Chinese and a meta-analysis. Asian Pacific

journal of cancer prevention : APJCP. 2014;15(21):9241-7. www.epistemonikos.org/documents/c296ba3c5bce2d59a4e49ca504add388c2ba7f1c

1823. Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax. 2002;57(1):20-8. www.epistemonikos.org/documents/c29e524a67dcc7af145d78c94c14ecaaf4992692

1824. Yao X, Gomes MM, Tsao MS, Allen CJ, Geddie W, Sekhon H. Fine-needle aspiration biopsy versus core-needle biopsy in diagnosing lung cancer: a systematic review. Current oncology (Toronto, Ont.). 2012;19(1):e16-27. www.epistemonikos.org/documents/c29e67c9962428a832c6bb98608faab9b0db99ab

1825. Zhong K., Chen W., Xiao N., Zhao J.. The clinicopathological significance and potential drug target of E-cadherin in NSCLC. Tumor Biology. 2015;36((Zhong K.; Xiao N.; Zhao J., jianzhaomd@yeah.net) Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China):6139-48.www.epistemonikos.org/documents/c2d44d82abe0e8cf0302b0b07597b8bd7bfe8a04

1826. Dong M, Liu J, Sun X, Xing L. Prognositc significance of SUVmax on pretreatment (18) F-FDG PET/CT in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy: A meta-analysis. Journal of medical imaging and radiation oncology. 2017;61(5):652-659.www.epistemonikos.org/documents/c2d565c19464288d3e61030d3869814a34095a7e

1827. Murray P, Franks K, Hanna GG. A systematic review of outcomes following Stereotactic Ablative Radiotherapy in the treatment of early stage primary lung cancer. The British journal of radiology. 2017;90(1071):20160732. www.epistemonikos.org/documents/c2f619e5f48f4bfc22aaf6cc21dd387dcf81c616

1828. Wo H, He J, Zhao Y, Yu H, Chen F, Yi H. The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials. Journal of Cancer. 2018;9(8):1455-1465. www.epistemonikos.org/documents/c322ce71430ab865fe3afaeac76478e97ae19317

1829. Sculier JP, Ghisdal L, Berghmans T, Branle F, Lafitte JJ, Vallot F, Meert AP, Lemaitre F, Steels E, Burniat A, Mascaux C, European Lung Cancer Working Party. The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature. British journal of cancer. 2001;84(9):1150-5.www.epistemonikos.org/documents/c34ef262f55932c5ddcbfc2bdf01291e31085987

1830. Wang J, Li G, Yu L, Mo T, Wu Q, Zhou Z. Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: a meta-analysis of 42 RCTs following the PRISMA guidelines. Journal of ethnopharmacology. 2018;221:137-150. www.epistemonikos.org/documents/c35f6ff61d5d13223db127406b7ed37213f400be

1831. Viani GA, Boin AC, Ikeda VY, Vianna BS, Silva RS, Santanella F. Thirty years of prophylactic cranial irradiation in patients with small cell lung cancer: a meta-analysis of randomized clinical trials. Jornal brasileiro de pneumologia : publicação oficial da Sociedade Brasileira de Pneumologia e Tisilogia. 2012;38(3):372-81.www.epistemonikos.org/documents/c37b2d95e9c0e2321d3066bbe8ea85b88e44eff1

1832. Ajrouche R, Ielsch G, Cléro E, Roudier C, Gay D, Guillevic J, Laurier D, Le Tertre A. Quantitative Health Risk Assessment of Indoor Radon: A Systematic Review. Radiation protection dosimetry. 2017;177(1-2):1-9. www.epistemonikos.org/documents/c3985f72f16933e7ffa0508c0fa5f27a625b06d9

1833. Lopes G., Tan P.S., Acharyya S., Bilger M., Haaland B.. Network meta-analysis comparing first-line therapies and maintenance regimens in EGFR mutated advanced non-small-cell lung cancer (NSCLC). Journal of Clinical Oncology. 2016; www.epistemonikos.org/documents/c3a0fd94676158f499182b822dd81bf2840121c0

1834. Billiet C., Decaluwe H., Peeters S., Vansteenkiste J., Dooms C., De Leyn P., De Ruysscher D.. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local

control and survival: A publication-based meta-analysis. Journal of Thoracic Oncology. 2013;:S834.www.epistemonikos.org/documents/c3b42649158ef25807f44a3e334bce9a1da3464b

1835. Jiang H, Shao W, Zhao W. VEGF-C in non-small cell lung cancer: meta-analysis. Clinica chimica acta; international journal of clinical chemistry. 2014;427C:94-99.www.epistemonikos.org/documents/c3bc6a874c5258327fed9252620f6f4b146bd5f8

1836. Aboshi M, Kaneko M, Narukawa M. Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer. Journal of cancer research and clinical oncology. 2014;140(5):839-48.www.epistemonikos.org/documents/c3f11dea4ab7048b07fa779b3aa83528980ce710

1837. Huang Q., Zhang H., Hai J., Socinski M.A., Lim E., Chen H., Stebbing J.. Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials. OncoImmunology. 2018;7(12):e1396403.www.epistemonikos.org/documents/c404183c1bf271d36244736d90d9c46bf0517bd2

1838. Peng S, Tong X, Liu S, Feng Y, Fan H. Association between the COMT 158 G/A polymorphism and lung cancer risk: a meta-analysis. International journal of clinical and experimental medicine. 2015;8(10):17739-47. www.epistemonikos.org/documents/c457fe0e760eea955de8b5818d85e214e9f0ecc4

1839. Hu F, Mao X, Zhang Y, Zheng X, Gu P, Wang H, Zhang X. Reliability of using circulating tumor cells for detecting epidermal growth factor receptor mutation status in advanced non-small-cell lung cancer patients: a meta-analysis and systematic review. OncoTargets and therapy. 2018;11:1373-1384.www.epistemonikos.org/documents/c48f961e620aa119e23d9d667bb1d91879539450

1840. Huang J, Wang K, Xu J, Huang J, Zhang T. Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis. PloS one. 2013;8(11):e78070. www.epistemonikos.org/documents/c49f5119b6bc56e771161e2303aea99c3cc895da

1841. Xue X.-J., Gao Q., Qiao J.-H., Zhang J., Xu C.-P., Liu J.. Red and processed meat consumption and the risk of lung cancer: A dose-response meta-analysis of 33 published studies. International Journal of Clinical and Experimental Medicine. 2014;7(6):1542-1553.www.epistemonikos.org/documents/c49f887f52526f3690928dbe9a2f464e8c458a2c

1842. Horita N, Nagashima A, Nakashima K, Shibata Y, Ito K, Goto A, Yamanaka T, Kaneko T. The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis. Scientific reports. 2017;7(1):13185. www.epistemonikos.org/documents/c4c4fa5cda1318ee28028d6ecfe947b45cf6fc24

1843. Di BS, Wei KP, Tian JH, Xiao XJ, Li Y, Zhang XH, Yu Q, Yang KH, Ge L, Huang WH, Zhang FW. Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced non-small cell lung cancer: a systematic review and meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2014;15(8):3419-24.www.epistemonikos.org/documents/c4c651f16e488da1e09f9e91bc7fb64e8f06fd84

1844. Zhou H, Zeng C, Wang LY, Xie H, Zhou J, Diao P, Yao WX, Zhao X, Wei Y. Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of 6,844 patients. Chinese medical journal. 2013;126(17):3348-55. www.epistemonikos.org/documents/c5582a709e1fb42712c95f75d2dc0d831138e2a4

1845. Yuan Z, Zeng X, Yang D, Wang W, Liu Z. Effects of Common Polymorphism rs11614913 in Hsa-miR-196a2 on Lung Cancer Risk. PloS one. 2013;8(4):e61047.www.epistemonikos.org/documents/c5721a446bac25b96d8a4ecb0fb742cd7ec1730f

1846. Wang T, Zhou C, Zhou Q. Extent of Visceral Pleural Invasion Affects Prognosis of Resected Non-small Cell Lung Cancer: A meta-analysis. Scientific reports.

2017;7(1):1527.www.epistemonikos.org/documents/c57b5094a4199a42252555ac0cc3de4cb8d3cb0c

1847. Rhea DJ, Lockwood S. Adults surviving lung cancer two or more years: A systematic review. JBI library of systematic reviews. 2012;10(34):2297-2349.www.epistemonikos.org/documents/c5d2d3697347d726a0dad413e6d962ee5eade8f7

1848. Ferrone M, Motl SE. Trastuzumab for the treatment of non-small-cell lung cancer. The Annals of pharmacotherapy. 2003;37(12):1904-8.www.epistemonikos.org/documents/c601a8ecd8467f7ee1c5d827953c3b4c6b99e10c

1849. Han Y, Liu J, Sun M, Zhang Z, Liu C, Sun Y. A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis. Disease markers. 2016;2016(no pagination):7643981.www.epistemonikos.org/documents/c60fb3d354f34e75f1dc5c5d91737a4816c2cece

1850. Liu K, Bao C, Yao N, Miao C, Varlotto J, Sun Q, Sun X. Expression of CXCR4 and non-small cell lung cancer prognosis: a meta-analysis. International journal of clinical and experimental medicine. 2015;8(5):7435-45. www.epistemonikos.org/documents/c63bd659239a1c91de802618786bbae42b970bd0

1851. Adams K, Shah PL, Edmonds L, Lim E. Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patients with lung cancer: systematic review and meta-analysis. Thorax. 2009;64(9):757-62. www.epistemonikos.org/documents/c63d86ffd73bf159ea41a431f5edadef958002ba

1852. Zhong A, Xiong X, Shi M, Xu H. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis. Drug design, development and therapy. 2015;9:3685-93.www.epistemonikos.org/documents/c679a900cff742442557be46b7a7969d9086dd0d

1853. O'Rourke N, Roqué I Figuls M, Farré Bernadó N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane database of systematic reviews (Online). 2010;(6):CD002140. www.epistemonikos.org/documents/c6874f09d99f5438db036799344785789e37d905

1854. Han S., Hong Y., Liu T., Wu N., Ye Z.. The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: A systematic review and meta-analysis. Oncotarget. 2018;9(18):14619-14629. www.epistemonikos.org/documents/c68d691a0668d6b804b0dd3fcb308b75f45eda06

1855. Ying HQ, Chen J, He BS, Pan YQ, Wang F, Deng QW, Sun HL, Liu X, Wang SK. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy. Scientific reports. 2015;5:11348. www.epistemonikos.org/documents/c6943d0ced7d416fd0884c80df5be0150cf046c4

1856. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest. 1994;106(3):861-5. www.epistemonikos.org/documents/c69f43b46994eaad33971b99c3bb7af7d71ec008

1857. Yao HY, Shi LY. [Meta-analysis of the risk factors on lung cancer in Chinese people]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2003;24(1):45-9.www.epistemonikos.org/documents/c6c8ddacc77d3e679b0923ecfa4c3c9c5ad9edef

1858. Xiong W.-M., Xu Q.-P., Li X., Xiao R.-D., Cai L., He F.. The association between human papillomavirus infection and lung cancer: A system review and meta-analysis. Oncotarget. 2017;8(56):96419-96432. www.epistemonikos.org/documents/c6f26729613b893c199caaca26c703e90b1f8279

1859. Kim JH, Kim HS, Kim BJ. Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis. Journal of Cancer. 2018;9(10):1836-1845.www.epistemonikos.org/documents/c71d1c1000e26149ec7cd456bd58caca3e8e4f90

1860. Xu TP, Shen H, Liu LX, Shu YQ. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. Gene. 2013;526(2):265-74.www.epistemonikos.org/documents/c756a93aee7cadd997c507a5590b53e7fdfa50e6

1861. Tian W, Ding W, Kim S, Zheng L, Zhang L, Li X, Gu J, Zhang L, Pan M, Chen S. Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis. PloS one. 2013;8(7):e67929. www.epistemonikos.org/documents/c77bd5ba4d5bb2d6d3c43305a21745c10e7e23f3

1862. Wu Y, Liu HB, Ding M, Liu JN, Zhan P, Fu XS, Lu G. The impact of E-cadherin expression on non-small cell lung cancer survival: a meta-analysis. Molecular biology reports. 2012;39(10):9621-8. www.epistemonikos.org/documents/c796822f55aab95a669861a6b1cae03ebd95aa70

1863. Taylor R, Cumming R, Woodward A, Black M. Passive smoking and lung cancer: a cumulative meta-analysis. Australian and New Zealand journal of public health. 2001;25(3):203-11. www.epistemonikos.org/documents/c7a13c7c7615ca8e234d6d92887de77cd15dd2c4

1864. Roviello, Giandomenico, Bachelot, Thomas, Hudis, Clifford A., Curigliano, Giuseppe, Reynolds, Andrew R., Petrioli, Roberto, Generali, Daniele. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. European Journal of Cancer. 2017;75:245-258.www.epistemonikos.org/documents/c7a888c391c009530a366b5a043c731f4c28a9af

1865. Humphrey L, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, Zakher B, Fu R, Slatore C. Screening for Lung Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. 2013;www.epistemonikos.org/documents/c7ade02816e8ff34948cab6d6c68d6a1012b057b

1866. Dedong C, Huilin X, Anbing H, Ximing X, Wei G. The Effect of ShenQi FuZheng Injection in Combination with Chemotherapy versus Chemotherapy Alone on the Improvement of Efficacy and Immune Function in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. PloS one. 2016;11(3):e0152270.www.epistemonikos.org/documents/c7af2eaec1a876136b5e7bbae572c60fd8513434

1867. Chen Y, Peng X, Zhou Y, Xia K, Zhuang W. Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis. World journal of surgical oncology. 2018;16(1):8. www.epistemonikos.org/documents/c7bc5fbc7794aa0f3cb3c14ed21edeb6d4c03394

1868. Xue XJ, Gao Q, Qiao JH, Zhang J, Xu CP, Liu J. Red and processed meat consumption and the risk of lung cancer: a dose-response meta-analysis of 33 published studies. International journal of clinical and experimental medicine. 2014;7(6):1542-53. www.epistemonikos.org/documents/c7bf603e59a8b71c4b21fd098d8b880241eaba86

1869. Dales RE, Stark RM, Raman S. Computed tomography to stage lung cancer. Approaching a controversy using meta-analysis. The American review of respiratory disease. 1990;141(5 Pt 1):1096-101. www.epistemonikos.org/documents/c800d62a1b519607acfd01e7bf36747b032514fb

1870. Queirolo P, Spagnolo F. Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. Cancer treatment reviews. 2017;59:71-78. www.epistemonikos.org/documents/c80707cce4248186644e683e2286fa73c0d5fc5c

1871. Sebastian M, Schmittel A, Reck M. First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology. European respiratory review : an official journal of the European Respiratory Society. 2014;23(131):92-105. www.epistemonikos.org/documents/c81c3dc52a80ccbb2e81571dc21db6dc3cb404e8

1872. Passiglia F, Rizzo S, Maio MD, Galvano A, Badalamenti G, Listì A, Gulotta L, Castiglia M, Bazan V, Russo A, Fulfaro F. The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. Scientific reports.

2018;8(1):13379.www.epistemonikos.org/documents/c82da7f52904df1e91bd53ad2612d184b787c621

1873. Liang W, Wu X, Fang W, Zhao Y, Yang Y, Hu Z, Xue C, Zhang J, Zhang J, Ma Y, Zhou T, Yan Y, Hou X, Qin T, Dinglin X, Tian Y, Huang P, Huang Y, Zhao H, Zhang L. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PloS one. 2014;9(2):e85245.www.epistemonikos.org/documents/c8a79fbb843ef86e09d42006aa00f61d06bf651b

1874. SHI Hong-ping, HOU Yang-shao, ZHANG Qiu-ning. Zoledronic acid combined with chemotherapy for non-small cell lung cancer with bone metastasis: a meta-analysis. 实用肿瘤杂志 (Journal of Practical Oncology). 2014;29(1):55-61. www.epistemonikos.org/documents/c8ccc0e0658047970497918b4618f171e16141f1

1875. Wang X, Cao H. A meta-analysis of comprehensive care on quality of life in patients with lung cancer. Journal of cancer research and therapeutics. 2015;11 Suppl 1(5):C112-4. www.epistemonikos.org/documents/c8d6f22beec244f6533856c023969938f1677332

1876. Liu ZL, Zhu WR, Zhou WC, Ying HF, Zheng L, Guo YB, Chen JX, Shen XH. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis. Journal of integrative medicine. 2014;12(4):346-58.www.epistemonikos.org/documents/c907e7679b8428bb3f2b2565d00d9a138b359495

1877. Li B.T., Hasovits C., Lee A., Li A.E., Khasraw M., Marx G., Pavlakis N.. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for advanced non-small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials. Journal of Thoracic Oncology. 2013;:S608.www.epistemonikos.org/documents/c92b6604a56356d427f4ceabf1cc6a35a9bd16ab

1878. Ge W, Cao DD, Wang HM, Jie FF, Zheng YF, Chen Y. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2011;12(11):2901-7. www.epistemonikos.org/documents/c93e8aa6833841d89f0fb3d179b2ed43ec8ad87d

1879. Dahabreh I.J., Paulus J.K.. Parity and risk of lung cancer in women: Systematic review and meta-analysis of epidemiological studies. American Journal of Epidemiology. 2011;:S90. www.epistemonikos.org/documents/c93f455ea3e7f7f685aadd81a790cc9991430846

1880. Zhang Y, Yin Z, Shen L, Wan Y, Zhou B. Menstrual factors, reproductive factors and lung cancer risk: a meta-analysis. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2012;15(12):701-19. www.epistemonikos.org/documents/c954217427d72b90f297f4d2470ed1d687e1c8f7

1881. Wang Q, Huang H, Zeng X, Ma Y, Zhao X, Huang M. Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials. PeerJ. 2016;4(10):e2550. www.epistemonikos.org/documents/c9546a958d8726882fa1390a2abdbc28d7ad1fd8

1882. Qi WX, Shen Z, Yao Y. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer. Cancer chemotherapy and pharmacology. 2012;69(1):99-106. www.epistemonikos.org/documents/c95c174bb4b88b92c5f9c8b070b9fe523629aca2

1883. Wang H, Huang J, Yu X, Han S, Yan X, Sun S, Zhu X. Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis. Journal of cancer research and clinical oncology. 2014;140(11):1901-9.www.epistemonikos.org/documents/c96ccce2fbd34b608686374f24e2d8336df4753b

1884. Bao F, Ye P, Yang Y, Wang L, Zhang C, Lv X, Hu J. Segmentectomy or lobectomy for early stage lung cancer: a meta-analysis. European journal of cardio-thoracic surgery : official journal of

the European Association for Cardio-thoracic Surgery. 2014;46(1):1-7. www.epistemonikos.org/documents/c9730bcc56c21f2702191d5ff1fb3359b9a23617

1885. Vidal Serrano S, Llanos Méndez A. [CT screening for lung cancer; sistematic review]. Medicina clínica. 2007;129(15):582-7.www.epistemonikos.org/documents/c973688a529a309784c16a48e560b5aa8a6f561f

1886. Tsoi CT, Tse LA. Professional drivers and lung cancer: a systematic review and meta-analysis. Occupational and environmental medicine. 2012;69(11):831-6.www.epistemonikos.org/documents/c99655f8c008828f4a410fad06bcf207c45b4d8c

1887. Qi W., Yao Y., Shen Z., He A., Lin F.. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: A systematic review and meta-analysis. Annals of Oncology. 2012;:ix398. www.epistemonikos.org/documents/c9b3dddcbec0af1ac18effce68481d6a36e314a2

1888. Wu D., Duan C., Wu F., Chen L., Chen S.. Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy. Oncotarget. 2017;8(39):66491-66503.www.epistemonikos.org/documents/c9cb38462f9718216e059f9e40629e53faebaef4

1889. Abdel-Rahman O., Elhalawani H.. S-1-based regimens for locally advanced/metastatic non-small-cell lung cancer: A meta-analysis. Future Oncology. 2016;12(5):701-713.www.epistemonikos.org/documents/c9e1b995326fed2c5115eb127fab5480229e47f3

1890. Calman L, Beaver K, Hind D, Lorigan P, Roberts C, Lloyd-Jones M. Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011;6(12):1993-2004.www.epistemonikos.org/documents/c9e1ec8148408e53c2137535d062f7af3c9683b2

1891. Leuzzi G, Galeone C, Gisabella M, Duranti L, Taverna F, Suatoni P, Morelli D, Pastorino U. Baseline C-reactive protein level predicts survival of early-stage lung cancer: evidence from a systematic review and meta-analysis. Tumori. 2016;102(5):0. www.epistemonikos.org/documents/ca009387361710d0fc3c8560e4f090824f619ad2

1892. Benhamou S., Lee W.J., Alexandrie A.-K., Boffetta P., Bouchardy C., Butkiewicz D., Brockmoller J., Clapper M.L., Daly A., Dolzan V., Ford J., Gaspari L., Haugen A., Hirvonen A., Husgafvel-Pursiainen K., Ingelman-Sundberg M., Kalina I., Kihara M., Kremers P., Le Marchand L., London S.J., Nazar-Stewart V., Onon-Kihara M., Rannug A., Romkes M., Ryberg D., Seidegard J., Shields P., Strange R.C., Stucker I., To-Figueras J., Brennan P., Taioli E.. Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis. 2002;23(8):1343-1350.www.epistemonikos.org/documents/ca40c1958c3803d37bef191adf0c827d9ee5b8fa

1893. Han H, Zhao Y, Chen H. Selective versus systematic lymph node dissection (other than sampling) for clinical N2-negative non-small cell lung cancer: a meta-analysis of observational studies. Journal of thoracic disease. 2018;10(6):3428-3435. www.epistemonikos.org/documents/ca68fef9bdc89c5af4c03fbc95628bdd2caabaea

1894. La Salvia, Anna, Rossi, Antonio, Galetta, Domenico, Gobbini, Elisa, De Luca, Emmanuele, Novello, Silvia, Di Maio, Massimo. Intercalated Chemotherapy and Epidermal Growth Factor Receptor Inhibitors for Patients With Advanced Non-Small-cell Lung Cancer: A Systematic Review and Meta-analysis. Clinical Lung Cancer. 2017;18(1):23-33.www.epistemonikos.org/documents/ca6e66d6dc48cbe253814971d59bfcb0d91b5780

1895. Ding H., Wang Y., Jiang H., Zhang S., Liu C., Tang W.. Association between the cyclooxygenase-2 rs5275T>C polymorphism and lung cancer susceptibility: A meta-analysis involving 11,682 subjects. International Journal of Clinical and Experimental Medicine. 2016;9(3):5584-5592.www.epistemonikos.org/documents/caa2129dade84f9772b8376ca42441aaa961ae2b

1896. Rosell R, Moreno I, Maestre J, Olazabal A, Carles J, Barnadas A, Abad-Esteve A, Ribelles N, Canela M. Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced nonsmall-cell lung cancer: a meta-analytic review. Journal of surgical oncology. 1990;45(2):124-30.www.epistemonikos.org/documents/caa63dc750426ae7df78eb042399a231c2b64065

1897. Wei W, He XF, Qin JB, Su J, Li SX, Liu Y, Zhang Y, Wang W. Association between the OGG1 Ser326Cys and APEX1 Asp148Glu polymorphisms and lung cancer risk: a meta-analysis. Molecular biology reports. 2012;39(12):11249-62. www.epistemonikos.org/documents/cad0188d65abd6a50a5eae14b9346be5ec83c963

1898. Shi CL, Li R, Xiong LW, Gu AQ, Han BH, Gu W. Lack of association between XRCC3 rs861539 (C > T) polymorphism and lung cancer risks: an update meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(3):1819-24.www.epistemonikos.org/documents/cae160c2f2ed49c7d7a20392a508a656d11d5a26

1899. Zhan M., Liu X., Lu J., Xu T.. Erlotinib for elderly patients with non-small-cell lung cancer: A systematic review. Chinese Journal of Evidence-Based Medicine. 2013;13(9):1084-1089. www.epistemonikos.org/documents/cae8ce9d2731b571c82195abbcf38fe3d627ac72

1900. Chen H, Laba JM, Boldt RG, Goodman CD, Palma DA, Senan S, Louie AV. Stereotactic Ablative Radiation Therapy Versus Surgery in Early Lung Cancer: A Meta-analysis of Propensity Score Studies. International journal of radiation oncology, biology, physics. 2018;101(1):186-194.www.epistemonikos.org/documents/cbb45184dc303d07646cc792617d515f24e8888f

1901. Yue A., Guo Y.-L., Wang G.-X., Zhang Y.-J., Sun T.-L., Zhang S.-F., Wang Z.. Astragalus-based Chinese traditional medicine combined with chemotherapy for non-small-cell lung cancer treatment: Meta-analysis of randomized trials. International Journal of Clinical and Experimental Medicine. 2016;9(11):20542-20551.www.epistemonikos.org/documents/cbda3186d5eae7d9f34f36feee69659ef6836765

1902. Humphrey LL. Lung cancer screening: an update for the U.S. Preventive Services Task Force [Systematic evidence review no 31]. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. 2007; www.epistemonikos.org/documents/cbeee455310ec0d105780166280a81c4233cf258

1903. Zhao J, Wang H, Hu W, Jin Y. Effect of HLA-B-associated transcript 3 polymorphisms on lung cancer risk: a meta-analysis. Medical science monitor : international medical journal of experimental and clinical research. 2014;20((Zhao J.; Wang H., wanghongyuan012345@126.com; Hu W.; Jin Y.) Respiratory Department, The Sixth Affiliated Hospital of Wenzhou Medical University, Peoplenulls Hospital, Lishui City, Zhejiang, China):2461-5.www.epistemonikos.org/documents/cbf78d9dcf7fb004873a6e7c14418387660db8fe

1904. Zhou C., Liu D., Li J., Zheng X., Wang S., Hong G., Mallampati S., Sun H., Zhou X., Cheng Z., Zhang H., Ma H.. Chemotherapy plus dendritic cells co-cultured with cytokine-induced killer cells versus chemotherapy alone to treat advanced non-small-cell lung cancer: A meta-analysis. Oncotarget. 2016;7(52):86500-86510.www.epistemonikos.org/documents/cbfd069b35b26be063287e66e1a0dfa12239d3ee

1905. Hu P, Liu W, Wang L, Yang M, Du J. High circulating VEGF level predicts poor overall survival in lung cancer. Journal of cancer research and clinical oncology. 2013;139(7):1157-67. www.epistemonikos.org/documents/cc241be596ffb100b6e9750cebf3cf82a061022f

1906. O'Bryant CL, Wenger SD, Kim M, Thompson LA. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. The Annals of pharmacotherapy. 2013;47(2):189-97. www.epistemonikos.org/documents/cc2e7fe5375e84bab9fde1d2e9c580da0613f519

1907. Qiu M, Xu L, Yang X, Ding X, Hu J, Jiang F, Xu L, Yin R. XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer. PloS one. 2013;8(10):e77005. www.epistemonikos.org/documents/cc3fd9db0a7b8c82872362c943df325866eaf01d

1908. Henshall CL, Allin L, Aveyard H. A Systematic Review and Narrative Synthesis to Explore the Effectiveness of Exercise-Based Interventions in Improving Fatigue, Dyspnea, and Depression in Lung Cancer Survivors. Cancer nursing. 2019;42(4):295-306. www.epistemonikos.org/documents/cc828844c70c4e9c6d9028902b41d0b9314a6730

1909. Vieira AR, Abar L, Vingeliene S, Chan DS, Aune D, Navarro-Rosenblatt D, Stevens C, Greenwood D, Norat T. Fruits, vegetables and lung cancer risk: a systematic review and meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2016;27(1):81-96.www.epistemonikos.org/documents/cc89f8db4b6ab94bc141bddc2f4d2b38052d4e24

1910. Zou S, Pan X, Hua C, Wu M, He B, Chen Z. Myeloperoxidase -463 G/A polymorphism is associated with lung cancer risk: A meta-analysis with 7420 cases and 9132 controls. Journal of cancer research and therapeutics. 2018;14(Supplement):S282-S287. www.epistemonikos.org/documents/cc9d58a92a89142ce40d13271374a087c279aee1

1911. Wang Z, Wang Y, Zhang X, Zhang T. Pretreatment prognostic nutritional index as a prognostic factor in lung cancer: Review and meta-analysis. Clinica chimica acta; international journal of clinical chemistry. 2018;486:303-310. www.epistemonikos.org/documents/cca581c5e2e3b1cc92cd527083aa03d0c2b42b61

1912. Zikos E, Ghislain I, Coens C, Ediebah DE, Sloan E, Quinten C, Koller M, van Meerbeeck JP, Flechtner HH, Stupp R, Pallis A, Czimbalmos A, Sprangers MA, Bottomley A. Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials. The lancet oncology. 2014;15(2):e78-89. www.epistemonikos.org/documents/ccd15b78df9d3a06382e2420c82fc17e7e219f31

1913. Li R., Wang R., Tang J.-H., Luo Q., An M.-M., Cai Y., Liang B.-B., Zhang G.-Y., Long L.-Y., Chen L.-A.. Paclitaxel for small cell lung cancer: A systematic review. Chinese Journal of Evidence-Based Medicine. 2008;8(10):851-860. www.epistemonikos.org/documents/cce3bf9069cbb5230f624632e7cafe5fb6529546

1914. Malik S.S., Masood N., Baig M., Yasmin A.. The association of GSTM1 and GSTT1 deletion polymorphisms with lung cancer risk: Evidence from an updated meta-analysis. Meta Gene. 2017;11:111-116. www.epistemonikos.org/documents/cce9df516124cc1ff66a8a36b926ad07a884412f

1915. Ali MS, Trick W, Mba BI, Mohananey D, Sethi J, Musani AI. Radial endobronchial ultrasound for the diagnosis of peripheral pulmonary lesions: A systematic review and meta-analysis. Respirology (Carlton, Vic.). 2017;22(3):443-453. www.epistemonikos.org/documents/ccecaf3685403d68e4cc0d21aee921e7b48c0d69

1916. Olsson JK, Schultz EM, Gould MK. Timeliness of care in patients with lung cancer: a systematic review. Thorax. 2009;64(9):749-56.www.epistemonikos.org/documents/ccfb9f94b2a0ae094a01b01c68ec9daf688aade7

1917. Tang N, Wu Y, Zhou B, Wang B, Yu R. Green tea, black tea consumption and risk of lung cancer: a meta-analysis. Lung cancer (Amsterdam, Netherlands). 2009;65(3):274-83. www.epistemonikos.org/documents/cd2b757ba1437739f1508ab701a74a2822a827fa

1918. Barlési F, Pujol JL. Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials. Lung cancer (Amsterdam, Netherlands). 2005;49(3):289-98. www.epistemonikos.org/documents/cd3989a6a029966bdece3affa213f882003c20ca

1919. Dong J, Su SY, Wang MY, Zhan Z. Shenqi fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review. Journal of experimental & clinical cancer research : CR. 2010;29(1):137.www.epistemonikos.org/documents/cd624ef99d5f5f59231e8b919228addc4fab6cb3

1920. Li S, Wang Z, Huang J, Fan J, Du H, Liu L, Che G. Systematic review of prognostic roles of body mass index for patients undergoing lung cancer surgery: does the 'obesity paradox' really exist?. European journal of cardio-thoracic surgery : official journal of the European Association for

Cardio-thoracic Surgery. 2017;51(5):817-828.www.epistemonikos.org/documents/cd8465cf8b399214fa8cde613fa505cc56a9ffd5

1921. Qingyuan Huang, Jinhui Li, Yihua Sun, Rui Wang, Xinghua Cheng, Haiquan Chen. Efficacy of EGFR Tyrosine Kinase Inhibitors in the Adjuvant Treatment for Operable Non-small Cell Lung Cancer by a Meta-Analysis. CHEST. 2016;149(6):1384-1392. www.epistemonikos.org/documents/cd8e118562b5f3b9c69fe65e5c92eb2022ca8cc7

1922. Wang X, Yue K, Hao L. Meta-analysis of methylenetetrahydrofolate reductase polymorphism and lung cancer risk in Chinese. International journal of clinical and experimental medicine. 2015;8(1):1521-5. www.epistemonikos.org/documents/cd9c8c25d849aa1ecd7861709448cd8340a66dfb

1923. Palma D.A., Senan S., Oberije C., Belderbos J., Rodriguez De Dios N., Jeffrey B., Barriger R., Moreno M., Kim T., Rodrigues G.. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: An individual patient data meta-analysis of >1000 patients. International Journal of Radiation Oncology Biology Physics. 2013;:S3-S4.www.epistemonikos.org/documents/cda7375e22838ddd2768f4a695f8c262b9ad1972

1924. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(19):3852-9.www.epistemonikos.org/documents/cdb922ace7a3e6746894562c458477ca7333309a

1925. Gao G, Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q. A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2009;65(3):339-44. www.epistemonikos.org/documents/cde3d2396037d6bb830979a94ee99e150d417d41

1926. Hou XH, Huang YM, Mi YY. Methylenetetrahydrofolate reductase gene C677T polymorphism and lung cancer: an updated meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2012;13(5):2025-9. www.epistemonikos.org/documents/cde7658828c4e4aa6cd41ed270c7030da854f720

1927. Su Q, Sun Z, Zhang C, Hou Y, Cao B. PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients, after first-line treatment option: systems assessment. Oncotarget. 2017;8(35):59677-59689. www.epistemonikos.org/documents/ce17e9e245e30a45fff291f936c2564aebadedc1

1928. Chen HY, Li SG, Cho WC, Zhang ZJ. The role of acupoint stimulation as an adjunct therapy for lung cancer: a systematic review and meta-analysis. BMC complementary and alternative medicine. 2013;13(1):362. www.epistemonikos.org/documents/ce4a7301b5c753625c648f4a6edd2340d08ca662

1929. Zhan P., Zhu Q.-Q., Miu Y.-Y., Liu Y.-F., Wang X.-X., Zhou Z.-J., Jin J.-J., Li Q., Sasada S., Izumo T., Tu C.-Y., Cheng W.-C., Evison M., Lv T.-F., Song Y.. Comparison between endobronchial ultrasound-guided transbronchial biopsy and CT-guided transthoracic lung biopsy for the diagnosis of peripheral lung cancer: A systematic review and meta-analysis. Translational Lung Cancer Research. 2017;6(1):23-34. www.epistemonikos.org/documents/ce56e8065455476edb741dfceb4a0174439062c1

1930. Yang YL, Luo XP, Xian L. The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis. PloS one. 2014;9(4):e93997. www.epistemonikos.org/documents/ce60c909f3b987543576a8ae56f3ff6bddcd65ac

1931. Yang Z., Li F.. O-6-methylguanine-DNA methyltransferase gene promoter methylation and lung cancer risk: A meta-Analysis. Journal of Cancer Research and Therapeutics. 2016;12(8):C233-C236. www.epistemonikos.org/documents/ce81cb5cdd0534fdd8dd42ddeec30182ec9b4674

1932. Jiang HY, Huang TB, Xu L, Yu J, Wu Y, Geng J, Yao XD. Aspirin use and lung cancer risk: a possible relationship? Evidence from an updated meta-analysis. PloS one. 2015;10(4):e0122962. www.epistemonikos.org/documents/cec39af691470dc59049e8a2777e324c265e1e36

1933. Liang HY, Li XL, Yu XS, Guan P, Yin ZH, He QC, Zhou BS. Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systematic review. International journal of cancer. Journal international du cancer. 2009;125(12):2936-44. www.epistemonikos.org/documents/ced4121a1c7eacabfb4dab0688601231cbedda0f

1934. Mamtani, Ravinder, Cheema, Sohaila, Sheikh, Javaid, Al Mulla, Ahmad, Lowenfels, Albert, Maisonneuve, Patrick. Cancer risk in waterpipe smokers: A meta-analysis. International Journal of Public Health. 2017;62(1):73-83. www.epistemonikos.org/documents/ceef0f99f299b4a5e52b69aac096ded900ea830a

1935. Xu X., Hua H., Fan B., Sun Q., Guo X., Zhang J.. EPHX1 rs2234922 polymorphism and lung cancer susceptibility in Asian populations: a meta-analysis. Journal of Thoracic Disease. 2015;7(7):1125-1129. www.epistemonikos.org/documents/cf34607c1c0c3c498064fdaa723bc6a57b6612af

1936. Fang N, Gu J, Wei H, You J, Zhou Q. [A meta-analysis of Association between MGMT gene promoter methylation and non-small cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2014;17(8):601-5. www.epistemonikos.org/documents/cf48daa2fb6fdd8844fc2926613ce0541bcaccfb

1937. Tang JH, Zhang XL, Zhang ZH, Wang R, Zhang HM, Zhang ZL, Wang JH, Ren WD. Diagnostic value of tumor marker pro-gastrin-releasing peptide in patients with small cell lung cancer: a systematic review. Chinese medical journal. 2011;124(10):1563-8. www.epistemonikos.org/documents/cf710ccff0deb13bc719f21a56bbdbbbffac1f99

1938. Ameratunga M, Pavlakis N, Gebski V, Broad A, Khasraw M. Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis. Asia-Pacific journal of clinical oncology. 2014;10(3):273-8. www.epistemonikos.org/documents/cf846eae43f789c1d8d2977fe6bd6962786c9fd6

1939. Liu WJ, Tan XH, Guo BP, Ke Q, Sun J, Cen H. Associations between RASSF1A promoter methylation and NSCLC: a meta-analysis of published data. Asian Pacific journal of cancer prevention : APJCP. 2013;14(6):3719-24. www.epistemonikos.org/documents/cfc9abdf2b0a49e4edd6f405dd41c8c990e91cf9

1940. Ren W.-W., Mi D.-H., Li Z., Tian J.-H., Yang K.-H., Zhang Z.-G.. Docetaxel or Pacfitaxe plus Cisplatin chemotherapy with concurrent radiotherapy versus sequential radiotherapy for non-small cell lung cancer: A Meta analysis. Chinese Journal of Cancer Prevention and Treatment. 2013;20(5):377-382.www.epistemonikos.org/documents/cfeb6364ca730d767bfa63cd9398c5adb74dcc9c

1941. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Annals of internal medicine. 1996;125(9):723-9. www.epistemonikos.org/documents/cff0406c5a68d1ffc3ed9687f0fd4c2388fcbf61

1942. Piñeiro B, Simmons VN, Palmer AM, Correa JB, Brandon TH. Smoking cessation interventions within the context of Low-Dose Computed Tomography lung cancer screening: A systematic review. Lung cancer (Amsterdam, Netherlands). 2016;98:91-8. www.epistemonikos.org/documents/cff45868c0b472ddce2e0606d093f4721aef974e

1943. Paesmans M., Wong C.-Y.O., Patz E.F., Komaki R., Eschmann S., Govindan R., Vansteenkiste J., Meert A.-P., De Jong W., Higashi K., Borst G., Van Baardwijk A., Ameye L., Lafitte J.-J., Berghmans T., Garcia C., Flamen P., Porta R.R., Sculier J.-P.. Is primary tumour standardized uptake value (SUV) an independent prognostic factor for non small cell lung cancer (NSCLC)? A meta-analysis based on individual data. European Respiratory Journal. 2011;www.epistemonikos.org/documents/d0034d48699b839632ed194852d2105a7f90ed74

1944. Jiao F, Xu D, Li Q, Liu G, Liu H, Ren T. Lack of association between -174G>C and -634C>G polymorphisms in interleukin-6 promoter region and lung cancer risk: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(5):5021-7.www.epistemonikos.org/documents/d01d742a48c46f822df6366f7a401fc49ee187ec

1945. Käsmann L, Niyazi M, Blanck O, Baues C, Baumann R, Dobiasch S, Eze C, Fleischmann D, Gauer T, Giordano FA, Goy Y, Hausmann J, Henkenberens C, Kaul D, Klook L, Krug D, Mäurer M, Panje CM, Rosenbrock J, Sautter L, Schmitt D, Süß C, Thieme AH, Trommer-Nestler M, Ziegler S, Ebert N, Medenwald D, Ostheimer C, Young DEGRO Trial Group. Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer : A systematic review. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]. 2018;194(2):1-12.www.epistemonikos.org/documents/d01f2a6ef9412410b1789e0ea4d34a199e4b22f8

1946. Lima J.P.D.S.N., Sasse A.D., Sasse E.C., Dos Santos L.V.. Outcomes of North American, Japanese, and European extensive-disease small cell lung cancer (ED-SCLC) patients under irinotecan-platinum or etoposide-platinum therapy: Systematic review and meta-analysis. Journal of Clinical Oncology. 2013;www.epistemonikos.org/documents/d0314b14fb5c1db664fca6a37a76639a1c8e5a94

1947. Alam N, Darling G, Shepherd FA, Mackay JA, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Postoperative chemotherapy in nonsmall cell lung cancer: a systematic review. The Annals of thoracic surgery. 2006;81(5):1926-36.www.epistemonikos.org/documents/d03b8427b6edb2906fed07098d35c646a87b62e9

1948. Xiao, Zheng, Wang, Chengqiong, Li, Lianhong, Tang, Xuemei, Li, Nana, Li, Jing, Chen, Ling, Gong, Qihai, Tang, Fushan, Feng, Jihong, Li, Xiaofei. Clinical Efficacy and Safety of Aidi Injection Plus Docetaxel-Based Chemotherapy in Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis of 36 Randomized Controlled Trials. Evidence-based Complementary & Alternative Medicine (eCAM). 2018;2018(no pagination):1-17. www.epistemonikos.org/documents/d0402131d5c685cba792cbdb0d152429a25b829b

1949. Christopoulos A, Saif MW, Sarris EG, Syrigos KN. Epidemiology of active tuberculosis in lung cancer patients: a systematic review. The clinical respiratory journal. 2014;8(4):375-81. www.epistemonikos.org/documents/d05e02d977760b163ca06305183b086b0abafab8

1950. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. The European respiratory journal. 2001;18(4):705-19.www.epistemonikos.org/documents/d065fb9264b73f0e9cd3bd587212d13cdfc6fff7

1951. Xie SS, Li M, Zhou CC, Song XL, Wang CH. Prophylactic cranial irradiation may impose a detrimental effect on overall survival of patients with nonsmall cell lung cancer: a systematic review and meta-analysis. PloS one. 2014;9(7):e103431. www.epistemonikos.org/documents/d0783cc8f32f979740d17471626b38ad3ce75aab

1952. Di Maio, M, Camps, C, Smit, E F, Schuette, W, Georgoulias, V, Takeda, K, Quoix, E, Wachters, F M, Gebbia, V, Gridelli, C. Prognostic factors in patients enrolled in clinical trials of second-line chemotherapy for advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 11 randomized trials. Journal of Clinical Oncology. 2009;27:8082-8082. www.epistemonikos.org/documents/d0b21eb85093ffc7df02716b666d64c81b0186d1

1953. Stewart L.A., Pignon J.P.. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ (Clinical research ed.). 1995;311(7010):899-909.www.epistemonikos.org/documents/d0ef17c91b64ab878c146ef6917939d8489de4cf

1954. Xu T., Cheng M., Xu W., Shen G., Hu S.. Clinicopathological and prognostic significance of circulating tumor cells in patients with lung cancer: A meta-analysis. Oncotarget. 2017;8(37):62524-62536. www.epistemonikos.org/documents/d11465c7c0760ff2ced2423757aaec62426464f6

1955. Wang XB, Li YS, Li J, Han Y, Liu ZD. Interleukin-8 -251A/T gene polymorphism and lung cancer susceptibility: a meta-analysis. Journal of cellular and molecular medicine. 2015;19(6):1218-22. www.epistemonikos.org/documents/d1192734064978e4f6baa6b91256384935fcaa2f

1956. Santos M., Lefeuvre D., Le Teuff G., Bourgier C., Le Pechoux C., Soria J., Pignon J., Deutsch E.. Meta-analysis of toxicities in phase i or ii trials studying the use of target therapy (tt) combined with radiation therapy in patients with locally advanced non-small cell lung cancer (NSCLC). International Journal of Radiation Oncology Biology Physics. 2012;:S68. www.epistemonikos.org/documents/d16603cf8bad9b118bd7884a6c3a9012be3ea4dc

1957. Labarca G, Aravena C, Ortega F, Arenas A, Majid A, Folch E, Mehta HJ, Jantz MA, Fernandez-Bussy S. Minimally Invasive Methods for Staging in Lung Cancer: Systematic Review and Meta-Analysis. Pulmonary medicine. 2016;2016(no pagination):1024709. www.epistemonikos.org/documents/d173e277718584643057b1950400fc3b817b780b

1958. Wotton R., Vad H., Pedersen S., Hvas A.-M., Naidu B., Bjerregaard Larsen T., Decker Christensen T.. Should patients undergoing surgery for primary lung cancer receive thromboprophylaxis in order to reduce the risk of venous thromboembolism? A systematic review. Lung Cancer. 2014;:S70.www.epistemonikos.org/documents/d1805deb1b4a9db5f8b4e5006d1be6bff3d474b7

1959. Huang LN, Wang DS, Chen YQ, Zhao CL, Gong BL, Jiang AB, Jia W, Hu FD. Expression of survivin and patients survival in non-small cell lung cancer: a meta-analysis of the published studies. Molecular biology reports. 2013;40(2):917-24. www.epistemonikos.org/documents/d18fe391340ac415472f14c07a193d7e1cf914dc

1960. Boffetta P, Hashim D. Exposure to silicon carbide and cancer risk: a systematic review. International archives of occupational and environmental health. 2017;90(1):1-12.www.epistemonikos.org/documents/d198c970072baed5762b350bcbcf6b797f00051f

1961. Gu X.-L., Ma C.-Y., Yuan D.-M., Song Y.. Expression of soluble intercellular adhesion molecule-1 and its prognostic and predictive value in lung cancer: A systematic review. Respirology. 2011;:154. www.epistemonikos.org/documents/d1ca6eecd3476d0ee47590b6fc83b84d01806bee

1962. Kelley MJ, McCrory DC. Prevention of lung cancer: summary of published evidence. Chest. 2003;123(1 Suppl):50S-59S.www.epistemonikos.org/documents/d1f3bc9cc8bbb0a43714e09152d15ab687ea0242

1963. Wang Z, Hu Y, Wang Y, Han W, Wang L, Xue F, Sui X, Song W, Shi R, Jiang J. Can CT Screening Give Rise to a Beneficial Stage Shift in Lung Cancer Patients? Systematic Review and Meta-Analysis. PloS one. 2016;11(10):e0164416. www.epistemonikos.org/documents/d1fa256af29391791720c319289c44bf78c2ce3e

1964. Lei T., Xu X.-L., Chen W., Xu Y.-P., Mao W.-M.. Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIAN2 non-small-cell lung cancer. OncoTargets and Therapy. 2016;9:921-928. www.epistemonikos.org/documents/d208a2b279a6b743af901434b027a08defc61d25

1965. Ung YC, Maziak DE, Vanderveen JA, Smith CA, Gulenchyn K, Lachetti C, Evans WK, Christina Lacchetti, Cancer Care Ontario Program in Evidence-Based Care, McMaster University Downtown Campus, 1280 Main St West, Hamilton, ON, Canada L8S 4L8, christina.lacchetti@ccopebc.ca. Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. JNCI: Journal of the National Cancer Institute. 2007;99(23):1753-1767.www.epistemonikos.org/documents/d2182148a0154ec9655fae1ac54b86b383a6877e

1966. Ding P.N., Lord S.J., Gebski V., Links M., Bray V., Gralla R.J., Yang J.C.-H., Lee C.K.. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 2017;12(4):633-643.www.epistemonikos.org/documents/d25d0aa76da7dbbb6ad0180a7ea52561c067056d

1967. Wang Y., Yang J., Liu H., Bi J.-R., Liu Y., Chen Y.-Y., Cao J.-Y., Lu Y.-J.. The association between osteopontin and survival in non-small-cell lung cancer patients: a meta-analysis of 13 cohorts. OncoTargets and Therapy. 2015;8:3513-3521. www.epistemonikos.org/documents/d27ccc04acb4459dbcb6e038ea860de141e50f0f

1968. Qian Q, Liu R, Lei Z, You J, Zhou Q, Zhang HT. [Meta analysis of association between Ser326Cys polymorphism of hOGG1 gene and risk of lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2011;14(3):205-10. www.epistemonikos.org/documents/d28b1a9c75b95af7ad3b79eae4f7317d13cdfd5e

1969. Kouranos V., Vassias A., Dimopoulos G., Syrigos K.N.. Antibiotic prophylaxis in chemotherapy-induced neutropenia in patients with lung cancer. Journal of Thoracic Oncology. 2011;:S1486-S1487. www.epistemonikos.org/documents/d2ae3114526b8be3c0f2a7e0ae5b20e4489546cc

1970. Schmidt K, Damm K, Prenzler A, Golpon H, Welte T. Preferences of lung cancer patients for treatment and decision-making: a systematic literature review. European journal of cancer care. 2016;25(4):580-91. www.epistemonikos.org/documents/d2c70de4de72b5421035543a54f16adf855add8d

1971. Guo W., Li J.-H., Wang F.. Effectiveness and safety of nedaplatin combined with chemotherapy for advanced non-small cell lung cancer: A meta-analysis. Chinese Journal of Evidence-Based Medicine. 2013;13(1):47-54. www.epistemonikos.org/documents/d2fc9bc844f29be010eb8398d74cdd1549e2feb6

1972. Billiet C, Decaluwé H, Peeters S, Vansteenkiste J, Dooms C, Haustermans K, De Leyn P, De Ruysscher D. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: a meta-analysis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2014;110(1):3-8. www.epistemonikos.org/documents/d300497cc53b3b6271e970b73e0f154e2ce9687e

1973. Liu W.-J., Zeng X.-T., Liu X.-Q., Qin H.-F., Tang C.-H., Guo Y.. Efectiveness of Endostar combined with chemotherapy for advanced non-small cell lung cancer: A systematic review. Chinese Journal of Evidence-Based Medicine. 2011;11(11):1268-1279. www.epistemonikos.org/documents/d3130ec33b8acf378aa3387c7034e118cb0b77ca

1974. Yan R.-H., Sheng H., Qiao Q., Li J.-P.. Effects of serum LDH level on prognosis of small cell lung cancer: A meta-analysis. Journal of Practical Oncology. 2014;29(1):48-51.www.epistemonikos.org/documents/d3509be3fb251194bfc978c50656e57d219e7cb2

1975. Treanor C, Kyaw T, Donnelly M. An international review and meta-analysis of prehabilitation compared to usual care for cancer patients. Journal of cancer survivorship : research and practice. 2018;12(1):64-73. www.epistemonikos.org/documents/d3578c66f43bcbf33ccadbcfb22d5a7eab360983

1976. Bi N, Shedden K, Zheng X, Kong F. Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Meta-analysis. Practical radiation oncology. 2013;3(2 Suppl 1):S19.www.epistemonikos.org/documents/d36a6dc34f9122458cfcd3865b2c4232176c7475

1977. Kaira K, Naito T, Takahashi T, Ayabe E, Shimoyama R, Kaira R, Ono A, Igawa S, Shukuya T, Murakami H, Tsuya A, Nakamura Y, Endo M, Yamamoto N. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2010;68(1):99-104.www.epistemonikos.org/documents/d383b26b470e7a25c9675d24d41cd8f7605153bd

1978. Suh CH, Park HS, Kim KW, Pyo J, Hatabu H, Nishino M. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC. Lung cancer (Amsterdam, Netherlands). 2018;123:60-69. www.epistemonikos.org/documents/d3844f35381cc9b81a6a8e1fc035327877b35dcb

1979. Yang H, Shen X, Li B, Ma R. Association between glutathione S-transferase T1 null genotype and risk of lung cancer: a meta-analysis of 55 studies. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(3):2359-66.www.epistemonikos.org/documents/d3a25f7c45ce63c384358e77ec067971af645876

1980. Shen XY, Lu FZ, Wu Y, Zhao LT, Lin ZF. XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and

meta-analysis. PloS one. 2013;8(8):e69553. www.epistemonikos.org/documents/d3b9c39806819a1dd4e3b7311ce4b62f9ce5819b

1981. Sheng M., Zhao Y., Wang F., Li S., Wang X., Shou T., Luo Y., Tang W.. Targeted drugs for unselected patients with advanced non-smallcell lung cancer: A network meta-analysis. Journal of Thoracic Disease. 2016;8(1):98-115. www.epistemonikos.org/documents/d3ebe363d8fb053682663a30b177e0313cb0dd9f

1982. Jiang L, Yang KH, Mi DH, Liu YL, Tian JH, Ma B, Tan JY, Bai ZG. Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: a metaanalysis. Clinical lung cancer. 2007;8(8):497-501. www.epistemonikos.org/documents/d43f736542cca27846c40781f2f1c874da832ec6

1983. Wu Y, Li P, Zhang H, Shi Y, Wu H, Zhang J, Qian Y, Li C, Yang J. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients. International journal of cancer. Journal international du cancer. 2013;132(2):E37-47.www.epistemonikos.org/documents/d498b8c0be65f8002d6807b139460d7ab88e1921

1984. Yang XQ, Li CY, Xu MF, Zhao H, Wang D. Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis. BMC cancer. 2015;15(1):949. www.epistemonikos.org/documents/d4c22dd61f961a5df869db672d4a6d0fee45fe09

1985. Wang JL, Jiao SC, Ye P, Li JY. [P53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer: a meta-analysis]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2008;28(5):770-3. www.epistemonikos.org/documents/d4c6899e47263a39614ff942a99e6931776ff315

1986. Shi S.-M., Su Z.-B., Zhao J.-J., Yu D.-J., Tu J.-W., Zhu J., Zhao J.-P., Sheng L., Wang S.-B., Sheng Y.-J., Chen H.-J., Tian J.-H., Zhang Y., Wang J.. Increased osteopontin protein expression may be correlated with poor prognosis in non-small-cell lung cancer: A meta analysis. Journal of Cancer Research and Therapeutics. 2016;12(1):277-282.www.epistemonikos.org/documents/d4c7fa22154af1cfe8a5c46b81ca78c4e45b1279

1987. Li W, Song LQ, Tan J. Combined effects of CYP1A1 MspI and GSTM1 genetic polymorphisms on risk of lung cancer: an updated meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(9):9281-90.www.epistemonikos.org/documents/d4ebe2f534f3d59f9ac308d5b5ddc59d6fdccc39

1988. Jin J., Zhan P., Qian H., Wang X., Katoh M., Phan K., Chung J.-H., Lv T., Song Y.. Prognostic value of wingless-type proteins in non-small cell lung cancer patients: A meta-analysis. Translational Lung Cancer Research. 2016;5(4):436-442. www.epistemonikos.org/documents/d4f844dc06a55f613f5e03d58949b5803a8a8c0f

1989. Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, Quoix E, Hatzidaki D, Wachters FM, Gebbia V, Tsai CM, Camps C, Schuette W, Chiodini P, Piccirillo MC, Perrone F, Gallo C, Gridelli C. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. European journal of cancer (Oxford, England : 1990). 2010;46(4):735-43.www.epistemonikos.org/documents/d51346d3206a5f0f7d40b9225beeada422871b4d

1990. Horita N, Yamamoto M, Sato T, Tsukahara T, Nagakura H, Tashiro K, Shibata Y, Watanabe H, Nagai K, Inoue M, Nakashima K, Ushio R, Shinkai M, Kudo M, Kaneko T. Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients. Scientific reports. 2015;5:15437.www.epistemonikos.org/documents/d51bcd7812e3200a23bf1c9076c1f037dce31184

1991. Xiao Z, Wang C, Tan Z, Hu S, Chen Y, Zhou M, Feng J, Liu S, Chen L, Ding J, Gong Q, Tang F, Liu H, Li X. Clinical efficacy and safety of sodium cantharidinate plus chemotherapy in non-small-cell lung cancer: A systematic review and meta-analysis of 38 randomized controlled trials. Journal of clinical pharmacy and therapeutics. 2019;44(1):23-38. www.epistemonikos.org/documents/d53dadcdbaf92aa07137eeea02532050723bb77c

1992. Hidayat K, Du X, Chen G, Shi M, Shi B. Abdominal Obesity and Lung Cancer Risk: Systematic Review and Meta-Analysis of Prospective Studies. Nutrients. 2016;8(12):810-822. www.epistemonikos.org/documents/d5a81407241d2cdb749e4285d7b1d5fa1063800a

1993. Mascaux C, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert AP, Lafitte JJ, Sculier JP. Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. British journal of cancer. 2006;95(2):139-45.www.epistemonikos.org/documents/d5c0023d1872ab83d8b3496358a3358a1cd51ea6

1994. Yang JP, Wang WB, Yang XX, Yang L, Ren L, Zhou FX, Hu L, He W, Li BY, Zhu Y, Jiang HG, Zhou YF. The MPO-463G>A polymorphism and lung cancer risk: a meta-analysis based on 22 case-control studies. PloS one. 2013;8(6):e65778. www.epistemonikos.org/documents/d5e159f884a959a406a2333e8ef2fad1d6d36bf2

1995. Liu Y, He S, Ding Y, Huang J, Zhang Y, Chen L. The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: a meta-analysis. Contemporary oncology (Poznań, Poland). 2014;18(1):39-47. www.epistemonikos.org/documents/d6084c98b2383f0356dd2febb50c384a9fca7ff1

1996. Mahjub H, Sadri GH. Meta-analysis of case-referent studies of specific environmental or occupational pollutants on lung cancer. Indian journal of cancer. 2006;43(4):169-73.www.epistemonikos.org/documents/d6307c9a93e0be5539806f0811b72b46984c0321

1997. Tian R.-H., Zhang Y.-G., Wu Z., Liu X., Yang J.-W., Ji H.-L.. Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis. Clinical and Translational Oncology. 2016;18(6):641-649. www.epistemonikos.org/documents/d631283edd665a3678a9266799837f8027073a4b

1998. Li J, Lu X, Zou X, Jiang Y, Yao J, Liu H, Ni B, Ma H. COX-2 rs5275 and rs689466 polymorphism and risk of lung cancer: A PRISMA-compliant meta-analysis. Medicine. 2018;97(35):e11859. www.epistemonikos.org/documents/d63ac5c3e610df20404b03a3c321e4143419449d

1999. Kim AW, Boffa DJ, Wang Z, Detterbeck FC. An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non-small cell lung cancer. The Journal of thoracic and cardiovascular surgery. 2012;143(1):55-63.www.epistemonikos.org/documents/d66dc917544f9e7e5087e8ff3e3b28b7b7aa2868

2000. Nie W, Zang Y, Chen J, Xiu Q. TERT rs2736100 polymorphism contributes to lung cancer risk: a meta-analysis including 49,869 cases and 73,464 controls. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(6):5569-74.www.epistemonikos.org/documents/d6808709cfdeb8bb69109b43db911167049b4127

2001. Schirren M., Bolukbas S., Oguzhan S., Sponholz S., Schirren J.. Importance of bronchial and bronchovascular sleeve resections for treatment of non-small cell lung cancer. Der Onkologe. 2014;20((Schirren M.; Bolukbas S.; Oguzhan S.; Sponholz S.; Schirren J., joachim.schirren@hsk-wiesbaden.de) Klinik fur Thoraxchirurgie, Dr. Horst Schmidt Klinik, Wiesbaden, 65199, Germany):961-968. www.epistemonikos.org/documents/d68f1edb9deb42d58e66018afa19bd8dadfa6113

2002. Bonomi P. Review of selected randomized trials in small cell lung cancer. Seminars in oncology. 1998;25(4 Suppl 9):70-8.www.epistemonikos.org/documents/d699814c99249147d06c2bd180ffad3f4811f655

2003. Zhang H, Zhang J, Ding H, Chen R, Liang F. [Clinical value of Tongguanteng (Radix seu Herba Marsdeniae Tenacissimae) extract combined with chemotherapy in the treatment of advanced non-small cell lung cancer: a Meta-analysis]. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan / sponsored by All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine. 2016;36(3):261-70.www.epistemonikos.org/documents/d69be782d3e3f6f9a8f56b59d183371f32ffcf15

2004. Lin C.-K., Hung H.-Y., Christiani D.C., Forastiere F., Lin R.-T.. Lung cancer mortality of residents living near petrochemical industrial complexes: A meta-analysis. Environmental Health:

A Global Access Science Source. 2017;16(1):101. www.epistemonikos.org/documents/d69ccf6f6952d3fa5e2ce2dc21b5d5ece9b40c06

2005. Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. The New England journal of medicine. 1999;341(7):476-84. www.epistemonikos.org/documents/d6ab2f152ce49cf5b1601c4d07a4e10a8fe83040

2006. Ung, Yee C., Bezjak, Andrea, Coakley, Nadia, Evans, William K., Ontario, the Lung Cancer Disease Site Group of Cancer Care. Positron Emission Tomography with 18Fluorodeoxyglucose in Radiation Treatment Planning for Non-small Cell Lung Cancer: A Systematic Review. Journal of Thoracic Oncology. 2011;6(1):86-97.www.epistemonikos.org/documents/d6b1c7d2821a19012077285bedc24f2e6c74b3d6

2007. Zhou C, Chen H, Wang A. P53 codon 72 polymorphism and lung cancer risk: evidence from 27,958 subjects. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(5):2961-9. www.epistemonikos.org/documents/d6b638c89166cc1b74b56e3b6e724f96e0a38d31

2008. Dawe D.E., Christiansen D., Zarychanski R., Abou-Setta A., Ellis P.M., Swaminath A., Rothney J., Rabbani R., Mahmud S.. Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review. Journal of Thoracic Oncology. 2015;:S286.www.epistemonikos.org/documents/d6b77a40178e09783425fcf4659be89cdb987486

2009. Abdel-Rahman O., Ahmed H., Elhalawani H.. Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: A meta-analysis. Expert Review of Respiratory Medicine. 2016;10(2):223-234. www.epistemonikos.org/documents/d6cfc87f8a54348e567ab347de57367e52379fc6

2010. Srinivasan M, Taioli E, Ragin CC. Human papillomavirus type 16 and 18 in primary lung cancers--a meta-analysis. Carcinogenesis. 2009;30(10):1722-8.www.epistemonikos.org/documents/d6e384453b7f693a89db283ff9fc10f685a44f1a

2011. Shen H, Che K, Cong L, Dong W, Zhang T, Liu Q, Du J. Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis. Oncotarget. 2017;8(22):36812-36823. www.epistemonikos.org/documents/d6fe1e9f8e65e474c0c9b21fb56cb9a37f8289f1

2012. Zhao Y., Wang H., Shi Y., Cai S., Wu T., Yan G., Cheng S., Cui K., Xi Y., Qi X., Zhang J., Ma W.. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 16 phase II/III randomized trials. Oncotarget. 2017;8(4):7014-7024.www.epistemonikos.org/documents/d7030fee299eab70fd5a7296450cfd1a37423647

2013. Sun H., Liu H., Zhang Z., Yu S.. Single-incision versus biportal video-assisted thoracoscopic surgery for lung cancer: A Meta-analysis. Tumor. 2018;38(3):235-241 and 249.www.epistemonikos.org/documents/d7135671bd9b32c75ec723bf5cff7800c40a70a5

2014. Tan P.S., Aguiar P., Haaland B., Lopes G.. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants. Lung Cancer. 2018;115:84-88.www.epistemonikos.org/documents/d795194f0213f03af5a735ad8c52e5e5d0db1567

2015. García-Tirado J, Rieger-Reyes C, Saz-Peiró P. [Effect of flavonoids in the prevention of lung cancer: systematic review]. Medicina clínica. 2012;139(8):358-63.www.epistemonikos.org/documents/d79dad160603a24547035282a9af0dda547aafda

2016. Liu Z., Yin Z.-H., Liang H.-Y., Jia Z.-F., Zhou B.-S.. Association between Chlamydia pneumoniae antibodies and lung cancer: A meta-analysis. Current Respiratory Medicine Reviews. 2010;6(3):201-206. www.epistemonikos.org/documents/d7babc9ea81fa046f8ab5092788e3e289d8c3159

2017. Zhu ML, Hua RX, Zheng L. Associations between polymorphisms of the XPC gene and lung cancer susceptibility: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(4):2931-9. www.epistemonikos.org/documents/d7ced9ba6e461831c2b113e8f0c67aa77e34af86

2018. Zhang X, Yang Q. Association between serum copper levels and lung cancer risk: A meta-analysis. The Journal of international medical research. 2018;46(12):300060518798507. www.epistemonikos.org/documents/d7f9851f5240c6124f8f6f2b25a4726d15a5337b

2019. Matsui M., Takagi H., Yamamoto H., Goto S.-N., Umemoto T.. A meta-analysis of randomized and risk-adjusted observational studies of mediastinal lymph node dissection versus sampling during resection of non-small cell lung cancer. Chest. 2011; www.epistemonikos.org/documents/d8101fea6c03a3d540a2ed6c18e54d9b29b1198d

2020. Gu A.-Q., Wang W.-M., Chen W.-Y., Shi C.-L., Lu J.-H., Han J.-Q.. XRCC1 genetic polymorphisms and sensitivity to platinum-based drugs in non-small cell lung cancer: An update meta-analysis based on 4708 subjects. International Journal of Clinical and Experimental Medicine. 2015;8(1):145-154.www.epistemonikos.org/documents/d8320c0cf8b8c77d1b138c654b6e41041cb455c7

2021. Lubin JH, Boice JD. Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies. Journal of the National Cancer Institute. 1997;89(1):49-57.www.epistemonikos.org/documents/d845a2809a25e0d1ebdb959734e79f5155203ce3

2022. Zacho HD, Karthigaseu NN, Fonager RF, Petersen LJ. Treatment with bone-seeking radionuclides for painful bone metastases in patients with lung cancer: a systematic review. BMJ supportive & palliative care. 2017;7(3):230-237. www.epistemonikos.org/documents/d8477feed9ee0ad47ae38736ee59d160bd803352

2023. Nishie K., Yamamoto S., Nagata C., Koizumi T., Hanaoka M.. Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis. Lung Cancer. 2017;112:25-34. www.epistemonikos.org/documents/d84aad99657ddda799138d17b26e976cc7ff63b1

2024. Lin C, Wang S, Xie W, Chang J, Gan Y. The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis. Cancer biology & therapy. 2015;16(7):1019-28. www.epistemonikos.org/documents/d84d1aa684884768ce880f37695401fe9d8e92ed

2025. Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. International journal of medical sciences. 2007;4(2):59-71. www.epistemonikos.org/documents/d85fcf3c00adcf2a6374f72b25d0a14a80d308fc

2026. Li G.-Q., Wu Z.-P., Li X.-B., Qi Z.-Z., Li S., Liang Y.-J., Wu M.-Y., Zhang Q., Yuan J., Xia Z.-Q., Li D., Chen Q.-L., Wang X.-P., Bai H.-G.. Association between -634G/C polymorphism in the IL-6 gene and the risk of lung cancer: A meta-analysis. Chinese Journal of Evidence-Based Medicine. 2015;15(12):1372-1377.www.epistemonikos.org/documents/d879c585297afea805b2f94c1a93ba473adf03f0

2027. Wei Y., Yang M., Zhang J.-Q., Bai G., Zhang L.. Systematic review: comparison of Platinum-based doublet versus non-Platinum single-agent as second-line treatment of advanced non-small cell lung cancer. Chinese Journal of Cancer Prevention and Treatment. 2015;22(4):293-299.www.epistemonikos.org/documents/d8995938f165f8b179df40828571b94488f692cc

2028. Sun X., Sun L., Zhang S.-L., Xiong Z.-C., Ma J.-T., Han C.-B.. Meta-analysis exploring the effectiveness of S-1-based chemotherapy for advanced non-small cell lung cancer. Tohoku Journal of Experimental Medicine. 2017;241(1):1-11. www.epistemonikos.org/documents/d89a790e85daec1ec7f3794d4c59d67a422b7715

2029. Choi YJ, Myung SK, Lee JH. Light Alcohol Drinking and Risk of Cancer: A Meta-analysis of Cohort Studies. Cancer research and treatment : official journal of Korean Cancer Association. 2018;50(2):474-487. www.epistemonikos.org/documents/d8a36ebf4a7a0bd29e4f3ee0561fb3f5e1084838

2030. Edwards S.J., Welton N., Borrill J.. Gefitinib compared with doublet chemotherapy for first-line treatment of non-small-cell lung cancer (NSCLC): A systematic review and adjusted indirect comparison. Value in Health. 2010;:A252-A253. www.epistemonikos.org/documents/d8a8557ed9f8a2c72f466e7b73f72c3d7f12db15

2031. Peerlings J, Troost EG, Nelemans PJ, Cobben DC, de Boer JC, Hoffmann AL, Beets-Tan RG. The Diagnostic Value of MR Imaging in Determining the Lymph Node Status of Patients with Non-Small Cell Lung Cancer: A Meta-Analysis. Radiology. 2016;281(1):151631.www.epistemonikos.org/documents/d8da0467ac02eab5441cdd1b51966361aa68a18b

2032. Le Chevalier T.. Chemotherapy for advanced NSCLC. Will meta-analysis provide the answer?. Chest. 1996;109(5 SUPPL.):107S-109S.www.epistemonikos.org/documents/d8f4215dacae3f149b1d8fe9f3fa1512fea6641c

2033. Zhang W, Wei Y, Jiang H, Xu J, Yu D. Thoracotomy is better than thoracoscopic lobectomy in the lymph node dissection of lung cancer: a systematic review and meta-analysis. World journal of surgical oncology. 2016;14(1):290. www.epistemonikos.org/documents/d90b188b1cf943ca1ba8c98bcb9a56ceaace04e9

2034. Fu ZZ, Sun XD, Li P, Zhang Z, Li GZ, Gu T, Shao SS. Relationship between serum VEGF level and radiosensitivity of patients with nonsmall cell lung cancer among asians: a meta-analysis. DNA and cell biology. 2014;33(7):426-37. www.epistemonikos.org/documents/d91eff6769546c3554553ece9bc73e3a07868571

2035. Zhao WX, Luo JF. Serum neuron-specific enolase levels were associated with the prognosis of small cell lung cancer: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(5):3245-8.www.epistemonikos.org/documents/d938a51bdd4fa742898018ca3c2dc5517d474117

2036. Wang F, Fang P, Hou DY, Leng ZJ, Cao LJ. Comparison of epidermal growth factor receptor mutations between primary tumors and lymph nodes in non-small cell lung cancer: a review and meta-analysis of published data. Asian Pacific journal of cancer prevention : APJCP. 2014;15(11):4493-7.www.epistemonikos.org/documents/d96f4cb16fef5adc8068e2257360066b0a8a2287

2037. Hu B, Huang Y, Yu RH, Mao HJ, Guan C, Zhao J. Quantitative assessment of the influence of common variations (rs8034191 and rs1051730) at 15q25 and lung cancer risk. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(3):2777-85.www.epistemonikos.org/documents/d9882595ba1a68cef508905102aabb9904feaf9c

2038. Zhang J., Chen S., Liu S., Luketich J., Gibson M., Wang R., Chen H.. The platinum-based treatments for advanced non-small cell lung cancer: Is excision repair cross-complementation group 1 low/negative expression better than its high/positive expression? A metaanalysis. Chest. 2010;www.epistemonikos.org/documents/d9942ce2dd6c247c1660bee030385b7b26cf85d3

2039. Wang H, Yang L, Zou L, Huang D, Guo Y, Pan M, Tan Y, Zhong H, Ji W, Ran P, Zhong N, Lu J. Association between chronic obstructive pulmonary disease and lung cancer: a case-control study in Southern Chinese and a meta-analysis. PloS one. 2012;7(9):e46144.www.epistemonikos.org/documents/d9b6fe5f2d9b3bcd715d9ed9e1ededa1d08e466a

2040. Zang Y, Nie W, Fang Z, Li B. Cleft lip and palate transmembrane protein 1 rs31489 polymorphism is associated with lung cancer risk: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(6):5583-8.www.epistemonikos.org/documents/d9b931f7c213977eba35727ed538349162cc4076

2041. Hong D, Zhang G, Zhang X, Lian X. Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Medicine. 2016;95(9):e3008. www.epistemonikos.org/documents/d9dbac7a21a87b10d42d89093ab09026bce224d1

2042. Lopez PG, Stewart DJ, Newman TE, Evans WK. Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group. Cancer prevention & control : CPC = Prévention & contrôle en cancérologie : PCC. 1997;1(1):18-27. www.epistemonikos.org/documents/da04f0dcfe914ddcc4986a35e0d397c6b2c3d779

2043. Li G, Xue M, Chen W, Yi S. Efficacy and safety of radiofrequency ablation for lung cancers: A systematic review and meta-analysis. European journal of radiology. 2018;100:92-98. www.epistemonikos.org/documents/da10bbf261a1224325c0d26e9aea734eb28763bb

2044. Zhang, Qiu-Ning, Wang, Dao-Ying, Wang, Xiao-Hu, Hui, Tian-jin, Yang, Ke-Hu, Li, Zheng, Li, Hai-Yang, Guo, Li-Yun. Non-conventional radiotherapy versus conventional radiotherapy for inoperable non-small-cell lung cancer: A meta-analysis of randomized clinical trials. Thoracic Cancer. 2012;3(3):269-279.www.epistemonikos.org/documents/da3a1c608549b8fef9dd26a9334df481ac084b05

2045. Wang M.-C., Yang J.-L., Gao T.-M.. Vandetanib plus docetaxel versus docetaxel for advanced non-small cell lung cancer: A meta-analysis. Chinese Journal of Evidence-Based Medicine. 2011;11(10):1151-1155. www.epistemonikos.org/documents/da594069be72e846e8ba04ac1f8dd75ea6599973

2046. Xiao J, Hu CP, He BX, Chen X, Lu XX, Xie MX, Li W, He SY, You SJ, Chen Q. PTEN expression is a prognostic marker for patients with non-small cell lung cancer: a systematic review and meta-analysis of the literature. Oncotarget. 2016;7(36):57832-57840. www.epistemonikos.org/documents/da9891d01e20135fef753e0c145b8badc740a222

2047. Ma H, Yao WX, Huang L, Jin SH, Liu DH, Liu Y, Tian X, Tian JH, Zhou JG. Efficacy of D5F3 IHC for detecting ALK gene rearrangement in NSCLC patients: a systematic review and meta-analysis. Oncotarget. 2016;7(43):70128-70142. www.epistemonikos.org/documents/db0f6290c0a8ba2cbd65c4faecd8440bdcc10055

2048. Tanvetyanon T, Robinson LA, Schell MJ, Strong VE, Kapoor R, Coit DG, Bepler G. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(7):1142-7. www.epistemonikos.org/documents/db35264eba078ad7910766cb637225c61ec0d0a0

2049. Zendehdel R, Tayefeh-Rahimian R, Kabir A. Chronic exposure to chlorophenol related compounds in the pesticide production workplace and lung cancer: a meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2014;15(13):5149-53. www.epistemonikos.org/documents/db624befca7ba69f9880b7ec68e780d34e51a9b4

2050. Hua F, Fang N, Li X, Zhu S, Zhang W, Gu J. A meta-analysis of the relationship between RARβ gene promoter methylation and non-small cell lung cancer. PloS one. 2014;9(5):e96163. www.epistemonikos.org/documents/db86ba091acba5c84fd4588cfed61404ac6a733d

2051. Yan Z, Tong X, Ma Y, Liu S, Yang L, Yang X, Yang X, Bai M, Fan H. Association between ATM gene polymorphisms, lung cancer susceptibility and radiation-induced pneumonitis: a meta-analysis. BMC pulmonary medicine. 2017;17(1):205. www.epistemonikos.org/documents/db8dcab14e406f02c5874c9faa04543f711c9d4f

2052. Wang Q, He X, Tian J, Wang X, Ru P, Ruan Z, Yang K. [A meta analysis of aidi injection plus taxotere and cisplatin in the treatment of non-small cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2010;13(11):1027-34. www.epistemonikos.org/documents/db96047d07da3425b458c7f870f4d4eae0d935b9

2053. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000;6(10):4055-63.www.epistemonikos.org/documents/dbc5435ad2654ed098b3fe03afbeac664f04054c

2054. Sun Y. [The relationship between FHIT gene promoter methylation and lung cancer risk: a meta-analysis]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2014;17(3):233-7. www.epistemonikos.org/documents/dbd59a6925c7acc62e0826ed559785c0aab8a5ce

2055. Yang Y, Dong J, Sun K, Zhao L, Zhao F, Wang L, Jiao Y. Obesity and incidence of lung cancer: a meta-analysis. International journal of cancer. Journal international du cancer. 2013;132(5):1162-9. www.epistemonikos.org/documents/dbe1263a48f788bb714fe5b560077dd0290b238e

2056. Tsujino K, Kawaguchi T, Kubo A, Aono N, Nakao K, Koh Y, Tachibana K, Isa S, Takada M, Kurata T. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009;4(8):994-1001. www.epistemonikos.org/documents/dbe6e404e30f7986eb2e4526bdc9e62dbe3745c1

2057. Tardon A, Lee WJ, Delgado-Rodriguez M, Dosemeci M, Albanes D, Hoover R, Blair A. Leisure-time physical activity and lung cancer: a meta-analysis. Cancer causes & control : CCC. 2005;16(4):389-97. www.epistemonikos.org/documents/dbf9db877aa783b5ce4ea5a325d307caf894608d

2058. Shah A.A., Berry M.F., Tzao C., Rajgor D., Pietrobon R., D'Amico T.A.. Induction chemoradiotherapy is not superior to induction chemotherapy alone in patients with stage IIIA(N2) non-small cell lung cancer: A systematic review and meta-analysis. Journal of Thoracic Oncology. 2011;:S1578-S1579.www.epistemonikos.org/documents/dbfb3c9b791c890dc9bf560f29ad1b022ddbeb35

2059. Tang J.-H., Zhang Z.-H., Wang R., Tang H.-L., Zhang G.-Y., Long L.-Y., Chen L.-A.. Level of serum neurone specific enolase and prognosis in small cell lung cancer: A systematic review. Chinese Journal of Evidence-Based Medicine. 2009;9(1):76-80. www.epistemonikos.org/documents/dc8fd8bc8e8131f4999c9c0839a7afa144807db7

2060. Aydiner A.. Efficacy of gefitinib in patients with epidermal growth factor receptor mutation positive advanced non-small-cell lung cancer - A metaanalysis of randomized controlled trials. European Journal of Cancer. 2011;:S630. www.epistemonikos.org/documents/dc99821e0785fe66d02818c94707766872fc4b4c

2061. Gu P, Zhao YZ, Jiang LY, Zhang W, Xin Y, Han BH. Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis. European journal of cancer (Oxford, England : 1990). 2009;45(8):1389-96.www.epistemonikos.org/documents/dca2960561bdc890d7dcc5ce7a7a7a1f477a8abe

2062. Zhou B, Liu J, Wang ZM, Xi T. C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. PloS one. 2012;7(8):e43075.www.epistemonikos.org/documents/dcb2049e1338bd99cb9f80fcda41670278c2a1be

2063. Hendriks LE, Hermans BC, van den Beuken-van Everdingen MH, Hochstenbag MM, Dingemans AM. Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(2):155-73. www.epistemonikos.org/documents/dcb6f16936d168324a91e576ea9ca76271a54b0c

2064. Berghmans T., Paesmans M., Meert A.P., CsToth I., Sculier J.P.. Are first-line platinum-based (PT) regimens improving survival in comparison with non-platinum (NPT) chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC)? A meta-analysis (MA) of randomised trials. Lung Cancer. 2013;:S31.www.epistemonikos.org/documents/dcfb8bcb86971389c50dac8585a0bfcba8105592

2065. Deng ZC, Cao C, Yu YM, Ma HY, Ye M. Vascular endothelial growth factor -634G/C and vascular endothelial growth factor -2578C/A polymorphisms and lung cancer risk: a case-control study and meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(3):1805-11.www.epistemonikos.org/documents/dd000fab589935f574c554edf0ad712e5f6bd704

2066. Li L, Liu D, Qiu ZX, Zhao S, Zhang L, Li WM. The Prognostic Role of mTOR and P-mTOR for Survival in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. PloS one.

2015;10(2):e0116771. www.epistemonikos.org/documents/dd040c7d6b0051e39189100b914a49bb317410f9

2067. Cao X., Wen Z.-S., Wang X.-D., Li Y., Liu K.-Y., Wang X.. The clinical effect of metformin on the survival of lung cancer patients with diabetes: A comprehensive systematic review and meta-analysis of retrospective studies. Journal of Cancer. 2017;8(13):2532-2541.www.epistemonikos.org/documents/dd3545e0ee7ac3fed059b067a8e7beba8fecad74

2068. Dai J, Yang L, Wang J, Xiao Y, Ruan Q. Prognostic Value of FOXM1 in Patients with Malignant Solid Tumor: A Meta-Analysis and System Review. Disease markers. 2015;2015(no pagination):352478. www.epistemonikos.org/documents/dd4da99ad8c6e99a357c93a23919bf59c4c85762

2069. Wang S, Yang Z, Wang Z. Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?. Oncotarget. 2015;6(20):18206-23.www.epistemonikos.org/documents/dd7ff74408e2cfb09306ce7075f67885a626ab71

2070. Mao C, Qiu LX, Liao RY, Du FB, Ding H, Yang WC, Li J, Chen Q. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung cancer (Amsterdam, Netherlands). 2010;69(3):272-8. www.epistemonikos.org/documents/dd8214b3afdc8bef0ca940ed52b7bef84b532835

2071. Lee C.K., Brown C., Gralla R., Hirsh V., Inoue A., Gebski V., Yang C.J.. Impact of epidermal growth factor receptor-tyrosine kinase inhibitor treatment in advanced non-small cell lung cancer: A meta-analysis. Annals of Oncology. 2012;:ix414. www.epistemonikos.org/documents/dd8d41029aeb4308054381e3fde48c971fb71501

2072. Li M, Zhang X, Hu K, Shi M, Dong G, Li D, Zhang P. Prognostic role of snail in lung cancer: Protocol for a systematic review. Medicine. 2018;97(28):e11539.www.epistemonikos.org/documents/dd997981bf089c999c88d099d0f7b35286fb0384

2073. Shen Y, Wang T, Yang T, Hu Q, Wan C, Chen L, Wen F. Diagnostic value of circulating microRNAs for lung cancer: a meta-analysis. Genetic testing and molecular biomarkers. 2013;17(5):359-66. www.epistemonikos.org/documents/ddb03cfb25090d9dda0c64fe17de5ae4dddec867

2074. Tao L, Zhuo W, Yang F, Zhu B. [Vandetanib for advanced non-small cell lung cancer: a meta-analysis]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2012;15(3):172-8. www.epistemonikos.org/documents/ddbc3fda60878a1a279b8b5787e7083869c6e188

2075. Wang, Bibo, Han, Yiping, Zang, Jiajie. Comparing irinotecan/cisplatin with etoposide/cisplatin in patients with ED-SCLC: A meta-analysis of efficacy and toxicity. Journal of Medical Colleges of PLA. 2012;27(4):210-225. www.epistemonikos.org/documents/ddcb944ea2ec674da1a8e7df56a04a9bf5516309

2076. Harris CG, James RS, Tian DH, Yan TD, Doyle MP, Gonzalez-Rivas D, Cao C. Systematic review and meta-analysis of uniportal versus multiportal video-assisted thoracoscopic lobectomy for lung cancer. Annals of cardiothoracic surgery. 2016;5(2):76-84.www.epistemonikos.org/documents/ddced430e87bdaa8dc758eced61691e9c1fb78a1

2077. Lu YY, Chen JH, Liang JA, Chu S, Lin WY, Kao CH. 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis. Nuclear medicine communications. 2014;35(7):697-703. www.epistemonikos.org/documents/dde36ef5a2f3f85bc4a22ccd82c0320b8acab401

2078. She J, Yang P, Hong Q, Bai C. Lung cancer in China: challenges and interventions. Chest. 2013;143(4):1117-26.www.epistemonikos.org/documents/dde6b79576b7c58c7321e15a23e191188adf8263

2079. Li Q, Zhan P, Yuan D, Lv T, Krupnick AS, Passaro A, Brunelli A, Smeltzer MP, Osarogiagbon RU, Song Y. Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: a systematic review with meta-analysis. Translational lung cancer research. 2016;5(3):258-64.www.epistemonikos.org/documents/dde9f46ed5b1d9e287b50b86dd163b6e8d9b3b5b

2080. Zhan P, Song Y. CHRNA3 rs1051730 polymorphism and lung cancer susceptibility in Asian population: a meta-analysis. Translational lung cancer research. 2015;4(1):104-8.www.epistemonikos.org/documents/de64362ed8a4a7bb27d40e14a507814cc7f44918

2081. Zhang T.T., Wang R.M., Yang Z., Chen G.B.. Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Clinical and Translational Oncology. 2016;18(6):576-581.www.epistemonikos.org/documents/de75bf4ea1fe9d8cd39ceedca61779cb15ee36c4

2082. Li B.T., Barnes T.A., Chan D.L., Naidoo J., Lee A., Khasraw M., Marx G.M., Kris M.G., Clarke S.J., Drilon A., Rudin C.M., Pavlakis N.. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Lung Cancer. 2016;102:21-27.www.epistemonikos.org/documents/de77def2c6b20085abc9a3d2679f059e8e868cb8

2083. Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP, Khuri FR, Ahmed R, Ramalingam SS. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer. 2018;124(2):271-277.www.epistemonikos.org/documents/de819c7cacfcc5f7b95f0e6682899ead665d0167

2084. Xu YH, Lu S. A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2014;40(3):311-7.www.epistemonikos.org/documents/de88075d7263b4179b751bab72019e1e5e1b1bab

2085. Andrew P., O'Connor S., Lee-Ying R., Jerat S.. Management of solid lung malignancy by CT-guided percutaneous catheter ablation-does adjuvant chemotherapy help?. Journal of Thoracic Oncology. 2013;:S725-S726. www.epistemonikos.org/documents/def95d3c256f461026a3b7edef41d03029f246c2

2086. Tang ZM, Ling ZG, Wang CM, Wu YB, Kong JL. Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis. PloS one. 2017;12(7):e0182117. www.epistemonikos.org/documents/df026fda454cf93819c00a0c3f6042c62dced461

2087. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert AP, Noel S, Lafitte JJ, Sculier JP. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. British journal of cancer. 2005;92(1):131-9.www.epistemonikos.org/documents/df1346fbfc965ad7b936e0668356af76d9bd0232

2088. Chen Y., Wang T., Wang W., Hu J., Li R., He S., Yang J.. Prognostic and clinicopathological significance of SIRT1 expression in NSCLC: A meta-analysis. Oncotarget. 2017;8(37):62537-62544. www.epistemonikos.org/documents/df3c65aa64d10a69c35877749f58b97ad13aa346

2089. Zhao B, Zhang W, Yu D, Xu J, Wei Y. Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials. Lung cancer (Amsterdam, Netherlands). 2018;122:10-21. www.epistemonikos.org/documents/df443d78410c79de106741d934a09d23a23423c7

2090. Zhang J, Qiu LX, Leaw SJ, Hu XC, Chang JH. The association between XPD Asp312Asn polymorphism and lung cancer risk: a meta-analysis including 16,949 subjects. Medical oncology (Northwood, London, England). 2011;28(3):655-60. www.epistemonikos.org/documents/df7b5c4613e3f95c4c524161c83116bf728cc94f

2091. Hu Q, Wang Q, Zhu H, Yao Y, Song Q. Irinotecan compared with etoposide in combination with platinum in previously untreated extensive stage small cell lung cancer: An updated systemic review. Journal of cancer research and therapeutics. 2016;12(2):881-7.www.epistemonikos.org/documents/df7c6c7f0a3b814d641f906322c6da34846f2850

2092. Balla A, D Subiela J, Bollo J, Martínez C, Rodriguez Luppi C, Hernández P, Pascual-González Y, Quaresima S, M Targarona E. Gastrointestinal metastasis from primary lung cancer.

Case series and systematic literature review. Cirugia espanola. 2018;96(4):184-197.www.epistemonikos.org/documents/df7edcb09ebb304296a71bc42ad11674b6eb8214

2093. Song X, Zhong X, Tang K, Wu G, Jiang Y. Serum magnesium levels and lung cancer risk: a meta-analysis. World journal of surgical oncology. 2018;16(1):137.www.epistemonikos.org/documents/dfa20470b0042cb60616650aa5a1e822744ec598

2094. Tian R.-H., Wu X., Liu X., Yang J.-W., Ji H.-L., Yan Y.-J.. The role of angiogenesis inhibitors in the treatment of elderly patients with advanced non-small-cell lung cancer: A meta-analysis of eleven randomized controlled trials. Journal of Cancer Research and Therapeutics. 2016;12(2):571-575.www.epistemonikos.org/documents/dfdba3e9cabcdd5ab45ca83483d6348ee936ab05

2095. Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2016;(5):CD010383.www.epistemonikos.org/documents/dfe32c06c3544f41607668e24b10b7b605de938c

2096. Yan HJ, Tan Y, Gu W. Neuron specific enolase and prognosis of non-small cell lung cancer: a systematic review and meta-analysis. Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 2014;19(1):153-6. www.epistemonikos.org/documents/dff3ca365e5b2946cd37caacfd3b172010c9d915

2097. Zhang J., Liu J., Chen H., Wu W., Li X., Wu Y., Zhang K., Gu L.. The impact of histological types on the efficacy of angiogenesis inhibitors in the treatment of advanced NSCLC: a meta-analysis of randomized controlled trials. OncoTargets and Therapy. 2015;8:2375-2382.www.epistemonikos.org/documents/dff818de71e166d03cee0e87006618a61da33e22

2098. Rossi A., Di Maio M., Chiodini P., Rudd R., Okamoto H., Skarlos D., Frueh M., Qian W., Tamura T., Samantas E., Shibata T., Perrone F., Gallo C., Gridelli C., Martelli O., Lee S.M.. COCIS individual patient data (IPD) meta-analysis: Carboplatin- or cisplatin-based chemotherapy (CT) as first-line treatment of small cell lung cancer (SCLC). Journal of Clinical Oncology. 2011; www.epistemonikos.org/documents/e00fa53b08f8571b324fd67c00045e4520070b56

2099. Zhou W, Zhang S, Hu Y, Na J, Wang N, Ma X, Yuan L, Meng F. Meta-analysis of the associations between TNF-α or IL-6 gene polymorphisms and susceptibility to lung cancer. European journal of medical research. 2015;20(1):28. www.epistemonikos.org/documents/e02b99c193bfbc071012e673fe925728e154076b

2100. Deng Y., Hu H.-L., Pan H.-X., Ren G., Yang L., Zhu X.-Q., Liu H.. Oxaliplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A systematic review. Chinese Journal of Evidence-Based Medicine. 2010;10(5):609-617. www.epistemonikos.org/documents/e0323e59c07fb1362bd79c9e9c24a1aa8d57b1f1

2101. Wang Z., Bao C., Su C., Xu W., Luo H., Chen L., Qi X.. Association between diabetes or antidiabetic therapy and lung cancer: A meta-analysis. Journal of Diabetes Investigation. 2013;4(6):659-666. www.epistemonikos.org/documents/e0410b9f110f9aad24a5ad0367967561f985a77a

2102. Lin JZ, Ma SK, Wu SX, Yu SH, Li XY. A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?. Medicine. 2018;97(30):e11569. www.epistemonikos.org/documents/e074469e862357b4c101ccb217452f38e3d81dae

2103. Hegi F., D'Souza M., Azzi M., De Ruysscher D.. Comparing the Outcomes of Stereotactic Ablative Radiotherapy and Non-Stereotactic Ablative Radiotherapy Definitive Radiotherapy Approaches to Thoracic Malignancy: A Systematic Review and Meta-Analysis. Clinical Lung Cancer. 2018;19(3):199-212.www.epistemonikos.org/documents/e08805dd75682c011578714f545c42a431c338b6

2104. Xiao Z, Wang C, Chen L, Tang X, Li L, Li N, Li J, Gong Q, Tang F, Feng J, Li X. Has aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in non-small cell

lung cancer? A meta-analysis of 36 randomized controlled trials. Oncotarget. 2017;8(1):1329-1342.www.epistemonikos.org/documents/e08de020148c69e7e52485a3422464cd9ced18cb

2105. Ding M, Yang J. Therapeutic vaccination for non-small-cell lung cancer: a meta-analysis. Medical oncology (Northwood, London, England). 2014;31(4):928.www.epistemonikos.org/documents/e09050fe8980173c6c6c9a98f57316a6d31c502b

2106. Zou X.-L., Wang C., Liu K., Nie W., Ding Z.-Y.. Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis. Molecular and Clinical Oncology. 2015;3(3):633-638. www.epistemonikos.org/documents/e09986a5e9dd0129c02a5e368a23651c9439b466

2107. Ma Q.-G., Deng J.-J., Shen L., Li H.-M.. Diagnostic value of serum pro-gastrin-releasing peptide (Pro-GRP) in small cell lung cancer patients: A systematic review. Chinese Journal of Evidence-Based Medicine. 2010;10(7):869-874. www.epistemonikos.org/documents/e09a861e7d1e9ea93d23761467963d2333ca533c

2108. Zhao I, Yates P, Institute of Health and Biomedical Innovation, School of Nursing, Queensland University of Technology, Queensland. Non-pharmacological interventions for breathlessness management in patients with lung cancer: a systematic review. Palliative Medicine. 2008;22(6):693-701.www.epistemonikos.org/documents/e0a20f00ffdf660f3097afd9575a4b65ba00ba10

2109. Zhang ZL, Sun J, Dong JY, Tian HL, Xue L, Qin LQ, Tong J. Residential radon and lung cancer risk: an updated meta- analysis of case-control studies. Asian Pacific journal of cancer prevention : APJCP. 2012;13(6):2459-65. www.epistemonikos.org/documents/e0aed880b28e94b7e30119a838826af29bd2d741

2110. Guo QX, Yang WH, Zhai JF, Han FC, Wang CY. XRCC1 codon 280 polymorphism and susceptibility to lung cancer: a meta-analysis of the literatures. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(5):2989-94.www.epistemonikos.org/documents/e0af05cbe51e80c2bfdeb97de4c4d3dbe6476cee

2111. Fan J, Xia Z, Zhang X, Chen Y, Qian R, Liu S, You D, Zhang J, Luo P. The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis. OncoTargets and therapy. 2018;11:1105-1115. www.epistemonikos.org/documents/e0b3de377394ffb85a4f331961bcee6cdacfac57

2112. Ren W, Li Z, Mi D, Yang K, Tian J, Zhang Z. [A meta analysis of radiosensitivity on non-small cell lung cancer by metronidazole amino acidum natrium]. 中国肺癌杂志 (Chinese Journal of Lung Cancer). 2012;15(6):340-7. www.epistemonikos.org/documents/e0d150630512559bc831dfd7f34463d02bdf6dca

2113. Fleiss J.L., Gross A.J.. Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: a critique. Journal of Clinical Epidemiology. 1991;44(2):127-139. www.epistemonikos.org/documents/e0f4764702b2130fd7ba79339d5500adfd7bd540

2114. Huang WF, Liu AH, Zhao HJ, Dong HM, Liu LY, Cai SX. BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis. Medicine. 2015;94(33):e1263.www.epistemonikos.org/documents/e10a7f92dd420a107af1d7e9683304a668291174

2115. Zhu L, Yu H, Liu SY, Xiao XS, Dong WH, Chen YN, Xu W, Zhu T. Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. PloS one. 2015;10(4):e0124230. www.epistemonikos.org/documents/e11c21b9cdc9e85f6cf1da20b5c8babf7d531022

2116. Lilenbaum RC, List M, Desch C. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a meta-analysis and the Cancer and Leukemia Group B randomized trial. Seminars in oncology. 1999;26(5 Suppl 15):52-4. www.epistemonikos.org/documents/e12589394d244626bc96decd91d97f4b9393e27e

2117. Yan W, Xu N, Han X, Zhou XM, He B. The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review. Scientific reports. 2016;6:19303. www.epistemonikos.org/documents/e13531b7235c1901dd78f35c7b7dce5d6cf8df4c

2118. Nadpara P., Madhavan S., Tworek C.. Social disparities across the continuum of lung cancer: A systematic review of the literature. Value in Health. 2010;:A48.www.epistemonikos.org/documents/e136d3ccb076d77bd436f1054917f30524b193b2

2119. Tang L.N., Zhang C.L., He H.R., Pan Z.Y., Fan D., He Y.L., You H.S., Li Y.J.. Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: A meta-analysis. OncoTargets and Therapy. 2018;11:665-675. www.epistemonikos.org/documents/e14aea65fb9fd6d3d7c19f4323d7e7dcf8c8d229

2120. Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation. Health technology assessment (Winchester, England). 2013;17(31):1-278. www.epistemonikos.org/documents/e1564cd5386708aeb71eee3093eccd517da6241c

2121. Wailoo A, Sutton A, Morgan A. The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis. British journal of cancer. 2009;100(3):436-41. www.epistemonikos.org/documents/e1707a4e08025880ff18ff15c10577db25940dd7

2122. Zhang X, Tian T, Sun W, Liu C, Fang X. Bmi-1 overexpression as an efficient prognostic marker in patients with nonsmall cell lung cancer. Medicine. 2017;96(26):e7346.www.epistemonikos.org/documents/e18229791aa287da2bad075e675cea7dd3f0bc4a

2123. Yang HY, Yang SY, Shao FY, Wang HY, Wang YD. Updated Assessment of the Association of the XRCC1 Arg399Gln Polymorphism with Lung Cancer Risk in the Chinese Population. Asian Pacific journal of cancer prevention : APJCP. 2015;16(2):495-500. www.epistemonikos.org/documents/e18d02478ef500a898ace061cb7a80faa2c2d24a

2124. Zhang S, Mao XD, Wang HT, Cai F, Xu J. Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis. BMJ open. 2016;6(6):e011714. www.epistemonikos.org/documents/e1909aaa86014832625008aa7f79be149c90660d

2125. Zhang W, Yan B, Jiang L. Predictive effect of XRCC3 Thr241Met polymorphism on platinum-based chemotherapy in lung cancer patients: meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(6):3989-93.www.epistemonikos.org/documents/e197488b74f3f8f0244f051fdf6fc14d137eac00

2126. Luo H., Yu X., Liang N., Xie J., Deng G., Liu Q., Zhang J., Ge H.. The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy A systematic review and meta-analysis. Medicine (United States). 2017;96(8):e6165.www.epistemonikos.org/documents/e1a1c9f3c3753dc07f95f2fc9bcfe60690a87859

2127. Wu J, Liu J, Zhou Y, Ying J, Zou H, Guo S, Wang L, Zhao N, Hu J, Lu D, Jin L, Li Q, Wang JC. Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012;18(14):3972-81. www.epistemonikos.org/documents/e1b87a462aba47ee44a405d82e6fa99a619e0f62

2128. Hotta K, Kato Y, Leighl N, Takigawa N, Gaafar RM, Kayatani H, Hirata T, Ohashi K, Kubo T, Tabata M, Tanimoto M, Kiura K. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review. PloS one.

2015;10(3):e0121211. www.epistemonikos.org/documents/e21f51ef30f2e3c93524aa102ed2da2e0af149b8

2129. Abar L, Vieira AR, Aune D, Stevens C, Vingeliene S, Navarro Rosenblatt DA, Chan D, Greenwood DC, Norat T. Blood concentrations of carotenoids and retinol and lung cancer risk: an update of the WCRF-AICR systematic review of published prospective studies. Cancer medicine. 2016;5(8):2069-83.www.epistemonikos.org/documents/e228decc22633ac5b90c27b27f2a84c81245463a

2130. Matsuda A, Yamaoka K, Tango T. Quality of life in advanced non-small cell lung cancer patients receiving palliative chemotherapy: A meta-analysis of randomized controlled trials. Experimental and therapeutic medicine. 2012;3(1):134-140. www.epistemonikos.org/documents/e233db93af616ab6348cf2f1322264010104c2ac

2131. Fritz H, Seely D, Kennedy DA, Fernandes R, Cooley K, Fergusson D. Green tea and lung cancer: a systematic review. Integrative cancer therapies. 2013;12(1):7-24.www.epistemonikos.org/documents/e241990dd65e3ed07c90ae9a2771adc43fecc727

2132. Zheng W, Zhou Y, Lu J, Xu H, Lei L, Chen C, Zhao J, Xu L. The prognostic value of miR-126 expression in non-small-cell lung cancer: a meta-analysis. Cancer cell international. 2017;17:71. www.epistemonikos.org/documents/e284971abdcc7f137593f78b68658d38918800b0

2133. Bu ZB, Ye M, Cheng Y, Wu WZ. Four polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene and lung cancer risk: a meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2014;15(14):5673-9. www.epistemonikos.org/documents/e292769b00b6a0362a4bcf0bfc163f08b2c8a90f

2134. Zhang Q., Tian J., Wang X.. Carbon ion radiotherapy for stage I non-small cell lung cancer: A Meta-analysis of 369 patients. Radiotherapy and Oncology. 2016;:S585.www.epistemonikos.org/documents/e29d3ba4d5e739c3cf3802add1f6f8f85c21238c

2135. Feng M., Zhu J., Liang L., Zeng N., Wu Y., Wan C., Shen Y., Wen F.. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis. International Journal of Clinical Oncology. 2017;22(2):1-8.www.epistemonikos.org/documents/e2ddf2cd1ba450623e96f52e7d1f14f42fb3b9d9

2136. Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lemaitre F, Meert AP, Vermylen P, Sculier JP, European Lung Cancer Working Party (ELCWP). A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung cancer (Amsterdam, Netherlands). 2000;30(1):23-36. www.epistemonikos.org/documents/e2ec2fff1998bcbc330cce4cccdee28301e35a91

2137. Hu C, Wang J, Xu Y, Li X, Chen H, Bunjhoo H, Xiong W, Xu Y, Zhao J. Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysis. Gene. 2013;517(1):65-71. www.epistemonikos.org/documents/e30491b1ccbfe7c460254d1e65ce8744579ab469

2138. Yan B, Zhang W, Jiang LY, Qin WX, Wang X. Reduced E-Cadherin expression is a prognostic biomarker of non-small cell lung cancer: a meta-analysis based on 2395 subjects. International journal of clinical and experimental medicine. 2014;7(11):4352-6.www.epistemonikos.org/documents/e344c1f56b358f504c022887edb05cff84f63505

2139. Song JU, Lee J. Peptide Nucleic Acid Clamping and Direct Sequencing in the Detection of Oncogenic Alterations in Lung Cancer: Systematic Review and Meta-Analysis. Yonsei medical journal. 2018;59(2):211-218. www.epistemonikos.org/documents/e353a0fdfe38ecd8aa55a80d273d29104fa59312

2140. Jiang H, Wang J, Zhao W. Cox-2 in non-small cell lung cancer: a meta-analysis. Clinica chimica acta; international journal of clinical chemistry. 2013;419:26-32.www.epistemonikos.org/documents/e3551c48ebb34dedbbc60a5b0127bb604eeb9066

2141. Hua Q, Zhu Y, Liu H. Detection of volatile organic compounds in exhaled breath to screen lung cancer: a systematic review. Future oncology (London, England). 2018;14(16):1647-1662. www.epistemonikos.org/documents/e3711e4f5475e1bc0b87ae98ed41c755b9fa4b68

2142. Yu Z, Zhang G, Yang M, Zhang S, Zhao B, Shen G, Chai Y. Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis. Oncotarget. 2017;8(3):4043-4050.www.epistemonikos.org/documents/e3b6608e14bc918d008fbfea4ae38ce43e49b411

2143. Stewart L.A., Burdett S., Parmar M.K.B., Souhami R.L., Arriagada R., Girling D.J., Pignon J.P., Torri V., Brichet A.H., Lafitte J.J., Dautzenberg B., Debevec M., Kovac V., Stephens R.J., Gregor A., Piantadosi S., Rocmans P., Van Houtte P., Wang M.. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet. 1998;352(9124):257-63.www.epistemonikos.org/documents/e3d36ab81a45656ca07749117f1449a4287dd353

2144. Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, Gebski V, Gralla RJ, Yang JC. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(17):1958-65.www.epistemonikos.org/documents/e4068adf0d1a8d26031ee078f235a4b7d41f138e

2145. Xu CH, Wang Q, Zhan P, Qian Q, Yu LK. GSTP1 Ile105Val polymorphism is associated with lung cancer risk among Asian population and smokers: an updated meta-analysis. Molecular biology reports. 2014;41(7):4199-212. www.epistemonikos.org/documents/e41e1723f0c987f2cc1cc70539025247e9bd8f26

2146. Zeng Y, Zhang Q, Wang H, Lu M, Kong H, Zhang Y, Shi H. Prognostic significance of interleukin-17 in solid tumors: a meta-analysis. International journal of clinical and experimental medicine. 2015;8(7):10515-36. www.epistemonikos.org/documents/e431baaefddec63b5c13872d194064b0ee7ee9b1

2147. Liu Y.-Y., Zhang X.-F., Feng G.-L., Wei M., Xu M.-C., Li S.-G., Pang L.-J.. Efficacy of Gefitinib combined with brain radiotherapy for patients with brain metastases from non-small cell lung cancer: A Meta analysis. Chinese Journal of Cancer Prevention and Treatment. 2016;23(2):121-127.www.epistemonikos.org/documents/e43faa977ac115e747d68e43aa5c424dda0c7821

2148. Bi N, Shedden K, Zheng X, Kong FS. Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis. International journal of radiation oncology, biology, physics. 2016;95(5):1378-1390.www.epistemonikos.org/documents/e4af76c90c5ea3a2d5224835c2f490072cfa1fee

2149. Yang H, Yang S, Liu J, Shao F, Wang H, Wang Y. The association of GSTM1 deletion polymorphism with lung cancer risk in Chinese population: evidence from an updated meta-analysis. Scientific reports. 2015;5:9392. www.epistemonikos.org/documents/e4cede824a4cd36cb1ee9260de3b9b82ae061750

2150. Yu M, Men HT, Niu ZM, Zhu YX, Tan BX, Li LH, Jiang J. Meta-Analysis of Circulating Endothelial Cells and Circulating Endothelial Progenitor Cells as Prognostic Factors in Lung Cancer. Asian Pacific journal of cancer prevention : APJCP. 2015;16(14):6123-8. www.epistemonikos.org/documents/e4cf8699c382b43348d17ef6d2a8a74c712c3d6b

2151. Patel SH, Ma Y, Wernicke AG, Nori D, Chao KS, Parashar B. Evidence supporting contemporary post-operative radiation therapy (PORT) using linear accelerators in N2 lung cancer. Lung cancer (Amsterdam, Netherlands). 2014;84(2):156-60. www.epistemonikos.org/documents/e4efdeba24db222fbb5d1f379484abfefb327529

2152. Shen G, Hu S, Deng H, Kuang A. Performance of DWI in the Nodal Characterization and Assessment of Lung Cancer: A Meta-Analysis. AJR. American journal of roentgenology. 2016;206(2):283-90. www.epistemonikos.org/documents/e4f41f736887cebb8d214a6566d8421df95e1add

2153. Zhang J, Gu SY, Zhang P, Jia Z, Chang JH. ERCC2 Lys751Gln polymorphism is associated with lung cancer among Caucasians. European journal of cancer (Oxford, England : 1990).

2010;46(13):2479-84. www.epistemonikos.org/documents/e502d8aab8dfe8c42f993ecdc85c5f32eca5c09d

2154. Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q, Lin H. DNA repair gene X-ray repair cross complementing group 1 Arg194Trp polymorphism on the risk of lung cancer: a meta-analysis on 22 studies. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010;5(11):1741-7.www.epistemonikos.org/documents/e51c6f6f4c368042ee34765ef47bb7763579f140

2155. Lan B, Ma C, Zhang C, Chai S, Wang P, Ding L, Wang K. Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis. Oncotarget. 2018;9(7):7684-7699. www.epistemonikos.org/documents/e54267e10d8166381c8a9d4628b7cead5c78b225

2156. Schmid D, Ricci C, Behrens G, Leitzmann MF. Does smoking influence the physical activity and lung cancer relation? A systematic review and meta-analysis. European journal of epidemiology. 2016;31(12):1-18. www.epistemonikos.org/documents/e5bb48522ba722acb7d673f5c102b22ddbe7e0b6

2157. Liu X, Xu F, Wang G, Diao X, Li Y, Chinese Cochrane/Evidence-Based Medicine Center, Chinese Journal of Evidence-Based Medicine, Periodical Press of West China Hospital of Sichuan University, Chengdu, China. Kanglaite injection plus chemotherapy versus chemotherapy alone for non--small cell lung cancer patients: a systematic review and meta-analysis. Current Therapeutic Research. 2008;69(5):381-411. www.epistemonikos.org/documents/e5c1436daf6daebac37bc293ba233334d86af431

2158. Sánchez Lerma B, Peñuelas Sánchez I, Guillén Grima F. [Docetaxel in combination with cisplatin for first-line treatment of locally advanced or metastatic non-small cell lung cancer: meta-analysis of randomized and controlled clinical trials]. Medicina clínica. 2004;122(8):281-7.www.epistemonikos.org/documents/e63a6b7f2aa3b01688b28bbe64d254a5c0974899

2159. Soon Y.Y., Leong C.N., Koh W.Y., Tham I.W.K.. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: A systematic review and meta-analysis. Radiotherapy and Oncology. 2015;114((Soon Y.Y., yysoon01@gmail.com; Leong C.N.; Koh W.Y.; Tham I.W.K.) Department of Radiation Oncology, National University Cancer Institute, Singapore, National University Health System, National University of Singapore, Singapore):167-72.www.epistemonikos.org/documents/e65ab599b7fe8e49053af7218232a1b5a4c492d4

2160. Yuan M., Li Q.-G.. Lung Cancer and Risk of Cardiovascular Disease: A Meta-analysis of Cohort Studies. Journal of Cardiothoracic and Vascular Anesthesia. 2018;32(1):e25-e27. www.epistemonikos.org/documents/e662f2a60e1ef6471dccf290622bf1517e723f3c

2161. Xue W, Duan G, Zhang X, Zhang H, Zhao Q, Xin Z. Meta-analysis of segmentectomy versus wedge resection in stage IA non-small-cell lung cancer. OncoTargets and therapy. 2018;11:3369-3375. www.epistemonikos.org/documents/e66920f300fef98a9522bc9a9a2ea57b9c52c984

2162. Ashworth A., Rodrigues G.B., Boldt G., Palma D.A.. Is there an oligometastatic state in non-small cell lung cancer (NSCLC)?: A systematic review of outcomes and prognostic factors. International Journal of Radiation Oncology Biology Physics. 2013;:S540. www.epistemonikos.org/documents/e68367c63478e13bf62fa61ab37abbe501e2416a

2163. Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, Zhou Q, Xu CR, Wang Z, Zhang GC, Mok T. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007;2(5):430-9.www.epistemonikos.org/documents/e687d0b5c0266df5958eca7e082fbd70352e24f7

2164. Smith AH, Lopipero PA, Barroga VR. Meta-analysis of studies of lung cancer among silicotics. Epidemiology (Cambridge, Mass.). 1995;6(6):617-24.www.epistemonikos.org/documents/e6a98f3889d3861eccd39b425d66ee3b2c578742

2165. Qiu H, Ji J, Shao Z, Wang J, Ma G, Zhang L, Zhang L. The Efficacy and Safety of Iodine-125 Brachytherapy Combined with Chemotherapy in Treatment of Advanced Lung Cancer: A Meta-Analysis. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2017;27(4):237-245.www.epistemonikos.org/documents/e6aace2b1f94216563da19a1ebc7e3315b9a0402

2166. Han H., Zhao Y., Chen H.. Selective versus systematic lymph node dissection (other than sampling) for clinical N2-negative non-small cell lung cancer: A meta-analysis of observational studies. Journal of Thoracic Disease. 2018;10(6):3428-3435. www.epistemonikos.org/documents/e6b55d18befd1d1a249a4679cf419f193b1c893f

2167. Hausheer F., Bain S., Perry M., Du L., Ohashi Y., Ariyoshi Y., Fukuolca M.. Comprehensive meta-analysis of survival outcomes from two randomized multicenter trials in first-line advanced non-small cell lung cancer in patients treated with the novel investigational antitumor-enhancing and chemoprotective agent Tavocept. Asia-Pacific Journal of Oncology and Hematology. 2010;2(1):1-13. www.epistemonikos.org/documents/e6da586e79b0aae4203155fdb2a5152627591ad0

2168. Dehua Z, Mingming C, Jisheng W. Meta-analysis of gemcitabine in brief versus prolonged low-dose infusion for advanced non-small cell lung cancer. PloS one. 2018;13(3):e0193814. www.epistemonikos.org/documents/e6f9088f5f75ca3ecca716c16a4873f4d1f24624

2169. Huang Q., Su X., Fu J., Luo K., Zhang S., Rong T., Bella A.E.. Clinicopathological features and outcome of gastric metastasis from primary lung cancer: A case report and systematic review. Journal of Thoracic Oncology. 2013;:S663. www.epistemonikos.org/documents/e70c1607115afaec3efa432875ae70449044ea94

2170. Yau G, Lock M, Rodrigues G. Systematic review of baseline low-dose CT lung cancer screening. Lung cancer (Amsterdam, Netherlands). 2007;58(2):161-70.www.epistemonikos.org/documents/e71d77162479dc9f1bb1f24110da5748d855f5ed

2171. Li SG, Chen HY, Ou-Yang CS, Wang XX, Yang ZJ, Tong Y, Cho WC. The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. PloS one. 2013;8(2):e57604. www.epistemonikos.org/documents/e7444dfcfe9212c29798d3b0f5ea843c613eae1b

2172. Wang Q., Ma L., Shen H.-L., Zhang T., Yuan S.-F., Yu T.-T., Shan L.. Pemetrexed plus platinum as first-line treatment for advanced non-small cell lung cancer: a Meta-analysis. Chinese Journal of Cancer Prevention and Treatment. 2014;21(1):61-66. www.epistemonikos.org/documents/e78809a4d86a4bc2a080196208d4717d52ec2511

2173. Linardou H., Dahabreh I., Bafaloukos D., Kosmidis P., Murray S.. Somatic K-RAS mutations predict resistance to gefitinib and erlotinib in NSCLC: A meta-analysis from a comprehensive EGFR somatic mutation database. Annals of Oncology. 2008;:viii104. www.epistemonikos.org/documents/e78b7fd813bfebbd5de4c056cf2da562bf75edb3

2174. Xu H., Minchella K., Zhou D., Al-Huniti N.. A meta-analysis of the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor treatment in nonsmall-cell lung cancer patients. Journal of Clinical Oncology. 2016; www.epistemonikos.org/documents/e7a51d28c6b37395b83280814b9d4c8fadf9f0c0

2175. Wang T., Ma B., Yang K., Ma L.. New agent triplet versus doublet chemotherapy in the treatment of advanced non-small cell lung cancer: A systematic review. Chinese Journal of Lung Cancer. 2009;12(6):565-570. www.epistemonikos.org/documents/e7ad924d1463be71300217489c966bc1bc6e942c

2176. Chen J, Zang YS, Xiu Q. BAT3 rs1052486 and rs3117582 polymorphisms are associated with lung cancer risk: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(10):9855-8. www.epistemonikos.org/documents/e7c37cf5b40fe26df9808c07aac82ffa82f3141b

2177. Sculier JP, Berghmans T, Castaigne C, Luce S, Sotiriou C, Vermylen P, Paesmans M. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung cancer (Amsterdam, Netherlands). 1998;19(2):141-51. www.epistemonikos.org/documents/e7dccd9f562f9fed844836c8c6df35ec5c850104

2178. Li R., Lin S., Wang L., Dong X., Yu L., Li W., Li B.. Involved field radiotherapy (IFRT) versus elective nodal irradiation (ENI) for locally advanced non-small cell lung cancer: A meta-analysis of incidence of elective nodal failure (ENF). Radiation Oncology. 2016;11(1):124.www.epistemonikos.org/documents/e7e53053ca3427b8ea35701debdd59e5f9a9fcaf

2179. Black C, Bagust A, Boland A, Walker S, McLeod C, De Verteuil R, Ayres J, Bain L, Thomas S, Godden D, Waugh N. The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. Health technology assessment (Winchester, England). 2006;10(3):iii-iv, ix-x, 1-90.www.epistemonikos.org/documents/e7ecf4d83705cc2b37973d35413e1f26fb5b4c20

2180. Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006;1(7):611-21.www.epistemonikos.org/documents/e800f46ba69ab38aab7ba0a8a88e473c9390f7f5

2181. Meert AP, Berghmans T, Branle F, Lemaître F, Mascaux C, Rubesova E, Vermylen P, Paesmans M, Sculier JP. Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment. Anticancer research. 1999;19(5C):4379-90.www.epistemonikos.org/documents/e80f96edee271431f64d0169c8dc64af6666095f

2182. Jiang L., Yuan G.-L., Liang Q.-L., Zhang H.-J., Huang J., Cheng S.-A., Peng X.-X.. Positive expression of Y-box binding protein 1 and prognosis in non-small cell lung cancer: A meta-analysis. Oncotarget. 2017;8(33):55613-55621. www.epistemonikos.org/documents/e8134b3f0f4d1e442783293d11f34459197c2271

2183. Wakai K, Nagata C, Mizoue T, Tanaka K, Nishino Y, Tsuji I, Inoue M, Tsugane S, Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan. Alcohol drinking and lung cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Japanese journal of clinical oncology. 2007;37(3):168-74. www.epistemonikos.org/documents/e878d5a0dfa89e870a299dd78d189ada7307708c

2184. Mazzone PJ, Silvestri GA, Patel S, Kanne JP, Kinsinger LS, Wiener RS, Soo Hoo G, Detterbeck FC. Screening for Lung Cancer: CHEST Guideline and Expert Panel Report. Chest. 2018;153(4):954-985. www.epistemonikos.org/documents/e87daa00c650a990420cadca9a08cd6acad0b9c3

2185. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1992;10(6):890-5. www.epistemonikos.org/documents/e8a59f4c8f558eb766d2058217753bee3a8daec2

2186. Manser RL, Irving LB, Byrnes G, Abramson MJ, Stone CA, Campbell DA. Screening for lung cancer: a systematic review and meta-analysis of controlled trials. Thorax. 2003;58(9):784-9. www.epistemonikos.org/documents/e8bb7477097bccd1a8be1ee337aaa8a3548760fe

2187. Jin B, Dong Y, Zhang X, Wang H, Han B. Association of XPC polymorphisms and lung cancer risk: a meta-analysis. PloS one. 2014;9(4):e93937.www.epistemonikos.org/documents/e9095809a17a7bbbf8cd6c7a10d507358b65f943

2188. Lai XX, Xu RA, Yu-Ping L, Yang H. Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. OncoTargets and therapy. 2016;9:2421-8. www.epistemonikos.org/documents/e91b0d921be95ab87b017a10b8d9871d09161ed8

2189. Syrjanen K.. Detection of human papillomavirus (HPV) in lung cancer: Systematic review and meta-analysis. Cytopathology. 2012;:70.www.epistemonikos.org/documents/e91c50c74c7e7dd1d19feb387cdbcac082eb5724

2190. Wang J, Li C, Tao H, Cheng Y, Han L, Li X, Hu Y. Statin use and risk of lung cancer: a meta-analysis of observational studies and randomized controlled trials. PloS one. 2013;8(10):e77950. www.epistemonikos.org/documents/e9274239469f93c14945ed3133f39dce385f3660
2191. Pujol JL, Pirker R, Lynch TJ, Butts CA, Rosell R, Shepherd FA, Vansteenkiste J, O'Byrne KJ, de Blas B, Heighway J, von Heydebreck A, Thatcher N. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2014;83(2):211-8. www.epistemonikos.org/documents/e929226dd5cdac82801fc21f2d606b74453dcf87
2192. Kepka L, Socha J. PET-CT use and the occurrence of elective nodal failure in involved field radiotherapy for non-small cell lung cancer: A systematic review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2015;115(2):151-6.www.epistemonikos.org/documents/e92c40de456574103c2be4a259c823ade3234e8b
2193. Yan H, Li H, Li Q, Zhao P, Wang W, Cao B. The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis. PloS one. 2015;10(8):e0135829. www.epistemonikos.org/documents/e939f399d2a158dadf844f5fc22810479d0ddbf4
2194. Lopez-Olivo MA, Shah NA, Pratt G, Risser JM, Symanski E, Suarez-Almazor ME. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2012;20(11):2985-98.www.epistemonikos.org/documents/e9abe0bcc45d05d58ec3ba4dca6ab170aa89229f
2195. Wei H, Fang N, Guo L, Wu Z, Zhou Q. [Meta-analysis of the Association between RASSF1A Gene Promoter Methylation and Non-small Cell Lung Cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2015;18(7):443-50. www.epistemonikos.org/documents/ea141eca021968a090201c07532b8fcf16af9b74
2196. Peng WJ, Zhang JQ, Wang BX, Pan HF, Lu MM, Wang J. Prognostic value of matrix metalloproteinase 9 expression in patients with non-small cell lung cancer. Clinica chimica acta; international journal of clinical chemistry. 2012;413(13-14):1121-6. www.epistemonikos.org/documents/ea32dd2421b9c2337339fbd601ee5fd6f78b8460
2197. Xu Z, Yu L, Zhang X. Association between the hOGG1 Ser326Cys polymorphism and lung cancer susceptibility: a meta-analysis based on 22,475 subjects. Diagnostic pathology. 2013;8:144. www.epistemonikos.org/documents/ea41da0c9e56929cf0dc9ce5e03c73aab0d39389
2198. Manenti G, Dragani TA. Pas1 haplotype-dependent genetic predisposition to lung tumorigenesis in rodents: a meta-analysis. Carcinogenesis. 2005;26(5):875-82.www.epistemonikos.org/documents/eafecb0301fba5e34013270f125e1ea4256dc36d
2199. Wang H.-J., Li Y.-Y., Wang H.-C., Zhai Y.-N., Zhuang G.-X., Wang Y.-B.. Diagnostic accuracy of 18F-FDG PET dual time point scan in identifying benign and malignant lung lesions: A meta-analysis. Chinese Journal of Evidence-Based Medicine. 2013;13(11):1326-1332.www.epistemonikos.org/documents/eb0ea6055c39263ae6aa1d9d89611c1040ab7122
2200. Xiao YY, Zhan P, Yuan DM, Liu HB, Lv TF, Shi Y, Song Y. Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials. Clinical oncology (Royal College of Radiologists (Great Britain)). 2013;25(1):e7-e15.www.epistemonikos.org/documents/eb1d82efe495c5f06f1cf3e8de03843912f4e9ac
2201. Sun G.-G., Wang Y.-D., Liu Q., Cheng Y.-J.. Associations of manganese superoxide dismutase genetic polymorphism with the susceptibilities of prostate, esophageal and lung cancers: A meta-analysis. Tumor. 2011;31(7):619-626. www.epistemonikos.org/documents/eb926c8ddfbc4163171637e0201f2c7340a58b16
2202. Torres-Durán M, Barros-Dios JM, Fernández-Villar A, Ruano-Ravina A. Residential radon and lung cancer in never smokers. A systematic review. Cancer letters. 2014;345(1):21-6. www.epistemonikos.org/documents/eba5c44551185b278b559b400f8a4e97dd4e3ed0

2203. Luo J, Shen L, Zheng D. Association between vitamin C intake and lung cancer: a dose-response meta-analysis. Scientific reports. 2014;4:6161.www.epistemonikos.org/documents/ec0da38a6be95350c14eae37b87210b10ba96fdb

2204. Dahabreh IJ, Trikalinos TA, Paulus JK. Parity and risk of lung cancer in women: systematic review and meta-analysis of epidemiological studies. Lung cancer (Amsterdam, Netherlands). 2012;76(2):150-8. www.epistemonikos.org/documents/ec12a5cbbcf73317bbb3de465bc6c3be60719ba4

2205. Qin H, Pan F, Li J, Zhang X, Liang H, Ruan Z. Whole brain radiotherapy plus concurrent chemotherapy in non-small cell lung cancer patients with brain metastases: a meta-analysis. PloS one. 2014;9(10):e111475. www.epistemonikos.org/documents/ec209c8a52a689e305446511a0fa94f29b97efef

2206. Zheng Y., Li X., Jiang Y., Xu Y., Song B., Zhou Q., Liang X., Yang X.. Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer A systematic meta-analysis. Medicine (United States). 2016;95(49):e5433. www.epistemonikos.org/documents/ec265556e297b660d2b935e8e1350a586c063bf0

2207. Lee HW, Lee CH, Park YS. Location of stage I-III non-small cell lung cancer and survival rate: Systematic review and meta-analysis. Thoracic cancer. 2018;9(12):1614-1622.www.epistemonikos.org/documents/ec3abde53a844dc3f212df02ac574af66ac3ad24

2208. Donnadieu N., Paesmans M., Sculier J.-P.. Chemotherapy of non-small cell lung cancer according to disease extent: A meta-analysis of the literature. Lung Cancer. 1991;7(4):243-252. www.epistemonikos.org/documents/ec5d8a17e72c55d25c99c01dd290eff0c6bd5c32

2209. Yu Y, Xu X, Du Z, Shi M. Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials. Cancer chemotherapy and pharmacology. 2012;69(5):1265-75.www.epistemonikos.org/documents/ec6095950fbdf4c6d6dbdca1ee55261c46008102

2210. Zhong H., Tang Y., Wang Y., Gu W.. Relationship between MTA1 expression and prognosis of Chinese lung cancer patients: A meta-analysis. Chinese Journal of Lung Cancer. 2017;20(10):683-689. www.epistemonikos.org/documents/ec8b4a10f2ded7ff451bbdd292c7018711de3f68

2211. Sun Y, Bochmann F, Nold A, Mattenklott M. Diesel exhaust exposure and the risk of lung cancer--a review of the epidemiological evidence. International journal of environmental research and public health. 2014;11(2):1312-40. www.epistemonikos.org/documents/eca2c846dc744392184cb3e985f34ea7bb32aa8e

2212. Zhang B, Zhang Y, Xu J, Zhang X, Chu T, Wang S, Qian J, Qiao R, Lu J, Zhang L, Han B. Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review. Targeted oncology. 2018;13(5):631-639.www.epistemonikos.org/documents/ecc4166775a8e85590ecf962230170a90dc19446

2213. Zhang Y., Su X., Shi Y.. Relationship between RRM1 expression and therapeutic effects of gemcitabine for advanced non-small cell lung cancer (NSCLC): A meta-analysis. Medical Journal of Chinese People's Liberation Army. 2012;37(2):135-140. www.epistemonikos.org/documents/ecce8f493d884421fadbf7cab3635a8fd1bd9fb3

2214. Huang G., Sun X., Liu D., Zhang Y., Zhang B., Xiao G., Li X., Gao X., Hu C., Wang M., Ren H., Qin S.. The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: A meta-analysis. Oncotarget. 2018;9(3):4239-4248.www.epistemonikos.org/documents/ece8f9ea7d20d774c6405d65c454e26800b6bf4e

2215. Syrigos K.N., Christopoulos A., Gkiozos I., Charpidou A., Merikas E., Sarris E.. Clinical characteristics and treatment response of active tuberculosis in patients with lung cancer. Journal of Thoracic Oncology. 2014;9(9):S202. www.epistemonikos.org/documents/ed2887952f057c4380b463e8d0715aa2750577dd

2216. Rowland C, Eiser C, Rowe R, Danson S. The effect of smoking on health-related quality of life in lung cancer patients: a systematic review. BMJ supportive & palliative care. 2012;2(4):312-8. www.epistemonikos.org/documents/ed2c163117f8fb7a6b2c718de9a4c92ab2b2652c

2217. Liang JX, Gao W, Liang Y, Zhou XM. Chemokine receptor CXCR4 expression and lung cancer prognosis: a meta-analysis. International journal of clinical and experimental medicine. 2015;8(4):5163-74. www.epistemonikos.org/documents/ed30a4001a3c3506201e7ece633eea88ec69db80

2218. Huang YZ, Wu W, Wu K, Xu XN, Tang WR. Association of RASSF1A promoter methylation with lung cancer risk: a meta-analysis. Asian Pacific journal of cancer prevention : APJCP. 2014;15(23):10325-8. www.epistemonikos.org/documents/ed46960dbf841ba784d78d6d93c5f3b37671b4e4

2219. Ji YN, Wang Q, Lin XQ, Suo LJ. CYP1A1 MspI polymorphisms and lung cancer risk: an updated meta-analysis involving 20,209 subjects. Cytokine. 2012;59(2):324-34.www.epistemonikos.org/documents/ed6573b668176651a79be3442938319dbd4ba3b0

2220. Zhuang Y, Yin HT, Yin XL, Wang J, Zhang DP. High p27 expression is associated with a better prognosis in East Asian non-small cell lung cancer patients. Clinica chimica acta; international journal of clinical chemistry. 2011;412(23-24):2228-31. www.epistemonikos.org/documents/ed9ee21324df437f6c3b6ad011b130def666fef8

2221. Khunger M., Rakshit S., Pasupuleti V., Hernandez A.V., Mazzone P., Stevenson J., Pennell N.A., Velcheti V.. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. Chest. 2017;152(2):271-281.www.epistemonikos.org/documents/edb9301da72b9d1425b31b938b4366b0cc417799

2222. Gazala S, Pelletier JS, Storie D, Johnson JA, Kutsogiannis DJ, Bédard EL. A systematic review and meta-analysis to assess patient-reported outcomes after lung cancer surgery. TheScientificWorldJournal. 2013;2013(no pagination):789625. www.epistemonikos.org/documents/edcf918c325129c0f95873eb4e289a5901d1b164

2223. Manser R, Lethaby A, Irving LB, Stone C, Byrnes G, Abramson MJ, Campbell D. Screening for lung cancer. Cochrane database of systematic reviews (Online). 2013;6(6):CD001991. www.epistemonikos.org/documents/ee0b6cb9d7d74e6b79b93c6290cfecb527940423

2224. Shi L, Tang J, Tong L, Liu Z. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung cancer (Amsterdam, Netherlands). 2014;83(2):231-9. www.epistemonikos.org/documents/ee238ee4b9b931e558999702c2882a57034d0fd9

2225. Zeng C., Fan W., Zhang N., Cao J., Zeng W., Tan T., Zhang X.. Diagnostic performance of circulating tumor cells in lung cancer: A systematic review and meta-analysis. International Journal of Clinical and Experimental Medicine. 2017;10(2):1805-1815. www.epistemonikos.org/documents/ee5aa12338a48428a1d9e974ab6334358b671042

2226. Liu Q, Yu Z, Xiang Y, Wu N, Wu L, Xu B, Wang L, Yang P, Li Y, Bai L. Prognostic and predictive significance of thymidylate synthase protein expression in non-small cell lung cancer: A systematic review and meta-analysis. Cancer biomarkers : section A of Disease markers. 2015;15(1):65-78.www.epistemonikos.org/documents/eea77886e176e676f24488a3df183d46705b9d9a

2227. Kuznetsov L, Mielck A. [Regional concentration of social disadvantage and of risks for lung cancer and colon cancer: systematic review and recommendations for research]. Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany)). 2012;74(6):e42-51.www.epistemonikos.org/documents/eec2e3dbbdf3300634b43f281882398f4073b72e

2228. Trivella M, Pezzella F, Pastorino U, Harris AL, Altman DG, Prognosis In Lung Cancer (PILC) Collaborative Study Group. Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. The Lancet. Oncology. 2007;8(6):488-99.www.epistemonikos.org/documents/eedb2f0b0ae228cfa8afb66c724d73f6cb097b6d

2229. Xin WX, Fang L, Fang QL, Zheng XW, Ding HY, Huang P. Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis. Medicine. 2018;97(9):e0035. www.epistemonikos.org/documents/eede9556a95f0cf9780cee10bc57969c00ab3ee9

2230. Cao C, Manganas C, Ang SC, Peeceeyen S, Yan TD. Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: a meta-analysis of propensity score-matched patients. Interactive cardiovascular and thoracic surgery. 2013;16(3):244-9.www.epistemonikos.org/documents/ef041fb1cca28a80d14692c5d94621665429a687

2231. Ramroth J., Cutter D.J., Darby S.C., Higgins G.S., McGale P., Partridge M., Taylor C.W.. Dose and Fractionation in Radiation Therapy of Curative Intent for Non-Small Cell Lung Cancer: Meta-Analysis of Randomized Trials. International Journal of Radiation Oncology Biology Physics. 2016;96(4):736-747.www.epistemonikos.org/documents/ef150be09da4ea32e3db4bd5d16948d0b9515cb9

2232. Haaland B, Tan PS, de Castro G, Lopes G. Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014;9(6):805-11.www.epistemonikos.org/documents/ef4c75e245f4eb1aa7ebd6c4331192a17c99d9e8

2233. Jiang T, Gao G, Fan G, Li M, Zhou C. FGFR1 amplification in lung squamous cell carcinoma: A systematic review with meta-analysis. Lung cancer (Amsterdam, Netherlands). 2015;87(1):1-7. www.epistemonikos.org/documents/ef4e0efce12222e3cec960576c97161f4b706cd3

2234. Lee JY, Jeon I, Lee JM, Yoon JM, Park SM. Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies. European journal of cancer (Oxford, England : 1990). 2013;49(10):2411-23. www.epistemonikos.org/documents/ef588c18f20cc07a5a0a0c9feb9cca7bf9e26666

2235. Ball D., Le Pechoux C., Mauguen A., Schild S., Saunders M., Turrisi A., Sause W., Belani C., Zajusz A., Pignon J.. Accelerated or hyperfractionated radiotherapy (RT) versus conventional RT in non-metastatic lung cancer (NMLC): Individual patient data (IPD) meta-analysis from 2279 patients (pts). Journal of Medical Imaging and Radiation Oncology. 2010;:A55. www.epistemonikos.org/documents/ef6dd5ff98b4ed29f55e3c93902681ca79c50a3c

2236. Zhang S., Sun X., Sun L., Xiong Z., Ma J., Han C.. Benefits of postoperative thoracic radiotherapy for small cell lung cancer subdivided by lymph node stage: A systematic review and meta-analysis. Journal of Thoracic Disease. 2017;9(5):1257-1264. www.epistemonikos.org/documents/ef79b25ff9daa25a024003c76033b47a855bcf5f

2237. Gu A.-Q., Wang W.-M., Chen W.-Y., Shi C.-L., Lu J.-H., Han J.-Q.. XRCC1 genetic polymorphisms and sensitivity to platinum-based drugs in non-small cell lung cancer: An update meta-analysis based on 4708 subjects. International Journal of Clinical and Experimental Medicine. 2015;8(1):145-154.www.epistemonikos.org/documents/ef86e10cd4e92f97c986b5ff359bf9e9be4f5991

2238. Sheng J., Yang Y.-P., Zhao Y.-Y., Qin T., Hu Z.-H., Zhou T., Zhang Y.-X., Hong S.-D., Ma Y.-X., Zhao H.-Y., Huang Y., Zhang L.. The Efficacy of Combining EGFR Monoclonal Antibody with Chemotherapy for Patients with Advanced Nonsmall Cell Lung Cancer. Medicine (United States). 2015;94(34):e1400.www.epistemonikos.org/documents/ef8bbb80f0cc23c26a479258ccddd763032861d9

2239. Li J, Xu W, Kong F, Sun X, Zuo X. Meta-analysis: accuracy of 18FDG PET-CT for distant metastasis staging in lung cancer patients. Surgical oncology. 2013;22(3):151-5.www.epistemonikos.org/documents/ef92ab78294b5e4cc3907144ca6194582da3022a

2240. Yu Y, Guan H, Xing LG, Xiang YB. Role of gross tumor volume in the prognosis of non-small cell lung cancer treated with 3D conformal radiotherapy: a meta-analysis. Clinical therapeutics. 2015;37(10):2256-66. www.epistemonikos.org/documents/efa5daddb307fc5c65908fb64065d6ec0ed075ac

2241. Cooley ME. Symptoms in adults with lung cancer: a systematic research review. Journal of pain and symptom management. 2000;19(2):137-53.www.epistemonikos.org/documents/efb7c14e054825765554e77e0b86695832973b44

2242. Li W, Li K, Zhao L, Zou H. DNA repair pathway genes and lung cancer susceptibility: a meta-analysis. Gene. 2014;538(2):361-5.www.epistemonikos.org/documents/efd45625700989300d9006906defbc0639808989

2243. Miao X.-H., Yuan D.-M., Lv Y.-L., Zhan P., Lv T., Liu H., Song Y.. Prognostic value of the ratio of ground glass opacity on computed tomography in small lung adenocarcinoma: A meta-analysis. Respirology. 2011;:160. www.epistemonikos.org/documents/eff336aa15cad9bc71ad24c2ad6b0b4068a48722

2244. Li YN, Shi HZ, Liang QL, Yang HB, Huang GM. Prognostic significance of pleural lavage cytology in patients with lung cancer: a meta-analysis. Lung cancer (Amsterdam, Netherlands). 2008;60(2):183-92. www.epistemonikos.org/documents/eff3cef2aaf0ffdbb82a2bfabe9142c8e32b3bdd

2245. Cui P, Huang Y, Han J, Song F, Chen K. Ambient particulate matter and lung cancer incidence and mortality: a meta-analysis of prospective studies. European journal of public health. 2015;25(2):324-9. www.epistemonikos.org/documents/eff4c340976e660e3031f52b2115e612d54777e8

2246. Liu, W, Pan, YL, Gao, CX, Shang, Z, Ning, LJ, Liu, X. Breathing exercises improve post-operative pulmonary function and quality of life in patients with lung cancer: a meta-analysis. Experimental and Therapeutic Medicine. 2013;5(4):1194-1200. www.epistemonikos.org/documents/effdeefcb35828f06d636a362f6760da6dc6e82c

2247. Yang Z, Shen Z, Zhou Q, Huang Y. Single-incision versus multiport video-assisted thoracoscopic surgery in the treatment of lung cancer: a systematic review and meta-analysis. Acta chirurgica Belgica. 2018;118(2):1-9. www.epistemonikos.org/documents/f04b777517413123ea93e8232f26475e3b203a88

2248. Li D, Li R, Zhang J, Li K, Wu Y. Association Between the LIG1 Polymorphisms and Lung Cancer Risk: A Meta-analysis of Case-Control Studies. Cell biochemistry and biophysics. 2015;73(2):381-387. www.epistemonikos.org/documents/f0571d75b3c9d00213f2f03c0d95bcabf2205ec4

2249. Li W, Lin X, Wang R, Wang F, Xie S, Ah Tse L. Hormone Therapy and Lung Cancer Mortality in Women: Systematic Review and Meta-analysis. Steroids. 2017;118:47-54.www.epistemonikos.org/documents/f06574d8c394f3bd1d56f8afee9acea2101a5498

2250. Zeng J, Zhan P, Wu G, Yang W, Liang W, Lv T, Song Y. Prognostic value of Twist in lung cancer: systematic review and meta-analysis. Translational lung cancer research. 2015;4(3):236-41. www.epistemonikos.org/documents/f07bcc6e7a486380ca23026f887b52f07e7c301f

2251. Sheng M., Wang F., Zhao Y., Li S., Wang X., Shou T., Luo Y., Tang W.. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: A meta-analysis. European Journal of Clinical Pharmacology. 2016;72(1):1-11.www.epistemonikos.org/documents/f08221acd92a51342b301316694eb15cf39cba16

2252. Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch CM, Onko-PET der Deutschen Gesellschaft fur Nuklearmedizin. [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000]. Pneumologie (Stuttgart, Germany). 2001;55(8):367-77. www.epistemonikos.org/documents/f0bbedc1dfbdf664c2704d31d7a6fbd778b49a8f

2253. Yao Y.-W., Yuan D.-M., Lv Y.-L., Li Y.-F., Song Y.. Screening for early lung cancer detection with lowdose computed tomography in high-risk people: A systematic review and meta-analysis. Respirology. 2011;:154. www.epistemonikos.org/documents/f0ee83147a3cdd6b201c17365b34d62cde6d67ed

2254. Bai L., Guo C., Wu H., Kaye A.D., Jin C., Deng L., Wang J., Guo Y., Duan X.. The prognostic value of C-X-C chemokine receptor 4 in non-small cell lung cancer: A meta-analysis. International

Journal of Clinical and Experimental Medicine. 2017;10(2):2285-2295.www.epistemonikos.org/documents/f10934fd8d51d72aa83f230e3ec300d917b52545

2255. Liu T, Xu JY, Xu W, Bai YR, Yan WL, Yang HL. Fluorine-18 deoxyglucose positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: which one is the best?--a meta-analysis. Clinical oncology (Royal College of Radiologists (Great Britain)). 2011;23(5):350-8.www.epistemonikos.org/documents/f1457eb682867287bb70235ad26937e91ca47be0

2256. Nita Patel, Jason F Lester, Bernadette Coles, Fergus Macbeth. Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2005;(2):CD005221.www.epistemonikos.org/documents/f148a176ebf5d422e9d77eee4f13862734faf2d7

2257. Lei QQ, Liu JW, Zheng H. Potential role of anti-p53 antibody in diagnosis of lung cancer: evidence from a bivariate meta-analysis. European review for medical and pharmacological sciences. 2013;17(22):3012-8. www.epistemonikos.org/documents/f17ea67a19617b2cdbbca8a0b4318bcc8b38efe0

2258. Wang S., Wang Z.. Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer. Clinical Oncology. 2015;27(1):30-39. www.epistemonikos.org/documents/f18ac327a879bdadf247b5fa7dd173fd28905bf5

2259. Lange A., Prenzler A., Frank M., Golpon H., Graf von der Schulenburg J.-M.. A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer. Onkologie. 2013;:251. www.epistemonikos.org/documents/f1b6ce8fafdfc2335d3efe6ceed5b50fff1aa030

2260. Wang X.-S., Wu T.-X., Hou M.. Topotecan for small cell lung cancer: A systematic review. Chinese Journal of Evidence-Based Medicine. 2007;7(3):189-203.www.epistemonikos.org/documents/f1b87667e6c09ae998e1acc397ed52c9354b0a7e

2261. García-Lavandeira JA, Ruano-Ravina A, Barros-Dios JM. Alcohol consumption and lung cancer risk in never smokers. Gaceta sanitaria / S.E.S.P.A.S. 2016;30(4):311-7.www.epistemonikos.org/documents/f1d780bee2c3781fbb76039eb240e84c9496de99

2262. Zhuo W, Zhang L, Zhu B, Ling J, Chen Z. Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls. PloS one. 2012;7(7):e41546. www.epistemonikos.org/documents/f22986f0a996f75d3d7a377094e934e2c79faa30

2263. Wright G, Manser RL, Byrnes G, Hart D, Campbell DA. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax. 2006;61(7):597-603. www.epistemonikos.org/documents/f23de7f555572041f1990631b1230ad6dffafd3e

2264. Hu X., He W., Wen S., Feng X., Fu X., Liu Y., Pu K.. Is IMRT superior or inferior to 3DCRT in radiotherapy for NSCLC? A meta-analysis. PLoS ONE. 2016;11(4):e0151988.www.epistemonikos.org/documents/f24234743c519b422179d84df7aaab7e9726378d

2265. Liu J, Zhu H, Jiang H, Zhang H, Wu D, Hu X, Zhang H. Tumor M2 pyruvate kinase in diagnosis of nonsmall cell lung cancer: A meta-analysis based on Chinese population. Journal of cancer research and therapeutics. 2015;11 Suppl 1(5):C104-6. www.epistemonikos.org/documents/f25be8f4f3917269227de6598d501d6e6d111e0a

2266. Stenehjem D., Jiao T., Rhien T., Bellows B.K., Kaldate R.R., Jones J., Brixner D.. Literature review and assessment to populate a decision-analytic model evaluating a novel prognostic in early lung cancer. Value in Health. 2013;:A589-A590. www.epistemonikos.org/documents/f26394fbca0d1013c6e9467969ebb3dba7c0f1f3

2267. Malgor RD, Bilfinger TV, Labropoulos N. A systematic review of pulmonary embolism in patients with lung cancer. The Annals of thoracic surgery. 2012;94(1):311-6.www.epistemonikos.org/documents/f27c460842efe74e55b54d8503bdd595945154b6

2268. Wang J, Wang B, Zhao W, Guo Y, Chen H, Chu H, Liang X, Bi J. Clinical significance and role of lymphatic vessel invasion as a major prognostic implication in non-small cell lung cancer: a meta-analysis. PloS one. 2012;7(12):e52704. www.epistemonikos.org/documents/f2876f7a12c786cd6402aa98cad7f01ec5809d58

2269. Qu Y.-L., Liu J., Zhang L.-X., Wu C.-M., Chu A.-J., Wen B.-L., Ma C., Yan X., Zhang X., Wang D.-M., Lv X., Hou S.-J.. Asthma and the risk of lung cancer: A meta-analysis. Oncotarget. 2017;8(7):11614-11620. www.epistemonikos.org/documents/f28e8a9f3035bfd826a62aae6059aef9ac4e8632

2270. Mörth C, Valachis A. Single-agent versus combination chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer and performance status 2: a literature-based meta-analysis of randomized studies. Lung cancer (Amsterdam, Netherlands). 2014;84(3):209-14.www.epistemonikos.org/documents/f29d48e32a94c5c7e71cafda352035e0524f364b

2271. Khan M, Lin J, Liao G, Tian Y, Liang Y, Li R, Liu M, Yuan Y. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. Medicine. 2018;97(33):e11936.www.epistemonikos.org/documents/f2dcb3f73e2bece6fa7c3df75f1f5bfe4c327f0e

2272. Tan LM, Qiu CF, Zhu T, Jin YX, Li X, Yin JY, Zhang W, Zhou HH, Liu ZQ. Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis. Scientific reports. 2017;7(1):5593.www.epistemonikos.org/documents/f2de6520aecd1ff852c06074adbb2cebfc57b255

2273. Koechlin A., Boyle P.. Lung cancer risk, diabetes, and diabetes treatments. Journal of Clinical Oncology. 2016;www.epistemonikos.org/documents/f2ef37b40e7ad80a4a59292806b0e59f77f96d09

2274. Petrelli F, Coinu A, Cabiddu M, Borgonovo K, Ghilardi M, Lonati V, Barni S. Efficacy of fourth-line chemotherapy in advanced non-small-cell lung cancer: a systematic review and pooled analysis of published studies. Anti-cancer drugs. 2015;26(8):807-12. www.epistemonikos.org/documents/f32c2028d6d1d5686f1294d4d400858865945498

2275. Chen D, Shen C, Du H, Zhou Y, Che G. Duplex value of caveolin-1 in non-small cell lung cancer: a meta analysis. Familial cancer. 2014;13(3):449-57.www.epistemonikos.org/documents/f32c71eff301ea5d33a42c1757768fad03d74453

2276. Chen G., Wan X., Yang G., Zou X.. Traffic-related air pollution and lung cancer: A meta-analysis. Thoracic Cancer. 2015;6(3):307-318.www.epistemonikos.org/documents/f339dbbd3f226f24a8ec23bc0ecb51bf97509743

2277. Russo A, Rizzo S, Fulfaro F, Adamo V, Santini D, Vincenzi B, Gebbia N, Carreca I. Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. Cancer. 2009;115(9):1924-31.www.epistemonikos.org/documents/f34f3f142058fb6777dd6049c818d577f061c6fa

2278. Aswanetmanee P., Limsuwat C., Kabach M., Alraiyes A.H., Kheir F.. The role of sedation in endobronchial ultrasound-guided transbronchial needle aspiration: Systematic review. Endoscopic Ultrasound. 2016;5(5):300-306. www.epistemonikos.org/documents/f352020529df7979c0874ff6e7a506f0f669b5cf

2279. Gnagnarella P, Caini S, Maisonneuve P, Gandini S. Carcinogenicity of High Consumption of Meat and Lung Cancer Risk Among Non-Smokers: A Comprehensive Meta-Analysis. Nutrition and cancer. 2018;70(1):1-13. www.epistemonikos.org/documents/f396bb05367b52116a2bca9e36c26942f4deccc6

2280. Huang JD, Dong CH, Shao SW, Gu TJ, Hu ZL, Ying J, Zhou DF, Xie YP. Circulating 25-hydroxyvitamin D level and prognosis of lung cancer patients: A systematic review and meta-analysis. Bulletin du cancer. 2017;104(7-8):675-682. www.epistemonikos.org/documents/f39d2b3ff3ea12b35c9b9deb6d71ee7cff6aa3bd

2281. Wang SF, Wang Q, Jiao LJ, Huang YL, Garfield D, Zhang J, Xu L. Astragalus-containing Traditional Chinese Medicine, with and without prescription based on syndrome differentiation, combined with chemotherapy for advanced non-small-cell lung cancer: a systemic review and meta-analysis. Current oncology (Toronto, Ont.). 2016;23(3):e188-95. www.epistemonikos.org/documents/f40b73b77b8b4904587d3ea903746291be153d4e

2282. Zhang S., Liu Y.. Diagnostic performances of 99mtc-methoxy isobutyl isonitrile scan in predicting the malignancy of lung lesions a meta-analysis. Medicine (United States). 2016;95(18):e3571. www.epistemonikos.org/documents/f439849d06b35a5f136ddcdeb288342a42430f8e

2283. Sheng L, Tu JW, Tian JH, Chen HJ, Pan CL, Zhou RZ. A meta-analysis of the relationship between environmental tobacco smoke and lung cancer risk of nonsmoker in China. Medicine. 2018;97(28):e11389. www.epistemonikos.org/documents/f4480367a4b26b675da566481880df339b42fb81

2284. Ellis PM, Coakley N, Feld R, Kuruvilla S, Ung YC. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. Current oncology (Toronto, Ont.). 2015;22(3):e183-215.www.epistemonikos.org/documents/f4699854b9be483ffc657aa2f87167cd15c13b55

2285. Rolfo C.D., Passiglia F., Bronte G., Rizzo S., Gil Bazo I., Fiorentino E., Van Meerbeeck J.P., Russo A.. A literature-based meta-analysis about the comparison between platinumbased doublet and single agent chemotherapy in ps 2 NSCLC patients. Journal of Thoracic Oncology. 2014;:S42-S43.www.epistemonikos.org/documents/f47107e0ba432c5603f665ae3347c7edc64609c5

2286. Yu Y, Li H, Xu K, Li X, Hu C, Wei H, Zeng X, Jing X. Dairy consumption and lung cancer risk: a meta-analysis of prospective cohort studies. OncoTargets and therapy. 2016;9:111-6. www.epistemonikos.org/documents/f4850df4491a4f2583c77216580393cbad736bfd

2287. Lin X, Liu L, Fu Y, Gao J, He Y, Wu Y, Lian X. Dietary Cholesterol Intake and Risk of Lung Cancer: A Meta-Analysis. Nutrients. 2018;10(2):185-194.www.epistemonikos.org/documents/f493311e55567aa411706c04bda71e26ced91bcd

2288. Zhu Q, Hu H, Jiang F, Guo CY, Yang XW, Liu X, Kuang YK. Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC. Oncotarget. 2017;8(43):75372-75380. www.epistemonikos.org/documents/f4a2ad2bc8b3a8d86b82fc2be0c32db56073e92f

2289. Zhang W., Liang Z., Li J., Cai S.. Angiotensin receptor blockers use and the risk of lung cancer: A meta-analysis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System. 2015;16(4):768-773. www.epistemonikos.org/documents/f4a8070924009fc40d0aa6a09b1d9e9f88fcc854

2290. Chen J, Chen J, Wu X, Shi T, Kang M. Efficacy of targeted agents in the treatment of elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis. OncoTargets and therapy. 2016;9:4797-803. www.epistemonikos.org/documents/f4ca71adb99d60fd1aa498fa42549bc00364a2de

2291. Shen Z.-T., Shen J.-S., Ji X.-Q., Li B., Zhu X.-X.. TGF-beta1 rs1982073 polymorphism contributes to radiation pneumonitis in lung cancer patients: a meta-analysis. Journal of Cellular and Molecular Medicine. 2016;20(12):2405-2409. www.epistemonikos.org/documents/f51010c519a91e40073a2177e2030114b8402f48

2292. Mouronte-Roibás C, Leiro-Fernández V, Fernández-Villar A, Botana-Rial M, Ramos-Hernández C, Ruano-Ravina A. COPD, emphysema and the onset of lung cancer. A systematic review. Cancer letters. 2016;382(2):240-244. www.epistemonikos.org/documents/f51e7e4ca3631656042b28fccee5105da3b49437

2293. Hu Z, Wei Q, Wang X, Shen H. DNA repair gene XPD polymorphism and lung cancer risk: a meta-analysis. Lung cancer (Amsterdam, Netherlands). 2004;46(1):1-10.www.epistemonikos.org/documents/f52901664f41946c90faa5f5d8028dcea790b4b5

2294. Weston A, Godbold JH. Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environmental health perspectives. 1997;105 Suppl 4(SUPPL. 4):919-26. www.epistemonikos.org/documents/f5291a350810bfdf808662d16dbc9c4cbb7306ff
2295. Li G, Dai WR, Shao FC. Effect of ALK-inhibitors in the treatment of non-small cell lung cancer: a systematic review and meta-analysis. European review for medical and pharmacological sciences. 2017;21(15):3496-3503. www.epistemonikos.org/documents/f544b82659fb10e7458e325e4e4fc2ee7755f84d
2296. Ren Y.-W., Wang D., Li K., Wan Y., Zhou B.-S.. Meta-analysis of compare triplet regimen based on Gemcitabine with doublet regimen for advanced NSCLC. Chinese Journal of Cancer Prevention and Treatment. 2012;19(6):457-460. www.epistemonikos.org/documents/f5514171a8ec3a0e2b07f232b93627f51bb98014
2297. Zhuo WL, Zhu B, Xiang ZL, Zhuo XL, Cai L, Chen ZT. Assessment of the relationship between Helicobacter pylori and lung cancer: a meta-analysis. Archives of medical research. 2009;40(5):406-10. www.epistemonikos.org/documents/f58ba9100dd79618d8b7f800692abfe6ea2565ef
2298. Lei Z, Liu R, Chen J, Zhou Q, Zhang H. [Meta Analysis of Association between Polymorphisms in Promoter Region of MMPs gene and Risk of Lung Cancer.]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2009;12(5):381-6. www.epistemonikos.org/documents/f5a613475a21a7496807d3c7b3bf6232b6668c57
2299. Hancock DG, Langley ME, Chia KL, Woodman RJ, Shanahan EM. Wood dust exposure and lung cancer risk: a meta-analysis. Occupational and environmental medicine. 2015;72(12):889-98. www.epistemonikos.org/documents/f5bb84f4507a8e5f837d7e0bceb6029de748fc40
2300. Liu, Ch, Wang, H, Zhai, J, Xing, D, Lei, X, Ren, M, Shang, H. Zilongjin for NSCLC: A Systematic Review. Liaoning Journal of Traditional Chinese Medicine. 2013;(12):2448-2453+2637. www.epistemonikos.org/documents/f5d5f5b438d21b4d40280eed6916ff0caf63a43b
2301. Tuo L, Sha S, Huayu Z, Du K. P16INK4a gene promoter methylation as a biomarker for the diagnosis of non-small cell lung cancer: An updated meta-analysis. Thoracic cancer. 2018;9(8):1032-1040. www.epistemonikos.org/documents/f5e625ac4e60587bc39ae9fd8871bb6f6a73ed79
2302. Wu Y, Liu HB, Shi XF, Song Y. Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis. PloS one. 2014;9(6):e99577.www.epistemonikos.org/documents/f5ea2253fb9f0ae8d735964e91336809aa224440
2303. Shen N, Fu P, Cui B, Bu CY, Bi JW. Associations between body mass index and the risk of mortality from lung cancer: A dose-response PRISMA-compliant meta-analysis of prospective cohort studies. Medicine. 2017;96(34):e7721. www.epistemonikos.org/documents/f5f8a441563ac42bf740b85960167de3538fff2b
2304. Pallis AG, Karampeazis A, Vamvakas L, Vardakis N, Kotsakis A, Bozionelou V, Kalykaki A, Hatzidaki D, Mavroudis D, Georgoulias V. Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2011;22(11):2448-55. www.epistemonikos.org/documents/f5fbbb4349261ec8e44a0e8fcec71fd653694657
2305. Yao N, Jiang L, Yang K, Ye Y, Mi D, Min G. [Irinotecan/cisplatin versus Etoposide/cisplatin for Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review.]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2009;12(8):884-8. www.epistemonikos.org/documents/f619aedea0160bd9b8501d13331019e3d035ce75
2306. Wang Y, Yang H, Wang H. The association of GSTT1 deletion polymorphism with lung cancer risk among Chinese population: evidence based on a cumulative meta-analysis. OncoTargets and therapy. 2015;8:2875-82. www.epistemonikos.org/documents/f61e5c2469ad62321e56fb6e32437094d4724245

2307. Huang J., Lin H., Wu X., Jin W., Zhang Z.. NQO1 C609T polymorphism and lung cancer susceptibility: Evidence from a comprehensive meta-analysis. Oncotarget. 2017;8(60):102301-102309. www.epistemonikos.org/documents/f62bb13c55bdae1807fa1975e9ddc503faaaeb86

2308. Wu H., Qiao N., Wang Y., Jiang M., Wang S., Wang C., Hu L.. Association between the telomerase reverse transcriptase (TERT) rs2736098 polymorphism and cancer risk: evidence from a case-control study of non-small-cell lung cancer and a meta-analysis. PLoS ONE. 2013;8(11):e76372.www.epistemonikos.org/documents/f62c9c738a741ac5dca87c7e17edc04c63c021a0

2309. Kossioris A., Karousi T.. Determinants of health-related quality of life in patients with small cell lung cancer: A systematic PubMed review and meta-analysis. Russian Open Medical Journal. 2016;5(1). www.epistemonikos.org/documents/f62fbb308b30a034571aa14f029929a0939bb145

2310. Sun CT, Xu X, Sheng W, Wang XW, Wen SL, Han JQ. A meta-analysis of pemetrexed-based doublet compared with pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer. Bratislavské lekárske listy. 2014;115(4):233-7. www.epistemonikos.org/documents/f631ddc15aac179be812bf3afeb2938b5f44e86b

2311. Luo L, Hu Q, Jiang JX, Yang X, Dinglin XX, Lin X, Yao HR. Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: A meta-analysis. Asia-Pacific journal of clinical oncology. 2015;11(3):253-61.www.epistemonikos.org/documents/f646de8ab58f19a2c5cd4a21a0688b353243c667

2312. Yan F., Wang R., Geng L.. The 341C/T polymorphism in the GSTP1 gene and lung cancer risk: A meta-analysis. Genetics and Molecular Research. 2016;15(3).www.epistemonikos.org/documents/f64a265503f3077b9a0bb2bccec592d272230c2c

2313. Zhang X., Jiang N., Wang L., Liu H., He R.. Chronic obstructive pulmonary disease and risk of lung cancer: A meta-analysis of prospective cohort studies. Oncotarget. 2017;8(44):78044-78056. www.epistemonikos.org/documents/f65a4aaff8a6c9d70617be5048487d4d0f0c7bd8

2314. Casagrande A, Pederiva F. Association Between Congenital Lung Malformations and Lung Tumors in Children and Adults. a Systematic Review. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(11):1837-1845.www.epistemonikos.org/documents/f693c93f9d030c69a22ff82922d10bae50f6fa30

2315. Kuan FC, Kuo LT, Chen MC, Yang CT, Shi CS, Teng D, Lee KD. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. British journal of cancer. 2015;113(10):1519-28.www.epistemonikos.org/documents/f6d56443dfa0dffc993daf8910c71317721ad403

2316. Vansteenkiste J, Fischer BM, Dooms C, Mortensen J, Head of Clinic, Department of Pulmonology, University Hospital Gasthuisberg, Catholic University, Herestraat 49, B-3000 Leuven, Belgium, johan.vansteenkiste@uz.kuleuven.ac.be. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncology. 2004;5(9):531-540. www.epistemonikos.org/documents/f71e63726b80c0de9e3e7873a13b06f1770cc09d

2317. Kiely BE, Alam M, Blinman P, Tattersall MH, Stockler MR. Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: a systematic review of contemporary randomized trials. Lung cancer (Amsterdam, Netherlands). 2012;77(3):537-44.www.epistemonikos.org/documents/f7cff45486bd56dbb6c1a1530161b65707412e64

2318. Sun GG, Wang YD, Lu YF, Hu WN. Different association of manganese superoxide dismutase gene polymorphisms with risk of prostate, esophageal, and lung cancers: evidence from a meta-analysis of 20,025 subjects. Asian Pacific journal of cancer prevention : APJCP. 2013;14(3):1937-43.www.epistemonikos.org/documents/f7e0ce11459917a2e269962e034a56d114b4cd9e

2319. Petrelli F, Barni S. Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis of 16 randomized trials. Medical oncology (Northwood, London, England). 2013;30(3):641. www.epistemonikos.org/documents/f7ec9bf084d21b7efcd13a1703f47cb0da0001e6

2320. Crandall K, Maguire R, Campbell A, Kearney N. Exercise intervention for patients surgically treated for Non-Small Cell Lung Cancer (NSCLC): a systematic review. Surgical oncology. 2014;23(1):17-30. www.epistemonikos.org/documents/f80a969a119ebc43cf218b06e259d74ea1076c0c

2321. Feng Q, Yang ZY, Zhang JT, Tang JL. Comparison of direct sequencing and amplification refractory mutation system for detecting epidermal growth factor receptor mutation in non-small-cell lung cancer patients: a systematic review and meta-analysis. Oncotarget. 2017;8(35):59552-59562.www.epistemonikos.org/documents/f8313752f6f6cd985d7403740558091ed9e9a40b

2322. Fu, Zhan-Zhao, Peng, Yong, Cao, Li-Yan, Chen, Yan-Sheng, Li, Kun, Fu, Bao-Hong. Correlations Between Serum IL-6 Levels and Radiation Pneumonitis in Lung Cancer Patients: A Meta-Analysis. Journal of Clinical Laboratory Analysis. 2016;30(2):145-154. www.epistemonikos.org/documents/f8442674b447436fea33653e7c68fbdf045e4deb

2323. Maeng CH, Song JU, Shim SR, Lee J. The Role of Prophylactic Cranial Irradiation in Patients With Extensive Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018;13(6):840-848.www.epistemonikos.org/documents/f8510dfdb016424b6e4da395584dccb917bc1c62

2324. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer. 1995;76(4):593-601. www.epistemonikos.org/documents/f85480c2730f0f7d975237895f926b3e6dacc648

2325. Li Z., Guo H., Lu Y., Hu J., Luo H., Gu W.. Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: A systematic review and meta-analysis. OncoTargets and Therapy. 2018;11:3697-3703.www.epistemonikos.org/documents/f86a120ba7ee160e57481ac40828ae408174692e

2326. Cheng Z, Ma R, Tan W, Zhang L, Tan Q. Lack of association between ACE insertion/deletion polymorphism and lung cancer: A meta-analysis. Journal of the renin-angiotensin-aldosterone system : JRAAS. 2015;16(2):453-8. www.epistemonikos.org/documents/f88984ec50da309ff9b9444aeca1bc7b162ce3fb

2327. Souza F.H., Castro G., Takahashi T.K., Rosa T.B.C., Hoff P.M.. Pemetrexed in comparison to gemcitabine as maintenance chemotherapy (MCT) in advanced nonsmall cell lung cancer (NSCLC): A systematic review and meta-analysis. Annals of Oncology. 2010;:viii159.www.epistemonikos.org/documents/f88e91adfa67721e50399f8b006dafae832366b4

2328. Zhu CM, Lian XY, Bi YH, Hu CC, Liang YW, Li QS. Prognostic value of ribonucleotide reductase subunit M1 (RRM1) in non-small cell lung Cancer: A meta-analysis. Clinica chimica acta; international journal of clinical chemistry. 2018;485:67-73. www.epistemonikos.org/documents/f8936fa9cb6a4cacdf6f2597f77d8f54c99a0e42

2329. Zhuansun Y., Huang F., Du Y., Lin L., Chen R., Li J.. Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: A metaanalysis of randomized controlled trials. Journal of Thoracic Disease. 2017;9(3):655-665.www.epistemonikos.org/documents/f8b3b2df31c3b824033cfce6458f2973ac078b14

2330. Biaoxue R, Hua L, Wenlong G, Shuanying Y. Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies. Oncotarget. 2016;7(52):86902-86913. www.epistemonikos.org/documents/f8e19834b16e65fa47dd4b47f827dd96d6124edb

2331. Zhang H, Jiang H, Hu X, Jia Z. Aidi injection combined with radiation in the treatment of non-small cell lung cancer: A meta-analysis evaluation the efficacy and side effects. Journal of cancer research and therapeutics. 2015;11 Suppl 1(5):C118-21. www.epistemonikos.org/documents/f979e455e8aa94d3f428993fd6b853df99fea8dd

2332. Gao JW, Zhan P, Qiu XY, Jin JJ, Lv TF, Song Y. Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials. Oncotarget. 2017;8(42):73258-73270.www.epistemonikos.org/documents/f9b07ab08fbf1740a2bd935bbc1df292167c4319

2333. Widesott L, Amichetti M, Schwarz M. Proton therapy in lung cancer: clinical outcomes and technical issues. A systematic review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2008;86(2):154-64. www.epistemonikos.org/documents/fa24a00b90ad45510335d835ddaff0c333c0dce4

2334. Ratko TA, Vats V, Brock J, Ruffner BW, Aronson N. Local Nonsurgical Therapies for Stage I and Symptomatic Obstructive Non–Small-Cell Lung Cancer. AHRQ Comparative Effectiveness Reviews. 2013; www.epistemonikos.org/documents/fa6624ccbe6677f8899e53cc8aa338a1d92ba3d1

2335. Song N, Liu B, Wu J, Zhang R, Duan L, He W, Zhang C. Vascular endothelial growth factor (VEGF) -2578C/A and -460C/T gene polymorphisms and lung cancer risk: a meta-analysis involving 11 case-control studies. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(1):859-70.www.epistemonikos.org/documents/fa884ad798409f40e83ff838c4611458695fd941

2336. Qu X, Huang X, Yan W, Wu L, Dai K. A meta-analysis of ^{18}FDG-PET-CT, ^{18}FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. European journal of radiology. 2012;81(5):1007-15. www.epistemonikos.org/documents/fa8d29da715b2623777927e0fee397f3c071a2fe

2337. Dobrzynski L, Fornalski KW, Reszczynska J. Meta-analysis of thirty-two case-control and two ecological radon studies of lung cancer. Journal of radiation research. 2018;59(2):1-15. www.epistemonikos.org/documents/fa94bb1e997e0edebef6d1cbb082e9113d938a39

2338. Tanvetyanon T, Bepler G. Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: a meta-analysis and evaluation of national brands. Cancer. 2008;113(1):150-7. www.epistemonikos.org/documents/facfb1c66e7fe985b5bb58feacdc8801cbfd9ad3

2339. Liu D, Peng H, Sun Q, Zhao Z, Yu X, Ge S, Wang H, Fang H, Gao Q, Liu J, Wu L, Song M, Wang Y. The Indirect Efficacy Comparison of DNA Methylation in Sputum for Early Screening and Auxiliary Detection of Lung Cancer: A Meta-Analysis. International journal of environmental research and public health. 2017;14(7).www.epistemonikos.org/documents/fafa85fb1a63da599ca249c99394c489e421da1b

2340. Tong J, Sun X, Cheng H, Zhao D, Ma J, Zhen Q, Cao Y, Zhu H, Bai J. Expression of p16 in non-small cell lung cancer and its prognostic significance: a meta-analysis of published literatures. Lung cancer (Amsterdam, Netherlands). 2011;74(2):155-63. www.epistemonikos.org/documents/fb12f7d1b13c816d3b7056b0bfd657e7a3ce6a95

2341. Xu Y, Zhang Y, Wang Z, Chen N, Zhou J, Liu L. The role of serum angiopoietin-2 levels in progression and prognosis of lung cancer: A meta-analysis. Medicine. 2017;96(37):e8063. www.epistemonikos.org/documents/fb165f5e1c777aa27af3014028eaa8200c59d9b9

2342. Prince RM, Atenafu EG, Krzyzanowska MK. Hospitalizations During Systemic Therapy for Metastatic Lung Cancer: A Systematic Review of Real World vs Clinical Trial Outcomes. JAMA oncology. 2015;1(9):1333-1339. www.epistemonikos.org/documents/fb550e09101b60774225ebe4c508ad8f774eeea5

2343. Gao P, Zhao H, You J, Jing F, Hu Y. Association between interleukin-8 -251A/T polymorphism and risk of lung cancer: a meta-analysis. Cancer investigation. 2014;32(10):518-25. www.epistemonikos.org/documents/fb65c808d5cef14fe7fd21e7cec155687153e631

2344. Tsuboi M., Hamada C., Ohta M., Fujimura S., Kodama K., Imaizumi M., Wada H.. Effect of postoperative adjuvant chemotherapy with UFT on survival in patients with clinical stage IA non-small-cell lung cancer: An exploratory analysis from a meta-analysis of 6 randomized controlled

trials. European Journal of Cancer, Supplement. 2009;:510.www.epistemonikos.org/documents/fb755b38489e27a3530486f914ec8736fbcf437f

2345. Jiang J, Shi HZ, Deng JM, Liang QL, Qin SM, Wu C. Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: A meta-analysis of the published literature. Lung cancer (Amsterdam, Netherlands). 2009;65(2):214-8. www.epistemonikos.org/documents/fb7a7b525e90d825b19c98d5c3c7138179ea01b1

2346. Hasegawa Y., Ando M., Maemondo M., Yamamoto S., Isa S.-I., Saka H., Kubo A., Kawaguchi T., Takada M., Rosell R., Kurata T., Ignatius Ou S.-H.. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: A meta-analysis of prospective randomized trials. Oncologist. 2015;20(3):307-315.www.epistemonikos.org/documents/fba7a39ba8524de5f4a32b39e6ffbdbf0073b1f4

2347. Loveman E, Jones J, Hartwell D, Bird A, Harris P, Welch K, Clegg A. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health technology assessment (Winchester, England). 2010;14(19):1-204.www.epistemonikos.org/documents/fbc8f9ec9dfa5766e55a039b433414cbcbe22989

2348. Lin CK, Hsu YT, Christiani DC, Hung HY, Lin RT. Risks and burden of lung cancer incidence for residential petrochemical industrial complexes: A meta-analysis and application. Environment international. 2018;121(Pt 1):404-414. www.epistemonikos.org/documents/fbdd1a780f3ee8747ec52eb77afe7e89db2baf43

2349. Gonzalez Casaurran G.A., i Vanaclocha B.V.. Systematic review on the efficacy of mushroom preparations as an adjuvant treatment of non-small cell lung cancer. Revista de Fitoterapia. 2017;17(2):101-115. www.epistemonikos.org/documents/fc1596ebc588044c1b60366bae2384cb3edc53f3

2350. Hori M, Tanaka H, Wakai K, Sasazuki S, Katanoda K. Secondhand smoke exposure and risk of lung cancer in Japan: a systematic review and meta-analysis of epidemiologic studies. Japanese journal of clinical oncology. 2016;46(10):942-951. www.epistemonikos.org/documents/fc589b9413fde0bb28bf198fc1e395659bbc2d89

2351. Bozcuk H, Artac M, Ozdogan M, Savas B. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials. Cancer. 2005;104(12):2650-7. www.epistemonikos.org/documents/fca5557d627cf3998217960d15095a9dbc9f645f

2352. He, H-l, Wang, Q, Zhao, Y, Liu, H-p, Cao, Zh-d, Zhou, X-m. Meta-analysis on Treatment of Non-small Cell Lung Cancer with Shenfu Injection in Combination with Platinum-contained First-line Chemotherapy. Chinese Journal of Experimental Traditional Medical Formulae. 2013;19(14):331-339.www.epistemonikos.org/documents/fcccd1dfe0af9dad435df7ea615f543cd818ce74

2353. Yu Y., Qian L., Cui J.. Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients. Molecular and Clinical Oncology. 2017;7(3):498-506. www.epistemonikos.org/documents/fce70a741be0cfdc07f173bde7c004293960ce00

2354. Wei X.-P., Hu J.. Cytochrome P450 1A1 exon 7 polymorphism and susceptibility to lung cancer in the Chinese population: an updated meta-analysis and review. OncoTargets and Therapy. 2015;8:1611-1618. www.epistemonikos.org/documents/fd0c9f25f3da7c41f90954eb5ab7e9d13686071e

2355. Guogui Sun, Wanning Hu, Yifang Lu, Yadi Wang, Hongfang Zhai, Dawei Cui. Correlation between Survivin Expression and Clinicopathological Characteristics in Patients with Non-Small Cell Lung Cancer. International Medical Journal. 2013;20(5):571-578. www.epistemonikos.org/documents/fd15865a704532848f54f6766b73617f611d8ead

2356. Chen B, Liu S, Xu W, Wang X, Zhao W, Wu J. IGF-I and IGFBP-3 and the risk of lung cancer: a meta-analysis based on nested case-control studies. Journal of experimental & clinical cancer

research : CR. 2009;28(1):89. www.epistemonikos.org/documents/fd40085ee94a2a9fd5fc959462cc497c76109fe5

2357. Yang X, Yang K, Kuang K. The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review. Current oncology reports. 2014;16(6):390. www.epistemonikos.org/documents/fd45f770cf61b520f73a06fdbb08712f09e699fa

2358. Sun L, Ma JT, Zhang SL, Zou HW, Han CB. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis. Medical oncology (Northwood, London, England). 2015;32(2):473. www.epistemonikos.org/documents/fd4ae3ce120bb128c754b53e6ccb8d3e9230aab6

2359. Ganganah O, Guo SL, Chiniah M, Li YS. Efficacy and safety of cryobiopsy versus forceps biopsy for interstitial lung diseases and lung tumours: A systematic review and meta-analysis. Respirology (Carlton, Vic.). 2016;21(5):834-41. www.epistemonikos.org/documents/fd56045a72ae4faa5eb5f4e31012ac1f3e45132c

2360. Lan B., Ma C., Zhang C., Chai S., Wang P., Ding L., Wang K.. Association between PD-L1 expression and driver gene status in nonsmall- cell lung cancer: A meta-analysis. Oncotarget. 2018;9(7):7684-7699. www.epistemonikos.org/documents/fd6aa2ac062bb8d0571e78ff37cc42ef2d18b6a6

2361. Ma X, Li Y, Zhang J, Huang J, Liu L. Prognostic role of D-dimer in patients with lung cancer: a meta-analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(3):2103-9. www.epistemonikos.org/documents/fd712136ee782253d67448c182aa5e3b837cd361

2362. Bayly JL, Lloyd-Williams M. Identifying functional impairment and rehabilitation needs in patients newly diagnosed with inoperable lung cancer: a structured literature review. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2016;24(5):2359-79.www.epistemonikos.org/documents/fd8387f57b10d39ffa14ca4804a6bd00375924c2

2363. Zhan P., Wang Q., Qian Q., Wei S.-Z., Yu L.-K.. CYP1A1 MspI and exon7 gene polymorphisms and lung cancer risk: an updated meta-analysis and review. Journal of Experimental and Clinical Cancer Research. 2011;30(1):99. www.epistemonikos.org/documents/fd9c82058f0fc2c1b463d699c427e54d9826c0a8

2364. Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ (Clinical research ed.). 2010;340(7740):b5569. www.epistemonikos.org/documents/fda5c58f63d155cfef1cad0a2eed6a8e8d503546

2365. Sun B.B., Wu J.Z., Li Y.G., Ma L.J.. Association between the null77T>C polymorphism in the DNA repair gene XRCC1 and lung cancer risk. Genetics and Molecular Research. 2014;13(4):10223-10230. www.epistemonikos.org/documents/fdb0d74d4f9018d33cecde485ef69121b30d4757

2366. Li Y., Lu D., Ma Y., Liu H.. Association between Retinoic acid receptor-beta hypermethylation and NSCLC risk: A meta-analysis and literature review. Oncotarget. 2017;8(4):5814-5822. www.epistemonikos.org/documents/fdb178e8d3705b876c29224c1207468e086e10fa

2367. Zhu J, Li R, Tiselius E, Roudi R, Teghararian O, Suo C, Song H. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. The Cochrane database of systematic reviews. 2017;12(12):CD011300.www.epistemonikos.org/documents/fdbe8d2eb5cc7f01796b57aee91e45f565b70e68

2368. DeLuzio MR, Moores C, Dhamija A, Wang Z, Cha C, Boffa DJ, Detterbeck FC, Kim AW. Resection of oligometastatic lung cancer to the pancreas may yield a survival benefit in select patients - A systematic review. Pancreatology : official journal of the International Association of

Pancreatology (IAP) ... [et al.]. 2015;15(5):456-62.www.epistemonikos.org/documents/fdc3467e662bcb50d9755a2c2e36fe67bdb5613f

2369. Rodríguez-Martínez Á, Torres-Durán M, Barros-Dios JM, Ruano-Ravina A. Residential radon and small cell lung cancer. A systematic review. Cancer letters. 2018;426:57-62.www.epistemonikos.org/documents/fdda24a2001b9bed2287ebd308a17bef35a5ffc9

2370. Jiang F, Zhou XY, Huang J. The value of surface enhanced laser desorption/ionization-time of flight mass spectrometry at the diagnosis of non-small cell lung cancer: a systematic review. Technology in cancer research & treatment. 2014;13(2):109-17. www.epistemonikos.org/documents/fdf826ad30975777004e6107145f7fa9ed0ccd73

2371. Mao R, Fan Y, Jin Y, Bai J, Fu S. Methylenetetrahydrofolate reductase gene polymorphisms and lung cancer: a meta-analysis. Journal of human genetics. 2008;53(4):340-8.www.epistemonikos.org/documents/fdfa9e811cc6209132db56899fa2172d0bf5a1cf

2372. Wang A., Wang H.Y., Liu Y., Zhao M.C., Zhang H.J., Lu Z.Y., Fang Y.C., Chen X.F., Liu G.T.. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis. European Journal of Surgical Oncology. 2015;41((Wang A.; Zhao M.C.; Lu Z.Y.; Fang Y.C.; Chen X.F., Dr_chenxiaofeng@126.com) Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Shanghai, China):450-6. www.epistemonikos.org/documents/fdfe49127acd7e5a99421efbd45a9ca5b5212f47

2373. Shao N, Jin S, Zhu W. An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012;7(2):470-2.www.epistemonikos.org/documents/fe09bec90c940cd26d8fbc2cc78096ed8028802f

2374. Palma D.A., Senan S., Tsujino K., Barriger R.B., Rengan R., Moreno M., Bradley J.D., Hyun Kim T., Marks L.B., Rodrigues G.. Predicting symptomatic radiation pneumonitis after concurrent chemoradiation therapy for non-small cell lung cancer: Results of an international individual patient data meta-analysis. International Journal of Radiation Oncology Biology Physics. 2012;:S549. www.epistemonikos.org/documents/fe0c3535b57fc7dbef9bbea91ed4db653f4af7f9

2375. Santiago A, Barczyk S, Jelen U, Engenhart-Cabillic R, Wittig A. Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?. Radiation oncology (London, England). 2016;11(1):67.www.epistemonikos.org/documents/fe19d175d8a6e89828875cccf490005444e5e532

2376. Wang X., Xu Y., Tang W., Liu L.. Efficacy and Safety of Radiotherapy Plus EGFR-TKIs in NSCLC Patients with Brain Metastases: A Meta-Analysis of Published Data. Translational Oncology. 2018;11(5):1119-1127. www.epistemonikos.org/documents/fe47581aa5238a69fffac2e41c18939bd64a7a7c

2377. Kaster TS, Yaremko B, Palma DA, Rodrigues GB. Radical-Intent Hypofractionated Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Systematic Review of the Literature. Clinical lung cancer. 2015;16(2):71-79. www.epistemonikos.org/documents/fe4ebec26e35d1192a7dd8db92de623f0035cabe

2378. O'Keeffe LM, Taylor G, Huxley RR, Mitchell P, Woodward M, Peters SAE. Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ open. 2018;8(10):e021611. www.epistemonikos.org/documents/fe58b8b541e76d1be11dd4d96085b5f4bd038630

2379. Xu X, Huang Z, Zheng L, Fan Y. The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer. International journal of cancer. 2018;142(11):2344-2354. www.epistemonikos.org/documents/fe61e9f1a6c121bf0cee9d4b5403359ce6827e75

2380. Huang J.-T., Zhang Z.-W., Zhang Y.-M., Yan W.-Q., Li Z.-G.. Efficacy and safety of non-platinum based doublets chemotherapy compared with platinum-based doublets chemotherapy in advanced non-small-cell lung cancer (NSCLC): A meta-analysis. International Journal of Clinical

and Experimental Medicine. 2016;9(8):15262-15273.www.epistemonikos.org/documents/fe7ec74bf537dc35d7a0f96ca7ea537d52457d59

2381. Raimondi S, Paracchini V, Autrup H, Barros-Dios JM, Benhamou S, Boffetta P, Cote ML, Dialyna IA, Dolzan V, Filiberti R, Garte S, Hirvonen A, Husgafvel-Pursiainen K, Imyanitov EN, Kalina I, Kang D, Kiyohara C, Kohno T, Kremers P, Lan Q, London S, Povey AC, Rannug A, Reszka E, Risch A, Romkes M, Schneider J, Seow A, Shields PG, Sobti RC, Sørensen M, Spinola M, Spitz MR, Strange RC, Stücker I, Sugimura H, To-Figueras J, Tokudome S, Yang P, Yuan JM, Warholm M, Taioli E. Meta- and pooled analysis of GSTT1 and lung cancer: a HuGE-GSEC review. American journal of epidemiology. 2006;164(11):1027-42.www.epistemonikos.org/documents/fe86a4c229d87c921914d0e8142d3451a64ccc5d

2382. Li B, Li Q, Chen C, Guan Y, Liu S. A systematic review and meta-analysis of the accuracy of diffusion-weighted MRI in the detection of malignant pulmonary nodules and masses. Academic radiology. 2014;21(1):21-9. www.epistemonikos.org/documents/fe8af62895f9deefc09db2a85fe79ec42de78282

2383. Sheng J, Yang YP, Yang BJ, Zhao YY, Ma YX, Hong SD, Zhang YX, Zhao HY, Huang Y, Zhang L. Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review. Medicine. 2015;94(31):e1282.www.epistemonikos.org/documents/fe903d8a350e5920718629dc3e4ab1735741d91d

2384. Tan Z., Yang C., Zhang X., Zheng P., Shen W.. Expression of glucose transporter 1 and prognosis in non-small cell lung cancer: A pooled analysis of 1665 patients. Oncotarget. 2017;8(37):60954-60961. www.epistemonikos.org/documents/fee672d6e917918c5236950027e73b1ef5b40c07

2385. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(20):3277-83.www.epistemonikos.org/documents/ff201871fdead650acbcbed92bcb0affd5ef1aaa

2386. Zhao DP, Yang CL, Zhou X, Ding JA, Jiang GN. Association between CLPTM1L polymorphisms (rs402710 and rs401681) and lung cancer susceptibility: evidence from 27 case-control studies. Molecular genetics and genomics : MGG. 2014;289(5):1001-12. www.epistemonikos.org/documents/ffc74f17729d0b77bd9ad239a63eb414f94fa89a

2387. Jia PL, Zhang C, Yu JJ, Xu C, Tang L, Sun X. The risk of lung cancer among cooking adults: a meta-analysis of 23 observational studies. Journal of cancer research and clinical oncology. 2018;144(2):229-240. www.epistemonikos.org/documents/ffe0b197f5f762bbf330c4db0ca5deb3ec399524